{"33c89e3d10c848038361604d20d227652ed558c9": [], "PMC2387173": [["BackgroundInfectious salmon anemia has since the early 1990's been one of the most dangerous viral diseases threatening Atlantic salmon aquaculture industry.", [["salmon anemia", "DISEASE", 21, 34], ["viral diseases", "DISEASE", 93, 107], ["Atlantic salmon", "SPECIES", 120, 135], ["Atlantic salmon", "SPECIES", 120, 135], ["BackgroundInfectious salmon anemia", "PROBLEM", 0, 34], ["Infectious", "OBSERVATION", 10, 20], ["salmon aquaculture", "OBSERVATION", 129, 147]]], ["The infectious salmon anemia virus (ISAV) is a negative single-stranded RNA virus assigned to the genus Isavirus within the family Orthomyxoviridae.", [["infectious salmon anemia", "DISEASE", 4, 28], ["infectious salmon anemia virus", "ORGANISM", 4, 34], ["ISAV", "ORGANISM", 36, 40], ["Isavirus", "GENE_OR_GENE_PRODUCT", 104, 112], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 131, 147], ["salmon anemia virus", "SPECIES", 15, 34], ["infectious salmon anemia virus", "SPECIES", 4, 34], ["ISAV", "SPECIES", 36, 40], ["The infectious salmon anemia virus", "PROBLEM", 0, 34], ["stranded RNA virus", "PROBLEM", 63, 81], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["salmon anemia virus", "OBSERVATION", 15, 34]]], ["It mainly infects endothelial cells and leukocytes and causes a multisystemic disease characterized by high mortality with exophthalmia, pale gills, ascites, hemorrhagic liver necrosis, renal interstitial hemorrhage and tubular nephrosis (reviewed in [1,2]).", [["endothelial cells", "ANATOMY", 18, 35], ["leukocytes", "ANATOMY", 40, 50], ["gills", "ANATOMY", 142, 147], ["ascites", "ANATOMY", 149, 156], ["liver", "ANATOMY", 170, 175], ["renal interstitial", "ANATOMY", 186, 204], ["tubular", "ANATOMY", 220, 227], ["multisystemic disease", "DISEASE", 64, 85], ["exophthalmia", "DISEASE", 123, 135], ["ascites", "DISEASE", 149, 156], ["hemorrhagic liver necrosis", "DISEASE", 158, 184], ["renal interstitial hemorrhage", "DISEASE", 186, 215], ["nephrosis", "DISEASE", 228, 237], ["endothelial cells", "CELL", 18, 35], ["leukocytes", "CELL", 40, 50], ["gills", "ORGAN", 142, 147], ["liver", "ORGAN", 170, 175], ["renal interstitial", "MULTI-TISSUE_STRUCTURE", 186, 204], ["tubular", "ORGAN", 220, 227], ["endothelial cells", "CELL_TYPE", 18, 35], ["leukocytes", "CELL_TYPE", 40, 50], ["leukocytes", "TEST", 40, 50], ["a multisystemic disease", "PROBLEM", 62, 85], ["high mortality with exophthalmia", "PROBLEM", 103, 135], ["pale gills", "PROBLEM", 137, 147], ["ascites", "PROBLEM", 149, 156], ["hemorrhagic liver necrosis", "PROBLEM", 158, 184], ["renal interstitial hemorrhage", "PROBLEM", 186, 215], ["tubular nephrosis", "PROBLEM", 220, 237], ["infects endothelial cells", "OBSERVATION", 10, 35], ["leukocytes", "OBSERVATION_MODIFIER", 40, 50], ["multisystemic", "OBSERVATION_MODIFIER", 64, 77], ["disease", "OBSERVATION", 78, 85], ["high", "OBSERVATION_MODIFIER", 103, 107], ["mortality", "OBSERVATION_MODIFIER", 108, 117], ["pale gills", "OBSERVATION", 137, 147], ["ascites", "OBSERVATION", 149, 156], ["hemorrhagic", "OBSERVATION_MODIFIER", 158, 169], ["liver", "ANATOMY", 170, 175], ["necrosis", "OBSERVATION", 176, 184], ["renal", "ANATOMY", 186, 191], ["interstitial", "ANATOMY_MODIFIER", 192, 204], ["hemorrhage", "OBSERVATION", 205, 215], ["tubular", "ANATOMY_MODIFIER", 220, 227], ["nephrosis", "OBSERVATION", 228, 237]]], ["Several ISAV strains with different pathogenicity are known and were recently categorized according to the genotype in the high polymorphic region of the hemagglutinin-esterase gene and the ability to induce acute versus protracted disease [3,4].", [["ISAV", "ORGANISM", 8, 12], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 154, 176], ["hemagglutinin-esterase gene", "DNA", 154, 181], ["Several ISAV strains", "PROBLEM", 0, 20], ["different pathogenicity", "PROBLEM", 26, 49], ["acute versus protracted disease", "PROBLEM", 208, 239], ["ISAV strains", "OBSERVATION", 8, 20], ["different", "OBSERVATION_MODIFIER", 26, 35], ["pathogenicity", "OBSERVATION", 36, 49], ["acute", "OBSERVATION_MODIFIER", 208, 213]]], ["The fact that the virus' receptor-destroying enzyme (RDE) lacks activity in Atlantic salmon is thought to have an important role in mediating the severe clinical manifestations of infection (e.g. hemagglutination and anemia) [5,6].", [["infection", "DISEASE", 180, 189], ["anemia", "DISEASE", 217, 223], ["receptor-destroying enzyme", "GENE_OR_GENE_PRODUCT", 25, 51], ["RDE", "GENE_OR_GENE_PRODUCT", 53, 56], ["Atlantic salmon", "ORGANISM", 76, 91], ["virus' receptor", "PROTEIN", 18, 33], ["destroying enzyme", "PROTEIN", 34, 51], ["RDE", "PROTEIN", 53, 56], ["Atlantic salmon", "SPECIES", 76, 91], ["Atlantic salmon", "SPECIES", 76, 91], ["the virus' receptor", "TEST", 14, 33], ["the severe clinical manifestations of infection", "PROBLEM", 142, 189], ["hemagglutination", "PROBLEM", 196, 212], ["anemia)", "PROBLEM", 217, 224], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["infection", "OBSERVATION", 180, 189]]], ["Nonetheless, host factors must make a significant contribution to the outcome of infection since high variation in susceptibility and resistance to ISAV has been observed.", [["infection", "DISEASE", 81, 90], ["ISAV", "DISEASE", 148, 152], ["ISAV", "ORGANISM", 148, 152], ["ISAV", "SPECIES", 148, 152], ["infection", "PROBLEM", 81, 90], ["high variation in susceptibility", "PROBLEM", 97, 129], ["ISAV", "PROBLEM", 148, 152], ["infection", "OBSERVATION", 81, 90], ["high variation", "OBSERVATION_MODIFIER", 97, 111]]], ["Survival during natural and experimental infections by any particular virus isolate can range from 0\u2013100% and varies significantly between families (R. Stigum Olsen, pers. comm.).", [["infections", "DISEASE", 41, 51], ["Survival", "TREATMENT", 0, 8], ["experimental infections", "PROBLEM", 28, 51], ["any particular virus isolate", "PROBLEM", 55, 83], ["infections", "OBSERVATION", 41, 51]]], ["The presence of a genetic component for disease resistance is strong evidence for the existence of protective antiviral responses, however potential molecular mechanisms that may account for protection against ISAV are unknown.", [["ISAV", "DISEASE", 210, 214], ["ISAV", "ORGANISM", 210, 214], ["ISAV", "SPECIES", 210, 214], ["a genetic component", "PROBLEM", 16, 35], ["disease resistance", "PROBLEM", 40, 58], ["potential molecular mechanisms", "PROBLEM", 139, 169], ["ISAV", "PROBLEM", 210, 214], ["may account for", "UNCERTAINTY", 175, 190]]], ["Association between specific MHCI alleles and survival has been shown [7], which imply that a collection of multiple host factors may explain disease resistance.", [["MHCI", "GENE_OR_GENE_PRODUCT", 29, 33], ["MHCI alleles", "DNA", 29, 41], ["multiple host factors", "PROBLEM", 108, 129], ["disease resistance", "PROBLEM", 142, 160], ["multiple", "OBSERVATION_MODIFIER", 108, 116], ["host factors", "OBSERVATION", 117, 129], ["may explain", "UNCERTAINTY", 130, 141], ["disease resistance", "OBSERVATION", 142, 160]]], ["Although far from completely resolved, it seems that type 1 interferon (IFN) does not confer antiviral protection; this might be related to virus-antagonistic mechanisms [8,9].", [["type 1 interferon", "GENE_OR_GENE_PRODUCT", 53, 70], ["IFN", "GENE_OR_GENE_PRODUCT", 72, 75], ["interferon", "PROTEIN", 60, 70], ["IFN", "PROTEIN", 72, 75], ["type 1 interferon (IFN)", "TREATMENT", 53, 76], ["antiviral protection", "TREATMENT", 93, 113], ["virus", "PROBLEM", 140, 145]]], ["Early studies also suggested that initial activation of T cells, but not B cells, and suppression of immune function caused by leukopenia is a general result of infection independent of anemia [10].", [["T cells", "ANATOMY", 56, 63], ["B cells", "ANATOMY", 73, 80], ["leukopenia", "DISEASE", 127, 137], ["infection", "DISEASE", 161, 170], ["anemia", "DISEASE", 186, 192], ["T cells", "CELL", 56, 63], ["B cells", "CELL", 73, 80], ["T cells", "CELL_TYPE", 56, 63], ["B cells", "CELL_TYPE", 73, 80], ["Early studies", "TEST", 0, 13], ["T cells", "PROBLEM", 56, 63], ["B cells", "PROBLEM", 73, 80], ["immune function", "PROBLEM", 101, 116], ["leukopenia", "PROBLEM", 127, 137], ["infection", "PROBLEM", 161, 170], ["anemia", "PROBLEM", 186, 192], ["infection", "OBSERVATION", 161, 170]]], ["Collectively, these results imply that optimal constellation of multiple host factors are explaining disease resistance.", [["multiple host factors", "PROBLEM", 64, 85], ["disease resistance", "PROBLEM", 101, 119], ["multiple", "OBSERVATION_MODIFIER", 64, 72]]], ["This is also supported by the fact that low progression is achieved when breeding for ISAV resistance (R. Stigum Olsen, pers. comm.) and that only weak effect quantitative trait loci (QTL) for this trait have been found (T. Moen, pers. comm.).BackgroundIn addition to the scientific interest, comparative studies of salmon with high and low resistance are of great importance for aquaculture.", [["ISAV", "ORGANISM", 86, 90], ["salmon", "ORGANISM", 316, 322], ["ISAV", "SPECIES", 86, 90], ["salmon", "SPECIES", 316, 322], ["low progression", "PROBLEM", 40, 55], ["ISAV resistance", "PROBLEM", 86, 101], ["weak effect quantitative trait loci", "PROBLEM", 147, 182], ["this trait", "PROBLEM", 193, 203], ["comparative studies", "TEST", 293, 312], ["salmon", "TREATMENT", 316, 322], ["low progression", "OBSERVATION_MODIFIER", 40, 55], ["low resistance", "OBSERVATION_MODIFIER", 337, 351]]], ["At present selective breeding and vaccination are key approaches to disease control, which employ respectively the innate and acquired protective mechanisms.", [["selective breeding", "TREATMENT", 11, 29], ["vaccination", "TREATMENT", 34, 45], ["disease control", "TREATMENT", 68, 83], ["selective", "OBSERVATION_MODIFIER", 11, 20], ["breeding", "OBSERVATION", 21, 29]]], ["Innate defence involves generalized antiviral responses, such as IFN and IFN-independent proteins and pathogen-specific antiviral factors referred to as restriction factors [11,12].", [["IFN", "GENE_OR_GENE_PRODUCT", 65, 68], ["IFN", "GENE_OR_GENE_PRODUCT", 73, 76], ["IFN", "PROTEIN", 65, 68], ["IFN", "PROTEIN", 73, 76], ["antiviral factors", "PROTEIN", 120, 137], ["restriction factors", "PROTEIN", 153, 172], ["Innate defence", "PROBLEM", 0, 14], ["generalized antiviral responses", "PROBLEM", 24, 55], ["IFN", "PROBLEM", 65, 68], ["IFN", "TREATMENT", 73, 76], ["independent proteins", "PROBLEM", 77, 97], ["pathogen", "PROBLEM", 102, 110], ["specific antiviral factors", "PROBLEM", 111, 137], ["generalized", "OBSERVATION_MODIFIER", 24, 35], ["antiviral responses", "OBSERVATION", 36, 55]]], ["Adaptive immunity in turn includes humoral and cellular components which interact with a complex network of immune factors.", [["cellular", "ANATOMY", 47, 55], ["cellular", "CELL", 47, 55], ["immune factors", "PROTEIN", 108, 122], ["Adaptive immunity", "TREATMENT", 0, 17], ["humoral and cellular components", "TREATMENT", 35, 66], ["immune factors", "TREATMENT", 108, 122], ["humoral", "ANATOMY", 35, 42], ["cellular components", "OBSERVATION", 47, 66]]], ["Assessment of the relative roles of these mechanisms is vital for the development of efficient disease control strategies.", [["efficient disease control strategies", "PROBLEM", 85, 121], ["efficient", "OBSERVATION_MODIFIER", 85, 94], ["disease", "OBSERVATION", 95, 102]]], ["Furthermore, today's selective breeding for disease resistance is hampered by a lack of predictive methods.", [["disease resistance", "PROBLEM", 44, 62]]], ["Pathogen challenge enables identification of the most resistant individuals; however, infected fish may become carriers of pathogens and therefore cannot be returned to the farming environment.", [["fish", "ORGANISM", 95, 99], ["the most resistant individuals", "PROBLEM", 45, 75], ["pathogens", "PROBLEM", 123, 132], ["most resistant", "OBSERVATION_MODIFIER", 49, 63]]], ["Thus, the development of methods for the prediction of resistance requires a better understanding of the protective host mechanisms.BackgroundTo obtain a more comprehensive understanding and elucidation of important molecular determinants for survival towards infectious salmon anemia disease we have compared differences in global gene expression in resistant and susceptible fish using microarrray technology.", [["infectious salmon anemia disease", "DISEASE", 260, 292], ["fish", "ORGANISM", 377, 381], ["infectious salmon anemia disease", "PROBLEM", 260, 292], ["microarrray technology", "TREATMENT", 388, 410]]], ["Survival time is commonly used as an estimate of susceptibility and resistance in pathogen challenge tests.", [["pathogen challenge tests", "TEST", 82, 106]]], ["Atlantic salmon were infected with a common acute ISAV isolate by cohabitance, which mimics the natural mode of virus transfer.", [["salmon", "ORGANISM", 9, 15], ["ISAV", "ORGANISM", 50, 54], ["Atlantic salmon", "SPECIES", 0, 15], ["Atlantic salmon", "SPECIES", 0, 15], ["ISAV", "SPECIES", 50, 54], ["a common acute ISAV isolate", "TREATMENT", 35, 62], ["virus transfer", "TREATMENT", 112, 126], ["ISAV", "OBSERVATION", 50, 54]]], ["Tissues from fish within early (EM), intermediate (IM) and late mortality (LM) groups were sampled and viral loads were determined by real-time qPCR.", [["Tissues", "ANATOMY", 0, 7], ["Tissues", "CANCER", 0, 7], ["fish", "ORGANISM_SUBDIVISION", 13, 17], ["viral loads", "TEST", 103, 114]]], ["We used a high-density salmonid fish cDNA microarray (SFA2.0 immunochip) designed for studies of responses to pathogens and stressors (GEO GPL1212) [13,14].", [["a high-density salmonid fish cDNA microarray", "TREATMENT", 8, 52], ["pathogens", "PROBLEM", 110, 119], ["high-density", "OBSERVATION_MODIFIER", 10, 22]]], ["In comparison with previous versions, the updated 1.8 K platform (GEO GPL6154) has a substantially improved coverage of immune genes.", [["K", "CHEMICAL", 54, 55], ["GPL6154", "CHEMICAL", 70, 77], ["immune genes", "DNA", 120, 132], ["immune genes", "PROBLEM", 120, 132], ["substantially", "OBSERVATION_MODIFIER", 85, 98], ["improved", "OBSERVATION_MODIFIER", 99, 107], ["coverage", "OBSERVATION_MODIFIER", 108, 116], ["immune genes", "OBSERVATION", 120, 132]]], ["The microarray analyses were conducted using EM and LM fish, and since the roles of tissues were not known we began with individual-pooled samples (n = 6) of gill, heart, spleen and liver.", [["tissues", "ANATOMY", 84, 91], ["samples", "ANATOMY", 139, 146], ["gill", "ANATOMY", 158, 162], ["heart", "ANATOMY", 164, 169], ["spleen", "ANATOMY", 171, 177], ["liver", "ANATOMY", 182, 187], ["tissues", "TISSUE", 84, 91], ["gill", "ORGAN", 158, 162], ["heart", "ORGAN", 164, 169], ["spleen", "ORGAN", 171, 177], ["liver", "ORGAN", 182, 187], ["The microarray analyses", "TEST", 0, 23], ["individual-pooled samples (n = 6) of gill, heart, spleen and liver", "PROBLEM", 121, 187], ["gill", "ANATOMY", 158, 162], ["heart", "ANATOMY", 164, 169], ["spleen", "ANATOMY", 171, 177], ["liver", "ANATOMY", 182, 187]]], ["Next, individual analysis on liver samples (n = 6) was performed to find prognostic markers, since liver had the highest number of differentially expressed genes.", [["liver samples", "ANATOMY", 29, 42], ["liver", "ANATOMY", 99, 104], ["liver samples", "CANCER", 29, 42], ["liver", "ORGAN", 99, 104], ["differentially expressed genes", "DNA", 131, 161], ["individual analysis", "TEST", 6, 25], ["liver samples", "TEST", 29, 42], ["prognostic markers", "TEST", 73, 91], ["liver", "ANATOMY", 29, 34], ["liver", "ANATOMY", 99, 104]]], ["The results of microarray analyses indicated possible molecular determinants of resistance, and to corroborate these conclusions, real-time qPCR analysis of genes selected by their functional roles and expression profiles were performed on individual samples (n = 4/n = 6).", [["samples", "ANATOMY", 251, 258], ["microarray analyses", "TEST", 15, 34], ["qPCR analysis", "TEST", 140, 153], ["expression profiles", "TEST", 202, 221], ["individual samples", "TEST", 240, 258]]], ["For this analysis we also included a number of genes being markers of adaptive immunity that were not present on the microarray platform.", [["this analysis", "TEST", 4, 17], ["adaptive immunity", "TREATMENT", 70, 87]]], ["The development of predictors began with individual microarray comparisons using the liver tissue.", [["liver tissue", "ANATOMY", 85, 97], ["liver tissue", "TISSUE", 85, 97], ["liver", "ANATOMY", 85, 90]]], ["Given high costs of microarray analyses it is customary to develop tests based on real-time qPCR trying to minimize the numbers of prognostic genes.", [["prognostic genes", "DNA", 131, 147], ["microarray analyses", "TEST", 20, 39], ["tests", "TEST", 67, 72]]], ["We analyzed expression of the candidate genes and used linear discriminant analysis for the classification of samples.Experimental infection ::: ResultsThe cohabitant transmission of virus from fish injected with a previously tested viral load enabled the investigation of the immune response in fish after a natural route of infection.", [["samples", "ANATOMY", 110, 117], ["infection", "DISEASE", 131, 140], ["infection", "DISEASE", 326, 335], ["fish", "ORGANISM", 194, 198], ["fish", "ORGANISM", 296, 300], ["candidate genes", "DNA", 30, 45], ["linear discriminant analysis", "TEST", 55, 83], ["Experimental infection", "PROBLEM", 118, 140], ["virus", "PROBLEM", 183, 188], ["a previously tested viral load", "TREATMENT", 213, 243], ["infection", "PROBLEM", 326, 335], ["infection", "OBSERVATION", 131, 140], ["virus", "OBSERVATION", 183, 188], ["infection", "OBSERVATION", 326, 335]]], ["The chosen ISAV strain (Glesvaer 2/90) is well characterized and is classified among isolates inducing acute disease progression [4].", [["ISAV", "ORGANISM", 11, 15], ["Glesvaer 2/90", "ORGANISM", 24, 37], ["The chosen ISAV strain", "PROBLEM", 0, 22], ["acute disease progression", "PROBLEM", 103, 128], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["disease", "OBSERVATION", 109, 116]]], ["A cumulative mortality (CM) of 84% in the cohabitant fish confirms the highly pathogenic nature of this ISAV strain (Fig. 1).", [["CM", "DISEASE", 24, 26], ["ISAV", "ORGANISM", 104, 108], ["A cumulative mortality", "TEST", 0, 22], ["the cohabitant fish", "TEST", 38, 57], ["this ISAV strain", "PROBLEM", 99, 115]]], ["By termination 49 days post-infection (DPI) mortality rate had reached a plateau phase, but if continued mortality would likely have approached 100% (see virus load in section below).", [["mortality rate", "TEST", 44, 58]]], ["The injected fish started to die at 12 DPI and at 20 DPI the cumulative mortality had reached 97%.", [["fish", "ORGANISM", 13, 17]]], ["Cohabitants started to die at 21 DPI when nearly all (97%) carrier fish were dead.", [["fish", "ORGANISM", 67, 71], ["Cohabitants", "TREATMENT", 0, 11]]], ["There was no mortality in the control tank.", [["mortality in the control tank", "PROBLEM", 13, 42], ["no", "UNCERTAINTY", 10, 12], ["mortality", "OBSERVATION", 13, 22]]], ["Tanks were monitored continuously and only moribund fish were sampled for RNA extraction.", [["fish", "ORGANISM", 52, 56], ["RNA extraction", "TREATMENT", 74, 88]]], ["Based on experience from similar experiments, sampling was divided into three stages: early mortality (EM, 0\u201310% CM), intermediate (IM, 35\u201355% CM) and late mortality (LM, 75\u201384% CM).Virus load ::: ResultsThe ISAV pathology in sampled fish was confirmed by clinical examination.", [["CM", "DISEASE", 113, 115], ["CM", "DISEASE", 143, 145], ["CM", "DISEASE", 178, 180], ["Virus", "ORGANISM", 182, 187], ["ISAV", "ORGANISM", 208, 212], ["fish", "ORGANISM", 234, 238], ["sampling", "TEST", 46, 54], ["late mortality", "PROBLEM", 151, 165], ["The ISAV pathology", "TEST", 204, 222], ["clinical examination", "TEST", 256, 276], ["LM", "ANATOMY", 167, 169], ["ISAV", "OBSERVATION_MODIFIER", 208, 212], ["pathology", "OBSERVATION", 213, 222]]], ["Levels of infection in four random fish from the EM, IM and LM stages were determined by real-time qPCR analysis of viral RNA in all tissues (Fig. 2).", [["tissues", "ANATOMY", 133, 140], ["infection", "DISEASE", 10, 19], ["tissues", "TISSUE", 133, 140], ["viral RNA", "RNA", 116, 125], ["infection", "PROBLEM", 10, 19], ["qPCR analysis", "TEST", 99, 112], ["viral RNA in all tissues", "PROBLEM", 116, 140], ["infection", "OBSERVATION", 10, 19], ["viral RNA", "OBSERVATION", 116, 125], ["all tissues", "ANATOMY", 129, 140]]], ["This is a very sensitive and precise assay, reported to be 100-fold more sensitive than end-point RT-PCR [15] which has a threshold detection in the range of 0.01\u20130.1 TCID50 [16].", [["precise assay", "TEST", 29, 42], ["RT-PCR", "TEST", 98, 104], ["a threshold detection", "TEST", 120, 141]]], ["Low standard deviations of CT (cycle threshold) values within each stage indicated that viral RNA levels were similar between individuals and justified the comparison of gene expression between the three groups of mortalities.", [["CT (cycle threshold) values", "TEST", 27, 54], ["viral RNA levels", "TEST", 88, 104], ["viral RNA", "OBSERVATION", 88, 97]]], ["In general, there was a high viral replication in EM and IM stages with no significant difference between these groups, while a marked reduction was observed in LM (except for liver).", [["liver", "ANATOMY", 176, 181], ["liver", "ORGAN", 176, 181], ["a high viral replication", "PROBLEM", 22, 46], ["a marked reduction", "PROBLEM", 126, 144], ["viral replication", "OBSERVATION", 29, 46], ["no", "UNCERTAINTY", 72, 74], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["difference", "OBSERVATION", 87, 97], ["marked", "OBSERVATION_MODIFIER", 128, 134], ["reduction", "OBSERVATION", 135, 144], ["liver", "ANATOMY", 176, 181]]], ["Levels in survivor fish (16%, not moribund) were similar to LM (data not shown).", [["Levels", "TEST", 0, 6], ["survivor fish", "TEST", 10, 23]]], ["When transforming CT values into viral particles based on a standard curve of CT from in vitro infected cells this corresponded to a 1000-fold reduction of viral particles in spleens only within 6 days (from 31\u201337 DPI), given that cohabitants were infected simultaneously.", [["cells", "ANATOMY", 104, 109], ["spleens", "ANATOMY", 175, 182], ["cells", "CELL", 104, 109], ["spleens", "ORGAN", 175, 182], ["transforming CT values", "TEST", 5, 27], ["viral particles", "PROBLEM", 33, 48], ["a standard curve of CT", "TEST", 58, 80], ["vitro infected cells", "PROBLEM", 89, 109], ["a 1000-fold reduction", "TREATMENT", 131, 152], ["viral particles in spleens", "PROBLEM", 156, 182], ["cohabitants", "PROBLEM", 231, 242], ["infected cells", "OBSERVATION", 95, 109], ["viral particles", "OBSERVATION", 156, 171], ["spleens", "ANATOMY", 175, 182], ["infected", "OBSERVATION", 248, 256]]], ["No significant difference was observed between levels of two ISAV segments (HA and NS1) (data not shown).Gene expression analyses ::: ResultsMicroarray analyses were conducted on gill, heart, liver and spleen samples pooled from six individuals for each tissue, and on individual samples of liver (n = 6).", [["gill", "ANATOMY", 179, 183], ["heart", "ANATOMY", 185, 190], ["liver", "ANATOMY", 192, 197], ["spleen samples", "ANATOMY", 202, 216], ["tissue", "ANATOMY", 254, 260], ["samples", "ANATOMY", 280, 287], ["liver", "ANATOMY", 291, 296], ["gill", "TISSUE", 179, 183], ["heart", "ORGAN", 185, 190], ["liver", "ORGAN", 192, 197], ["spleen samples", "CANCER", 202, 216], ["tissue", "TISSUE", 254, 260], ["liver", "ORGAN", 291, 296], ["ISAV segments", "PROTEIN", 61, 74], ["NS1", "PROTEIN", 83, 86], ["two ISAV segments (HA and NS1", "PROBLEM", 57, 86], ["ResultsMicroarray analyses", "TEST", 134, 160], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["two", "OBSERVATION_MODIFIER", 57, 60], ["ISAV", "OBSERVATION", 61, 65], ["segments", "ANATOMY_MODIFIER", 66, 74], ["heart", "ANATOMY", 185, 190], ["liver", "ANATOMY", 192, 197], ["spleen", "ANATOMY", 202, 208], ["liver", "ANATOMY", 291, 296]]], ["The former indicated tissue-specificity of responses while the latter allowed for statistical assessment of differences between the early and late mortalities (EM and LM).", [["tissue", "ANATOMY", 21, 27], ["tissue", "TISSUE", 21, 27], ["statistical assessment", "TEST", 82, 104]]], ["Genes with differential expression between EM and LM from microarray analyses were verified by real-time qPCR on individual heart samples (n = 4), and additional genes for adaptive immune responses not represented on the microarray were analysed on individual spleen samples (n = 6) from all stages (EM, IM and LM).Early mortalities show induced innate antiviral and stress responses ::: ResultsMany genes were regulated across all tissues and a large fraction of these showed markedly higher expression levels in EM compared to LM (Fig. 3).", [["heart samples", "ANATOMY", 124, 137], ["spleen samples", "ANATOMY", 260, 274], ["tissues", "ANATOMY", 432, 439], ["heart samples", "CANCER", 124, 137], ["spleen samples", "MULTI-TISSUE_STRUCTURE", 260, 274], ["tissues", "TISSUE", 432, 439], ["microarray analyses", "TEST", 58, 77], ["individual heart samples", "TEST", 113, 137], ["adaptive immune responses", "PROBLEM", 172, 197], ["the microarray", "TEST", 217, 231], ["individual spleen samples", "TEST", 249, 274], ["Early mortalities", "PROBLEM", 315, 332], ["a large fraction", "TEST", 444, 460], ["markedly higher expression levels", "PROBLEM", 477, 510], ["heart", "ANATOMY", 124, 129], ["spleen", "ANATOMY", 260, 266], ["innate antiviral", "OBSERVATION", 346, 362], ["large", "OBSERVATION_MODIFIER", 446, 451], ["markedly", "OBSERVATION_MODIFIER", 477, 485], ["higher expression", "OBSERVATION", 486, 503]]], ["Among these were several genes related to cellular stress (transcription factor jun-B, GADD45-\u03b2 and -\u03b3, 78 kDa and 94 kDa glucose-regulated proteins) as could be expected according to their involvement in pathological alterations.", [["cellular", "ANATOMY", 42, 50], ["glucose", "CHEMICAL", 122, 129], ["glucose", "CHEMICAL", 122, 129], ["cellular", "CELL", 42, 50], ["jun-B", "GENE_OR_GENE_PRODUCT", 80, 85], ["GADD45-\u03b2", "GENE_OR_GENE_PRODUCT", 87, 95], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 100, 102], ["glucose-regulated proteins", "GENE_OR_GENE_PRODUCT", 122, 148], ["transcription factor jun-B", "PROTEIN", 59, 85], ["GADD45", "PROTEIN", 87, 93], ["\u03b2", "PROTEIN", 94, 95], ["-\u03b3", "PROTEIN", 100, 102], ["78 kDa", "PROTEIN", 104, 110], ["94 kDa glucose-regulated proteins", "PROTEIN", 115, 148], ["cellular stress", "PROBLEM", 42, 57], ["transcription factor jun", "TEST", 59, 83], ["GADD45", "TEST", 87, 93], ["kDa", "TEST", 107, 110], ["kDa glucose", "TEST", 118, 129]]], ["Up-regulation of several proteins involved in extracellular transport (Tax binding protein, microtubule-associated protein RP/EB, vacuolar ATP synthase and 78 kDa glucose-regulated protein) was consistent with reticular stress as observed in various viral diseases [17].", [["extracellular", "ANATOMY", 46, 59], ["microtubule", "ANATOMY", 92, 103], ["reticular", "ANATOMY", 210, 219], ["ATP", "CHEMICAL", 139, 142], ["glucose", "CHEMICAL", 163, 170], ["viral diseases", "DISEASE", 250, 264], ["ATP", "CHEMICAL", 139, 142], ["glucose", "CHEMICAL", 163, 170], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 59], ["Tax binding protein", "GENE_OR_GENE_PRODUCT", 71, 90], ["microtubule-associated protein RP/EB", "GENE_OR_GENE_PRODUCT", 92, 128], ["vacuolar ATP synthase", "GENE_OR_GENE_PRODUCT", 130, 151], ["glucose-regulated protein", "GENE_OR_GENE_PRODUCT", 163, 188], ["Tax binding protein", "PROTEIN", 71, 90], ["microtubule-associated protein RP", "PROTEIN", 92, 125], ["EB", "PROTEIN", 126, 128], ["vacuolar ATP synthase", "PROTEIN", 130, 151], ["78 kDa glucose-regulated protein", "PROTEIN", 156, 188], ["extracellular transport", "TEST", 46, 69], ["Tax binding protein", "TEST", 71, 90], ["microtubule", "TEST", 92, 103], ["protein RP", "TEST", 115, 125], ["vacuolar ATP synthase", "TEST", 130, 151], ["kDa glucose", "TEST", 159, 170], ["reticular stress", "PROBLEM", 210, 226], ["various viral diseases", "PROBLEM", 242, 264], ["EB", "ANATOMY", 126, 128], ["consistent with", "UNCERTAINTY", 194, 209], ["reticular stress", "OBSERVATION", 210, 226], ["viral diseases", "OBSERVATION", 250, 264]]], ["Given the high viral replication and mortality in EM it was noteworthy how many genes with pivotal roles in innate antiviral responses were highly induced at this stage without conferring any protection (Fig. 3, 4).", [["the high viral replication", "PROBLEM", 6, 32], ["viral replication", "OBSERVATION", 15, 32]]], ["The src-type tyrosine kinase Jak and signal transducer/activator of transcription Stat1 play a key part in induction of IFN-dependent genes [18,19].", [["tyrosine", "CHEMICAL", 13, 21], ["tyrosine", "CHEMICAL", 13, 21], ["src-type tyrosine kinase Jak", "GENE_OR_GENE_PRODUCT", 4, 32], ["signal transducer/activator", "GENE_OR_GENE_PRODUCT", 37, 64], ["Stat1", "GENE_OR_GENE_PRODUCT", 82, 87], ["IFN", "GENE_OR_GENE_PRODUCT", 120, 123], ["src-type tyrosine kinase", "PROTEIN", 4, 28], ["Jak", "PROTEIN", 29, 32], ["signal transducer/activator of transcription", "PROTEIN", 37, 81], ["Stat1", "PROTEIN", 82, 87], ["IFN-dependent genes", "DNA", 120, 139], ["The src-type tyrosine kinase Jak", "TREATMENT", 0, 32], ["signal transducer/activator of transcription", "TREATMENT", 37, 81]]], ["Up-regulation of interferon induced protein 44 and double-stranded RNA-adenosine deaminase (ADAR-1), one of the key antiviral effectors, was additional evidence for activation of the IFN-axis.", [["adenosine", "CHEMICAL", 71, 80], ["adenosine", "CHEMICAL", 71, 80], ["interferon induced protein 44", "GENE_OR_GENE_PRODUCT", 17, 46], ["adenosine deaminase", "GENE_OR_GENE_PRODUCT", 71, 90], ["ADAR-1", "GENE_OR_GENE_PRODUCT", 92, 98], ["interferon induced protein 44", "PROTEIN", 17, 46], ["double-stranded RNA", "RNA", 51, 70], ["adenosine deaminase", "PROTEIN", 71, 90], ["ADAR", "PROTEIN", 92, 96], ["IFN", "PROTEIN", 183, 186], ["interferon induced protein", "TEST", 17, 43], ["double", "TEST", 51, 57], ["adenosine deaminase (ADAR", "TREATMENT", 71, 96], ["antiviral effectors", "OBSERVATION", 116, 135]]], ["Similar profiles were seen in src-related tyrosine-protein kinase FRK and ligand for Lck SH2 domain p62 which regulate various immune responses, being involved in a complex network of signal transduction pathways.", [["tyrosine", "CHEMICAL", 42, 50], ["tyrosine", "CHEMICAL", 42, 50], ["src-related tyrosine-protein kinase FRK", "GENE_OR_GENE_PRODUCT", 30, 69], ["Lck", "GENE_OR_GENE_PRODUCT", 85, 88], ["p62", "GENE_OR_GENE_PRODUCT", 100, 103], ["src-related tyrosine-protein kinase", "PROTEIN", 30, 65], ["FRK", "PROTEIN", 66, 69], ["Lck SH2 domain p62", "PROTEIN", 85, 103], ["Lck SH2 domain p62", "TEST", 85, 103]]], ["Further downstream, up-regulation of several IFN-responsive genes involved in antigen processing and presentation (\u03b22 m encoding MHCI light chain, tapasin, proteasome activator complex, ubiquitin, cathepsins) indicated an early activation of adaptive immunity in EM.", [["IFN", "GENE_OR_GENE_PRODUCT", 45, 48], ["antigen", "GENE_OR_GENE_PRODUCT", 78, 85], ["\u03b22 m", "GENE_OR_GENE_PRODUCT", 115, 119], ["MHCI light chain", "GENE_OR_GENE_PRODUCT", 129, 145], ["tapasin", "GENE_OR_GENE_PRODUCT", 147, 154], ["proteasome activator complex", "GENE_OR_GENE_PRODUCT", 156, 184], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 186, 195], ["cathepsins", "GENE_OR_GENE_PRODUCT", 197, 207], ["IFN-responsive genes", "DNA", 45, 65], ["\u03b22 m", "PROTEIN", 115, 119], ["MHCI light chain", "PROTEIN", 129, 145], ["tapasin", "PROTEIN", 147, 154], ["proteasome activator complex", "PROTEIN", 156, 184], ["ubiquitin", "PROTEIN", 186, 195], ["cathepsins", "PROTEIN", 197, 207], ["tapasin, proteasome activator complex", "TREATMENT", 147, 184], ["ubiquitin, cathepsins", "TREATMENT", 186, 207], ["responsive genes", "OBSERVATION", 49, 65]]], ["Broad induction of GADD45-\u03b2 and -\u03b3 could contribute to increased survival of immune cells through interaction with NF-\u03baB pathway [20,21].", [["immune cells", "ANATOMY", 77, 89], ["GADD45-\u03b2", "GENE_OR_GENE_PRODUCT", 19, 27], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 32, 34], ["immune cells", "CELL", 77, 89], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 115, 120], ["GADD45", "PROTEIN", 19, 25], ["\u03b2", "PROTEIN", 26, 27], ["-\u03b3", "PROTEIN", 32, 34], ["immune cells", "CELL_TYPE", 77, 89], ["NF-\u03baB", "PROTEIN", 115, 120], ["GADD45", "TEST", 19, 25], ["immune cells", "PROBLEM", 77, 89], ["NF", "TEST", 115, 117], ["immune cells", "OBSERVATION", 77, 89]]], ["Further evidence for early immune cell activation was increased leukocyte migration and recruitment (up-regulation of chemokines and receptors; SCYA110-2/CCL7-like, SCYA106/CCL21-like, CXCR4-like) and monocyte and lymphocyte maturation and activation (up-regulation of regulator of G-protein signalling/RGS1, Fc-gamma receptor/CD64, TNFR5/CD40, LECT2).", [["immune cell", "ANATOMY", 27, 38], ["leukocyte", "ANATOMY", 64, 73], ["monocyte", "ANATOMY", 201, 209], ["lymphocyte", "ANATOMY", 214, 224], ["immune cell", "CELL", 27, 38], ["leukocyte", "CELL", 64, 73], ["SCYA110-2", "GENE_OR_GENE_PRODUCT", 144, 153], ["CCL7", "GENE_OR_GENE_PRODUCT", 154, 158], ["SCYA106", "GENE_OR_GENE_PRODUCT", 165, 172], ["CCL21", "GENE_OR_GENE_PRODUCT", 173, 178], ["CXCR4", "GENE_OR_GENE_PRODUCT", 185, 190], ["monocyte", "CELL", 201, 209], ["lymphocyte", "CELL", 214, 224], ["G-protein", "GENE_OR_GENE_PRODUCT", 282, 291], ["RGS1", "GENE_OR_GENE_PRODUCT", 303, 307], ["Fc-gamma receptor", "GENE_OR_GENE_PRODUCT", 309, 326], ["CD64", "GENE_OR_GENE_PRODUCT", 327, 331], ["TNFR5", "GENE_OR_GENE_PRODUCT", 333, 338], ["CD40", "GENE_OR_GENE_PRODUCT", 339, 343], ["LECT2", "GENE_OR_GENE_PRODUCT", 345, 350], ["chemokines", "PROTEIN", 118, 128], ["SCYA110", "PROTEIN", 144, 151], ["CCL7", "PROTEIN", 154, 158], ["SCYA106", "PROTEIN", 165, 172], ["CCL21", "PROTEIN", 173, 178], ["CXCR4", "PROTEIN", 185, 190], ["G-protein", "PROTEIN", 282, 291], ["RGS1", "PROTEIN", 303, 307], ["Fc", "PROTEIN", 309, 311], ["gamma receptor", "PROTEIN", 312, 326], ["CD64", "PROTEIN", 327, 331], ["TNFR5", "PROTEIN", 333, 338], ["CD40", "PROTEIN", 339, 343], ["LECT2", "PROTEIN", 345, 350], ["early immune cell activation", "PROBLEM", 21, 49], ["increased leukocyte migration", "PROBLEM", 54, 83], ["chemokines", "TEST", 118, 128], ["receptors", "TEST", 133, 142], ["SCYA110", "TEST", 144, 151], ["CCL7", "TEST", 154, 158], ["SCYA106", "TEST", 165, 172], ["CCL21", "TEST", 173, 178], ["CXCR4", "TEST", 185, 190], ["monocyte", "TEST", 201, 209], ["lymphocyte maturation", "TEST", 214, 235], ["activation", "TEST", 240, 250], ["G-protein signalling", "TEST", 282, 302], ["RGS1", "TEST", 303, 307], ["Fc", "TEST", 309, 311], ["gamma receptor", "TEST", 312, 326], ["CD64", "TEST", 327, 331], ["TNFR5", "TEST", 333, 338], ["evidence for", "UNCERTAINTY", 8, 20], ["early", "OBSERVATION_MODIFIER", 21, 26], ["immune cell activation", "OBSERVATION", 27, 49], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["leukocyte migration", "OBSERVATION", 64, 83], ["monocyte", "ANATOMY", 201, 209], ["lymphocyte maturation", "OBSERVATION", 214, 235]]], ["A number of EM-induced genes could be involved in other functions along with antiviral defense; galectins are small, highly conserved proteins that bind sugars and other ligands and can work as both positive and negative regulators of various immune functions [22,23].", [["sugars", "CHEMICAL", 153, 159], ["EM", "GENE_OR_GENE_PRODUCT", 12, 14], ["galectins", "GENE_OR_GENE_PRODUCT", 96, 105], ["sugars", "SIMPLE_CHEMICAL", 153, 159], ["EM-induced genes", "DNA", 12, 28], ["galectins", "PROTEIN", 96, 105], ["antiviral defense", "PROBLEM", 77, 94], ["bind sugars", "TEST", 148, 159], ["small", "OBSERVATION_MODIFIER", 110, 115]]], ["Coordinated regulation of galectins and interferons was reported in mammals [24,25].Late survival is associated with reduced viral load and activation of adaptive immunity ::: ResultsA group of genes induced at the LM versus EM stage was of major interest since they could point to responses important for resistance or late survival.", [["LM", "ANATOMY", 215, 217], ["galectins", "GENE_OR_GENE_PRODUCT", 26, 35], ["interferons", "GENE_OR_GENE_PRODUCT", 40, 51], ["galectins", "PROTEIN", 26, 35], ["interferons", "PROTEIN", 40, 51], ["galectins and interferons", "TREATMENT", 26, 51], ["Late survival", "PROBLEM", 84, 97], ["reduced viral load", "PROBLEM", 117, 135], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["viral load", "OBSERVATION", 125, 135]]], ["Microarray analyses of heart, spleen and gills revealed a coordinated induction of Ig-related genes (Fig. 5).", [["heart", "ANATOMY", 23, 28], ["spleen", "ANATOMY", 30, 36], ["gills", "ANATOMY", 41, 46], ["heart", "ORGAN", 23, 28], ["spleen", "ORGAN", 30, 36], ["gills", "ORGAN", 41, 46], ["Ig", "GENE_OR_GENE_PRODUCT", 83, 85], ["Ig", "PROTEIN", 83, 85], ["Microarray analyses", "TEST", 0, 19], ["heart", "ANATOMY", 23, 28], ["spleen", "ANATOMY", 30, 36], ["gills", "ANATOMY", 41, 46], ["coordinated", "OBSERVATION_MODIFIER", 58, 69]]], ["A gene similar to CD179\u03b2 (Ig-kappa chain V-I; see Additional file 1) encodes a receptor found on the surface of pre- and pro-B cells involved in signal transduction and differentiation, allelic exclusion at the Ig heavy chain locus, and promotion of Ig light chain gene rearrangements [26].", [["surface", "ANATOMY", 101, 108], ["pre- and pro-B cells", "ANATOMY", 112, 132], ["CD179", "GENE_OR_GENE_PRODUCT", 18, 23], ["Ig-kappa chain V-I", "GENE_OR_GENE_PRODUCT", 26, 44], ["see Additional file 1", "GENE_OR_GENE_PRODUCT", 46, 67], ["surface", "CELLULAR_COMPONENT", 101, 108], ["pro-B cells", "CELL", 121, 132], ["Ig heavy chain", "GENE_OR_GENE_PRODUCT", 211, 225], ["Ig light chain", "GENE_OR_GENE_PRODUCT", 250, 264], ["CD179", "DNA", 18, 23], ["Ig-kappa chain V-I; see Additional file 1", "PROTEIN", 26, 67], ["pre- and pro-B cells", "CELL_TYPE", 112, 132], ["Ig heavy chain", "PROTEIN", 211, 225], ["Ig light chain gene rearrangements", "DNA", 250, 284], ["Ig", "TEST", 26, 28], ["a receptor", "TEST", 77, 87], ["pre- and pro-B cells", "TREATMENT", 112, 132], ["signal transduction", "TREATMENT", 145, 164], ["allelic exclusion", "PROBLEM", 186, 203]]], ["Functionally related were also two other similarly induced transcripts of the IgM heavy chain (Ig-mu heavy chain disease protein and Ig-mu chain C region membrane-bound).", [["IgM heavy chain", "GENE_OR_GENE_PRODUCT", 78, 93], ["Ig-mu heavy chain", "GENE_OR_GENE_PRODUCT", 95, 112], ["Ig-mu chain C", "GENE_OR_GENE_PRODUCT", 133, 146], ["membrane", "CELLULAR_COMPONENT", 154, 162], ["IgM heavy chain", "PROTEIN", 78, 93], ["Ig", "PROTEIN", 95, 97], ["mu heavy chain disease protein", "PROTEIN", 98, 128], ["Ig", "PROTEIN", 133, 135], ["mu chain C region", "PROTEIN", 136, 153], ["the IgM heavy chain", "PROBLEM", 74, 93], ["Ig", "TEST", 95, 97], ["heavy chain disease protein", "PROBLEM", 101, 128], ["Ig", "TEST", 133, 135], ["mu chain C region membrane", "PROBLEM", 136, 162]]], ["The CD84 leukocyte antigen is also interesting in this context, being highly expressed in certain B-cell subsets and belonging to the recently discovered family of signaling lymphocyte activating molecule (SLAM)-related receptors (SRR), a group of surface molecules whose main function seems to be the fine-tuning of lymphocyte responses [27].", [["CD84 leukocyte", "ANATOMY", 4, 18], ["B-cell", "ANATOMY", 98, 104], ["surface", "ANATOMY", 248, 255], ["lymphocyte", "ANATOMY", 317, 327], ["CD84 leukocyte antigen", "GENE_OR_GENE_PRODUCT", 4, 26], ["B-cell subsets", "CELL", 98, 112], ["signaling lymphocyte activating molecule (SLAM)-related receptors", "GENE_OR_GENE_PRODUCT", 164, 229], ["SRR", "GENE_OR_GENE_PRODUCT", 231, 234], ["lymphocyte", "CELL", 317, 327], ["CD84 leukocyte antigen", "PROTEIN", 4, 26], ["B-cell subsets", "CELL_TYPE", 98, 112], ["signaling lymphocyte activating molecule (SLAM)-related receptors", "PROTEIN", 164, 229], ["SRR", "PROTEIN", 231, 234], ["surface molecules", "PROTEIN", 248, 265], ["The CD84 leukocyte antigen", "TEST", 0, 26], ["signaling lymphocyte activating molecule", "PROBLEM", 164, 204], ["cell subsets", "OBSERVATION", 100, 112]]], ["Among this class of LM induced genes were also five Ig-kappa genes involved in B-cell receptor (CD79\u03b1/\u03b2) signalling (Ig-kappa chains V-IV region B17-1+2, V-III region VG, V-IV region JI and V-IV region Len).", [["B-cell", "ANATOMY", 79, 85], ["Ig-kappa", "GENE_OR_GENE_PRODUCT", 52, 60], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 79, 94], ["CD79\u03b1", "GENE_OR_GENE_PRODUCT", 96, 101], ["\u03b2", "GENE_OR_GENE_PRODUCT", 102, 103], ["Ig-kappa", "GENE_OR_GENE_PRODUCT", 117, 125], ["V-IV", "GENE_OR_GENE_PRODUCT", 133, 137], ["V-III", "GENE_OR_GENE_PRODUCT", 154, 159], ["V-IV", "GENE_OR_GENE_PRODUCT", 171, 175], ["V-IV", "GENE_OR_GENE_PRODUCT", 190, 194], ["LM induced genes", "DNA", 20, 36], ["Ig-kappa genes", "DNA", 52, 66], ["B-cell receptor", "PROTEIN", 79, 94], ["CD79\u03b1", "PROTEIN", 96, 101], ["\u03b2", "PROTEIN", 102, 103], ["Ig", "PROTEIN", 117, 119], ["1+2", "PROTEIN", 149, 152], ["V-III region", "DNA", 154, 166], ["V-IV region", "DNA", 171, 182], ["V-IV region", "DNA", 190, 201], ["Ig", "TEST", 52, 54], ["B-cell receptor", "TEST", 79, 94], ["CD79", "TEST", 96, 100], ["signalling", "TEST", 105, 115], ["Ig", "TEST", 117, 119], ["B17", "TEST", 145, 148]]], ["Collectively, the expression profiles of these genes indicated that a general activation of B-lymphocyte maturation and humoral immunity occurred among the late survivors.", [["B-lymphocyte", "ANATOMY", 92, 104], ["B-lymphocyte", "CELL", 92, 104], ["B-lymphocyte maturation", "TREATMENT", 92, 115], ["humoral immunity", "PROBLEM", 120, 136]]], ["However, the gene homologous to the B-cell receptor itself was unregulated or down-regulated in spleen together with some B-cell regulatory genes.", [["B-cell", "ANATOMY", 36, 42], ["spleen", "ANATOMY", 96, 102], ["B-cell", "ANATOMY", 122, 128], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 36, 51], ["spleen", "ORGAN", 96, 102], ["B-cell", "CELL", 122, 128], ["B-cell receptor", "PROTEIN", 36, 51], ["B-cell regulatory genes", "DNA", 122, 145], ["spleen", "ANATOMY", 96, 102], ["cell regulatory genes", "OBSERVATION", 124, 145]]], ["Notably, MHC class II (\u03b1- and invariant chain Il), which is the mediator of Ag-presentation in B-cells (and other APCs), was also down-regulated in spleen at both EM and LM stages, but was induced in heart of LM but not EM.Late survival is associated with reduced viral load and activation of adaptive immunity ::: ResultsTo further detail the features of the adaptive immune responses observed in LM we designed qPCR primers for well-known genes of humoral (IgM, -Z and -D heavy chain) and T-cell mediated (CD8+ CTL response; CD8\u03b1, CD4+ TH1 response; IFN-\u03b3 and TH2 response; TGF-\u03b2) immunity.", [["B-cells", "ANATOMY", 95, 102], ["APCs", "ANATOMY", 114, 118], ["spleen", "ANATOMY", 148, 154], ["heart", "ANATOMY", 200, 205], ["T-cell", "ANATOMY", 491, 497], ["CD8+ CTL", "ANATOMY", 508, 516], ["Ag", "CHEMICAL", 76, 78], ["MHC class II", "GENE_OR_GENE_PRODUCT", 9, 21], ["\u03b1", "GENE_OR_GENE_PRODUCT", 23, 24], ["invariant chain Il", "GENE_OR_GENE_PRODUCT", 30, 48], ["Ag", "GENE_OR_GENE_PRODUCT", 76, 78], ["B-cells", "CELL", 95, 102], ["APCs", "CELL", 114, 118], ["spleen", "ORGAN", 148, 154], ["heart", "ORGAN", 200, 205], ["IgM", "GENE_OR_GENE_PRODUCT", 459, 462], ["-Z", "GENE_OR_GENE_PRODUCT", 464, 466], ["-D heavy chain", "GENE_OR_GENE_PRODUCT", 471, 485], ["T-cell", "CELL", 491, 497], ["CD8", "GENE_OR_GENE_PRODUCT", 508, 511], ["CD8\u03b1", "GENE_OR_GENE_PRODUCT", 527, 531], ["CD4", "GENE_OR_GENE_PRODUCT", 533, 536], ["TH1", "GENE_OR_GENE_PRODUCT", 538, 541], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 552, 557], ["TH2", "GENE_OR_GENE_PRODUCT", 562, 565], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 576, 581], ["MHC class II", "PROTEIN", 9, 21], ["\u03b1", "PROTEIN", 23, 24], ["Il", "PROTEIN", 46, 48], ["Ag", "PROTEIN", 76, 78], ["B-cells", "CELL_TYPE", 95, 102], ["APCs", "CELL_TYPE", 114, 118], ["IgM", "PROTEIN", 459, 462], ["Z", "PROTEIN", 465, 466], ["CD8", "PROTEIN", 508, 511], ["CD8\u03b1", "PROTEIN", 527, 531], ["CD4", "PROTEIN", 533, 536], ["IFN", "PROTEIN", 552, 555], ["TGF", "PROTEIN", 576, 579], ["Late survival", "PROBLEM", 223, 236], ["reduced viral load", "PROBLEM", 256, 274], ["qPCR primers", "TEST", 413, 425], ["humoral (IgM", "TEST", 450, 462], ["Z", "TEST", 465, 466], ["CD8", "TEST", 508, 511], ["CTL response", "TEST", 513, 525], ["CD8\u03b1", "TEST", 527, 531], ["CD4", "TEST", 533, 536], ["TH1 response", "TEST", 538, 550], ["IFN", "TEST", 552, 555], ["\u03b3", "TEST", 556, 557], ["TH2 response", "TEST", 562, 574], ["TGF", "TEST", 576, 579], ["spleen", "ANATOMY", 148, 154], ["heart", "ANATOMY", 200, 205], ["LM", "ANATOMY", 209, 211], ["reduced", "OBSERVATION_MODIFIER", 256, 263], ["viral load", "OBSERVATION", 264, 274], ["humoral", "ANATOMY", 450, 457]]], ["For this analysis we also included fish in the IM stage and increased the number of individuals (6 per stage) to see if the viral clearance observed in LM was explained by a general activation of adaptive immunity in IM.", [["fish", "ORGANISM", 35, 39], ["this analysis", "TEST", 4, 17], ["the viral clearance", "TEST", 120, 139], ["increased", "OBSERVATION_MODIFIER", 60, 69]]], ["The results showed that IgM and IgZ, but not IgD (data not shown), were induced at all stages versus control but in opposite manners (Fig. 6).", [["IgM", "GENE_OR_GENE_PRODUCT", 24, 27], ["IgZ", "GENE_OR_GENE_PRODUCT", 32, 35], ["IgD", "GENE_OR_GENE_PRODUCT", 45, 48], ["IgM", "PROTEIN", 24, 27], ["IgZ", "PROTEIN", 32, 35], ["IgD", "PROTEIN", 45, 48], ["IgM and IgZ", "PROBLEM", 24, 35], ["IgD", "PROBLEM", 45, 48], ["IgM", "OBSERVATION", 24, 27]]], ["IgM mRNA peaked at EM and declined towards the later stages (IM and LM) while IgZ was steadily induced towards peak levels at LM.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgZ", "GENE_OR_GENE_PRODUCT", 78, 81], ["IgM mRNA", "RNA", 0, 8], ["IgZ", "PROTEIN", 78, 81], ["IgM mRNA", "TEST", 0, 8], ["LM", "ANATOMY", 68, 70]]], ["Kinetics of IgM expression was similar to CD4 and TGF-\u03b2.", [["IgM", "GENE_OR_GENE_PRODUCT", 12, 15], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["TGF-\u03b2.", "GENE_OR_GENE_PRODUCT", 50, 56], ["IgM", "PROTEIN", 12, 15], ["CD4", "PROTEIN", 42, 45], ["TGF", "PROTEIN", 50, 53], ["IgM expression", "TEST", 12, 26], ["CD4", "TEST", 42, 45], ["TGF", "TEST", 50, 53], ["IgM expression", "OBSERVATION", 12, 26]]], ["In contrast, expression of CD8\u03b1 was markedly induced from EM to IM/LM stages and correlated with IFN-\u03b3 expression (from the EM to IM stage).", [["CD8\u03b1", "GENE_OR_GENE_PRODUCT", 27, 31], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 97, 102], ["CD8\u03b1", "PROTEIN", 27, 31], ["IFN", "PROTEIN", 97, 100], ["\u03b3", "PROTEIN", 101, 102], ["IFN", "TEST", 97, 100]]], ["It must be noted that the significance of the data varied due to individual variation, but all qPCRs were replicated three times in both the reverse transcription step and in PCR, giving identical results.", [["the data", "TEST", 42, 50], ["individual variation", "PROBLEM", 65, 85], ["PCR", "TEST", 175, 178]]], ["Thus, the pronounced reduction in virus load from IM to LM might be explained by both developing antibody responses (IgZ) and activation of T-cell mediated immunity at IM, either through a specific CD8+ cytotoxic and/or TH1 response.", [["T-cell", "ANATOMY", 140, 146], ["IgZ", "GENE_OR_GENE_PRODUCT", 117, 120], ["T-cell", "CELL", 140, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 198, 201], ["TH1", "GENE_OR_GENE_PRODUCT", 220, 223], ["IgZ", "PROTEIN", 117, 120], ["CD8", "PROTEIN", 198, 201], ["the pronounced reduction in virus load", "PROBLEM", 6, 44], ["developing antibody responses", "PROBLEM", 86, 115], ["TH1 response", "PROBLEM", 220, 232], ["pronounced", "OBSERVATION_MODIFIER", 10, 20], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["virus load", "OBSERVATION", 34, 44], ["antibody", "OBSERVATION", 97, 105]]], ["Notably, this activation corresponded with induced antigen presentation, e.g. a broad elevation of MHCI mRNA levels across all tissues.", [["tissues", "ANATOMY", 127, 134], ["MHCI", "GENE_OR_GENE_PRODUCT", 99, 103], ["tissues", "TISSUE", 127, 134], ["MHCI mRNA", "RNA", 99, 108], ["induced antigen presentation", "PROBLEM", 43, 71], ["a broad elevation of MHCI mRNA levels", "PROBLEM", 78, 115], ["broad", "OBSERVATION_MODIFIER", 80, 85], ["elevation", "OBSERVATION", 86, 95], ["MHCI mRNA", "OBSERVATION", 99, 108], ["all tissues", "ANATOMY", 123, 134]]], ["However, MHCII (\u03b1- and invariant chain) was generally down-regulated in late survivors except for up-regulation in heart LM, the tissue with highest viral RNA levels.Late mortalities show reduced hepatic expression of chaperones and genes involved in metabolism of steroids, lipids and xenobiotics ::: ResultsA suite of chaperones from different groups (heat shock proteins and cognates, DnaJ homologs and T-complex proteins) showed consistently lower expression levels in liver from LM compared to EM (Table 1).", [["heart LM", "ANATOMY", 115, 123], ["tissue", "ANATOMY", 129, 135], ["hepatic", "ANATOMY", 196, 203], ["liver", "ANATOMY", 473, 478], ["LM", "ANATOMY", 484, 486], ["steroids", "CHEMICAL", 265, 273], ["steroids", "CHEMICAL", 265, 273], ["MHCII", "GENE_OR_GENE_PRODUCT", 9, 14], ["\u03b1- and invariant chain", "GENE_OR_GENE_PRODUCT", 16, 38], ["heart LM", "MULTI-TISSUE_STRUCTURE", 115, 123], ["tissue", "TISSUE", 129, 135], ["hepatic", "MULTI-TISSUE_STRUCTURE", 196, 203], ["steroids", "SIMPLE_CHEMICAL", 265, 273], ["lipids", "SIMPLE_CHEMICAL", 275, 281], ["xenobiotics", "SIMPLE_CHEMICAL", 286, 297], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 354, 373], ["DnaJ", "GENE_OR_GENE_PRODUCT", 388, 392], ["T-complex", "GENE_OR_GENE_PRODUCT", 406, 415], ["liver", "ORGAN", 473, 478], ["MHCII", "PROTEIN", 9, 14], ["\u03b1", "PROTEIN", 16, 17], ["invariant chain", "PROTEIN", 23, 38], ["chaperones", "PROTEIN", 218, 228], ["heat shock proteins", "PROTEIN", 354, 373], ["DnaJ homologs", "PROTEIN", 388, 401], ["T-complex proteins", "PROTEIN", 406, 424], ["highest viral RNA levels", "PROBLEM", 141, 165], ["Late mortalities", "PROBLEM", 166, 182], ["reduced hepatic expression of chaperones", "PROBLEM", 188, 228], ["steroids", "TREATMENT", 265, 273], ["heat shock proteins", "TEST", 354, 373], ["cognates", "TEST", 378, 386], ["DnaJ homologs", "TEST", 388, 401], ["T-complex proteins", "TEST", 406, 424], ["consistently lower expression levels in liver", "PROBLEM", 433, 478], ["heart LM", "ANATOMY", 115, 123], ["tissue", "ANATOMY", 129, 135], ["highest", "OBSERVATION_MODIFIER", 141, 148], ["viral RNA", "OBSERVATION", 149, 158], ["reduced", "OBSERVATION_MODIFIER", 188, 195], ["hepatic", "ANATOMY", 196, 203], ["lower expression", "OBSERVATION", 446, 462], ["liver", "ANATOMY", 473, 478], ["LM", "ANATOMY", 484, 486]]], ["Chaperones are essential for the life cycle of viruses, being involved in replication, translation, transport and assembly of viral proteins.", [["viral proteins", "PROTEIN", 126, 140], ["Chaperones", "TREATMENT", 0, 10], ["viral proteins", "PROBLEM", 126, 140], ["viruses", "OBSERVATION", 47, 54]]], ["Viruses from diverse groups are known to use chaperones of the hosts and/or produce own proteins with protein folding properties [28-31].", [["Viruses", "PROBLEM", 0, 7], ["protein folding properties", "TEST", 102, 128]]], ["Chaperones are commonly used as markers of cellular stress.", [["cellular", "ANATOMY", 43, 51], ["cellular", "CELL", 43, 51], ["Chaperones", "TREATMENT", 0, 10], ["cellular stress", "PROBLEM", 43, 58], ["cellular stress", "OBSERVATION", 43, 58]]], ["Although fish from all study groups was sampled in a moribund state, higher expression levels of chaperones suggested more severe stress in individuals with early mortality.Late mortalities show reduced hepatic expression of chaperones and genes involved in metabolism of steroids, lipids and xenobiotics ::: ResultsIn liver ISAV also affected genes involved in steroid and lipid metabolism (Table 2).", [["hepatic", "ANATOMY", 203, 210], ["liver", "ANATOMY", 319, 324], ["steroids", "CHEMICAL", 272, 280], ["steroid", "CHEMICAL", 362, 369], ["steroids", "CHEMICAL", 272, 280], ["steroid", "CHEMICAL", 362, 369], ["fish", "ORGANISM", 9, 13], ["hepatic", "MULTI-TISSUE_STRUCTURE", 203, 210], ["steroids", "SIMPLE_CHEMICAL", 272, 280], ["lipids", "SIMPLE_CHEMICAL", 282, 288], ["xenobiotics", "SIMPLE_CHEMICAL", 293, 304], ["liver", "ORGAN", 319, 324], ["ISAV", "ORGANISM", 325, 329], ["steroid", "SIMPLE_CHEMICAL", 362, 369], ["lipid", "SIMPLE_CHEMICAL", 374, 379], ["chaperones", "PROTEIN", 225, 235], ["ISAV", "SPECIES", 325, 329], ["all study groups", "TEST", 19, 35], ["severe stress in individuals", "PROBLEM", 123, 151], ["early mortality", "PROBLEM", 157, 172], ["Late mortalities", "PROBLEM", 173, 189], ["reduced hepatic expression of chaperones", "PROBLEM", 195, 235], ["steroids", "TREATMENT", 272, 280], ["steroid and lipid metabolism", "TREATMENT", 362, 390], ["more severe", "OBSERVATION_MODIFIER", 118, 129], ["reduced", "OBSERVATION_MODIFIER", 195, 202], ["hepatic", "ANATOMY", 203, 210], ["liver", "ANATOMY", 319, 324], ["ISAV", "OBSERVATION", 325, 329]]], ["Functional consequences of the potential decrease in metabolism of highly unsaturated fatty acids (delta-6 fatty acid desaturase), bile (sodium/bile acid cotransporter) and steroids (3-oxo-5-beta-steroid 4-dehydrogenase and estradiol 17 beta-dehydrogenase) are unclear given the complex interaction of these pathways with virus replication, immunity and stress.", [["fatty acids", "CHEMICAL", 86, 97], ["delta-6 fatty acid", "CHEMICAL", 99, 117], ["sodium", "CHEMICAL", 137, 143], ["bile acid", "CHEMICAL", 144, 153], ["steroids", "CHEMICAL", 173, 181], ["3-oxo-5-beta-steroid", "CHEMICAL", 183, 203], ["estradiol 17 beta-dehydrogenase", "CHEMICAL", 224, 255], ["unsaturated fatty acids", "CHEMICAL", 74, 97], ["delta-6 fatty acid", "CHEMICAL", 99, 117], ["sodium", "CHEMICAL", 137, 143], ["bile acid", "CHEMICAL", 144, 153], ["steroids", "CHEMICAL", 173, 181], ["3-oxo-5-beta-steroid", "CHEMICAL", 183, 203], ["estradiol", "CHEMICAL", 224, 233], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 74, 97], ["delta-6 fatty acid desaturase", "GENE_OR_GENE_PRODUCT", 99, 128], ["bile", "SIMPLE_CHEMICAL", 131, 135], ["sodium", "SIMPLE_CHEMICAL", 137, 143], ["bile acid cotransporter", "SIMPLE_CHEMICAL", 144, 167], ["steroids", "SIMPLE_CHEMICAL", 173, 181], ["3-oxo-5-beta-steroid 4-dehydrogenase", "GENE_OR_GENE_PRODUCT", 183, 219], ["estradiol 17 beta-dehydrogenase", "GENE_OR_GENE_PRODUCT", 224, 255], ["delta-6 fatty acid desaturase", "PROTEIN", 99, 128], ["steroid 4-dehydrogenase", "PROTEIN", 196, 219], ["estradiol 17 beta-dehydrogenase", "PROTEIN", 224, 255], ["highly unsaturated fatty acids", "PROBLEM", 67, 97], ["delta", "TEST", 99, 104], ["fatty acid desaturase", "TEST", 107, 128], ["bile (sodium/bile acid cotransporter", "TREATMENT", 131, 167], ["steroids", "TREATMENT", 173, 181], ["oxo", "TEST", 185, 188], ["beta-steroid", "TREATMENT", 191, 203], ["dehydrogenase", "TREATMENT", 206, 219], ["estradiol", "TREATMENT", 224, 233], ["virus replication", "TREATMENT", 322, 339], ["decrease", "OBSERVATION_MODIFIER", 41, 49], ["bile", "ANATOMY", 131, 135], ["bile", "ANATOMY", 144, 148]]], ["However since these genes showed little or no difference between EM and LM, their expression apparently did not influence resistance to virus in our experiment.", [["little", "OBSERVATION_MODIFIER", 33, 39]]], ["Disparity between fish with different survival times was better seen in a group of genes associated with metabolism of eicosanoids, which may play both positive and negative roles in viral diseases as regulators of pathogen life cycle (replication) and inflammation [32,33].", [["eicosanoids", "CHEMICAL", 119, 130], ["viral diseases", "DISEASE", 183, 197], ["inflammation", "DISEASE", 253, 265], ["fish", "ORGANISM", 18, 22], ["metabolism of eicosanoids", "PROBLEM", 105, 130], ["viral diseases", "PROBLEM", 183, 197], ["inflammation", "PROBLEM", 253, 265], ["viral diseases", "OBSERVATION", 183, 197]]], ["Cytochromes P450 can have different modes of action being involved in metabolism of eicosanoids and xenobiotics as well carboxylesterase HU1 [34].", [["eicosanoids", "CHEMICAL", 84, 95], ["eicosanoids", "CHEMICAL", 84, 95], ["Cytochromes P450", "GENE_OR_GENE_PRODUCT", 0, 16], ["eicosanoids", "SIMPLE_CHEMICAL", 84, 95], ["carboxylesterase", "GENE_OR_GENE_PRODUCT", 120, 136], ["Cytochromes P450", "PROTEIN", 0, 16], ["carboxylesterase", "PROTEIN", 120, 136], ["Cytochromes P450", "PROBLEM", 0, 16], ["eicosanoids", "TREATMENT", 84, 95], ["xenobiotics", "TREATMENT", 100, 111], ["carboxylesterase HU1", "TEST", 120, 140]]], ["C/EBP delta, an agonist of peroxisome proliferator-activated receptor is one of the key factors required for differentiation of adipocytes [35].", [["adipocytes", "ANATOMY", 128, 138], ["C/EBP delta", "GENE_OR_GENE_PRODUCT", 0, 11], ["peroxisome proliferator-activated receptor", "GENE_OR_GENE_PRODUCT", 27, 69], ["adipocytes", "CELL", 128, 138], ["C/EBP delta", "PROTEIN", 0, 11], ["peroxisome proliferator-activated receptor", "PROTEIN", 27, 69], ["adipocytes", "CELL_TYPE", 128, 138], ["C/EBP delta", "TEST", 0, 11], ["peroxisome proliferator", "PROBLEM", 27, 50], ["adipocytes", "PROBLEM", 128, 138]]], ["This gene was suppressed in contrast to alpha/beta type (Fig. 3, 4).", [["alpha/beta type", "GENE_OR_GENE_PRODUCT", 40, 55], ["beta type", "OBSERVATION_MODIFIER", 46, 55]]], ["Differential regulation of C/EBP isoforms has been reported under various acute conditions [36,37].Development of prognostic markers ::: ResultsMicroarray screening with subsequent qPCR analyses of candidate genes is a widely used approach for developing prognostic markers.", [["C/EBP", "GENE_OR_GENE_PRODUCT", 27, 32], ["C/EBP isoforms", "PROTEIN", 27, 41], ["candidate genes", "DNA", 198, 213], ["C/EBP isoforms", "PROBLEM", 27, 41], ["various acute conditions", "PROBLEM", 66, 90], ["ResultsMicroarray screening", "TEST", 137, 164], ["subsequent qPCR analyses", "TEST", 170, 194], ["acute", "OBSERVATION_MODIFIER", 74, 79]]], ["We wished to try a hypothesis-free strategy meaning that gene expression profiles were used with no surmise on gene functions.", [["a hypothesis", "PROBLEM", 17, 29], ["gene expression profiles", "PROBLEM", 57, 81]]], ["Therefore the candidate genes (Table 3) were chosen exclusively by their expression profiles (differences between EM and LM).", [["Table 3", "GENE_OR_GENE_PRODUCT", 31, 38], ["candidate genes", "DNA", 14, 29]]], ["Six individual liver samples from each of EM and LM stages were used as a training set in a linear discriminant analysis.", [["liver samples", "ANATOMY", 15, 28], ["liver samples", "CANCER", 15, 28], ["Six individual liver samples", "TEST", 0, 28], ["a training", "TREATMENT", 72, 82], ["a linear discriminant analysis", "TEST", 90, 120], ["liver", "ANATOMY", 15, 20]]], ["For this analysis a function was constructed which took positive values in EM and negative values in LM while intercept with X-axis marked a boundary between these groups (Fig. 7).", [["this analysis", "TEST", 4, 17]]], ["Furthermore, the classifier was verified in an independent test set, which included fish from all stages and controls.", [["fish", "ORGANISM", 84, 88], ["an independent test set", "TEST", 44, 67]]], ["The uninfected fish were well separated from the challenged, and as expected, the values of predictor function were negative as well as in LM.", [["fish", "ORGANISM", 15, 19], ["predictor function", "TEST", 92, 110], ["uninfected fish", "OBSERVATION", 4, 19]]], ["To evaluate the minimum number of genes required for the correct class assignment we used forward and reverse procedures.", [["reverse procedures", "TREATMENT", 102, 120]]], ["In both cases, four genes (5-lipoxygenase activating protein, cytochrome P450 2K4, galectin-9 and annexin A1) were determined as the minimum number required to build the function that ensured robust class prediction.", [["5-lipoxygenase", "GENE_OR_GENE_PRODUCT", 27, 41], ["cytochrome P450 2K4", "GENE_OR_GENE_PRODUCT", 62, 81], ["galectin-9", "GENE_OR_GENE_PRODUCT", 83, 93], ["annexin A1", "GENE_OR_GENE_PRODUCT", 98, 108], ["5-lipoxygenase activating protein", "PROTEIN", 27, 60], ["cytochrome P450 2K4", "PROTEIN", 62, 81], ["galectin-9", "PROTEIN", 83, 93], ["annexin A1", "PROTEIN", 98, 108], ["lipoxygenase activating protein", "TREATMENT", 29, 60], ["cytochrome P450", "TEST", 62, 77], ["galectin", "TEST", 83, 91]]], ["These genes changed expression in different directions (Table 2) and interestingly, three of four genes were related to metabolism of eicosanoids which are inflammatory regulators of lipid origin.DiscussionWe searched for the host factors that may account for different susceptibility and resistance to ISAV in Atlantic salmon.", [["ISAV", "DISEASE", 303, 307], ["eicosanoids", "CHEMICAL", 134, 145], ["lipid", "SIMPLE_CHEMICAL", 183, 188], ["ISAV", "ORGANISM", 303, 307], ["Atlantic salmon", "ORGANISM", 311, 326], ["inflammatory regulators", "PROTEIN", 156, 179], ["Atlantic salmon", "SPECIES", 311, 326], ["ISAV", "SPECIES", 303, 307], ["Atlantic salmon", "SPECIES", 311, 326], ["metabolism of eicosanoids", "PROBLEM", 120, 145], ["different susceptibility", "PROBLEM", 260, 284], ["eicosanoids", "ANATOMY", 134, 145], ["inflammatory", "OBSERVATION_MODIFIER", 156, 168], ["lipid origin", "OBSERVATION", 183, 195], ["may account for", "UNCERTAINTY", 244, 259]]], ["This question is of great importance for the development of protective strategies in aquaculture.", [["protective strategies", "TREATMENT", 60, 81]]], ["With the exception of one study that reported possible association of specific MHC class I alleles with survival [7] there is no evidence in the literature of defensive/offensive responses that could underlie individual variation resistance to ISAV.", [["ISAV", "DISEASE", 244, 248], ["ISAV", "ORGANISM", 244, 248], ["MHC class I alleles", "DNA", 79, 98], ["one study", "TEST", 22, 31], ["individual variation resistance to ISAV", "PROBLEM", 209, 248], ["no evidence in", "UNCERTAINTY", 126, 140], ["variation resistance", "OBSERVATION", 220, 240]]], ["An advantage of research on infectious diseases in fish is the possibility to challenge large numbers of individuals and to locate groups with markedly different performance.", [["infectious diseases", "DISEASE", 28, 47], ["fish", "ORGANISM", 51, 55], ["infectious", "OBSERVATION", 28, 38]]], ["Survival time is commonly used as a simple measure of resistance based on the assumption that it is determined principally by antiviral defense and/or severity of the pathological alterations.", [["the pathological alterations", "PROBLEM", 163, 191], ["antiviral defense", "OBSERVATION", 126, 143], ["pathological", "OBSERVATION", 167, 179]]], ["Then given similar physiological conditions (all fish were sampled in a moribund state) we could expect comparable phenotypes in the groups with different survival times; however our studies revealed marked differences between the study groups (stages).", [["similar physiological conditions", "PROBLEM", 11, 43], ["comparable phenotypes in the groups", "PROBLEM", 104, 139], ["our studies", "TEST", 179, 190], ["the study", "TEST", 227, 236], ["marked", "OBSERVATION_MODIFIER", 200, 206]]], ["Survival time can depend on the level of infection determined by the probability and time-point of encounter with pathogens and/or with active or passive protective mechanisms.", [["infection", "DISEASE", 41, 50], ["infection", "PROBLEM", 41, 50], ["pathogens", "PROBLEM", 114, 123], ["passive protective mechanisms", "TREATMENT", 146, 175], ["infection", "OBSERVATION", 41, 50]]], ["Notably, an identical challenge test as used here was previously shown to be very efficient in that all cohabitants were simultaneously infected [38], justifying that survival times could be explained by protective mechanisms.", [["an identical challenge test", "TEST", 9, 36]]], ["The viral loads were remarkably lower in LM however we did not find significant difference between EM and IM (except for liver).", [["liver", "ANATOMY", 121, 126], ["liver", "ORGAN", 121, 126], ["The viral loads", "TEST", 0, 15], ["viral loads", "OBSERVATION", 4, 15], ["lower", "OBSERVATION_MODIFIER", 32, 37], ["liver", "ANATOMY", 121, 126]]], ["Therefore viral load was an important, but not the only factor, influencing survival times.", [["viral load", "TEST", 10, 20], ["viral load", "OBSERVATION", 10, 20]]], ["Such responses were observed at different cellular levels with possible affects on the binding of ligands, perception and transduction of signals, regulation of gene expression and antiviral effectors.", [["cellular", "ANATOMY", 42, 50], ["cellular", "CELL", 42, 50], ["antiviral effectors", "PROTEIN", 181, 200], ["antiviral effectors", "TREATMENT", 181, 200], ["antiviral effectors", "OBSERVATION", 181, 200]]], ["Importantly, many genes with significantly higher expression levels in EM are known to be IFN-dependent and as expected these responses were characterised by low tissue specificity.", [["tissue", "ANATOMY", 162, 168], ["EM", "MULTI-TISSUE_STRUCTURE", 71, 73], ["IFN", "GENE_OR_GENE_PRODUCT", 90, 93], ["tissue", "TISSUE", 162, 168], ["IFN", "PROTEIN", 90, 93], ["significantly higher expression levels", "PROBLEM", 29, 67], ["low tissue specificity", "PROBLEM", 158, 180], ["low tissue", "OBSERVATION_MODIFIER", 158, 168]]], ["Our result was in line with a recent finding that induction of type I IFN and IFN-dependent genes in ISAV infected fish and cells did not provide protection against virus [8,39].", [["fish", "ANATOMY", 115, 119], ["cells", "ANATOMY", 124, 129], ["type I IFN", "GENE_OR_GENE_PRODUCT", 63, 73], ["IFN", "GENE_OR_GENE_PRODUCT", 78, 81], ["ISAV", "ORGANISM", 101, 105], ["fish", "ORGANISM", 115, 119], ["cells", "CELL", 124, 129], ["type I IFN and IFN-dependent genes", "DNA", 63, 97], ["ISAV", "SPECIES", 101, 105], ["type I IFN", "PROBLEM", 63, 73], ["IFN", "PROBLEM", 78, 81], ["dependent genes", "PROBLEM", 82, 97], ["ISAV infected fish and cells", "PROBLEM", 101, 129], ["virus", "PROBLEM", 165, 170]]], ["In addition, knowledge is emerging on potential IFN-antagonistic mechanisms of ISAV's NS1 protein [9], which is well-known from influenza [40].", [["influenza", "DISEASE", 128, 137], ["IFN", "GENE_OR_GENE_PRODUCT", 48, 51], ["ISAV", "ORGANISM", 79, 83], ["NS1", "GENE_OR_GENE_PRODUCT", 86, 89], ["influenza [40", "ORGANISM", 128, 141], ["IFN", "PROTEIN", 48, 51], ["NS1 protein", "PROTEIN", 86, 97], ["ISAV", "SPECIES", 79, 83], ["potential IFN", "TREATMENT", 38, 51], ["ISAV's NS1 protein", "TEST", 79, 97], ["influenza", "PROBLEM", 128, 137]]], ["We do not know whether strong antiviral responses were detrimental to fish.", [["fish", "ORGANISM", 70, 74]]], ["Such a possibility cannot be excluded, however, it is likely that activity of the IFN axis was directly related to the viral load (which was greater in EM).", [["IFN", "GENE_OR_GENE_PRODUCT", 82, 85], ["IFN", "PROTEIN", 82, 85], ["the IFN axis", "PROBLEM", 78, 90], ["the viral load", "PROBLEM", 115, 129], ["possibility cannot be excluded", "UNCERTAINTY", 7, 37], ["viral load", "OBSERVATION", 119, 129]]], ["Induction of galectins was a striking feature of the early broad tissue responses to ISAV.", [["tissue", "ANATOMY", 65, 71], ["galectins", "GENE_OR_GENE_PRODUCT", 13, 22], ["tissue", "TISSUE", 65, 71], ["ISAV", "ORGANISM", 85, 89], ["galectins", "PROTEIN", 13, 22], ["early", "OBSERVATION_MODIFIER", 53, 58], ["broad tissue", "OBSERVATION", 59, 71]]], ["Regulation of these genes with IFN was reported in higher vertebrates [24,25] and recently in trout macrophages [41].", [["macrophages", "ANATOMY", 100, 111], ["IFN", "GENE_OR_GENE_PRODUCT", 31, 34], ["trout macrophages", "CELL", 94, 111], ["IFN", "PROTEIN", 31, 34], ["trout macrophages", "CELL_TYPE", 94, 111], ["trout", "SPECIES", 94, 99], ["IFN", "PROBLEM", 31, 34]]], ["It is known that galectins can be used by virus [42].", [["galectins", "GENE_OR_GENE_PRODUCT", 17, 26], ["galectins", "PROTEIN", 17, 26], ["galectins", "TREATMENT", 17, 26]]], ["However, strong responses in phylogenetically remote species (fish and mammals) to diverse viruses such as ISAV in salmon and rhabdovirus (VHSV) in trout [43] make such a possibility very unlikely.", [["fish", "ORGANISM_SUBDIVISION", 62, 66], ["ISAV", "ORGANISM", 107, 111], ["salmon", "ORGANISM", 115, 121], ["rhabdovirus (VHSV", "ORGANISM", 126, 143], ["salmon", "SPECIES", 115, 121], ["VHSV", "SPECIES", 139, 143], ["trout", "SPECIES", 148, 153], ["salmon", "SPECIES", 115, 121], ["VHSV", "SPECIES", 139, 143], ["trout", "SPECIES", 148, 153], ["phylogenetically remote species", "PROBLEM", 29, 60], ["diverse viruses", "PROBLEM", 83, 98], ["ISAV", "PROBLEM", 107, 111], ["rhabdovirus", "PROBLEM", 126, 137], ["viruses", "OBSERVATION", 91, 98]]], ["Proteins with ability to bind diverse ligands can work as factors that restrict the propagation of the virus.", [["the virus", "PROBLEM", 99, 108]]], ["Studies on these mechanisms, which unlike the generalized antiviral responses appear more pathogen-specific, represent a rapidly emerging area.", [["these mechanisms", "TEST", 11, 27], ["the generalized antiviral responses", "PROBLEM", 42, 77], ["generalized", "OBSERVATION_MODIFIER", 46, 57], ["antiviral", "OBSERVATION", 58, 67], ["rapidly", "OBSERVATION_MODIFIER", 121, 128]]], ["Probably the best known achievement is identification of tripartite motif proteins and cyclophilin A, that may account for inter-specific differences in resistance to HIV [12].", [["cyclophilin A", "GENE_OR_GENE_PRODUCT", 87, 100], ["tripartite motif proteins", "PROTEIN", 57, 82], ["cyclophilin A", "PROTEIN", 87, 100], ["HIV", "SPECIES", 167, 170], ["HIV", "SPECIES", 167, 170], ["tripartite motif proteins", "PROBLEM", 57, 82], ["cyclophilin A", "PROBLEM", 87, 100], ["HIV", "PROBLEM", 167, 170]]], ["Interestingly, we observed up-regulation of ring finger/tripartite motif protein and cyclophilins, but without association to increased survival.", [["cyclophilins", "GENE_OR_GENE_PRODUCT", 85, 97], ["ring finger/tripartite motif protein", "PROTEIN", 44, 80], ["cyclophilins", "PROTEIN", 85, 97], ["ring finger/tripartite motif protein", "TREATMENT", 44, 80], ["cyclophilins", "TREATMENT", 85, 97], ["increased survival", "PROBLEM", 126, 144], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["survival", "OBSERVATION", 136, 144]]], ["We cannot reject the potential variation in the ability to restrict propagation of ISAV.", [["ISAV", "DISEASE", 83, 87], ["ISAV", "ORGANISM", 83, 87], ["ISAV", "SPECIES", 83, 87]]], ["To assess this possibility it will be necessary to screen for viral loads in a large number of challenged individuals, preferably from families with markedly different resistance.", [["viral loads", "PROBLEM", 62, 73], ["markedly different resistance", "PROBLEM", 149, 178]]], ["Overall, it was obvious that the innate antiviral responses did not provide protection to ISAV-infected salmon.DiscussionApart from active protection, survival time may depend on the tolerance or ability to endure high viral loads, and comparison of the hepatic responses tended to support this possibility.", [["hepatic", "ANATOMY", 254, 261], ["ISAV-infected", "DISEASE", 90, 103], ["ISAV", "ORGANISM", 90, 94], ["salmon", "ORGANISM", 104, 110], ["hepatic", "ORGAN", 254, 261], ["salmon", "SPECIES", 104, 110], ["ISAV", "SPECIES", 90, 94], ["ISAV", "PROBLEM", 90, 94], ["infected salmon", "PROBLEM", 95, 110], ["active protection", "TREATMENT", 132, 149], ["high viral loads", "PROBLEM", 214, 230], ["infected", "OBSERVATION", 95, 103], ["viral loads", "OBSERVATION", 219, 230], ["hepatic", "ANATOMY", 254, 261]]], ["Regulation of heat shock proteins plus other chaperones regarded as evidence for cellular stress, is a common feature of various viral diseases [44].", [["cellular", "ANATOMY", 81, 89], ["viral diseases", "DISEASE", 129, 143], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 14, 33], ["cellular", "CELL", 81, 89], ["heat shock proteins", "PROTEIN", 14, 33], ["heat shock proteins", "TREATMENT", 14, 33], ["other chaperones", "TREATMENT", 39, 55], ["cellular stress", "PROBLEM", 81, 96], ["various viral diseases", "PROBLEM", 121, 143], ["evidence for", "UNCERTAINTY", 68, 80], ["cellular stress", "OBSERVATION", 81, 96], ["various", "OBSERVATION_MODIFIER", 121, 128], ["viral", "OBSERVATION", 129, 134]]], ["These chaperones changed expression in both directions, however levels in LM were consistently lower than in EM.", [["levels in LM", "TEST", 64, 76], ["LM", "ANATOMY", 74, 76], ["lower", "OBSERVATION_MODIFIER", 95, 100]]], ["We could also see evidence for less severe inflammatory responses in LM.", [["LM", "CANCER", 69, 71], ["less severe inflammatory responses in LM", "PROBLEM", 31, 71], ["evidence for", "UNCERTAINTY", 18, 30], ["less", "OBSERVATION_MODIFIER", 31, 35], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["inflammatory", "OBSERVATION", 43, 55], ["LM", "ANATOMY", 69, 71]]], ["While many inflammatory regulators showed similar profiles at all stages, there was a difference in expression of genes involved in the metabolism of eicosanoids, which have been found to play an important part in pathogenesis of many viral diseases [33].", [["viral diseases", "DISEASE", 235, 249], ["inflammatory regulators", "PROTEIN", 11, 34], ["many inflammatory regulators", "PROBLEM", 6, 34], ["many viral diseases", "PROBLEM", 230, 249], ["inflammatory", "OBSERVATION", 11, 23], ["viral diseases", "OBSERVATION", 235, 249]]], ["Importantly, two genes induced in LM (5-lipoxygenase activating protein and annexin A1) were identified as the most valuable markers for the discrimination of groups with different survival times.", [["LM", "MULTI-TISSUE_STRUCTURE", 34, 36], ["5-lipoxygenase activating protein", "GENE_OR_GENE_PRODUCT", 38, 71], ["annexin A1", "GENE_OR_GENE_PRODUCT", 76, 86], ["5-lipoxygenase activating protein", "PROTEIN", 38, 71], ["annexin A1", "PROTEIN", 76, 86], ["annexin A1", "TREATMENT", 76, 86], ["LM", "ANATOMY", 34, 36]]], ["Both genes encode for proteins associated with phospholipase A2 and are regarded as important targets for anti-inflammatory therapy [45,46].", [["phospholipase A2", "GENE_OR_GENE_PRODUCT", 47, 63], ["phospholipase A2", "PROTEIN", 47, 63], ["phospholipase A2", "TREATMENT", 47, 63], ["anti-inflammatory therapy", "TREATMENT", 106, 131]]], ["Annexin AI inhibits phospholipase A2, which releases arachidonic acid from cellular membranes.", [["cellular membranes", "ANATOMY", 75, 93], ["Annexin", "CHEMICAL", 0, 7], ["arachidonic acid", "CHEMICAL", 53, 69], ["arachidonic acid", "CHEMICAL", 53, 69], ["Annexin AI", "GENE_OR_GENE_PRODUCT", 0, 10], ["phospholipase A2", "GENE_OR_GENE_PRODUCT", 20, 36], ["arachidonic acid", "SIMPLE_CHEMICAL", 53, 69], ["cellular membranes", "CELLULAR_COMPONENT", 75, 93], ["phospholipase A2", "PROTEIN", 20, 36], ["Annexin AI", "TREATMENT", 0, 10], ["phospholipase A2", "TREATMENT", 20, 36], ["arachidonic acid", "TEST", 53, 69], ["arachidonic acid", "OBSERVATION", 53, 69], ["cellular membranes", "OBSERVATION", 75, 93]]], ["Arachidonic acid is subsequently transformed to prostaglandins, thromboxane and leukotrienes collectively termed eicosanoids (reviewed in [47]) and 5-lipoxygenase activating protein plays a key part in one of these pathways.", [["Arachidonic acid", "CHEMICAL", 0, 16], ["prostaglandins", "CHEMICAL", 48, 62], ["thromboxane", "CHEMICAL", 64, 75], ["leukotrienes", "CHEMICAL", 80, 92], ["eicosanoids", "CHEMICAL", 113, 124], ["Arachidonic acid", "CHEMICAL", 0, 16], ["prostaglandins", "CHEMICAL", 48, 62], ["thromboxane", "CHEMICAL", 64, 75], ["leukotrienes", "CHEMICAL", 80, 92], ["eicosanoids", "CHEMICAL", 113, 124], ["Arachidonic acid", "SIMPLE_CHEMICAL", 0, 16], ["prostaglandins", "SIMPLE_CHEMICAL", 48, 62], ["thromboxane", "SIMPLE_CHEMICAL", 64, 75], ["leukotrienes", "SIMPLE_CHEMICAL", 80, 92], ["eicosanoids", "SIMPLE_CHEMICAL", 113, 124], ["[47]", "SIMPLE_CHEMICAL", 138, 142], ["5-lipoxygenase", "GENE_OR_GENE_PRODUCT", 148, 162], ["lipoxygenase activating protein", "PROTEIN", 150, 181], ["Arachidonic acid", "TREATMENT", 0, 16], ["prostaglandins", "TREATMENT", 48, 62], ["thromboxane", "TREATMENT", 64, 75], ["leukotrienes", "TREATMENT", 80, 92], ["lipoxygenase activating protein", "TREATMENT", 150, 181]]], ["Differences between EM and LM were seen in several more genes of eicosanoid metabolism while prostaglandin D synthase was equally down-regulated in both groups.DiscussionMicroarray analyses revealed only one group of genes (immunoglobulin-related) that were higher induced in LM compared to EM.", [["prostaglandin D", "CHEMICAL", 93, 108], ["eicosanoid", "CHEMICAL", 65, 75], ["prostaglandin D", "CHEMICAL", 93, 108], ["eicosanoid", "SIMPLE_CHEMICAL", 65, 75], ["prostaglandin D synthase", "GENE_OR_GENE_PRODUCT", 93, 117], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 224, 238], ["prostaglandin D synthase", "PROTEIN", 93, 117], ["immunoglobulin", "PROTEIN", 224, 238], ["eicosanoid metabolism", "PROBLEM", 65, 86], ["prostaglandin D synthase", "TEST", 93, 117], ["Microarray analyses", "TEST", 170, 189], ["LM", "ANATOMY", 27, 29], ["eicosanoid metabolism", "OBSERVATION", 65, 86]]], ["Changes in levels of these transcripts could be due to maturation and/or migration of immune cells to the heart and spleen, the two most heavily infected organs, and suggested an activation of adaptive immune responses in late survivors.", [["immune cells", "ANATOMY", 86, 98], ["heart", "ANATOMY", 106, 111], ["spleen", "ANATOMY", 116, 122], ["organs", "ANATOMY", 154, 160], ["immune cells", "CELL", 86, 98], ["heart", "ORGAN", 106, 111], ["spleen", "ORGAN", 116, 122], ["organs", "ORGAN", 154, 160], ["immune cells", "CELL_TYPE", 86, 98], ["maturation", "PROBLEM", 55, 65], ["immune cells", "PROBLEM", 86, 98], ["could be due to", "UNCERTAINTY", 39, 54], ["heart", "ANATOMY", 106, 111], ["spleen", "ANATOMY", 116, 122], ["most", "OBSERVATION_MODIFIER", 132, 136], ["heavily", "OBSERVATION_MODIFIER", 137, 144], ["infected", "OBSERVATION", 145, 153]]], ["The microarray includes eleven Ig clones corresponding to seven Unigene clusters.", [["Ig", "GENE_OR_GENE_PRODUCT", 31, 33], ["Ig clones", "DNA", 31, 40], ["The microarray", "TEST", 0, 14], ["eleven Ig clones", "TREATMENT", 24, 40], ["Ig clones", "OBSERVATION", 31, 40], ["Unigene clusters", "OBSERVATION", 64, 80]]], ["The exact roles of these salmon genes are not known, however their putative mammalian homologs are involved in early B-cell development.", [["B-cell", "ANATOMY", 117, 123], ["B-cell", "CELL", 117, 123], ["salmon genes", "DNA", 25, 37], ["-cell", "OBSERVATION_MODIFIER", 118, 123]]], ["Apart from mediating antibody responses, mature B cells are crucial for activation of effector helper T cells [48].", [["B cells", "ANATOMY", 48, 55], ["effector helper T cells", "ANATOMY", 86, 109], ["B cells", "CELL", 48, 55], ["T cells", "CELL", 102, 109], ["mature B cells", "CELL_TYPE", 41, 55], ["effector helper T cells", "CELL_TYPE", 86, 109], ["mediating antibody responses", "TEST", 11, 39], ["mature B cells", "PROBLEM", 41, 55], ["antibody responses", "OBSERVATION", 21, 39]]], ["Equally important was the fact that induction of these Igs correlated with a viral clearance among LM fish.", [["Igs", "GENE_OR_GENE_PRODUCT", 55, 58], ["Igs", "PROTEIN", 55, 58], ["these Igs", "PROBLEM", 49, 58], ["a viral clearance", "TEST", 75, 92]]], ["This prompted an extended qPCR analysis including all arms of adaptive cellular immunity, and showed that the expression kinetics of IgM, -D and -Z heavy chains, the most likely mediators of antibody responses in salmon, were quite different.", [["cellular", "ANATOMY", 71, 79], ["cellular", "CELL", 71, 79], ["IgM", "GENE_OR_GENE_PRODUCT", 133, 136], ["-D", "GENE_OR_GENE_PRODUCT", 138, 140], ["-Z heavy chains", "GENE_OR_GENE_PRODUCT", 145, 160], ["salmon", "ORGANISM", 213, 219], ["IgM, -D and -Z heavy chains", "PROTEIN", 133, 160], ["salmon", "SPECIES", 213, 219], ["an extended qPCR analysis", "TEST", 14, 39], ["IgM", "TEST", 133, 136], ["Z heavy chains", "TREATMENT", 146, 160], ["antibody responses", "TEST", 191, 209], ["most likely", "UNCERTAINTY", 166, 177]]], ["The reason for this is at best speculative, but it could indicate different roles for IgM and IgZ in salmonid immunity (e.g. innate natural versus humoral neutralizing antibodies).", [["IgM", "GENE_OR_GENE_PRODUCT", 86, 89], ["IgZ", "GENE_OR_GENE_PRODUCT", 94, 97], ["IgM", "PROTEIN", 86, 89], ["IgZ", "PROTEIN", 94, 97], ["humoral neutralizing antibodies", "PROTEIN", 147, 178], ["IgM", "PROBLEM", 86, 89], ["IgZ", "TREATMENT", 94, 97], ["humoral neutralizing antibodies", "TREATMENT", 147, 178]]], ["Perhaps more interesting was the induction of CD8\u03b1 and IFN-\u03b3, but not TGF-\u03b2 (TH2 marker), in IM and LM fish which correlated with viral clearance in LM fish.", [["IM", "ANATOMY", 93, 95], ["LM fish", "ANATOMY", 149, 156], ["CD8\u03b1", "GENE_OR_GENE_PRODUCT", 46, 50], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 55, 60], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["TH2", "GENE_OR_GENE_PRODUCT", 77, 80], ["IM", "PATHOLOGICAL_FORMATION", 93, 95], ["LM fish", "ORGANISM", 100, 107], ["CD8\u03b1", "PROTEIN", 46, 50], ["IFN", "PROTEIN", 55, 58], ["\u03b3", "PROTEIN", 59, 60], ["TGF-\u03b2", "PROTEIN", 70, 75], ["TH2 marker", "PROTEIN", 77, 87], ["CD8", "TEST", 46, 49], ["IFN", "TEST", 55, 58], ["TGF", "TEST", 70, 73], ["LM", "ANATOMY", 100, 102]]], ["An optimal TH1 response, consisting of virus-specific (IFN-\u03b3)-secreting CD4+ T cells and cytotoxic CD8+ T cells that lyse virus-infected cells [49], is crucial for clearance of influenza virus infection in humans [50].", [["CD4+ T cells", "ANATOMY", 72, 84], ["cytotoxic CD8+ T cells", "ANATOMY", 89, 111], ["cells", "ANATOMY", 137, 142], ["influenza virus infection", "DISEASE", 177, 202], ["TH1", "GENE_OR_GENE_PRODUCT", 11, 14], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 55, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 72, 75], ["CD8", "GENE_OR_GENE_PRODUCT", 99, 102], ["cells", "CELL", 137, 142], ["influenza virus", "ORGANISM", 177, 192], ["humans", "ORGANISM", 206, 212], ["IFN", "PROTEIN", 55, 58], ["CD4", "PROTEIN", 72, 75], ["T cells", "CELL_TYPE", 77, 84], ["cytotoxic CD8+ T cells", "CELL_TYPE", 89, 111], ["influenza virus", "SPECIES", 177, 192], ["humans", "SPECIES", 206, 212], ["influenza virus", "SPECIES", 177, 192], ["humans", "SPECIES", 206, 212], ["An optimal TH1 response", "TEST", 0, 23], ["virus", "TEST", 39, 44], ["IFN", "TEST", 55, 58], ["\u03b3", "TEST", 59, 60], ["secreting CD4", "TEST", 62, 75], ["T cells", "PROBLEM", 77, 84], ["cytotoxic CD8", "TEST", 89, 102], ["T cells", "PROBLEM", 104, 111], ["lyse virus", "TEST", 117, 127], ["infected cells", "PROBLEM", 128, 142], ["influenza virus infection", "PROBLEM", 177, 202], ["TH1 response", "OBSERVATION", 11, 23], ["influenza virus", "OBSERVATION", 177, 192]]], ["Further strengthening the significance of a cytotoxic response was the fact that MHC class I, the key activator of CD8+ T cells, was consistently induced in all tissues and stages.", [["CD8+ T cells", "ANATOMY", 115, 127], ["tissues", "ANATOMY", 161, 168], ["MHC class I", "GENE_OR_GENE_PRODUCT", 81, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 115, 118], ["tissues", "TISSUE", 161, 168], ["MHC class I", "PROTEIN", 81, 92], ["CD8", "PROTEIN", 115, 118], ["T cells", "CELL_TYPE", 120, 127], ["a cytotoxic response", "PROBLEM", 42, 62], ["T cells", "PROBLEM", 120, 127], ["all tissues", "ANATOMY", 157, 168]]], ["These results also support recent observations that ISAV survival correlated more strongly to the level of cell-mediated responses than did humoral responses [4].DiscussionCollectively, these findings demonstrate the power of functional genomics in untangling the complexities of virus-host interactions and viral pathogenesis.", [["cell", "ANATOMY", 107, 111], ["ISAV", "ORGANISM", 52, 56], ["cell", "CELL", 107, 111], ["ISAV survival", "PROBLEM", 52, 65], ["viral pathogenesis", "PROBLEM", 308, 326], ["functional genomics", "OBSERVATION", 226, 245], ["virus", "OBSERVATION", 280, 285], ["viral pathogenesis", "OBSERVATION", 308, 326]]], ["From analysis of gene expression profiles we suggest that common features of highly pathogenic ISAV include high viral replication, dramatic induction of innate immunity without protection and subsequent activation of cell-mediated immunity and reduced inflammation associated with viral clearance.", [["cell", "ANATOMY", 218, 222], ["inflammation", "DISEASE", 253, 265], ["ISAV", "ORGANISM", 95, 99], ["cell", "CELL", 218, 222], ["gene expression profiles", "PROBLEM", 17, 41], ["highly pathogenic ISAV", "PROBLEM", 77, 99], ["high viral replication", "TREATMENT", 108, 130], ["innate immunity", "TREATMENT", 154, 169], ["protection", "TREATMENT", 178, 188], ["cell-mediated immunity", "TREATMENT", 218, 240], ["reduced inflammation", "PROBLEM", 245, 265], ["viral clearance", "PROBLEM", 282, 297], ["viral replication", "OBSERVATION", 113, 130], ["reduced", "OBSERVATION_MODIFIER", 245, 252], ["inflammation", "OBSERVATION", 253, 265]]], ["Similarities to influenza pathogenesis are striking; fatalities of the 1918 influenza virus is caused by rapid replication kinetics resulting in an excessively vigorous innate immune and inflammatory response that contributes to severe tissue damage, disease and death [51,52].DiscussionThe need for prognostic and diagnostic tools for control of aquaculture diseases is urgent.", [["tissue", "ANATOMY", 236, 242], ["influenza", "DISEASE", 16, 25], ["influenza virus", "DISEASE", 76, 91], ["tissue damage", "DISEASE", 236, 249], ["death", "DISEASE", 263, 268], ["aquaculture diseases", "DISEASE", 347, 367], ["1918 influenza virus", "ORGANISM", 71, 91], ["tissue", "TISSUE", 236, 242], ["1918 influenza virus", "SPECIES", 71, 91], ["1918 influenza virus", "SPECIES", 71, 91], ["influenza pathogenesis", "PROBLEM", 16, 38], ["the 1918 influenza virus", "PROBLEM", 67, 91], ["rapid replication kinetics", "PROBLEM", 105, 131], ["an excessively vigorous innate immune and inflammatory response", "PROBLEM", 145, 208], ["severe tissue damage", "PROBLEM", 229, 249], ["disease", "PROBLEM", 251, 258], ["death", "PROBLEM", 263, 268], ["diagnostic tools", "TEST", 315, 331], ["aquaculture diseases", "PROBLEM", 347, 367], ["influenza", "OBSERVATION", 16, 25], ["inflammatory", "OBSERVATION_MODIFIER", 187, 199], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["tissue", "ANATOMY", 236, 242], ["damage", "OBSERVATION", 243, 249]]], ["We compared consequences of the acute and protracted forms of ISAV infection, but to search for prognostic markers our experimental design was not appropriate as analyses should have been conducted before challenge.", [["ISAV infection", "DISEASE", 62, 76], ["ISAV", "ORGANISM", 62, 66], ["ISAV", "SPECIES", 62, 66], ["the acute", "PROBLEM", 28, 37], ["ISAV infection", "PROBLEM", 62, 76], ["prognostic markers", "TEST", 96, 114], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["protracted", "OBSERVATION_MODIFIER", 42, 52], ["ISAV", "OBSERVATION_MODIFIER", 62, 66], ["infection", "OBSERVATION", 67, 76]]], ["Nonetheless, we regard this study as a step towards this task, which can help to clarify a number of important questions.", [["this study", "TEST", 23, 33]]], ["An ideal strategy for prediction of resistance would be an in vitro test, such as stimulation of primary cultures (e.g. peripheral blood cells) with ISAV and subsequent gene expression analysis.", [["primary cultures", "ANATOMY", 97, 113], ["peripheral blood cells", "ANATOMY", 120, 142], ["peripheral blood cells", "CELL", 120, 142], ["primary cultures", "CELL_LINE", 97, 113], ["peripheral blood cells", "CELL_TYPE", 120, 142], ["ISAV", "SPECIES", 149, 153], ["an in vitro test", "TEST", 56, 72], ["primary cultures", "TEST", 97, 113], ["peripheral blood cells", "TEST", 120, 142], ["ISAV", "TREATMENT", 149, 153], ["subsequent gene expression analysis", "TEST", 158, 193]]], ["However because we did not find any broad-tissue responses associated with improved resistance the feasibility of such approach is ambiguous.", [["tissue", "ANATOMY", 42, 48], ["tissue", "TISSUE", 42, 48]]], ["The LM group was characterized by activation of adaptive immune responses which are systemic by nature and require complex interactions of different cellular elements and humoral factors.", [["cellular", "ANATOMY", 149, 157], ["cellular", "CELL", 149, 157], ["cellular elements", "DNA", 149, 166], ["humoral factors", "PROTEIN", 171, 186], ["humoral factors", "PROBLEM", 171, 186], ["cellular elements", "OBSERVATION", 149, 166], ["humoral factors", "OBSERVATION", 171, 186]]], ["Given the pivotal role of acquired responses, the development of animal models will be essential for studies on fish resistance to viral pathogens.", [["fish", "ORGANISM_SUBDIVISION", 112, 116], ["viral pathogens", "PROBLEM", 131, 146]]], ["We used materials from this experiment as a pilot study for the development of predictors based on microarray and qPCR analyses.", [["a pilot study", "TEST", 42, 55], ["microarray", "TEST", 99, 109], ["qPCR analyses", "TEST", 114, 127]]], ["Four genes were sufficient for accurate class assignment and importantly, this was achieved using linear discriminate analyses, a gold standard approach to tasks of this kind.ConclusionIn conclusion, three groups with different survival times were characterized by distinct phenotypes suggesting that resistance at early and late stages of ISAV could be explained by different molecular host determinants.", [["ISAV", "DISEASE", 340, 344], ["ISAV", "ORGANISM", 340, 344], ["ISAV", "SPECIES", 340, 344], ["a gold standard approach", "TREATMENT", 128, 152], ["distinct phenotypes", "PROBLEM", 265, 284], ["resistance", "PROBLEM", 301, 311], ["ISAV", "PROBLEM", 340, 344], ["distinct phenotypes", "OBSERVATION", 265, 284], ["resistance", "OBSERVATION_MODIFIER", 301, 311], ["late stages", "OBSERVATION_MODIFIER", 325, 336], ["ISAV", "OBSERVATION", 340, 344], ["could be explained", "UNCERTAINTY", 345, 363], ["different", "OBSERVATION_MODIFIER", 367, 376], ["molecular host", "OBSERVATION", 377, 391]]], ["Early mortality associated with highly pathogenic form of ISAV was characterized by high viral replication, dramatic up-regulation of innate immune mechanisms and cellular stress.", [["cellular", "ANATOMY", 163, 171], ["ISAV", "DISEASE", 58, 62], ["ISAV", "ORGANISM", 58, 62], ["cellular", "CELL", 163, 171], ["ISAV", "SPECIES", 58, 62], ["Early mortality", "PROBLEM", 0, 15], ["ISAV", "PROBLEM", 58, 62], ["high viral replication", "PROBLEM", 84, 106], ["innate immune mechanisms", "TREATMENT", 134, 158], ["cellular stress", "PROBLEM", 163, 178], ["highly", "OBSERVATION_MODIFIER", 32, 38], ["pathogenic", "OBSERVATION", 39, 49], ["ISAV", "OBSERVATION", 58, 62], ["high", "OBSERVATION_MODIFIER", 84, 88], ["viral replication", "OBSERVATION", 89, 106], ["cellular stress", "OBSERVATION", 163, 178]]], ["Intermediate mortalities shared common features with EM (high viral load) in contrast to the late group of survivors where a significant viral clearance coincided with activation of adaptive cellular immunity and reduced inflammation.", [["cellular", "ANATOMY", 191, 199], ["inflammation", "DISEASE", 221, 233], ["cellular", "CELL", 191, 199], ["Intermediate mortalities", "PROBLEM", 0, 24], ["EM (high viral load)", "PROBLEM", 53, 73], ["a significant viral clearance", "PROBLEM", 123, 152], ["adaptive cellular immunity", "PROBLEM", 182, 208], ["reduced inflammation", "PROBLEM", 213, 233], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["viral clearance", "OBSERVATION", 137, 152], ["cellular immunity", "OBSERVATION", 191, 208], ["reduced", "OBSERVATION_MODIFIER", 213, 220], ["inflammation", "OBSERVATION", 221, 233]]], ["Overall, development of adaptive immune responses in salmonid fish requires several weeks after pathogen challenge, which is consistent with our results.", [["salmonid", "ORGANISM", 53, 61], ["fish", "ORGANISM_SUBDIVISION", 62, 66], ["adaptive immune responses", "TREATMENT", 24, 49], ["pathogen challenge", "TEST", 96, 114], ["adaptive immune responses", "OBSERVATION", 24, 49], ["consistent with", "UNCERTAINTY", 125, 140]]], ["Ability to survive to this point is likely to have crucial importance for the outcome of disease.Experimental infection ::: MethodsTissue samples from control and ISAV infected fish originated from a reference challenge trial performed at VESO Vikan (Veterinary Science Opportunities, Namsos, Norway).", [["MethodsTissue samples", "ANATOMY", 124, 145], ["infection", "DISEASE", 110, 119], ["ISAV", "ORGANISM", 163, 167], ["fish", "ORGANISM", 177, 181], ["ISAV", "SPECIES", 163, 167], ["disease", "PROBLEM", 89, 96], ["Experimental infection", "PROBLEM", 97, 119], ["MethodsTissue samples", "TEST", 124, 145], ["infection", "OBSERVATION", 110, 119]]], ["The trial was approved by The National Animal Research Authority (see Availability and requirements section for URL) according to the 'European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes' (EST 123).", [["the Protection of Vertebrate Animals", "TREATMENT", 159, 195]]], ["Unvaccinated juvenile Atlantic salmon (average size 22.8 gram at start) were kept in separate tanks at 12\u00b0C under controlled conditions (water flow, fish density etc.) and acclimatised for one week before challenged.", [["salmon", "ORGANISM", 31, 37], ["Atlantic salmon", "SPECIES", 22, 37], ["Atlantic salmon", "SPECIES", 22, 37], ["Unvaccinated juvenile Atlantic salmon (average size", "TREATMENT", 0, 51], ["juvenile", "OBSERVATION_MODIFIER", 13, 21], ["Atlantic salmon", "OBSERVATION", 22, 37]]], ["In one tank, 300 fish (hereafter referred to as cohabitants) were cohabitated with 60 marked fish each i.p.-injected with a virus dose of 7.2 \u00d7 103 TCID50 of a third passage of ISAV strain Glesvaer 2/90 (National Veterinary Institute, Oslo, Norway).", [["i.p.-", "CHEMICAL", 103, 108], ["fish", "ORGANISM", 17, 21], ["fish", "ORGANISM", 93, 97], ["ISAV", "ORGANISM", 177, 181], ["ISAV strain Glesvaer 2/90", "SPECIES", 177, 202], ["a virus dose", "TREATMENT", 122, 134]]], ["A separate tank contained 40 unvaccinated control fish of same size and origin which were kept under identical conditions (density, temperature, water flow and feeding) as challenged fish.", [["fish", "ORGANISM", 50, 54], ["fish", "ORGANISM", 183, 187], ["A separate tank", "TREATMENT", 0, 15], ["size", "OBSERVATION_MODIFIER", 63, 67], ["origin", "ANATOMY_MODIFIER", 72, 78]]], ["Standardized tissue sampling (heart, spleen, gills and liver) was performed from 12, 24 and 12 moribund fish from respectively EM (0\u201310% CM), IM (35\u201355% CM) and LM (75\u201384% CM) stages (cohabitants) and similarly from half the number of controls at the same time-points as challenged fish.", [["tissue", "ANATOMY", 13, 19], ["heart", "ANATOMY", 30, 35], ["spleen", "ANATOMY", 37, 43], ["gills", "ANATOMY", 45, 50], ["liver", "ANATOMY", 55, 60], ["CM", "DISEASE", 137, 139], ["CM", "DISEASE", 153, 155], ["tissue", "TISSUE", 13, 19], ["heart", "ORGAN", 30, 35], ["spleen", "ORGAN", 37, 43], ["gills", "ORGAN", 45, 50], ["liver", "ORGAN", 55, 60], ["fish", "ORGANISM", 104, 108], ["fish", "ORGANISM", 282, 286], ["Standardized tissue sampling", "TEST", 0, 28], ["EM", "TEST", 127, 129], ["IM", "TEST", 142, 144], ["LM", "TEST", 161, 163], ["stages (cohabitants)", "PROBLEM", 176, 196], ["heart", "ANATOMY", 30, 35], ["spleen", "ANATOMY", 37, 43], ["gills", "ANATOMY", 45, 50], ["liver", "ANATOMY", 55, 60], ["LM", "ANATOMY", 161, 163]]], ["Samples were immediately stored in >10\u00d7 excess volume of RNAlater (Invitrogen, Carlsbad, CA, USA) at 4\u00b0C overnight following -20\u00b0C until RNA extraction.", [["Samples", "ANATOMY", 0, 7], ["C", "GENE_OR_GENE_PRODUCT", 129, 130], ["Samples", "TEST", 0, 7], ["RNAlater", "TEST", 57, 65], ["Invitrogen", "TEST", 67, 77], ["RNA extraction", "TREATMENT", 137, 151]]], ["All fish were negatively tested for immune status by ELISA testing for Vibrio salmonicidae, Vibrio anguillarum O1 and O2, Moritella viscosa and IPNV before challenge.", [["fish", "ORGANISM", 4, 8], ["Vibrio salmonicidae", "ORGANISM", 71, 90], ["Vibrio anguillarum", "ORGANISM", 92, 110], ["O1", "ORGANISM", 111, 113], ["O2", "SIMPLE_CHEMICAL", 118, 120], ["Moritella viscosa", "ORGANISM", 122, 139], ["IPNV", "ORGANISM", 144, 148], ["Vibrio salmonicidae", "SPECIES", 71, 90], ["Vibrio anguillarum", "SPECIES", 92, 110], ["Moritella viscosa", "SPECIES", 122, 139], ["Vibrio salmonicidae", "SPECIES", 71, 90], ["Vibrio anguillarum", "SPECIES", 92, 110], ["Moritella viscosa", "SPECIES", 122, 139], ["All fish", "TEST", 0, 8], ["ELISA testing", "TEST", 53, 66], ["Vibrio salmonicidae", "TREATMENT", 71, 90], ["Vibrio anguillarum O1", "TREATMENT", 92, 113], ["O2", "TREATMENT", 118, 120], ["Moritella viscosa", "TREATMENT", 122, 139], ["IPNV", "TREATMENT", 144, 148]]], ["Moribund fish were confirmed clinically positive for ISAV.", [["fish", "ORGANISM", 9, 13], ["ISAV", "ORGANISM", 53, 57], ["ISAV", "SPECIES", 53, 57], ["Moribund fish", "TEST", 0, 13], ["ISAV", "PROBLEM", 53, 57]]], ["No mortality was observed among control fish.RNA extraction and cDNA synthesis ::: MethodsTotal RNA from tissue was isolated using PureLink Micro-Midi kit (Invitrogen) using manufacturer's protocols and guidelines.", [["tissue", "ANATOMY", 105, 111], ["tissue", "TISSUE", 105, 111], ["mortality", "PROBLEM", 3, 12], ["RNA extraction", "TREATMENT", 45, 59], ["MethodsTotal RNA from tissue", "PROBLEM", 83, 111], ["PureLink Micro-Midi kit (Invitrogen", "TREATMENT", 131, 166], ["manufacturer's protocols", "TREATMENT", 174, 198], ["mortality", "OBSERVATION", 3, 12]]], ["RNA quantity was measured by Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA) and integrity confirmed by gel electrophoresis.", [["RNA quantity", "TEST", 0, 12], ["gel electrophoresis", "TEST", 110, 129], ["quantity", "OBSERVATION_MODIFIER", 4, 12]]], ["Samples were precipitated and stored under ethanol at -70\u00b0C. cDNA synthesis was performed on 2 \u03bcg DNAse-treated (Turbo DNA-free\u2122, Ambion, Austin, TX, USA) total RNA using TaqMan\u00ae Reverse Transcription reagents (Applied Biosystems, Foster City, CA, USA) and random hexamer primers, according to manufacturer's protocol.Microarray analyses ::: MethodsThe salmonid fish cDNA microarray SFA2.0 immunochip contains 1800 unique clones printed each in six spot replicates.", [["Samples", "ANATOMY", 0, 7], ["clones", "ANATOMY", 422, 428], ["ethanol", "CHEMICAL", 43, 50], ["ethanol", "CHEMICAL", 43, 50], ["ethanol", "SIMPLE_CHEMICAL", 43, 50], ["fish", "ORGANISM", 362, 366], ["clones", "CELL", 422, 428], ["cDNA", "DNA", 61, 65], ["salmonid fish cDNA microarray SFA2.0 immunochip", "DNA", 353, 400], ["Samples", "TEST", 0, 7], ["cDNA synthesis", "TEST", 61, 75], ["2 \u03bcg DNAse", "TREATMENT", 93, 103], ["total RNA", "TREATMENT", 155, 164], ["Reverse Transcription reagents", "TREATMENT", 179, 209], ["random hexamer primers", "TREATMENT", 257, 279], ["manufacturer's protocol", "TREATMENT", 294, 317], ["Microarray analyses", "TEST", 318, 337], ["Methods", "TREATMENT", 342, 349], ["The salmonid fish cDNA microarray", "TREATMENT", 349, 382], ["immunochip", "TEST", 390, 400], ["unique clones", "TREATMENT", 415, 428]]], ["The genes were selected by their functional roles and the platform is enriched in a number of functional classes such as immune response (236 genes), cell communication (291 genes), signal transduction (245 genes) and receptor activity (126 genes), apoptosis (120 genes), cell cycle (76 genes), protein catabolism (90 genes) and folding (70 genes) and response to oxidative stress (39 genes).", [["cell", "ANATOMY", 150, 154], ["cell", "ANATOMY", 272, 276], ["cell", "CELL", 150, 154], ["cell", "CELL", 272, 276], ["245 genes", "DNA", 203, 212], ["120 genes", "DNA", 260, 269], ["70 genes", "DNA", 338, 346], ["cell communication", "TEST", 150, 168], ["signal transduction", "TEST", 182, 201], ["receptor activity", "TEST", 218, 235], ["apoptosis", "TEST", 249, 258], ["cell cycle", "TEST", 272, 282], ["protein catabolism", "TEST", 295, 313]]], ["Microarray analyses were conducted on fish from EM and LM stages.", [["Microarray analyses", "TEST", 0, 19]]], ["A common reference design of hybridization was applied and RNA pooled from 6 uninfected fish per tissue and per stage was used as control.", [["tissue", "ANATOMY", 97, 103], ["fish", "ORGANISM", 88, 92], ["tissue", "TISSUE", 97, 103], ["hybridization", "TREATMENT", 29, 42], ["RNA", "TEST", 59, 62]]], ["Pooled samples of gill, liver, heart and spleen (equal amounts of RNA from 6 individuals per tissue) were analyzed in a dye-swap design; two slides were used for each sample with reverse assignment of dyes.", [["samples", "ANATOMY", 7, 14], ["gill", "ANATOMY", 18, 22], ["liver", "ANATOMY", 24, 29], ["heart", "ANATOMY", 31, 36], ["spleen", "ANATOMY", 41, 47], ["tissue", "ANATOMY", 93, 99], ["gill", "ORGAN", 18, 22], ["liver", "ORGAN", 24, 29], ["heart", "ORGAN", 31, 36], ["spleen", "ORGAN", 41, 47], ["tissue", "TISSUE", 93, 99], ["Pooled samples of gill, liver, heart and spleen (equal amounts of RNA", "PROBLEM", 0, 69], ["two slides", "TREATMENT", 137, 147], ["gill", "ANATOMY", 18, 22], ["liver", "ANATOMY", 24, 29], ["heart", "ANATOMY", 31, 36], ["spleen", "ANATOMY", 41, 47], ["equal", "OBSERVATION_MODIFIER", 49, 54], ["amounts", "OBSERVATION_MODIFIER", 55, 62]]], ["Individual comparisons (6 fish from EM and 6 fish from LM) were done on liver samples in a single-slide format and one slide per each sample was used.", [["liver samples", "ANATOMY", 72, 85], ["liver samples", "CANCER", 72, 85], ["liver samples", "TEST", 72, 85], ["liver", "ANATOMY", 72, 77]]], ["The samples (20 \u03bcg RNA in each) were labeled with Cy3-dUTP and Cy5-dUTP (Amersham Pharmacia, Little Chalfont, UK) using the SuperScript\u2122 Direct cDNA Labeling System (Invitrogen).", [["samples", "ANATOMY", 4, 11], ["Cy3-dUTP", "CHEMICAL", 50, 58], ["Cy5-dUTP", "CHEMICAL", 63, 71], ["dUTP", "CHEMICAL", 54, 58], ["dUTP", "CHEMICAL", 67, 71], ["Cy3-dUTP", "SIMPLE_CHEMICAL", 50, 58], ["Cy5-dUTP", "SIMPLE_CHEMICAL", 63, 71], ["The samples", "TEST", 0, 11], ["Cy3", "TEST", 50, 53], ["dUTP", "TEST", 54, 58], ["Cy5", "TEST", 63, 66], ["dUTP (Amersham Pharmacia", "TREATMENT", 67, 91]]], ["The cDNA synthesis was performed at 43\u00b0C for 3 hours in a 20 \u03bcl reaction volume, followed with RNA degradation with 0.2 M NaOH at 37\u00b0C for 15 min and alkaline neutralization with 0.6 M Hepes.", [["NaOH", "CHEMICAL", 122, 126], ["NaOH", "CHEMICAL", 122, 126], ["The cDNA synthesis", "TEST", 0, 18], ["a 20 \u03bcl reaction volume", "TREATMENT", 56, 79], ["RNA degradation", "PROBLEM", 95, 110], ["alkaline neutralization", "TREATMENT", 150, 173]]], ["Labeled cDNA was purified with Microcon YM30 (Millipore, Beford, MA, USA).", [["cDNA", "DNA", 8, 12]]], ["The slides were pretreated with 1% BSA fraction V, 5 \u00d7 SSC, 0.1% SDS for 30 min at 50\u00b0C and washed with 2 \u00d7 SSC for 3 min and 0.2 \u00d7 SSC for 3 min at room temperature and hybridized overnight at 60\u00b0C in a cocktail containing 1.3 \u00d7 Denhardt's, 3 \u00d7 SSC, 0.3% SDS, 0.67 \u03bcg \u03bcl-1 polyadenylate and 1.4 \u03bcg \u03bcl-1 yeast tRNA.", [["SDS", "CHEMICAL", 256, 259], ["BSA", "SIMPLE_CHEMICAL", 35, 38], ["C", "SIMPLE_CHEMICAL", 197, 198], ["yeast", "SPECIES", 304, 309], ["yeast", "SPECIES", 304, 309], ["1% BSA fraction V", "TREATMENT", 32, 49], ["Denhardt's", "TEST", 230, 240], ["SSC", "TEST", 246, 249], ["polyadenylate", "TREATMENT", 274, 287], ["SSC", "ANATOMY", 246, 249], ["yeast tRNA", "OBSERVATION", 304, 314]]], ["After hybridization slides were washed at room temperature in 0.5 \u00d7 SSC and 0.1% SDS for 15 min, 0.5 \u00d7 SSC and 0.01% SDS for 15 min, and twice in 0.06 \u00d7 SSC for 2 and 1 min, respectively.", [["hybridization slides", "TEST", 6, 26], ["0.1% SDS", "TREATMENT", 76, 84], ["0.01% SDS", "TREATMENT", 111, 120]]], ["Scanning was performed with GSI Lumonics ScanArray 4000 (PerkinElmer Life Sciences, Zaventem, Belgium) and images were processed with GenePix Pro 6.0 (Axon, Union City, CA, USA).", [["Scanning", "TEST", 0, 8], ["images", "TEST", 107, 113]]], ["The spots were filtered by criterion (I-B)/(SI+SB) \u2265 0.6, where I and B are the mean signal and background intensities and SI, SB are the standard deviations.", [["background", "OBSERVATION_MODIFIER", 96, 106], ["intensities", "OBSERVATION_MODIFIER", 107, 118], ["SI", "OBSERVATION_MODIFIER", 123, 125], ["SB", "ANATOMY", 127, 129], ["standard deviations", "OBSERVATION", 138, 157]]], ["The low quality spots were excluded from analysis and genes presented with less than three high quality spots on a slide were discarded.", [["The low quality spots", "PROBLEM", 0, 21], ["analysis", "TEST", 41, 49], ["a slide", "TREATMENT", 113, 120], ["low quality", "OBSERVATION_MODIFIER", 4, 15]]], ["After subtraction of median background from median signal intensities, the expression ratios (ER) were calculated.", [["ER", "GENE_OR_GENE_PRODUCT", 94, 96], ["ER", "PROTEIN", 94, 96], ["median", "OBSERVATION_MODIFIER", 21, 27], ["median signal", "OBSERVATION", 44, 57]]], ["Lowess normalization was performed first for the whole slide and next for twelve rows and four columns per slide.", [["the whole slide", "TEST", 45, 60]]], ["The differential expression was assessed by difference of the mean log-ER from zero (6 spot replicates per each gene, Student's t-test, p < 0.01).", [["ER", "GENE_OR_GENE_PRODUCT", 71, 73], ["ER", "PROTEIN", 71, 73], ["Student's t-test", "TEST", 118, 134]]], ["The log-ER values in individual liver samples were compared with t-test (p < 0.05).", [["liver samples", "ANATOMY", 32, 45], ["ER", "GENE_OR_GENE_PRODUCT", 8, 10], ["liver samples", "CANCER", 32, 45], ["ER", "PROTEIN", 8, 10], ["individual liver samples", "TEST", 21, 45], ["t-test", "TEST", 65, 71], ["liver", "ANATOMY", 32, 37]]], ["Data were submitted to GEO (GPL6154).Quantitative real-time RT-PCR (qPCR) ::: MethodsqPCR primers (Table 3) were designed using the Vector NTI software (Invitrogen) and synthesized by Invitrogen.", [["Invitrogen", "GENE_OR_GENE_PRODUCT", 184, 194], ["MethodsqPCR primers", "DNA", 78, 97], ["Quantitative real-time RT-PCR", "TEST", 37, 66], ["MethodsqPCR primers", "TREATMENT", 78, 97], ["the Vector NTI software (Invitrogen)", "TREATMENT", 128, 164]]], ["To avoid genomic DNA amplification, amplicons were when possible placed over introns and product size and specificity were confirmed by agarose gel electrophoresis and melting curve analysis (Tm calling; LightCycler 480, Roche Diagnostics, Mannheim, Germany).", [["DNA", "CELLULAR_COMPONENT", 17, 20], ["agarose", "SIMPLE_CHEMICAL", 136, 143], ["introns", "DNA", 77, 84], ["genomic DNA amplification", "TREATMENT", 9, 34], ["amplicons", "TREATMENT", 36, 45], ["agarose gel electrophoresis", "TEST", 136, 163], ["melting curve analysis", "TEST", 168, 190], ["size", "OBSERVATION_MODIFIER", 97, 101]]], ["PCR efficiency (E) was determined from tenfold serial dilutions of cDNA for each primer pair and calculated according to Rasmussen [53].", [["cDNA", "DNA", 67, 71], ["primer pair", "DNA", 81, 92], ["PCR efficiency", "TEST", 0, 14], ["tenfold serial dilutions of cDNA", "TREATMENT", 39, 71], ["each primer pair", "PROBLEM", 76, 92]]], ["Each pair of primers was tested on different samples in the same plate to ensure optimal reproducibility and repeated testing was performed on whole template setup or a random selection of samples to ensure inter-assay reproducibility.", [["samples", "ANATOMY", 45, 52], ["samples", "ANATOMY", 189, 196], ["Each pair of primers", "PROBLEM", 0, 20], ["different samples", "TEST", 35, 52], ["repeated testing", "TEST", 109, 125], ["whole template setup", "TREATMENT", 143, 163], ["inter-assay reproducibility", "TEST", 207, 234]]], ["As common reference gene 18S rRNA was used, which was previously optimised and validated [54].", [["common reference gene 18S rRNA", "DNA", 3, 33], ["18S rRNA", "OBSERVATION", 25, 33]]], ["Four potential reference genes were tested (18S rRNA, EF-1alpha and two other non-regulated genes from the microarray results; SEC13-related protein and NADH-ubiquinone oxidoreductase 19 kDa subunit) using the BestKeeper [55] and GeNorm [56] software, however only 18S rRNA met qualifications of stability.", [["NADH", "CHEMICAL", 153, 157], ["ubiquinone", "CHEMICAL", 158, 168], ["EF-1alpha", "GENE_OR_GENE_PRODUCT", 54, 63], ["SEC13-related protein", "GENE_OR_GENE_PRODUCT", 127, 148], ["NADH-ubiquinone oxidoreductase", "GENE_OR_GENE_PRODUCT", 153, 183], ["reference genes", "DNA", 15, 30], ["18S rRNA", "DNA", 44, 52], ["EF", "DNA", 54, 56], ["1alpha", "DNA", 57, 63], ["non-regulated genes", "DNA", 78, 97], ["SEC13", "DNA", 127, 132], ["NADH", "PROTEIN", 153, 157], ["ubiquinone oxidoreductase 19 kDa subunit", "PROTEIN", 158, 198], ["18S rRNA", "DNA", 265, 273], ["18S rRNA", "TEST", 44, 52], ["EF", "TEST", 54, 56], ["1alpha", "TEST", 57, 63], ["the microarray", "TEST", 103, 117], ["SEC13", "TEST", 127, 132], ["protein", "TEST", 141, 148], ["NADH", "TEST", 153, 157], ["ubiquinone oxidoreductase 19 kDa subunit", "TREATMENT", 158, 198], ["18S rRNA", "TEST", 265, 273], ["stability", "OBSERVATION_MODIFIER", 296, 305]]], ["PCR assays were optimized using 2 \u00d7 SYBR\u00ae Green Master Mix (Roche Diagnostics) and varying amounts of cDNA and primer concentrations.", [["PCR assays", "TEST", 0, 10], ["cDNA and primer concentrations", "TREATMENT", 102, 132]]], ["Optimal PCR conditions in a 12 \u03bcl reaction volume were 3 \u03bcl 1:10 diluted cDNA for all assays (1:2000 for 18S rRNA).", [["Optimal PCR conditions", "TEST", 0, 22], ["a 12 \u03bcl reaction volume", "TEST", 26, 49], ["all assays", "TEST", 82, 92]]], ["Primer concentrations were 0.4\u20130.6 \u03bcM.", [["Primer concentrations", "TEST", 0, 21]]], ["PCR was performed in duplicates (triplicates for E-curves) in 96-well optical plates on LightCycler 480 (Roche Diagnostics).", [["PCR", "TEST", 0, 3], ["E-curves", "TEST", 49, 57], ["LightCycler", "TEST", 88, 99]]], ["Cycle threshold (CT) values were calculated using both the fit points and second derivative methods (Roche Diagnostics), with respective rejection of CT values above 37 and 35.", [["Cycle threshold", "TEST", 0, 15], ["CT) values", "TEST", 17, 27], ["second derivative methods", "TREATMENT", 74, 99], ["CT values", "TEST", 150, 159], ["rejection", "OBSERVATION", 137, 146]]], ["Relative expression of mRNA was calculated using the \u0394\u0394CT method adjusted for E. Statistics was calculated using Unistat version 5.5 (Unistat, London, UK).", [["mRNA", "RNA", 23, 27], ["the \u0394\u0394CT method", "TREATMENT", 49, 64], ["Unistat version", "TREATMENT", 113, 128]]], ["Difference between groups was analyzed with ANOVA with subsequent Newman-Keuls test (p < 0.05).", [["Keuls test", "TEST", 73, 83]]], ["The design of analyses and numbers of samples are indicated in Table 3.Development and verification of predictors based on qPCR analyses ::: MethodsEight genes were chosen for the development of predictors based on results from microarray analyses of the liver (Table 3).", [["samples", "ANATOMY", 38, 45], ["liver", "ANATOMY", 255, 260], ["samples", "CANCER", 38, 45], ["liver", "ORGAN", 255, 260], ["numbers of samples", "TEST", 27, 45], ["qPCR analyses", "TEST", 123, 136], ["microarray analyses", "TEST", 228, 247], ["liver", "ANATOMY", 255, 260]]], ["A training group included six fish from EM plus six fish from LM.", [["fish", "ORGANISM", 30, 34], ["fish", "ORGANISM", 52, 56], ["A training group", "TREATMENT", 0, 16], ["LM", "ANATOMY", 62, 64]]], ["The CT values as determined by qPCR were processed with linear discriminant analyses using Statistica 6.0.", [["The CT values", "TEST", 0, 13], ["qPCR", "TEST", 31, 35], ["Statistica", "TEST", 91, 101]]], ["The prediction function was verified with independent samples from all study groups (10 individuals from control, 9 from EM, 14 from IM and 12 from LM).Availability and requirementsThe National Animal Research Authority:Competing interestsThe author(s) declare that they have no competing interests.Authors' contributionsSMJ and AK designed the study, conducted gene expression analyses and drafted the manuscript.", [["The prediction function", "TEST", 0, 23], ["all study groups", "TEST", 67, 83], ["the study", "TEST", 341, 350]]], ["SA developed software for processing of microarray data and performed the statistical analyses.", [["microarray data", "TEST", 40, 55], ["the statistical analyses", "TEST", 70, 94]]]], "d027bd00b6bded2ec7a8f95ef688978411024314": [["Dear Sir,Myalgia is a common symptom in patients with viral infections such as novel coronavirus disease 2019 (COVID-19) and influenza.", [["Myalgia", "DISEASE", 9, 16], ["viral infections", "DISEASE", 54, 70], ["coronavirus disease", "DISEASE", 85, 104], ["COVID-19", "CHEMICAL", 111, 119], ["influenza", "DISEASE", 125, 134], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["Myalgia", "PROBLEM", 9, 16], ["a common symptom", "PROBLEM", 20, 36], ["viral infections", "PROBLEM", 54, 70], ["novel coronavirus disease", "PROBLEM", 79, 104], ["COVID", "TEST", 111, 116], ["influenza", "PROBLEM", 125, 134]]], ["Myalgia reflects generalized inflammation and cytokine response and can be the onset symptom of 36% of patients with COVID-19 [1] .", [["Myalgia", "DISEASE", 0, 7], ["inflammation", "DISEASE", 29, 41], ["COVID-19", "CHEMICAL", 117, 125], ["patients", "ORGANISM", 103, 111], ["cytokine", "PROTEIN", 46, 54], ["patients", "SPECIES", 103, 111], ["Myalgia", "PROBLEM", 0, 7], ["generalized inflammation", "PROBLEM", 17, 41], ["cytokine response", "PROBLEM", 46, 63], ["COVID", "TEST", 117, 122], ["generalized", "OBSERVATION_MODIFIER", 17, 28], ["inflammation", "OBSERVATION", 29, 41], ["cytokine response", "OBSERVATION", 46, 63]]], ["Back pain in COVID-19 may usually indicate pneumonia.", [["Back pain", "DISEASE", 0, 9], ["pneumonia", "DISEASE", 43, 52], ["Back pain", "PROBLEM", 0, 9], ["COVID", "TEST", 13, 18], ["pneumonia", "PROBLEM", 43, 52], ["pain", "OBSERVATION", 5, 9], ["pneumonia", "OBSERVATION", 43, 52]]], ["Why is the common myalgia caused by COVID-19 longer and more severe than myalgia of other viral infections?", [["myalgia", "DISEASE", 18, 25], ["myalgia", "DISEASE", 73, 80], ["viral infections", "DISEASE", 90, 106], ["the common myalgia", "PROBLEM", 7, 25], ["COVID", "TEST", 36, 41], ["myalgia", "PROBLEM", 73, 80], ["other viral infections", "PROBLEM", 84, 106], ["common myalgia", "ANATOMY", 11, 25], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["infections", "OBSERVATION", 96, 106]]], ["Myalgia and fatigue in patients with COVID-19 may be longer in duration than other viral infections and may be unresponsive to conventional painkillers.", [["Myalgia", "DISEASE", 0, 7], ["fatigue", "DISEASE", 12, 19], ["COVID-19", "CHEMICAL", 37, 45], ["viral infections", "DISEASE", 83, 99], ["COVID-19", "CHEMICAL", 37, 45], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["Myalgia", "PROBLEM", 0, 7], ["fatigue", "PROBLEM", 12, 19], ["COVID", "TEST", 37, 42], ["other viral infections", "PROBLEM", 77, 99], ["conventional painkillers", "TREATMENT", 127, 151], ["fatigue", "OBSERVATION", 12, 19], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["infections", "OBSERVATION", 89, 99]]], ["According to our observation, when viral load is reduced with virus treatment, muscle pain may decrease.", [["muscle", "ANATOMY", 79, 85], ["muscle pain", "DISEASE", 79, 90], ["muscle", "ORGAN", 79, 85], ["viral load", "PROBLEM", 35, 45], ["virus treatment", "TREATMENT", 62, 77], ["muscle pain", "PROBLEM", 79, 90], ["muscle", "ANATOMY", 79, 85]]], ["In addition to the classic mechanisms of myalgia known in viral infections, COVID-19 can cause musculoskeletal pain with completely different mechanisms.Dear Sir,COVID-19 enters the cell by penetrating ACE2 at low cytosolic pH and causes infection in the pulmonary system [2, 3] .", [["musculoskeletal", "ANATOMY", 95, 110], ["cell", "ANATOMY", 182, 186], ["cytosolic", "ANATOMY", 214, 223], ["pulmonary system", "ANATOMY", 255, 271], ["myalgia", "DISEASE", 41, 48], ["viral infections", "DISEASE", 58, 74], ["COVID-19", "CHEMICAL", 76, 84], ["musculoskeletal pain", "DISEASE", 95, 115], ["COVID-19", "CHEMICAL", 162, 170], ["infection", "DISEASE", 238, 247], ["COVID-19", "CHEMICAL", 76, 84], ["myalgia", "ORGANISM_SUBDIVISION", 41, 48], ["COVID-19", "SIMPLE_CHEMICAL", 162, 170], ["cell", "CELL", 182, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 202, 206], ["pulmonary", "ORGAN", 255, 264], ["ACE2", "PROTEIN", 202, 206], ["myalgia", "PROBLEM", 41, 48], ["viral infections", "PROBLEM", 58, 74], ["COVID", "TREATMENT", 76, 81], ["musculoskeletal pain", "PROBLEM", 95, 115], ["COVID", "TEST", 162, 167], ["penetrating ACE2 at low cytosolic pH", "PROBLEM", 190, 226], ["infection in the pulmonary system", "PROBLEM", 238, 271], ["myalgia", "OBSERVATION", 41, 48], ["viral infections", "OBSERVATION", 58, 74], ["musculoskeletal", "ANATOMY", 95, 110], ["infection", "OBSERVATION", 238, 247], ["pulmonary system", "ANATOMY", 255, 271]]], ["The presence of ACE2 has also been demonstrated in the brain, kidney, vascular smooth muscle, and skeletal muscles [4, 5] .", [["brain", "ANATOMY", 55, 60], ["kidney", "ANATOMY", 62, 68], ["vascular smooth muscle", "ANATOMY", 70, 92], ["skeletal muscles", "ANATOMY", 98, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["brain", "ORGAN", 55, 60], ["kidney", "ORGAN", 62, 68], ["vascular smooth muscle", "TISSUE", 70, 92], ["skeletal muscles", "TISSUE", 98, 114], ["ACE2", "PROTEIN", 16, 20], ["ACE2", "PROBLEM", 16, 20], ["ACE2", "OBSERVATION", 16, 20], ["brain", "ANATOMY", 55, 60], ["kidney", "ANATOMY", 62, 68], ["vascular", "ANATOMY_MODIFIER", 70, 78], ["smooth muscle", "ANATOMY", 79, 92], ["skeletal muscles", "ANATOMY", 98, 114]]], ["A recent article reported that lactate levels increased due to surplus cell damage during COVID-19 infection [6] .", [["cell", "ANATOMY", 71, 75], ["lactate", "CHEMICAL", 31, 38], ["COVID-19", "CHEMICAL", 90, 98], ["infection", "DISEASE", 99, 108], ["lactate", "CHEMICAL", 31, 38], ["COVID-19", "CHEMICAL", 90, 98], ["lactate", "SIMPLE_CHEMICAL", 31, 38], ["cell", "CELL", 71, 75], ["lactate levels", "TEST", 31, 45], ["surplus cell damage", "PROBLEM", 63, 82], ["COVID-19 infection", "PROBLEM", 90, 108], ["surplus cell damage", "OBSERVATION", 63, 82]]], ["In hyperlactatemia, the oxygen-carrying capacity of erythrocytes to the tissues is impaired and the tissues remain hypoxic.", [["erythrocytes", "ANATOMY", 52, 64], ["tissues", "ANATOMY", 72, 79], ["tissues", "ANATOMY", 100, 107], ["hyperlactatemia", "DISEASE", 3, 18], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["erythrocytes", "CELL", 52, 64], ["tissues", "TISSUE", 72, 79], ["tissues", "TISSUE", 100, 107], ["erythrocytes", "CELL_TYPE", 52, 64], ["hyperlactatemia", "PROBLEM", 3, 18], ["the oxygen", "TREATMENT", 20, 30], ["hypoxic", "PROBLEM", 115, 122], ["hyperlactatemia", "OBSERVATION", 3, 18], ["oxygen", "OBSERVATION_MODIFIER", 24, 30], ["erythrocytes", "OBSERVATION", 52, 64], ["tissues", "ANATOMY", 72, 79], ["impaired", "OBSERVATION", 83, 91], ["hypoxic", "OBSERVATION", 115, 122]]], ["The virus can spread through the bloodstream or vascular endothelium and cause infection in all tissues containing ACE2 such as the heart and brain.", [["bloodstream", "ANATOMY", 33, 44], ["vascular endothelium", "ANATOMY", 48, 68], ["tissues", "ANATOMY", 96, 103], ["heart", "ANATOMY", 132, 137], ["brain", "ANATOMY", 142, 147], ["infection", "DISEASE", 79, 88], ["vascular endothelium", "TISSUE", 48, 68], ["tissues", "TISSUE", 96, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["heart", "ORGAN", 132, 137], ["brain", "ORGAN", 142, 147], ["ACE2", "PROTEIN", 115, 119], ["The virus", "PROBLEM", 0, 9], ["infection in all tissues", "PROBLEM", 79, 103], ["virus", "OBSERVATION", 4, 9], ["bloodstream", "OBSERVATION", 33, 44], ["vascular endothelium", "ANATOMY", 48, 68], ["infection", "OBSERVATION", 79, 88], ["heart", "ANATOMY", 132, 137], ["brain", "ANATOMY", 142, 147]]], ["Therefore, the musculoskeletal system can also undergo infection.", [["musculoskeletal system", "ANATOMY", 15, 37], ["infection", "DISEASE", 55, 64], ["infection", "PROBLEM", 55, 64], ["musculoskeletal system", "ANATOMY", 15, 37], ["infection", "OBSERVATION", 55, 64]]], ["Increasing creatinine kinase levels during COVID-19 infection proves muscle involvement.Dear Sir,When muscle tissue cannot provide the necessary energy in aerobic ways during exercise, lactate begins to accumulate in the muscles.", [["muscle", "ANATOMY", 69, 75], ["muscle tissue", "ANATOMY", 102, 115], ["muscles", "ANATOMY", 221, 228], ["creatinine", "CHEMICAL", 11, 21], ["COVID-19", "CHEMICAL", 43, 51], ["infection", "DISEASE", 52, 61], ["lactate", "CHEMICAL", 185, 192], ["creatinine", "CHEMICAL", 11, 21], ["lactate", "CHEMICAL", 185, 192], ["creatinine kinase", "GENE_OR_GENE_PRODUCT", 11, 28], ["COVID-19", "GENE_OR_GENE_PRODUCT", 43, 51], ["muscle", "ORGAN", 69, 75], ["muscle tissue", "TISSUE", 102, 115], ["lactate", "SIMPLE_CHEMICAL", 185, 192], ["muscles", "ORGAN", 221, 228], ["creatinine kinase", "PROTEIN", 11, 28], ["Increasing creatinine kinase levels", "PROBLEM", 0, 35], ["COVID", "TEST", 43, 48], ["infection", "PROBLEM", 52, 61], ["muscle involvement", "PROBLEM", 69, 87], ["lactate", "TEST", 185, 192], ["infection", "OBSERVATION", 52, 61], ["muscle", "ANATOMY", 69, 75], ["muscles", "ANATOMY", 221, 228]]], ["Monocarboxylate transporter (MCT) (synonym, lactate/H + ion symporter) is activated to prevent lactate accumulation [7] .", [["Monocarboxylate", "CHEMICAL", 0, 15], ["lactate", "CHEMICAL", 44, 51], ["H", "CHEMICAL", 52, 53], ["lactate", "CHEMICAL", 95, 102], ["Monocarboxylate", "CHEMICAL", 0, 15], ["lactate", "CHEMICAL", 44, 51], ["H +", "CHEMICAL", 52, 55], ["lactate", "CHEMICAL", 95, 102], ["Monocarboxylate transporter", "GENE_OR_GENE_PRODUCT", 0, 27], ["MCT", "GENE_OR_GENE_PRODUCT", 29, 32], ["lactate", "SIMPLE_CHEMICAL", 44, 51], ["H + ion symporter", "GENE_OR_GENE_PRODUCT", 52, 69], ["lactate", "SIMPLE_CHEMICAL", 95, 102], ["Monocarboxylate transporter", "PROTEIN", 0, 27], ["MCT", "PROTEIN", 29, 32], ["lactate/H + ion symporter", "PROTEIN", 44, 69], ["Monocarboxylate transporter", "TEST", 0, 27], ["lactate", "TEST", 44, 51], ["lactate accumulation", "PROBLEM", 95, 115]]], ["MCT pumps lactate and H + ion simultaneously from the extracellular space to the intracellular space and from the intracellular space to the mitochondria.", [["extracellular space", "ANATOMY", 54, 73], ["intracellular space", "ANATOMY", 81, 100], ["intracellular space", "ANATOMY", 114, 133], ["mitochondria", "ANATOMY", 141, 153], ["lactate", "CHEMICAL", 10, 17], ["H", "CHEMICAL", 22, 23], ["lactate", "CHEMICAL", 10, 17], ["H +", "CHEMICAL", 22, 25], ["MCT", "GENE_OR_GENE_PRODUCT", 0, 3], ["lactate", "SIMPLE_CHEMICAL", 10, 17], ["H +", "SIMPLE_CHEMICAL", 22, 25], ["extracellular space", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 73], ["intracellular space", "CELLULAR_COMPONENT", 81, 100], ["intracellular space", "CELLULAR_COMPONENT", 114, 133], ["mitochondria", "CELLULAR_COMPONENT", 141, 153], ["MCT pumps lactate", "TEST", 0, 17], ["extracellular space", "OBSERVATION", 54, 73], ["intracellular space", "ANATOMY", 81, 100], ["intracellular space", "OBSERVATION", 114, 133], ["mitochondria", "ANATOMY", 141, 153]]], ["In anaerobic conditions, lactate dehydrogenase (LDH) increases lactate formation from pyruvate [7, 8] .", [["lactate", "CHEMICAL", 25, 32], ["lactate", "CHEMICAL", 63, 70], ["pyruvate", "CHEMICAL", 86, 94], ["lactate", "CHEMICAL", 25, 32], ["lactate", "CHEMICAL", 63, 70], ["pyruvate", "CHEMICAL", 86, 94], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 25, 46], ["LDH", "SIMPLE_CHEMICAL", 48, 51], ["lactate", "SIMPLE_CHEMICAL", 63, 70], ["pyruvate", "SIMPLE_CHEMICAL", 86, 94], ["lactate dehydrogenase", "PROTEIN", 25, 46], ["LDH", "PROTEIN", 48, 51], ["anaerobic conditions", "TEST", 3, 23], ["lactate dehydrogenase", "TEST", 25, 46], ["LDH)", "TEST", 48, 52], ["lactate formation", "TEST", 63, 80], ["pyruvate", "TEST", 86, 94], ["anaerobic conditions", "OBSERVATION", 3, 23]]], ["Under normal conditions, MCTs increase between 32 and 76% during exercise [7, 8] .", [["MCTs", "GENE_OR_GENE_PRODUCT", 25, 29], ["normal conditions", "OBSERVATION", 6, 23]]], ["During intensive exercise, MCT capacities may increase up to 3-4 times as maximum [7] .", [["MCT", "GENE_OR_GENE_PRODUCT", 27, 30], ["MCT capacities", "PROBLEM", 27, 41], ["increase", "OBSERVATION_MODIFIER", 46, 54]]], ["Due to exceeding the capacity of MCTs and other regulatory pumps, lactate and H + ion accumulation occur in the cytosol, and the cytosol pH decreases [8] .", [["cytosol", "ANATOMY", 112, 119], ["cytosol", "ANATOMY", 129, 136], ["lactate", "CHEMICAL", 66, 73], ["H", "CHEMICAL", 78, 79], ["lactate", "CHEMICAL", 66, 73], ["H +", "CHEMICAL", 78, 81], ["MCTs", "GENE_OR_GENE_PRODUCT", 33, 37], ["lactate", "SIMPLE_CHEMICAL", 66, 73], ["H +", "SIMPLE_CHEMICAL", 78, 81], ["cytosol", "CELLULAR_COMPONENT", 112, 119], ["cytosol", "CELLULAR_COMPONENT", 129, 136], ["MCTs", "TEST", 33, 37], ["other regulatory pumps", "TREATMENT", 42, 64], ["lactate", "TEST", 66, 73], ["ion accumulation", "PROBLEM", 82, 98], ["the cytosol", "TEST", 108, 119], ["the cytosol pH", "TEST", 125, 139]]], ["ATP synthesis is reduced due to anaerobic glycolysis.", [["ATP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["ATP synthesis", "PROBLEM", 0, 13], ["anaerobic glycolysis", "PROBLEM", 32, 52], ["reduced", "OBSERVATION_MODIFIER", 17, 24], ["anaerobic glycolysis", "OBSERVATION", 32, 52]]], ["Decreased ATP synthesis and low intracellular pH cause pain and fatigue [7, 9] .", [["intracellular", "ANATOMY", 32, 45], ["ATP", "CHEMICAL", 10, 13], ["pain", "DISEASE", 55, 59], ["fatigue", "DISEASE", 64, 71], ["ATP", "CHEMICAL", 10, 13], ["ATP", "SIMPLE_CHEMICAL", 10, 13], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["Decreased ATP synthesis", "PROBLEM", 0, 23], ["low intracellular pH", "PROBLEM", 28, 48], ["pain", "PROBLEM", 55, 59], ["fatigue", "PROBLEM", 64, 71], ["ATP synthesis", "OBSERVATION", 10, 23], ["low", "OBSERVATION_MODIFIER", 28, 31]]], ["In hyperlactatemia, the oxygen-carrying capacity of erythrocytes and the transport of oxygen to the tissues are highly reduced.", [["erythrocytes", "ANATOMY", 52, 64], ["tissues", "ANATOMY", 100, 107], ["hyperlactatemia", "DISEASE", 3, 18], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 86, 92], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 86, 92], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["erythrocytes", "CELL", 52, 64], ["oxygen", "SIMPLE_CHEMICAL", 86, 92], ["tissues", "TISSUE", 100, 107], ["erythrocytes", "CELL_TYPE", 52, 64], ["hyperlactatemia", "PROBLEM", 3, 18], ["the oxygen-carrying capacity of erythrocytes", "PROBLEM", 20, 64], ["the transport of oxygen", "TREATMENT", 69, 92], ["hyperlactatemia", "OBSERVATION", 3, 18], ["oxygen", "OBSERVATION_MODIFIER", 24, 30], ["tissues", "ANATOMY", 100, 107], ["highly", "OBSERVATION_MODIFIER", 112, 118], ["reduced", "OBSERVATION", 119, 126]]], ["As if exercising intensely, the musculoskeletal system may remain deoxygenated and muscles may take place ischemic during COVID-19 infection.", [["musculoskeletal system", "ANATOMY", 32, 54], ["muscles", "ANATOMY", 83, 90], ["infection", "DISEASE", 131, 140], ["muscles", "ORGAN", 83, 90], ["ischemic", "PROBLEM", 106, 114], ["COVID-19 infection", "PROBLEM", 122, 140], ["musculoskeletal", "ANATOMY", 32, 47], ["muscles", "ANATOMY", 83, 90], ["infection", "OBSERVATION", 131, 140]]], ["Therefore, pain may occur in the muscle tissues remaining ischemic with a mechanism similar to sickle cell disease.", [["muscle tissues", "ANATOMY", 33, 47], ["sickle cell", "ANATOMY", 95, 106], ["pain", "DISEASE", 11, 15], ["sickle cell disease", "DISEASE", 95, 114], ["muscle tissues", "TISSUE", 33, 47], ["sickle cell", "CELL", 95, 106], ["pain", "PROBLEM", 11, 15], ["ischemic", "PROBLEM", 58, 66], ["sickle cell disease", "PROBLEM", 95, 114], ["muscle tissues", "ANATOMY", 33, 47], ["ischemic", "OBSERVATION", 58, 66], ["sickle cell disease", "OBSERVATION", 95, 114]]], ["Also, during the hypoxic ischemia, the increase of growth factors, cytokines levels, ischemic conditions, and microvascular changes can trigger pain by overexpression in the dorsal root ganglion [10] .Dear Sir,In conclusion, LDH increases when the virus damages muscles and other tissues.", [["microvascular", "ANATOMY", 110, 123], ["dorsal root ganglion", "ANATOMY", 174, 194], ["muscles", "ANATOMY", 262, 269], ["tissues", "ANATOMY", 280, 287], ["ischemia", "DISEASE", 25, 33], ["pain", "DISEASE", 144, 148], ["microvascular", "MULTI-TISSUE_STRUCTURE", 110, 123], ["LDH", "GENE_OR_GENE_PRODUCT", 225, 228], ["muscles", "ORGAN", 262, 269], ["tissues", "TISSUE", 280, 287], ["growth factors", "PROTEIN", 51, 65], ["cytokines", "PROTEIN", 67, 76], ["the hypoxic ischemia", "PROBLEM", 13, 33], ["growth factors", "PROBLEM", 51, 65], ["cytokines levels", "TEST", 67, 83], ["ischemic conditions", "PROBLEM", 85, 104], ["microvascular changes", "PROBLEM", 110, 131], ["pain", "PROBLEM", 144, 148], ["overexpression in the dorsal root ganglion", "PROBLEM", 152, 194], ["LDH", "TEST", 225, 228], ["the virus damages muscles and other tissues", "PROBLEM", 244, 287], ["hypoxic", "OBSERVATION_MODIFIER", 17, 24], ["ischemia", "OBSERVATION", 25, 33], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["growth", "OBSERVATION_MODIFIER", 51, 57], ["ischemic", "OBSERVATION_MODIFIER", 85, 93], ["microvascular", "ANATOMY", 110, 123], ["dorsal", "ANATOMY_MODIFIER", 174, 180], ["root ganglion", "ANATOMY", 181, 194]]], ["Due to both increased LDH and anaerobic glycolysis, lactate level may increase excessively.", [["lactate", "CHEMICAL", 52, 59], ["lactate", "CHEMICAL", 52, 59], ["LDH", "SIMPLE_CHEMICAL", 22, 25], ["lactate", "SIMPLE_CHEMICAL", 52, 59], ["both increased LDH and anaerobic glycolysis", "PROBLEM", 7, 50], ["lactate level", "TEST", 52, 65], ["both", "OBSERVATION_MODIFIER", 7, 11], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["LDH", "ANATOMY", 22, 25], ["anaerobic glycolysis", "OBSERVATION", 30, 50]]], ["Cytosolic pH may decrease more.", [["Cytosolic", "ORGANISM_SUBSTANCE", 0, 9], ["Cytosolic pH", "TEST", 0, 12], ["decrease", "OBSERVATION_MODIFIER", 17, 25]]], ["Muscle pain may increase", [["Muscle", "ANATOMY", 0, 6], ["Muscle pain", "DISEASE", 0, 11], ["Muscle", "ORGAN", 0, 6], ["Muscle pain", "PROBLEM", 0, 11], ["increase", "OBSERVATION_MODIFIER", 16, 24]]]], "ebadaaaf1d5948fae5ecf78a61d18a7db3e0ca4b": [["IntroductionThe clinical burden of COVID-19 in the current pandemic is undoubtedly considerable, but the socioeconomic burden must equally weigh in determining how the world will move forward until either an effective chemotherapy and/or vaccine is devised [1] .", [["COVID-19", "CHEMICAL", 35, 43], ["COVID", "TEST", 35, 40], ["the socioeconomic burden", "PROBLEM", 101, 125], ["an effective chemotherapy", "TREATMENT", 205, 230], ["vaccine", "TREATMENT", 238, 245]]], ["Pending that such success in treatment and/or prevention are achieved, the continuous or relapsing lockdown of societies and hence economies has the potential to cause more damage than may be initially apparent [2] .", [["treatment", "TREATMENT", 29, 38]]], ["Indeed, it could be prognosticated that the relative economic standstill may cause more damage to humanity than the disease itself.", [["the disease itself", "PROBLEM", 112, 130], ["disease", "OBSERVATION", 116, 123]]], ["Many countries have attempted to partially restore pre-pandemic functions only to experience yet second waves of increasing infections during July and August, 2020.", [["infections", "DISEASE", 124, 134], ["increasing infections", "PROBLEM", 113, 134], ["increasing", "OBSERVATION_MODIFIER", 113, 123], ["infections", "OBSERVATION", 124, 134]]], ["To some, the answer may be to tolerate the expectations of herd immunity with lesser in the way of resistance to infection spread [3, 4] .", [["infection", "DISEASE", 113, 122], ["herd", "ORGANISM_SUBDIVISION", 59, 63], ["herd immunity", "TREATMENT", 59, 72], ["infection spread", "PROBLEM", 113, 129], ["infection", "OBSERVATION", 113, 122]]], ["To others at the other end of the spectrum, a more cautious approach has been to create the best environment for disease prevention while patching holes for or propping up failures in the economy as they appear [3] .", [["disease prevention", "TREATMENT", 113, 131], ["patching holes", "TREATMENT", 138, 152]]], ["Somewhere in the midst of this maelstrom, there will need to be practical strategies for achieving success with both the pandemic and the economies simultaneously.", [["practical strategies", "TREATMENT", 64, 84]]], ["Contexts of disease and economy will no doubt vary along a spectrum and may require somewhat different approaches in their detail.IntroductionIn this review, a minimalist strategy is proposed to in part provide some solutions towards regaining economic focus while preventing disease.", [["disease", "PROBLEM", 12, 19], ["a minimalist strategy", "TREATMENT", 158, 179], ["some solutions", "TREATMENT", 211, 225], ["disease", "PROBLEM", 276, 283], ["disease", "OBSERVATION", 12, 19]]], ["These steps are a modest beginning from the perspective of devising recognition for protective immunity that will progressively allow segments of society to proceed with their lives as they once were or nearly so.", [["protective immunity", "TREATMENT", 84, 103]]], ["Such a strategy will thereafter be enhanced as treatment or vaccine developments arise.Provisional Acceptance of What Constitutes ImmunityStudies with passive immunity are highly suggestive that antibody has a significant role in protection of coronavirus infection [5] [6] [7] [8] [9] [10] [11] [12] .", [["coronavirus infection", "DISEASE", 244, 265], ["[5] [6] [7] [8] [9] [10] [11]", "CHEMICAL", 266, 295], ["coronavirus", "ORGANISM", 244, 255], ["[5] [6] [7] [8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 266, 300], ["treatment", "TREATMENT", 47, 56], ["vaccine developments", "TREATMENT", 60, 80], ["passive immunity", "PROBLEM", 151, 167], ["coronavirus infection", "PROBLEM", 244, 265]]], ["The latter includes passive administration of anti-SARS-CoV-2 human monoclonal antibody in animal systems [13] .", [["anti-SARS-CoV-2", "ORGANISM", 46, 61], ["human", "ORGANISM", 62, 67], ["anti-SARS-CoV-2 human monoclonal antibody", "PROTEIN", 46, 87], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["anti-SARS", "TEST", 46, 55], ["CoV", "TEST", 56, 59]]], ["These findings are critical to our theme since direct antibody in some way may be used as the correlate with neutralization if not directly then by association.", [["direct antibody", "TREATMENT", 47, 62]]], ["Therefore, the prospects of finding a serological assay based on antibody detection that defines in some way neutralization and then after disease prevention are considerable.Provisional Acceptance of What Constitutes ImmunityInfection with coronaviruses generally protects against reinfection [12, [14] [15] [16] [17] [18] [19] [20] [21] [22] .", [["coronaviruses", "ORGANISM", 241, 254], ["[14] [15] [16] [17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 299, 343], ["a serological assay", "TEST", 36, 55], ["antibody detection", "TEST", 65, 83], ["disease prevention", "TREATMENT", 139, 157], ["coronaviruses", "PROBLEM", 241, 254], ["reinfection", "PROBLEM", 282, 293], ["neutralization", "OBSERVATION", 109, 123]]], ["Analogous to the role of passive immunity, pre-existing immunity can potentially be defined with the right measures.Provisional Acceptance of What Constitutes ImmunityBoth parenteral neutralizing antibody and secretory IgA (sIgA) are associated with protection in model systems [14, 15, [23] [24] [25] [26] [27] . sIgA has logistical problems with collection and analysis, although technological advances are quite likely capable of overcoming the latter.", [["secretory IgA", "GENE_OR_GENE_PRODUCT", 209, 222], ["sIgA", "GENE_OR_GENE_PRODUCT", 224, 228], ["[23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 287, 311], ["sIgA", "GENE_OR_GENE_PRODUCT", 314, 318], ["ImmunityBoth parenteral neutralizing antibody", "PROTEIN", 159, 204], ["secretory IgA", "PROTEIN", 209, 222], ["sIgA", "PROTEIN", 224, 228], ["sIgA", "PROTEIN", 314, 318], ["ImmunityBoth parenteral neutralizing antibody", "TEST", 159, 204], ["protection in model systems", "TEST", 250, 277], ["logistical problems", "PROBLEM", 323, 342], ["collection and analysis", "TEST", 348, 371], ["right", "ANATOMY_MODIFIER", 101, 106]]], ["Therefore and in the interim, serum neutralizing antibody measurements will generally be applied as the standard, and other correlates of the latter could be put into common use.Provisional Acceptance of What Constitutes ImmunityFor MERS, mild infection was associated with decreased antibody levels [28] [29] [30] .", [["serum", "ANATOMY", 30, 35], ["infection", "DISEASE", 244, 253], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["serum neutralizing antibody", "PROTEIN", 30, 57], ["serum neutralizing antibody measurements", "TEST", 30, 70], ["MERS", "PROBLEM", 233, 237], ["mild infection", "PROBLEM", 239, 253], ["decreased antibody levels", "PROBLEM", 274, 299], ["mild", "OBSERVATION_MODIFIER", 239, 243], ["infection", "OBSERVATION", 244, 253]]], ["Severe infections are associated with long-lived neutralizing antibody.", [["infections", "DISEASE", 7, 17], ["long-lived neutralizing antibody", "PROTEIN", 38, 70], ["Severe infections", "PROBLEM", 0, 17], ["long-lived neutralizing antibody", "PROBLEM", 38, 70], ["infections", "OBSERVATION", 7, 17], ["neutralizing antibody", "OBSERVATION", 49, 70]]], ["Increased neutralizing antibody is associated with decreased viral shedding, but there have not been enough natural infections to allow for study and analysis of natural protection as would be desirable.", [["infections", "DISEASE", 116, 126], ["neutralizing antibody", "PROTEIN", 10, 31], ["Increased neutralizing antibody", "PROBLEM", 0, 31], ["decreased viral shedding", "PROBLEM", 51, 75], ["natural infections", "PROBLEM", 108, 126], ["study", "TEST", 140, 145], ["analysis", "TEST", 150, 158], ["natural protection", "TREATMENT", 162, 180], ["neutralizing antibody", "OBSERVATION", 10, 31], ["decreased", "OBSERVATION_MODIFIER", 51, 60], ["viral shedding", "OBSERVATION", 61, 75], ["infections", "OBSERVATION", 116, 126]]], ["Likewise for SARS, field studies for the practical protective effects of neutralizing antibody could not be studied due to the short-lived spread of the virus.Provisional Acceptance of What Constitutes ImmunityIn studies for SARS-CoV-2, of over 700 control sera from uninfected patients, no neutralizing antibodies were found [31] .", [["sera", "ANATOMY", 257, 261], ["SARS", "DISEASE", 13, 17], ["SARS-CoV-2", "ORGANISM", 225, 235], ["sera", "ORGANISM_SUBSTANCE", 257, 261], ["patients", "ORGANISM", 278, 286], ["neutralizing antibody", "PROTEIN", 73, 94], ["neutralizing antibodies", "PROTEIN", 291, 314], ["patients", "SPECIES", 278, 286], ["SARS-CoV", "SPECIES", 225, 233], ["SARS", "PROBLEM", 13, 17], ["field studies", "TEST", 19, 32], ["neutralizing antibody", "TREATMENT", 73, 94], ["the virus", "PROBLEM", 149, 158], ["ImmunityIn studies", "TEST", 202, 220], ["SARS", "PROBLEM", 225, 229], ["CoV", "TEST", 230, 233], ["neutralizing antibodies", "TEST", 291, 314]]], ["Severe disease was associated with earlier generation of anti-SARS-CoV-2 antibody, and peak neutralizing antibody was measured at approximately 2 \u00bd weeks.", [["anti-SARS-CoV-2 antibody", "GENE_OR_GENE_PRODUCT", 57, 81], ["anti-SARS-CoV-2 antibody", "PROTEIN", 57, 81], ["peak neutralizing antibody", "PROTEIN", 87, 113], ["Severe disease", "PROBLEM", 0, 14], ["anti-SARS", "TEST", 57, 66], ["CoV-2 antibody", "TEST", 67, 81], ["peak neutralizing antibody", "TEST", 87, 113], ["disease", "OBSERVATION", 7, 14]]], ["Stereotypic antibody responses to SARS-CoV-2 led to hypotheses that there should be cross-reactivity with SARS-CoV in the constant RBD [32] .", [["SARS", "DISEASE", 34, 38], ["SARS", "DISEASE", 106, 110], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 106, 114], ["SARS-CoV", "SPECIES", 106, 114], ["Stereotypic antibody responses", "TEST", 0, 30], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["SARS", "PROBLEM", 106, 110]]], ["In both humans and animals, such cross-reactivity was suspected to be due to non-neutralizing anti-S antibody again likely relating to a conserved region [33] .", [["humans", "ORGANISM", 8, 14], ["anti-S antibody", "GENE_OR_GENE_PRODUCT", 94, 109], ["non-neutralizing anti-S antibody", "PROTEIN", 77, 109], ["humans", "SPECIES", 8, 14], ["humans", "SPECIES", 8, 14], ["non-neutralizing anti-S antibody", "PROBLEM", 77, 109], ["both", "ANATOMY_MODIFIER", 3, 7], ["humans", "ANATOMY", 8, 14]]], ["Crossneutralization was however uncommon, but conceivably there could be other reasons for any such non-specificity [34] [35] [36] .", [["any such non-specificity", "PROBLEM", 91, 115]]], ["Among humans, S-specific antibody dominates and may correlate better with neutralization [34, 35, 37] .", [["humans", "ORGANISM", 6, 12], ["S-specific antibody", "PROTEIN", 14, 33], ["humans", "SPECIES", 6, 12], ["humans", "SPECIES", 6, 12]]], ["Furthermore, the correlation between antibodies for different antigens (e.g., S and N proteins) may not be as initially conceived [35, 38] .", [["antibodies", "PROTEIN", 37, 47], ["antigens", "PROTEIN", 62, 70], ["S and N proteins", "PROTEIN", 78, 94], ["antibodies", "TEST", 37, 47], ["different antigens", "TEST", 52, 70], ["S and N proteins", "TEST", 78, 94]]], ["Human monoclonal antibodies that neutralize virus or pseudovirus especially recognized the RBD [39] .", [["RBD", "DISEASE", 91, 94], ["Human", "ORGANISM", 0, 5], ["pseudovirus", "ORGANISM", 53, 64], ["Human monoclonal antibodies", "PROTEIN", 0, 27], ["RBD", "PROTEIN", 91, 94], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human monoclonal antibodies", "TEST", 0, 27], ["neutralize virus", "PROBLEM", 33, 49], ["pseudovirus", "PROBLEM", 53, 64]]], ["Collaborative groups have found a strong association between neutralizing antibodies and IgG antibodies to the RBD [36, 40] .", [["RBD", "DISEASE", 111, 114], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 89, 103], ["neutralizing antibodies", "PROTEIN", 61, 84], ["IgG antibodies", "PROTEIN", 89, 103], ["RBD", "PROTEIN", 111, 114], ["neutralizing antibodies", "TEST", 61, 84], ["IgG antibodies", "TEST", 89, 103]]], ["Others have found strong correlations between neutralizing antibodies and EIA-detected antibodies to various SARS-CoV-2 antigens [41, 42] .Some have found diversity in immune responses contingent on the nature of presenting disease [38, 43] .", [["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 109, 128], ["neutralizing antibodies", "PROTEIN", 46, 69], ["antibodies", "PROTEIN", 87, 97], ["SARS-CoV-2 antigens", "PROTEIN", 109, 128], ["neutralizing antibodies", "TEST", 46, 69], ["EIA", "TEST", 74, 77], ["antibodies", "TEST", 87, 97], ["various SARS", "TEST", 101, 113], ["CoV", "TEST", 114, 117], ["presenting disease", "PROBLEM", 213, 231], ["diversity", "OBSERVATION", 155, 164], ["immune responses", "OBSERVATION", 168, 184]]], ["The latter would be consistent with the variable antibody responses now determined for the spectrum of pediatric disease [44] .", [["the variable antibody responses", "PROBLEM", 36, 67], ["pediatric disease", "PROBLEM", 103, 120], ["would be consistent with", "UNCERTAINTY", 11, 35]]], ["For EIA-based antibody studies otherwise, we have learned so far that the type and severity of disease and age may have bearing on the quality and quantity of antibody responses [34, [45] [46] [47] [48] .", [["EIA-based antibody studies", "TEST", 4, 30], ["disease", "PROBLEM", 95, 102], ["antibody responses", "TEST", 159, 177], ["disease", "OBSERVATION", 95, 102]]], ["Gender may also possibly affect antibody responses or other relevant immune responses [34, 49] .Provisional Acceptance of What Constitutes ImmunityDoes neutralization antibody ensure protection?", [["antibody responses", "TEST", 32, 50], ["may also possibly", "UNCERTAINTY", 7, 24]]], ["At this time, we can reasonably conclude that the existence of neutralizing antibody and its quantitation associate with protection against coronavirus infections.", [["coronavirus infections", "DISEASE", 140, 162], ["coronavirus", "ORGANISM", 140, 151], ["neutralizing antibody", "PROTEIN", 63, 84], ["coronavirus", "SPECIES", 140, 151], ["neutralizing antibody", "TREATMENT", 63, 84], ["coronavirus infections", "PROBLEM", 140, 162]]], ["What we cannot do, however, is guarantee that the presence of all such neutralizing antibody, as measured by conventional live virus neutralization methods in vitro, will ensure protection.", [["neutralizing antibody", "PROTEIN", 71, 92], ["all such neutralizing antibody", "PROBLEM", 62, 92], ["conventional live virus neutralization methods", "TREATMENT", 109, 155]]], ["That is, laboratory methods measure neutralization as so defined but not protection directly.", [["laboratory methods", "TEST", 9, 27]]], ["Therefore, it can be held that not all neutralization methods duly measure the same effect that leads to that neutralization outcome [50] .Provisional Acceptance of What Constitutes ImmunityIn essence, what creates an in vitro neutralization may or may not truly block viral entry, prevent intracellular events, or ameliorate disease.", [["intracellular", "ANATOMY", 290, 303], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 290, 303], ["all neutralization methods", "TREATMENT", 35, 61], ["intracellular events", "PROBLEM", 290, 310], ["ameliorate disease", "PROBLEM", 315, 333]]], ["One potential and theoretical approach to vetting sera that have a higher likelihood of indication for protection is to choose those with higher neutralizing titres.Provisional Acceptance of What Constitutes ImmunityThere are several limitations with the application of neutralization as a surrogate for protection [25, 51] .", [["sera", "ANATOMY", 50, 54], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["protection", "TREATMENT", 103, 113], ["higher neutralizing titres", "TREATMENT", 138, 164], ["neutralization", "TREATMENT", 270, 284], ["several", "OBSERVATION_MODIFIER", 226, 233]]], ["Infections with coronaviruses do not always lead to a major increase in such antibody.", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10], ["coronaviruses", "PROBLEM", 16, 29], ["a major increase in such antibody", "PROBLEM", 52, 85], ["coronaviruses", "OBSERVATION", 16, 29], ["major", "OBSERVATION_MODIFIER", 54, 59], ["increase", "OBSERVATION_MODIFIER", 60, 68]]], ["Previously acquired antibody is not always protective for subsequent infection, but low levels of antibody better correlate with susceptibility.", [["infection", "DISEASE", 69, 78], ["Previously acquired antibody", "PROBLEM", 0, 28], ["subsequent infection", "PROBLEM", 58, 78], ["low levels of antibody", "PROBLEM", 84, 106], ["not always", "UNCERTAINTY", 32, 42], ["infection", "OBSERVATION", 69, 78], ["low levels", "OBSERVATION_MODIFIER", 84, 94]]], ["Resistance is best to the homologous coronavirus, but susceptibility can be had to heterologous strains.", [["coronavirus", "ORGANISM", 37, 48], ["the homologous coronavirus", "PROBLEM", 22, 48], ["heterologous strains", "PROBLEM", 83, 103]]], ["There is also the prospect that subsequent changes in viral genome may be accompanied by changes in epitopes that afford neutralization with an accompanying change in neutralization capacity of post-infection or post-vaccination sera [52] .", [["sera", "ANATOMY", 229, 233], ["sera", "ORGANISM_SUBSTANCE", 229, 233], ["viral genome", "DNA", 54, 66], ["epitopes", "PROTEIN", 100, 108], ["subsequent changes in viral genome", "PROBLEM", 32, 66], ["changes in epitopes", "PROBLEM", 89, 108], ["neutralization", "TREATMENT", 121, 135], ["neutralization capacity", "PROBLEM", 167, 190], ["post-infection", "PROBLEM", 194, 208], ["post-vaccination sera", "TEST", 212, 233], ["viral genome", "OBSERVATION", 54, 66], ["neutralization capacity", "OBSERVATION", 167, 190]]], ["The latter may also be the prelude to emerging reports of possible SARS-CoV-2 repeat infections [54] .Provisional Acceptance of What Constitutes ImmunityThe traditional approach to determining antibody responses is likely to dominate the search for protective immunity, but due consideration and open-mindedness should be maintained for measuring T cell post-infection immunity and its correlates [55] [56] [57] [58] .The Need for Blocking Tests or Fingerprints in Confirmatory COVID-19 SeroepidemiologyWith the availability of viral antigen, most scientists in the know-how would be able to fashion a test for antibody determination in short order and most would likely choose an enzyme immunoassay (EIA) (or nearly equivalent non-enzymebased assay) for its potential of automation and widespread use.", [["T cell", "ANATOMY", 347, 353], ["infections", "DISEASE", 85, 95], ["infection", "DISEASE", 359, 368], ["SARS-CoV-2", "ORGANISM", 67, 77], ["T cell", "CELL", 347, 353], ["viral antigen", "PROTEIN", 528, 541], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["repeat infections", "PROBLEM", 78, 95], ["The traditional approach", "TREATMENT", 153, 177], ["open-mindedness", "TREATMENT", 296, 311], ["measuring T cell post-infection immunity", "PROBLEM", 337, 377], ["Blocking Tests", "TEST", 431, 445], ["Confirmatory COVID", "TEST", 465, 483], ["viral antigen", "PROBLEM", 528, 541], ["a test", "TEST", 600, 606], ["antibody determination", "TEST", 611, 633], ["an enzyme immunoassay", "TEST", 678, 699], ["may also be", "UNCERTAINTY", 11, 22]]], ["The latter is especially likely in the current context where a majority of serodiagnostic tests are of that methodology.", [["serodiagnostic tests", "TEST", 75, 95], ["especially likely", "UNCERTAINTY", 14, 31]]], ["The expeditious derivation of an EIA or equivalent is a common goal when serodiagnosis is deemed to be of potential value.", [["an EIA", "TEST", 30, 36]]], ["Whereas the creation of an EIA is seemingly a relatively easy task, the application of any such is where the test of the matter lies.", [["an EIA", "TEST", 24, 30], ["EIA", "OBSERVATION", 27, 30]]], ["Historically, whether for antibody or antigen detection, EIA approaches had a number of pitfalls that were repetitively realized for nearly every such system that was subsequently developed [59, 60] .", [["antibody", "PROBLEM", 26, 34], ["antigen detection", "TEST", 38, 55], ["EIA approaches", "TEST", 57, 71]]], ["As would naturally be desirable, an assay with very high sensitivity at the appropriate timing is one evident target.", [["an assay", "TEST", 33, 41], ["very high sensitivity", "PROBLEM", 47, 68]]], ["Furthermore, an assay with a highly specific result is another evident target.", [["an assay", "TEST", 13, 21]]], ["The reality of serodiagnostic systems, however, is that there is generally a gray or indeterminate zone where sensitivity and specificity collide [60] .", [["serodiagnostic systems", "TEST", 15, 37], ["indeterminate", "OBSERVATION_MODIFIER", 85, 98], ["zone", "OBSERVATION_MODIFIER", 99, 103]]], ["There is an intersection of true positive results and false positive results more or less in almost every system with few exceptions.", [["false positive results", "PROBLEM", 54, 76], ["positive", "OBSERVATION_MODIFIER", 60, 68]]], ["For whatever maneuver is conceived to diminish that overlap, EIA or an equivalent for antibody detection can be modulated to enhance predictive values in one direction or another, but commonly realizing that there will be a trade-off.The Need for Blocking Tests or Fingerprints in Confirmatory COVID-19 SeroepidemiologyThe application of a serodiagnostic assay for antibody postinfection or vaccine is furthermore complicated in its evaluation.", [["EIA", "TEST", 61, 64], ["antibody detection", "TEST", 86, 104], ["Blocking Tests", "TEST", 247, 261], ["Confirmatory COVID", "TEST", 281, 299], ["a serodiagnostic assay", "TEST", 338, 360], ["antibody postinfection", "PROBLEM", 365, 387], ["vaccine", "TREATMENT", 391, 398], ["its evaluation", "TEST", 429, 443]]], ["Typically, a standard set of known or presumed \"negative\" sera are tested as is a standard set of known or presumed \"positive\" sera.", [["sera", "ANATOMY", 58, 62], ["sera", "ANATOMY", 127, 131], ["sera", "ORGANISM_SUBSTANCE", 58, 62], ["sera", "ORGANISM_SUBSTANCE", 127, 131], ["\"positive\" sera", "PROBLEM", 116, 131]]], ["The jeopardy here is that the prevalence of true disease in the population of patients from whom sera are acquired can vary considerably.", [["sera", "ANATOMY", 97, 101], ["patients", "ORGANISM", 78, 86], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["patients", "SPECIES", 78, 86], ["true disease", "PROBLEM", 44, 56], ["disease", "OBSERVATION", 49, 56]]], ["There is an inherent bias in such assessments to ensure that the tested serum pool has a considerable number of true positive samples.", [["serum", "ANATOMY", 72, 77], ["samples", "ANATOMY", 126, 133], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["such assessments", "TEST", 29, 45], ["the tested serum pool", "TEST", 61, 82], ["true positive samples", "PROBLEM", 112, 133], ["inherent bias", "OBSERVATION", 12, 25]]], ["Given the functionality of these assays, the predictive values of positive or negative tests vary considerably depending on the prevalence of the infection in the population so studied [63] .", [["infection", "DISEASE", 146, 155], ["these assays", "TEST", 27, 39], ["the predictive values", "TEST", 41, 62], ["positive or negative tests", "PROBLEM", 66, 92], ["the infection", "PROBLEM", 142, 155], ["infection", "OBSERVATION", 146, 155]]], ["For example, even for a given high sensitivity and specificity, a reduction in prevalence from 30 to 3% can lead to a situation where the false positive assays nearly equal the number of true positive assays.", [["the false positive assays", "TEST", 134, 159], ["true positive assays", "PROBLEM", 187, 207]]], ["The latter scenario can occur when assessments are performed on preselected sera rather than on sera from patients prospectively collected in a larger population.", [["sera", "ANATOMY", 76, 80], ["sera", "ANATOMY", 96, 100], ["sera", "ORGANISM_SUBSTANCE", 76, 80], ["sera", "ORGANISM_SUBSTANCE", 96, 100], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["assessments", "TEST", 35, 46], ["sera", "TEST", 96, 100], ["larger", "OBSERVATION_MODIFIER", 144, 150], ["population", "OBSERVATION", 151, 161]]], ["Therefore, unless there is considerably widespread infection leading to a proportionately high seroprevalence, serodiagnostic tests will likely suffer with their predictive values.", [["infection", "DISEASE", 51, 60], ["widespread infection", "PROBLEM", 40, 60], ["serodiagnostic tests", "TEST", 111, 131], ["widespread", "OBSERVATION_MODIFIER", 40, 50], ["infection", "OBSERVATION", 51, 60]]], ["How would this dilemma then be potentially overcome?The Need for Blocking Tests or Fingerprints in Confirmatory COVID-19 SeroepidemiologyOne such approach to improving specificity would be to conduct blocking assays (direct or competitive) for positive sera in order to reduce the number of false positive tests [64] .", [["sera", "ANATOMY", 253, 257], ["sera", "ORGANISM_SUBSTANCE", 253, 257], ["Blocking Tests", "TEST", 65, 79], ["Confirmatory COVID", "TEST", 99, 117], ["blocking assays", "TEST", 200, 215], ["positive sera", "PROBLEM", 244, 257], ["false positive tests", "PROBLEM", 291, 311]]], ["This is a time-honored approach that is often forgotten when new serodiagnostic assays are initially created.", [["new serodiagnostic assays", "TEST", 61, 86]]], ["The implementation of a blocking step can be entered into an automated procedure in tandem from the start or may be performed as a confirmatory test.", [["a blocking step", "TREATMENT", 22, 37], ["an automated procedure", "TREATMENT", 58, 80], ["a confirmatory test", "TEST", 129, 148]]], ["The latter is especially suited to a scenario where the proportion of positive tests is low.", [["positive tests", "TEST", 70, 84], ["positive", "OBSERVATION", 70, 78], ["low", "OBSERVATION_MODIFIER", 88, 91]]], ["The simplicity of a blocking test mandates only a brief turnaround time if it is performed in an algorithmic second step.", [["a blocking test", "TEST", 18, 33]]], ["There may be various approaches to the definition of antigen used in the blocking test, but it would be best in the inaugural stages to choose antigen(s) that are deemed inherent to the neutralization effects seen in postinfectious sera.", [["sera", "ANATOMY", 232, 236], ["sera", "ORGANISM_SUBSTANCE", 232, 236], ["the blocking test", "TEST", 69, 86], ["the neutralization effects", "PROBLEM", 182, 208], ["postinfectious sera", "PROBLEM", 217, 236], ["neutralization", "OBSERVATION", 186, 200], ["postinfectious", "OBSERVATION_MODIFIER", 217, 231]]], ["Although it could prove that one antigen, e.g., RBD or spike protein sequence otherwise, may alone suffice, pilot studies would be better to work backwards after establishing the antigen-neutralization correlates as described above.", [["RBD", "PROTEIN", 48, 51], ["spike protein sequence", "PROTEIN", 55, 77], ["one antigen", "TEST", 29, 40], ["RBD", "PROBLEM", 48, 51], ["spike protein sequence", "PROBLEM", 55, 77], ["pilot studies", "TEST", 108, 121], ["the antigen", "TEST", 175, 186]]], ["Purity of the blocking antigen is essential to avoid non-specific competition of non-viral elements if virus is acquired from tissue cultures.", [["tissue cultures", "ANATOMY", 126, 141], ["tissue cultures", "CELL", 126, 141], ["blocking antigen", "PROTEIN", 14, 30], ["non-viral elements", "DNA", 81, 99], ["the blocking antigen", "TREATMENT", 10, 30], ["non-viral elements", "PROBLEM", 81, 99], ["virus", "PROBLEM", 103, 108], ["tissue cultures", "TEST", 126, 141]]], ["Another approach to a blocking assay would be the competition between antibody in the human serum specimen and a known monoclonal antibody with affinity to SARS-CoV-2.", [["serum specimen", "ANATOMY", 92, 106], ["human", "ORGANISM", 86, 91], ["serum specimen", "ORGANISM_SUBSTANCE", 92, 106], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 156, 166], ["monoclonal antibody", "PROTEIN", 119, 138], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["SARS-CoV", "SPECIES", 156, 164], ["a blocking assay", "TEST", 20, 36], ["the human serum specimen", "TEST", 82, 106], ["a known monoclonal antibody", "PROBLEM", 111, 138], ["SARS", "TEST", 156, 160], ["CoV", "TEST", 161, 164], ["monoclonal antibody", "OBSERVATION", 119, 138]]], ["Choice of a specific monoclonal antibody, or several for this purpose, requires specific characterization.", [["monoclonal antibody", "PROTEIN", 21, 40], ["a specific monoclonal antibody", "TEST", 10, 40], ["specific characterization", "TEST", 80, 105]]], ["There are many commercial assays for SARS-CoV-2 antibody that have emerged, but for a survey sample of several so assessed thus far, none has blocking assays as potentially part of the procedure [65] [66] [67] [68] [69] [70] [71] .", [["[65] [66] [67] [68] [69] [70]", "CHEMICAL", 195, 224], ["SARS-CoV-2", "ORGANISM", 37, 47], ["[66] [67] [68] [69] [70] [71]", "SIMPLE_CHEMICAL", 200, 229], ["SARS-CoV-2 antibody", "PROTEIN", 37, 56], ["SARS-CoV", "SPECIES", 37, 45], ["many commercial assays", "TEST", 10, 32], ["SARS", "PROBLEM", 37, 41], ["CoV-2 antibody", "TEST", 42, 56], ["a survey sample", "TEST", 84, 99]]], ["Developmental assays also commonly do not include blocking assays [72] [73] [74] .", [["Developmental assays", "TEST", 0, 20], ["blocking assays", "TEST", 50, 65]]], ["IgM assays are particularly an issue with non-specificity since apparent IgM rises may relate in part to solid phase (e.g., polystyrene) absorption or non-specific IgM antibody (e.g., rheumatoid factor).", [["polystyrene", "CHEMICAL", 124, 135], ["IgM", "GENE_OR_GENE_PRODUCT", 73, 76], ["polystyrene", "SIMPLE_CHEMICAL", 124, 135], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 184, 201], ["IgM", "PROTEIN", 0, 3], ["IgM", "PROTEIN", 73, 76], ["IgM antibody", "PROTEIN", 164, 176], ["rheumatoid factor", "PROTEIN", 184, 201], ["IgM assays", "TEST", 0, 10], ["apparent IgM rises", "PROBLEM", 64, 82], ["solid phase (e.g., polystyrene) absorption", "PROBLEM", 105, 147], ["non-specific IgM antibody", "PROBLEM", 151, 176], ["rheumatoid factor", "PROBLEM", 184, 201]]], ["Of note, early reports have now emerged of blocking assay variations for systems relating to either MERS-CoV or SARS-CoV-2 [75] [76] [77] .The Need for Blocking Tests or Fingerprints in Confirmatory COVID-19 SeroepidemiologyAs suggested above, antigen detection can also suffer from non-specificity, and this dilemma has now been found in some systems [78] [79] [80] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["MERS-CoV", "SPECIES", 100, 108], ["blocking assay variations for systems", "PROBLEM", 43, 80], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["Blocking Tests", "TEST", 152, 166], ["Confirmatory COVID", "TEST", 186, 204], ["antigen detection", "TEST", 244, 261]]], ["Again, a blocking assay in any such configuration for antigen detection has potential to resolve this critical issue especially when raising the threshold for the enhancement of sensitivity is being considered.The Need for Blocking Tests or Fingerprints in Confirmatory COVID-19 SeroepidemiologyA second approach, alone or alongside an EIA-blocking assay, could be immunoblotting.", [["a blocking assay", "TEST", 7, 23], ["antigen detection", "TEST", 54, 71], ["the enhancement of sensitivity", "PROBLEM", 159, 189], ["Blocking Tests", "TEST", 223, 237], ["Confirmatory COVID", "TEST", 257, 275], ["an EIA", "TEST", 333, 339]]], ["Again, it could prove that one antigen substrate may suffice, but it would be prudent to work backwards after establishing the antigen-neutralization correlates.", [["the antigen", "TEST", 123, 134]]], ["As experienced pointedly with Lyme disease or HIV infections, the immunoblot response can be considerably variable, but a confirmatory fingerprint or several fingerprints can be defined as minimal diagnostic thresholds.", [["Lyme disease", "DISEASE", 30, 42], ["HIV infections", "DISEASE", 46, 60], ["HIV", "ORGANISM", 46, 49], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 46, 49], ["Lyme disease", "PROBLEM", 30, 42], ["HIV infections", "PROBLEM", 46, 60], ["the immunoblot response", "TEST", 62, 85], ["a confirmatory fingerprint", "TEST", 120, 146], ["HIV infections", "OBSERVATION", 46, 60]]], ["A higher threshold stringency can enhance serodiagnostic specificity.", [["A higher threshold stringency", "PROBLEM", 0, 29], ["serodiagnostic specificity", "TEST", 42, 68]]], ["Guan and others provided some key insights in this regard with SARS-CoV immunoblotting, and it is only highly probable that similar findings will be had with SARS-CoV-2 [81] .", [["SARS-CoV", "SPECIES", 63, 71], ["CoV immunoblotting", "TEST", 68, 86], ["CoV", "TEST", 163, 166]]], ["Not all antigens identified in immunoblotting may have functions in neutralization, and likewise, there may be more antigens that are capable of inducing neutralization than are identified by resolving antigens in denaturing electrophoresis procedures [50] .", [["denaturing electrophoresis procedures", "TREATMENT", 214, 251]]], ["Given advances as detailed by Olvera et al. and several others, the fingerprint patterns could also conceivably be assessed with peptide sets rather than larger antigens which may bear non-specific epitopes [50, 81, 82] .", [["antigens", "PROTEIN", 161, 169], ["epitopes", "PROTEIN", 198, 206], ["peptide sets", "TEST", 129, 141], ["non-specific epitopes", "PROBLEM", 185, 206]]], ["Furthermore, we should not restrict ourselves to common antigens that are currently thought relevant since novel key antigens may yet arise [55] .The Need for Blocking Tests or Fingerprints in Confirmatory COVID-19 SeroepidemiologyIf serological methods of choice later prove to be a surrogate for infectious virus neutralization, e.g., viral pseudoparticles, blocking test components can also be built into those processes [84] [85] [86] [87] [88] .", [["[84] [85] [86] [87] [88]", "SIMPLE_CHEMICAL", 424, 448], ["antigens", "PROTEIN", 117, 125], ["Blocking Tests", "TEST", 159, 173], ["Confirmatory COVID", "TEST", 193, 211], ["infectious virus neutralization", "PROBLEM", 298, 329], ["viral pseudoparticles", "PROBLEM", 337, 358], ["blocking test components", "PROBLEM", 360, 384]]], ["The latter approaches too are capable of automation design or large batch processing.", [["large batch processing", "TREATMENT", 62, 84]]], ["If conventional neutralization assays yield titres in lower dilution than pseudotype virus neutralization assays (e.g., S protein-bearing pseudoviruses with murine leukemia virus), the latter may set higher thresholds as the correlation dictates [89] .Setting Safe Thresholds for Protective ImmunityIf neutralizing antibody correlates with protection, is there a threshold at which the prediction can be confident?", [["murine leukemia virus", "DISEASE", 157, 178], ["pseudotype virus", "ORGANISM", 74, 90], ["murine leukemia virus", "ORGANISM", 157, 178], ["S protein", "PROTEIN", 120, 129], ["neutralizing antibody", "PROTEIN", 302, 323], ["murine", "SPECIES", 157, 163], ["pseudotype virus", "SPECIES", 74, 90], ["murine leukemia virus", "SPECIES", 157, 178], ["conventional neutralization assays", "TEST", 3, 37], ["titres", "TEST", 44, 50], ["lower dilution", "PROBLEM", 54, 68], ["pseudotype virus neutralization assays", "TEST", 74, 112], ["S protein", "TEST", 120, 129], ["murine leukemia virus", "PROBLEM", 157, 178], ["Protective Immunity", "TREATMENT", 280, 299], ["neutralizing antibody", "TEST", 302, 323]]], ["Whereas there are no guarantees, if the presence of neutralizing antibody correlates with protection, it can be reasonably hypothesized that more protection correlates with higher titres.", [["neutralizing antibody", "PROTEIN", 52, 73], ["neutralizing antibody", "PROBLEM", 52, 73], ["no", "UNCERTAINTY", 18, 20], ["guarantees", "OBSERVATION", 21, 31]]], ["Such a hypothesis is easily testable in the current pandemic given preliminary consensus for the type of neutralization assay to be used.", [["neutralization assay", "TREATMENT", 105, 125]]], ["It is proposed that the 1:32-1:40 standard of conventional neutralizing antibody be used as the minimal threshold in inaugural studies.", [["neutralizing antibody", "PROTEIN", 59, 80], ["conventional neutralizing antibody", "TREATMENT", 46, 80], ["inaugural studies", "TEST", 117, 134], ["minimal", "OBSERVATION_MODIFIER", 96, 103]]], ["The threshold could be raised or lowered depending on the outcome of field assessments.", [["field assessments", "TEST", 69, 86]]], ["Prospective follow-up of study subjects with the established minimum neutralizing antibody and its potential change in titre and/or protection would be determinable over time.Setting Safe Thresholds for Protective ImmunityThere is then a role for other measures of antibody thereafter.", [["neutralizing antibody", "PROTEIN", 69, 90], ["study subjects", "TEST", 25, 39], ["minimum neutralizing antibody", "TREATMENT", 61, 90], ["titre", "TREATMENT", 119, 124], ["protection", "TREATMENT", 132, 142], ["Protective Immunity", "TREATMENT", 203, 222]]], ["As the initial neutralizing antibody threshold for protection is established, correlates with other tests as surrogates can then begin.", [["the initial neutralizing antibody threshold", "TREATMENT", 3, 46], ["other tests", "TEST", 94, 105]]], ["In the latter, it would also be best to choose higher thresholds of positivity rather than any positive test per se.", [["any positive test", "PROBLEM", 91, 108]]], ["Such thresholds could thereafter vary pending correlations that become apparent.", [["Such thresholds", "PROBLEM", 0, 15]]], ["Such an approach provides an abundance of precaution rather than the converse.The Acid Tests of Assessing a StrategyThe test of a minimalist strategy and thereafter its refinement is currently feasible in the milieu of the current pandemic.", [["precaution", "TREATMENT", 42, 52], ["The Acid Tests", "TEST", 78, 92], ["a minimalist strategy", "TREATMENT", 128, 149]]], ["Given the magnitude of infected individuals throughout the world, the numbers required to test for protection could be easily acquired from a multi-centered approach with highly endemic foci or with even a regional study again in a highly endemic area.", [["infected individuals", "PROBLEM", 23, 43], ["protection", "TREATMENT", 99, 109], ["a multi-centered approach", "TREATMENT", 140, 165], ["highly endemic foci", "PROBLEM", 171, 190], ["a regional study", "TEST", 204, 220], ["infected", "OBSERVATION", 23, 31], ["endemic", "OBSERVATION_MODIFIER", 178, 185], ["foci", "OBSERVATION", 186, 190]]], ["There will be concern in allowing previously infected, neutralizing antibody-positive individuals to be naturally exposed once again in the community, but such an approach has little difference to the broad testing of candidate vaccines.", [["neutralizing antibody", "TEST", 55, 76], ["positive individuals", "PROBLEM", 77, 97], ["candidate vaccines", "TREATMENT", 218, 236]]], ["Indeed, the answers may come sooner than the answers of whether vaccine candidates will succeed.The Acid Tests of Assessing a StrategyInfection exposures in the community for those previously infected with or without such antibody markers will also slowly answer other questions relating to those with low level neutralizing antibody (e.g., below threshold), those that do not have any measurable antibody, anamnestic responses, and susceptibility to changing virus.The Acid Tests of Assessing a StrategyFurthermore, the minimalist strategy will potentially set the goal posts for vaccine evaluations.Translational Case Studies and their ImplicationsReports of repeat SARS-CoV-2 infections have already begun to emerge as the pandemic continues [54, [90] [91] [92] .", [["SARS-CoV-2 infections", "DISEASE", 668, 689], ["SARS-CoV-2", "ORGANISM", 668, 678], ["antibody markers", "PROTEIN", 222, 238], ["neutralizing antibody", "PROTEIN", 312, 333], ["vaccine candidates", "TREATMENT", 64, 82], ["The Acid Tests", "TEST", 96, 110], ["a StrategyInfection exposures", "PROBLEM", 124, 153], ["such antibody markers", "PROBLEM", 217, 238], ["low level neutralizing antibody", "PROBLEM", 302, 333], ["any measurable antibody", "PROBLEM", 382, 405], ["anamnestic responses", "PROBLEM", 407, 427], ["changing virus", "PROBLEM", 451, 465], ["The Acid Tests", "TEST", 466, 480], ["the minimalist strategy", "TREATMENT", 517, 540], ["vaccine evaluations", "TEST", 581, 600], ["repeat SARS", "TEST", 661, 672], ["CoV", "TEST", 673, 676], ["2 infections", "PROBLEM", 677, 689], ["Infection", "OBSERVATION", 134, 143]]], ["An analysis of these is relevant in considering any minimalist strategy.Translational Case Studies and their ImplicationsGousseff et al. present a case series of healthcare workers and community patients who appeared to have a relapsing pattern of COVID-19 [90] .", [["COVID-19", "CHEMICAL", 248, 256], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["An analysis", "TEST", 0, 11], ["COVID", "TEST", 248, 253]]], ["The establishment of re-infection within such a short period of time is tenuous at best.", [["re-infection", "PROBLEM", 21, 33], ["re-infection", "OBSERVATION", 21, 33], ["tenuous", "OBSERVATION", 72, 79]]], ["Early and later positive diagnostic samples could be assessed with viral sequencing.", [["samples", "ANATOMY", 36, 43], ["samples", "CANCER", 36, 43], ["diagnostic samples", "TEST", 25, 43], ["viral sequencing", "TEST", 67, 83]]], ["Serological profiling with both IgG and IgM and correlation with viral neutralization are additional tools of interest.", [["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["IgM", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgG", "PROTEIN", 32, 35], ["IgM", "PROTEIN", 40, 43], ["Serological profiling", "TEST", 0, 21], ["both IgG", "TEST", 27, 35], ["IgM", "TEST", 40, 43], ["viral neutralization", "PROBLEM", 65, 85]]], ["The persistence of viral genome after acute infection, and as determined with genetic amplification technology, is well-known and can be measured in weeks.", [["acute infection", "DISEASE", 38, 53], ["viral genome", "DNA", 19, 31], ["viral genome", "PROBLEM", 19, 31], ["acute infection", "PROBLEM", 38, 53], ["viral genome", "OBSERVATION", 19, 31], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 44, 53]]], ["Accordingly, comparison of diagnostic cycle thresholds can be of value as was done.", [["diagnostic cycle thresholds", "TEST", 27, 54]]], ["Co-determination of other pathogens, especially viral for co-infection, is essential.", [["co-infection", "DISEASE", 58, 70], ["other pathogens", "PROBLEM", 20, 35], ["co-infection", "PROBLEM", 58, 70], ["pathogens", "OBSERVATION", 26, 35]]], ["That some patients may clinically relapse with a complicating respiratory illness after an initial non-complicated illness is in keeping with many other respiratory infections.", [["respiratory", "ANATOMY", 62, 73], ["respiratory", "ANATOMY", 153, 164], ["respiratory illness", "DISEASE", 62, 81], ["respiratory infections", "DISEASE", 153, 175], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["a complicating respiratory illness", "PROBLEM", 47, 81], ["an initial non-complicated illness", "PROBLEM", 88, 122], ["many other respiratory infections", "PROBLEM", 142, 175], ["non-complicated", "OBSERVATION_MODIFIER", 99, 114], ["illness", "OBSERVATION", 115, 122], ["respiratory", "ANATOMY", 153, 164], ["infections", "OBSERVATION", 165, 175]]], ["Viral culture to confirm live virus provides an additional step in confirmation but evidently is difficult to achieve without support from reference level 3 laboratories.", [["Viral culture", "TEST", 0, 13], ["live virus", "PROBLEM", 25, 35]]], ["As the authors suggest, are these examples simply ones of persistence or re-infection?Translational Case Studies and their ImplicationsBentivegna et al. describe a 69-year female with possible re-infection in which repeat RT-PCR positive samples of the respiratory tract were obtained in the context of four negative samples in between over a 6-7-week period [91] .", [["samples", "ANATOMY", 238, 245], ["respiratory tract", "ANATOMY", 253, 270], ["samples", "ANATOMY", 317, 324], ["female", "ORGANISM", 172, 178], ["respiratory tract", "ORGANISM_SUBDIVISION", 253, 270], ["re-infection", "PROBLEM", 73, 85], ["re-infection", "PROBLEM", 193, 205], ["repeat RT-PCR", "TEST", 215, 228], ["the respiratory tract", "TEST", 249, 270], ["re-infection", "OBSERVATION", 73, 85], ["possible", "UNCERTAINTY", 184, 192], ["re-infection", "OBSERVATION", 193, 205], ["respiratory tract", "ANATOMY", 253, 270]]], ["Immunoglobulin G serology was reactive on each occasion.", [["Immunoglobulin G", "GENE_OR_GENE_PRODUCT", 0, 16], ["Immunoglobulin G serology", "TEST", 0, 25], ["reactive", "OBSERVATION_MODIFIER", 30, 38]]], ["IgM serology was reactive only late in the second putative infection.", [["infection", "DISEASE", 59, 68], ["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgM", "PROTEIN", 0, 3], ["IgM serology", "TEST", 0, 12], ["the second putative infection", "PROBLEM", 39, 68], ["reactive", "OBSERVATION_MODIFIER", 17, 25], ["infection", "OBSERVATION", 59, 68]]], ["Blocking assays for the second serology could have potential use if devised.", [["Blocking assays", "TEST", 0, 15], ["the second serology", "TEST", 20, 39]]], ["Neutralization tests would have been of value to correlate with putative protection.", [["Neutralization tests", "TEST", 0, 20], ["putative protection", "TREATMENT", 64, 83]]], ["An established fingerprint of immunoblotting if devised could be sought for in both early and later blood samples to further characterize the quality of immune reactivity.", [["blood samples", "ANATOMY", 100, 113], ["blood samples", "ORGANISM_SUBSTANCE", 100, 113], ["immunoblotting", "TREATMENT", 30, 44], ["blood samples", "TEST", 100, 113], ["immune reactivity", "PROBLEM", 153, 170], ["immune reactivity", "OBSERVATION", 153, 170]]], ["This case report emphasizes the role for a better understanding of applicable diagnostic and confirmatory serology.Translational Case Studies and their ImplicationsTomassini et al. highlight a case series of six patients who were possibly re-infected [92] .", [["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["confirmatory serology", "TEST", 93, 114]]], ["IgM serology, blocking for IgG serology, neutralization correlates, and comparison of diagnostic Ct values all have their potential merit.Translational Case Studies and their ImplicationsTo and colleagues describe a repeat infection in a 33-year male in which two distinct isolates were believed to have been identified by whole-genome sequencing [54] .", [["repeat infection", "DISEASE", 216, 232], ["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 27, 30], ["IgM", "PROTEIN", 0, 3], ["IgG", "PROTEIN", 27, 30], ["IgM serology", "TEST", 0, 12], ["IgG serology", "TEST", 27, 39], ["Ct values", "TEST", 97, 106], ["a repeat infection", "PROBLEM", 214, 232]]], ["The episodes occurred some 5 months apart.", [["The episodes", "PROBLEM", 0, 12]]], ["Measurable IgG was not detected within 10 days of the first episode.", [["IgG", "GENE_OR_GENE_PRODUCT", 11, 14], ["IgG", "PROTEIN", 11, 14], ["Measurable IgG", "TEST", 0, 14], ["IgG", "OBSERVATION", 11, 14]]], ["IgM diagnostics, blocking for IgG serology, and neutralization correlates all have their potential merit.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgM", "PROTEIN", 0, 3], ["IgG", "PROTEIN", 30, 33], ["IgM diagnostics", "TEST", 0, 15], ["IgG serology", "TEST", 30, 42]]], ["The authors initiate relevant dialog about the relevance of genetic drift and possible re-infection.Translational Case Studies and their ImplicationsVan Elslande et al. provide some evidence for a repeat infection after a 3-month interval [93] .", [["infection", "DISEASE", 204, 213], ["genetic drift", "PROBLEM", 60, 73], ["re-infection", "PROBLEM", 87, 99], ["a repeat infection", "PROBLEM", 195, 213], ["possible", "UNCERTAINTY", 78, 86], ["re-infection", "OBSERVATION", 87, 99], ["infection", "OBSERVATION", 204, 213]]], ["A comparison of diagnostic samples suggested repeat infection with phylogenetically distinct strain detections.", [["samples", "ANATOMY", 27, 34], ["infection", "DISEASE", 52, 61], ["diagnostic samples", "TEST", 16, 34], ["repeat infection", "PROBLEM", 45, 61], ["phylogenetically distinct strain detections", "TEST", 67, 110], ["infection", "OBSERVATION", 52, 61]]], ["Diagnostic serology with blocking studies, neutralization correlates, and comparison of diagnostic Ct value all have their potential merit.", [["Diagnostic serology", "TEST", 0, 19], ["blocking studies", "TEST", 25, 41], ["Ct value", "TEST", 99, 107]]], ["These authors repeat the theme on genetic drift and its implications.Translational Case Studies and their ImplicationsIn any of the aforementioned, sample collection and recollection validation shortly after the initial diagnostic specimen test positive can also contribute to overall accuracy of determining re-infections.Interim Fidelity to Practical PreventionsWhile such an approach to defining protective immunity in the interim reaches our goals if that is possible, the otherwise sensible approaches to disease prevention should continue to be enforced.", [["specimen", "ANATOMY", 231, 239], ["genetic drift", "TEST", 34, 47], ["sample collection", "TEST", 148, 165], ["recollection validation", "TEST", 170, 193], ["the initial diagnostic specimen test", "TEST", 208, 244], ["disease prevention", "TREATMENT", 510, 528]]], ["Given the current evidence on person-person direct transmission, person-person aerosol transmission, and environment-person indirect transmission, adherence to the basic principles of abrogating infection spread should be maintained as is practical.", [["infection", "DISEASE", 195, 204], ["person", "SPECIES", 30, 36], ["person", "SPECIES", 37, 43], ["person", "SPECIES", 65, 71], ["person", "SPECIES", 72, 78], ["person", "SPECIES", 117, 123], ["abrogating infection spread", "PROBLEM", 184, 211], ["infection", "OBSERVATION", 195, 204]]], ["Facets of physical distancing, appropriate decontamination and disinfection, and contextappropriate use of masking all have their roles in minimizing risk.", [["disinfection", "TREATMENT", 63, 75], ["physical", "OBSERVATION_MODIFIER", 10, 18], ["distancing", "OBSERVATION", 19, 29], ["decontamination", "OBSERVATION", 43, 58]]], ["It will be the study populations where some of these preventions may be less stringent in order to test the hypotheses of natural protection after infection or vaccine prevention.", [["infection", "DISEASE", 147, 156], ["the study populations", "TEST", 11, 32], ["natural protection", "TREATMENT", 122, 140], ["infection", "PROBLEM", 147, 156], ["vaccine prevention", "TREATMENT", 160, 178]]], ["Nevertheless, if we do define a highly probable and preventative serodiagnostic correlation, the modes of prevention may eventually be seen in alternative fashion or stringency.", [["stringency", "PROBLEM", 166, 176]]], ["The overall approach to disease control will be fluid and will adapt as the potential arises.", [["disease control", "TREATMENT", 24, 39], ["fluid", "PROBLEM", 48, 53]]]], "PMC7486809": [["IntroductionMicrobial infections are major concern for the public health.", [["Microbial infections", "DISEASE", 12, 32], ["IntroductionMicrobial infections", "PROBLEM", 0, 32], ["infections", "OBSERVATION", 22, 32]]], ["In present situation of COVID-19 pandemic, the chances of secondary infections remain higher and become complicated during treatment procedures [1].", [["infections", "DISEASE", 68, 78], ["COVID", "TEST", 24, 29], ["secondary infections", "PROBLEM", 58, 78], ["treatment procedures", "TREATMENT", 123, 143], ["secondary", "OBSERVATION_MODIFIER", 58, 67], ["infections", "OBSERVATION", 68, 78]]], ["The most common pathogens, Listeria monocytogenes, Escherichia coli, Staphylococcus aureus, Salmonella Typhimurium, etc., are hard to be eliminated from food and human environments.", [["Staphylococcus aureus", "DISEASE", 69, 90], ["Listeria monocytogenes", "ORGANISM", 27, 49], ["Escherichia coli", "ORGANISM", 51, 67], ["Staphylococcus aureus", "ORGANISM", 69, 90], ["Salmonella Typhimurium", "ORGANISM", 92, 114], ["human", "ORGANISM", 162, 167], ["Listeria monocytogenes", "SPECIES", 27, 49], ["Escherichia coli", "SPECIES", 51, 67], ["Staphylococcus aureus", "SPECIES", 69, 90], ["Salmonella Typhimurium", "SPECIES", 92, 114], ["human", "SPECIES", 162, 167], ["Listeria monocytogenes", "SPECIES", 27, 49], ["Escherichia coli", "SPECIES", 51, 67], ["Staphylococcus aureus", "SPECIES", 69, 90], ["Salmonella Typhimurium", "SPECIES", 92, 114], ["human", "SPECIES", 162, 167], ["The most common pathogens", "PROBLEM", 0, 25], ["Listeria monocytogenes", "PROBLEM", 27, 49], ["Escherichia coli", "PROBLEM", 51, 67], ["Staphylococcus aureus", "PROBLEM", 69, 90], ["Salmonella Typhimurium", "PROBLEM", 92, 114], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["Listeria monocytogenes", "OBSERVATION", 27, 49], ["Escherichia coli", "OBSERVATION", 51, 67], ["Staphylococcus aureus", "OBSERVATION", 69, 90], ["Salmonella Typhimurium", "OBSERVATION", 92, 114]]], ["Staph. aureus is the major human pathogen causing a wide range of infections such as bacteremia and infective endocarditis.", [["infections", "DISEASE", 66, 76], ["bacteremia", "DISEASE", 85, 95], ["infective endocarditis", "DISEASE", 100, 122], ["aureus", "ORGANISM", 7, 13], ["human", "ORGANISM", 27, 32], ["aureus", "SPECIES", 7, 13], ["human", "SPECIES", 27, 32], ["aureus", "SPECIES", 7, 13], ["human", "SPECIES", 27, 32], ["Staph", "PROBLEM", 0, 5], ["aureus", "PROBLEM", 7, 13], ["the major human pathogen", "PROBLEM", 17, 41], ["infections", "PROBLEM", 66, 76], ["bacteremia", "PROBLEM", 85, 95], ["infective endocarditis", "PROBLEM", 100, 122], ["major human", "OBSERVATION_MODIFIER", 21, 32], ["pathogen", "OBSERVATION", 33, 41], ["wide range", "OBSERVATION_MODIFIER", 52, 62], ["infections", "OBSERVATION", 66, 76], ["bacteremia", "OBSERVATION", 85, 95], ["infective", "OBSERVATION_MODIFIER", 100, 109], ["endocarditis", "OBSERVATION", 110, 122]]], ["The treatment remains challenging due to the emergence of multidrug resistant strains such as MRSA (methicillin-resistant Staph. aureus) [2].", [["MRSA", "CHEMICAL", 94, 98], ["methicillin", "CHEMICAL", 100, 111], ["methicillin", "CHEMICAL", 100, 111], ["methicillin", "SIMPLE_CHEMICAL", 100, 111], ["aureus", "ORGANISM", 129, 135], ["MRSA", "SPECIES", 94, 98], ["aureus", "SPECIES", 129, 135], ["MRSA", "SPECIES", 94, 98], ["aureus", "SPECIES", 129, 135], ["The treatment", "TREATMENT", 0, 13], ["multidrug resistant strains", "PROBLEM", 58, 85], ["MRSA", "PROBLEM", 94, 98], ["methicillin-resistant Staph", "PROBLEM", 100, 127], ["aureus", "PROBLEM", 129, 135], ["MRSA", "OBSERVATION", 94, 98], ["Staph", "OBSERVATION", 122, 127]]], ["Typhimurium is the most dominant serovar around the world associated with food-borne outbreaks in both developing and high-income countries [3].", [["food-borne outbreaks", "DISEASE", 74, 94], ["Typhimurium", "ORGANISM", 0, 11], ["Typhimurium", "SPECIES", 0, 11], ["Typhimurium", "SPECIES", 0, 11], ["Typhimurium", "PROBLEM", 0, 11], ["most dominant", "OBSERVATION_MODIFIER", 19, 32], ["serovar", "OBSERVATION_MODIFIER", 33, 40]]], ["Human infection with Salm.", [["infection", "DISEASE", 6, 15], ["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human infection", "PROBLEM", 0, 15], ["infection", "OBSERVATION", 6, 15]]], ["Typhimurium normally occurs through consumption of undercooked meat, dairy products and especially raw eggs.", [["meat", "ANATOMY", 63, 67], ["eggs", "ANATOMY", 103, 107], ["Typhimurium", "ORGANISM", 0, 11], ["meat", "ORGANISM_SUBDIVISION", 63, 67], ["Typhimurium", "SPECIES", 0, 11], ["Typhimurium", "SPECIES", 0, 11], ["Typhimurium", "PROBLEM", 0, 11]]], ["Enteritidis and Salm.", [["Enteritidis", "ORGANISM", 0, 11], ["Enteritidis", "SPECIES", 0, 11], ["Enteritidis", "PROBLEM", 0, 11]]], ["Newport has been linked to uncooked ground beef, runny scrambled eggs or omelettes [4].", [["eggs", "ANATOMY", 65, 69], ["beef", "SPECIES", 43, 47], ["beef", "SPECIES", 43, 47], ["runny scrambled eggs", "PROBLEM", 49, 69]]], ["Salmonellosis is one of the most common food-borne diseases worldwide, accounting around 93.8 million food-borne illnesses and 155,000 deaths per year worldwide [5].", [["Salmonellosis", "DISEASE", 0, 13], ["food-borne diseases", "DISEASE", 40, 59], ["food-borne illnesses", "DISEASE", 102, 122], ["deaths", "DISEASE", 135, 141], ["Salmonellosis", "PROBLEM", 0, 13], ["most common", "OBSERVATION_MODIFIER", 28, 39]]], ["Therefore, it is essential to use effective and safe antimicrobials for the control of such pathogens.IntroductionThe use of chemical preservatives has been recognized as effective in limiting food-borne pathogens but causes severe toxicity to the consumers.", [["toxicity", "DISEASE", 232, 240], ["safe antimicrobials", "TREATMENT", 48, 67], ["such pathogens", "PROBLEM", 87, 101], ["chemical preservatives", "TREATMENT", 125, 147], ["borne pathogens", "PROBLEM", 198, 213], ["severe toxicity", "PROBLEM", 225, 240], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["toxicity", "OBSERVATION", 232, 240]]], ["Similarly, overdose of antibiotics during the treatment of infectious diseases has resulted development of multidrug resistance in pathogens [2, 6].", [["overdose", "DISEASE", 11, 19], ["infectious diseases", "DISEASE", 59, 78], ["antibiotics", "TREATMENT", 23, 34], ["infectious diseases", "PROBLEM", 59, 78], ["multidrug resistance in pathogens", "PROBLEM", 107, 140], ["infectious", "OBSERVATION", 59, 69], ["multidrug resistance", "OBSERVATION", 107, 127]]], ["Since the past, several compounds have been searched in food safety and clinical applications, but nature-derived products have always been the preference.", [["clinical applications", "TREATMENT", 72, 93]]], ["Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria exhibiting narrow spectra of activity against related species, whereas others display broader activity spectra against unrelated species [7].", [["Bacteriocins", "SIMPLE_CHEMICAL", 0, 12], ["Bacteriocins", "TREATMENT", 0, 12], ["ribosomally synthesized antimicrobial peptides", "PROBLEM", 17, 63], ["bacteria", "PROBLEM", 76, 84], ["narrow spectra of activity", "PROBLEM", 96, 122], ["related species", "PROBLEM", 131, 146], ["unrelated species", "PROBLEM", 204, 221], ["narrow spectra", "OBSERVATION_MODIFIER", 96, 110]]], ["In particular, most bacteriocins from lactic acid bacteria (LAB) have been attractive as potential natural antimicrobials due to the non-toxic nature of the compounds [8].", [["lactic acid bacteria", "CHEMICAL", 38, 58], ["LAB", "CHEMICAL", 60, 63], ["lactic acid", "CHEMICAL", 38, 49], ["lactic acid bacteria", "SIMPLE_CHEMICAL", 38, 58], ["LAB", "SIMPLE_CHEMICAL", 60, 63], ["lactic acid bacteria", "PROBLEM", 38, 58], ["natural antimicrobials", "TREATMENT", 99, 121]]], ["Although, bacteriocins are mostly non-toxic and considered safe, exceptions do exist; e.g. cytolysin produced by several enterococci has known cytotoxic activity [9].", [["cytolysin", "GENE_OR_GENE_PRODUCT", 91, 100], ["enterococci", "CANCER", 121, 132], ["cytolysin", "PROTEIN", 91, 100], ["bacteriocins", "PROBLEM", 10, 22], ["cytolysin", "TEST", 91, 100], ["several enterococci", "PROBLEM", 113, 132], ["known cytotoxic activity", "PROBLEM", 137, 161], ["enterococci", "OBSERVATION", 121, 132], ["cytotoxic activity", "OBSERVATION", 143, 161]]], ["In most cases, cytotoxicity has only been noted at levels much higher than the MIC required to inhibit food spoiling microorganisms [10, 11].", [["cytotoxicity", "PROBLEM", 15, 27]]], ["Generally, bacteriocins demonstrate strong activity against sensitive strains in the nanomolar range rendering them more effective antimicrobials.", [["bacteriocins", "TREATMENT", 11, 23], ["sensitive strains", "PROBLEM", 60, 77], ["strong activity", "OBSERVATION_MODIFIER", 36, 51]]], ["However, perhaps an even better option is to combine bacteriocins along with other existing antimicrobials for effective killing of the target strains [11].", [["bacteriocins", "TREATMENT", 53, 65], ["other existing antimicrobials", "TREATMENT", 77, 106], ["the target strains", "PROBLEM", 132, 150]]], ["It is plausible that the use of synergistically acting bacteriocins with other antimicrobials may accelerate each other\u2019s effects, thereby dropping the likelihood of resistance development by target strains [12].", [["synergistically acting bacteriocins", "TREATMENT", 32, 67], ["other antimicrobials", "TREATMENT", 73, 93], ["resistance development", "PROBLEM", 166, 188], ["target strains", "PROBLEM", 192, 206]]], ["As reported earlier, the combined effect of nisin and pediocin displayed a synergistic activity against Lactobacillus sakei and also resulted in additive effect against Bacillus cereus and L. monocytogenes.", [["nisin", "CHEMICAL", 44, 49], ["pediocin", "CHEMICAL", 54, 62], ["Lactobacillus sakei", "CHEMICAL", 104, 123], ["pediocin", "CHEMICAL", 54, 62], ["nisin", "SIMPLE_CHEMICAL", 44, 49], ["pediocin", "SIMPLE_CHEMICAL", 54, 62], ["Lactobacillus sakei", "SIMPLE_CHEMICAL", 104, 123], ["Bacillus cereus", "ORGANISM", 169, 184], ["L. monocytogenes", "ORGANISM", 189, 205], ["Lactobacillus sakei", "SPECIES", 104, 123], ["Bacillus cereus", "SPECIES", 169, 184], ["L. monocytogenes", "SPECIES", 189, 205], ["Lactobacillus sakei", "SPECIES", 104, 123], ["Bacillus cereus", "SPECIES", 169, 184], ["L. monocytogenes", "SPECIES", 189, 205], ["nisin", "TREATMENT", 44, 49], ["pediocin", "TREATMENT", 54, 62], ["Lactobacillus sakei", "PROBLEM", 104, 123], ["Bacillus cereus and L. monocytogenes", "PROBLEM", 169, 205], ["L. monocytogenes", "OBSERVATION", 189, 205]]], ["These combined bacteriocins may represent potential candidates applied in food systems for controlling pathogenic or food spoilage bacteria [13].", [["These combined bacteriocins", "TREATMENT", 0, 27], ["food spoilage bacteria", "PROBLEM", 117, 139], ["may represent", "UNCERTAINTY", 28, 41]]], ["Furthermore, the combined use of these compounds may also reduce the concentration and thus decrease financial burden related with the synthesis and management of expensive antibiotics [14].IntroductionKeeping these views in consideration, enterocin LD3 and plantaricin LD4 have been studied to evaluate their individual and combined effects against pathogenic bacteria.", [["plantaricin", "CHEMICAL", 258, 269], ["plantaricin", "CHEMICAL", 258, 269], ["enterocin LD3", "SIMPLE_CHEMICAL", 240, 253], ["plantaricin LD4", "SIMPLE_CHEMICAL", 258, 273], ["these compounds", "TREATMENT", 33, 48], ["decrease financial burden", "PROBLEM", 92, 117], ["the synthesis", "TREATMENT", 131, 144], ["expensive antibiotics", "TREATMENT", 163, 184], ["these views", "TEST", 210, 221], ["enterocin LD3", "TREATMENT", 240, 253], ["pathogenic bacteria", "PROBLEM", 350, 369]]], ["These bacteriocins are produced from Lactobacillus plantarum LD4 and Enterococcus hirae LD3 isolated from indigenous fermented food, Dosa, which is most commonly consumed in the southern part of India.", [["Lactobacillus plantarum LD4", "CHEMICAL", 37, 64], ["Enterococcus hirae LD3", "CHEMICAL", 69, 91], ["Dosa", "CHEMICAL", 133, 137], ["Lactobacillus plantarum LD4", "ORGANISM", 37, 64], ["Enterococcus hirae LD3", "ORGANISM", 69, 91], ["Dosa", "SIMPLE_CHEMICAL", 133, 137], ["Lactobacillus plantarum", "SPECIES", 37, 60], ["Enterococcus hirae", "SPECIES", 69, 87], ["Lactobacillus plantarum LD4", "SPECIES", 37, 64], ["Enterococcus hirae LD3", "SPECIES", 69, 91], ["These bacteriocins", "PROBLEM", 0, 18], ["Lactobacillus plantarum LD4", "PROBLEM", 37, 64], ["Enterococcus hirae LD3", "PROBLEM", 69, 91], ["Lactobacillus plantarum", "OBSERVATION", 37, 60], ["Enterococcus hirae", "OBSERVATION", 69, 87], ["indigenous", "OBSERVATION_MODIFIER", 106, 116], ["fermented food", "OBSERVATION", 117, 131]]], ["Strain LD3 and LD4 have been previously characterized for their probiotic efficacy in vitro and found to lower cholesterol, tolerance to low pH, higher hydrophobicity and antimicrobial activity against food-borne and clinical pathogens [6, 15].", [["LD4", "CHEMICAL", 15, 18], ["cholesterol", "CHEMICAL", 111, 122], ["cholesterol", "CHEMICAL", 111, 122], ["LD4", "SIMPLE_CHEMICAL", 15, 18], ["cholesterol", "SIMPLE_CHEMICAL", 111, 122], ["Strain LD3", "TEST", 0, 10], ["low pH", "PROBLEM", 137, 143], ["higher hydrophobicity", "PROBLEM", 145, 166], ["antimicrobial activity", "TEST", 171, 193], ["clinical pathogens", "PROBLEM", 217, 235], ["low pH", "OBSERVATION_MODIFIER", 137, 143], ["higher hydrophobicity", "OBSERVATION_MODIFIER", 145, 166], ["antimicrobial activity", "OBSERVATION_MODIFIER", 171, 193]]], ["Later, enterocin LD3 purified from cell-free supernatant (CFS) of Ent. hirae LD3 showed novel characteristics such as unique mass (4114.62 Da), N-terminal sequence (H2NQGGQANQ\u2013COOH), pH and heat stability with broad host-range activity.", [["cell", "ANATOMY", 35, 39], ["supernatant", "ANATOMY", 45, 56], ["N-", "CHEMICAL", 144, 146], ["COOH", "CHEMICAL", 176, 180], ["enterocin LD3", "GENE_OR_GENE_PRODUCT", 7, 20], ["cell", "CELL", 35, 39], ["supernatant", "ORGANISM_SUBSTANCE", 45, 56], ["Ent. hirae LD3", "CELL", 66, 80], ["enterocin LD3", "PROTEIN", 7, 20], ["N-terminal sequence", "PROTEIN", 144, 163], ["COOH", "PROTEIN", 176, 180], ["Ent. hirae", "SPECIES", 66, 76], ["Ent. hirae", "SPECIES", 66, 76], ["enterocin", "TEST", 7, 16], ["Ent. hirae LD3", "TEST", 66, 80], ["unique mass", "PROBLEM", 118, 129], ["N-terminal sequence", "TEST", 144, 163], ["heat stability", "TEST", 190, 204], ["mass", "OBSERVATION", 125, 129], ["heat stability", "OBSERVATION", 190, 204], ["range activity", "OBSERVATION", 221, 235]]], ["In laboratory conditions, enterocin LD3 demonstrated antimicrobial activity against different pathogens and related LAB [16].", [["enterocin LD3", "CHEMICAL", 26, 39], ["enterocin LD3", "SIMPLE_CHEMICAL", 26, 39], ["enterocin", "TREATMENT", 26, 35], ["antimicrobial activity", "PROBLEM", 53, 75], ["different pathogens", "PROBLEM", 84, 103], ["antimicrobial activity", "OBSERVATION", 53, 75]]], ["Further, mode of action of enterocin LD3 was found to be bactericidal; involving dissipation of membrane potential and efflux of ATP, ions, proteins and nucleic acids was recorded [16, 17].", [["membrane", "ANATOMY", 96, 104], ["enterocin LD3", "CHEMICAL", 27, 40], ["ATP", "CHEMICAL", 129, 132], ["nucleic acids", "CHEMICAL", 153, 166], ["enterocin LD3", "CHEMICAL", 27, 40], ["ATP", "CHEMICAL", 129, 132], ["enterocin LD3", "SIMPLE_CHEMICAL", 27, 40], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["ATP", "SIMPLE_CHEMICAL", 129, 132], ["ions", "SIMPLE_CHEMICAL", 134, 138], ["nucleic acids", "SIMPLE_CHEMICAL", 153, 166], ["enterocin LD3", "TREATMENT", 27, 40], ["bactericidal", "PROBLEM", 57, 69], ["efflux of ATP", "PROBLEM", 119, 132], ["nucleic acids", "TEST", 153, 166], ["bactericidal", "OBSERVATION", 57, 69]]], ["Plantaricin LD4 was found to be approx.", [["Plantaricin", "CHEMICAL", 0, 11], ["Plantaricin LD4", "CHEMICAL", 0, 15], ["Plantaricin", "GENE_OR_GENE_PRODUCT", 0, 11], ["Plantaricin LD4", "TEST", 0, 15]]], ["6 kDa in size, stable up to 121 \u00b0C and below pH 7.0.", [["kDa in size", "TEST", 2, 13], ["pH", "TEST", 45, 47], ["kDa", "OBSERVATION_MODIFIER", 2, 5], ["size", "OBSERVATION_MODIFIER", 9, 13], ["stable", "OBSERVATION_MODIFIER", 15, 21]]], ["It was also able to inhibit several pathogens, haloarchaea and related strains as described previously [6].", [["several pathogens", "PROBLEM", 28, 45], ["related strains", "PROBLEM", 63, 78], ["pathogens", "OBSERVATION", 36, 45]]], ["Recently, we have also demonstrated antistaphylococal activity of enterocin LD3 and plantaricin LD4 in pasteurized milk indicating their efficacy in food safety [18].", [["milk", "ANATOMY", 115, 119], ["enterocin LD3", "CHEMICAL", 66, 79], ["plantaricin", "CHEMICAL", 84, 95], ["plantaricin", "CHEMICAL", 84, 95], ["enterocin LD3", "SIMPLE_CHEMICAL", 66, 79], ["plantaricin LD4", "SIMPLE_CHEMICAL", 84, 99], ["milk", "ORGANISM_SUBSTANCE", 115, 119], ["milk", "SPECIES", 115, 119], ["enterocin LD3", "TREATMENT", 66, 79], ["plantaricin", "TREATMENT", 84, 95]]], ["The aim of the present study is to explore the synergistic effect of these bacteriocins against selected food-borne pathogens, Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 for their applications in food safety and/or as clinical antimicrobials.Bacterial Strains and Growth Conditions ::: Materials and MethodsEnt. hirae LD3 and L. plantarum LD4 were grown in MRS medium at 37 \u00b0C for 18 h.", [["ATCC13311", "CHEMICAL", 220, 229], ["aureus", "ORGANISM", 134, 140], ["enterica", "ORGANISM", 175, 183], ["enterica serovar Typhimurium", "ORGANISM", 191, 219], ["ATCC13311", "ORGANISM", 220, 229], ["hirae LD3", "ORGANISM", 372, 381], ["L. plantarum LD4", "ORGANISM", 386, 402], ["aureus subsp", "SPECIES", 134, 146], ["aureus", "SPECIES", 148, 154], ["enterica subsp", "SPECIES", 175, 189], ["enterica serovar Typhimurium", "SPECIES", 191, 219], ["L. plantarum", "SPECIES", 386, 398], ["aureus subsp", "SPECIES", 134, 146], ["aureus", "SPECIES", 148, 154], ["enterica subsp", "SPECIES", 175, 189], ["enterica serovar Typhimurium", "SPECIES", 191, 219], ["L. plantarum", "SPECIES", 386, 398], ["the present study", "TEST", 11, 28], ["these bacteriocins", "TREATMENT", 69, 87], ["borne pathogens", "PROBLEM", 110, 125], ["Staph", "PROBLEM", 127, 132], ["aureus subsp", "PROBLEM", 134, 146], ["aureus", "PROBLEM", 148, 154], ["enterica subsp", "PROBLEM", 175, 189], ["enterica serovar Typhimurium", "TREATMENT", 191, 219], ["clinical antimicrobials", "TREATMENT", 278, 301], ["Bacterial Strains", "PROBLEM", 302, 319], ["hirae LD3", "TEST", 372, 381], ["L. plantarum LD4", "TEST", 386, 402], ["subsp", "OBSERVATION", 141, 146], ["subsp", "OBSERVATION_MODIFIER", 184, 189], ["serovar Typhimurium", "OBSERVATION", 200, 219], ["Strains", "OBSERVATION", 312, 319], ["Growth Conditions", "OBSERVATION", 324, 341], ["L.", "ANATOMY_MODIFIER", 386, 388], ["plantarum LD4", "ANATOMY", 389, 402]]], ["Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 were obtained from Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India, and grown in nutrient broth (NB) at 37 \u00b0C overnight in a BOD incubator (Scigenics Biotech, Chennai, India).", [["aureus", "ORGANISM", 7, 13], ["enterica", "ORGANISM", 48, 56], ["enterica serovar Typhimurium", "ORGANISM", 64, 92], ["ATCC13311", "ORGANISM", 93, 102], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["enterica subsp", "SPECIES", 48, 62], ["enterica serovar Typhimurium", "SPECIES", 64, 92], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["enterica subsp", "SPECIES", 48, 62], ["enterica serovar Typhimurium", "SPECIES", 64, 92], ["Staph", "PROBLEM", 0, 5], ["aureus subsp", "PROBLEM", 7, 19], ["aureus", "PROBLEM", 21, 27], ["enterica subsp", "PROBLEM", 48, 62], ["enterica serovar Typhimurium", "TEST", 64, 92], ["a BOD incubator", "TREATMENT", 260, 275], ["subsp", "OBSERVATION", 14, 19], ["subsp", "OBSERVATION_MODIFIER", 57, 62], ["serovar Typhimurium", "OBSERVATION", 73, 92]]], ["All the media components were purchased from Hi-Media, Mumbai, India.Determination of Minimum Inhibitory Concentrations ::: Materials and MethodsEnterocin LD3 and plantaricin LD4 were purified using activity-guided multistep chromatographic techniques such as cation exchange chromatography, gel-filtration chromatography and reverse-phase ultra-performance liquid chromatography as reported previously [16].", [["plantaricin", "CHEMICAL", 163, 174], ["plantaricin LD4", "CHEMICAL", 163, 178], ["Enterocin LD3", "SIMPLE_CHEMICAL", 145, 158], ["plantaricin LD4", "SIMPLE_CHEMICAL", 163, 178], ["cation", "SIMPLE_CHEMICAL", 260, 266], ["Materials", "TREATMENT", 124, 133], ["MethodsEnterocin", "TREATMENT", 138, 154], ["plantaricin LD4", "TREATMENT", 163, 178], ["activity-guided multistep chromatographic techniques", "TREATMENT", 199, 251], ["cation exchange chromatography", "TEST", 260, 290], ["gel-filtration chromatography", "TEST", 292, 321], ["reverse-phase ultra-performance liquid chromatography", "TEST", 326, 379]]], ["The minimum inhibitory concentrations (MICs) of purified bacteriocins against Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 were determined using the broth microdilution method as suggested by Weeks et al. [19].", [["aureus", "ORGANISM", 85, 91], ["enterica", "ORGANISM", 126, 134], ["enterica serovar Typhimurium", "ORGANISM", 142, 170], ["ATCC13311", "ORGANISM", 171, 180], ["aureus subsp", "SPECIES", 85, 97], ["aureus", "SPECIES", 99, 105], ["enterica subsp", "SPECIES", 126, 140], ["enterica serovar Typhimurium", "SPECIES", 142, 170], ["aureus subsp", "SPECIES", 85, 97], ["aureus", "SPECIES", 99, 105], ["enterica subsp", "SPECIES", 126, 140], ["enterica serovar Typhimurium", "SPECIES", 142, 170], ["The minimum inhibitory concentrations (MICs", "TREATMENT", 0, 43], ["purified bacteriocins", "TREATMENT", 48, 69], ["Staph", "PROBLEM", 78, 83], ["aureus subsp", "PROBLEM", 85, 97], ["aureus", "PROBLEM", 99, 105], ["enterica subsp", "PROBLEM", 126, 140], ["enterica serovar Typhimurium", "TEST", 142, 170], ["the broth microdilution method", "TREATMENT", 203, 233], ["subsp", "OBSERVATION", 92, 97], ["subsp", "OBSERVATION_MODIFIER", 135, 140], ["serovar Typhimurium", "OBSERVATION", 151, 170]]], ["Briefly, different concentrations (0\u2013340 \u03bcg/mL) of enterocin LD3 and plantaricin LD4 were added individually into the wells of 96-well polypropylene plates containing 100 \u03bcL cell suspension of Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 in NB medium (OD600 0.02) and incubated at 37 \u00b0C for 24 h as mentioned in CLSI manual [20].", [["cell", "ANATOMY", 174, 178], ["enterocin LD3", "CHEMICAL", 51, 64], ["plantaricin", "CHEMICAL", 69, 80], ["ATCC13311", "CHEMICAL", 286, 295], ["plantaricin LD4", "CHEMICAL", 69, 84], ["polypropylene", "CHEMICAL", 135, 148], ["enterocin LD3", "SIMPLE_CHEMICAL", 51, 64], ["plantaricin LD4", "SIMPLE_CHEMICAL", 69, 84], ["cell", "CELL", 174, 178], ["aureus", "ORGANISM", 200, 206], ["enterica", "ORGANISM", 241, 249], ["enterica serovar Typhimurium", "ORGANISM", 257, 285], ["ATCC13311", "ORGANISM", 286, 295], ["aureus subsp", "SPECIES", 200, 212], ["aureus", "SPECIES", 214, 220], ["enterica subsp", "SPECIES", 241, 255], ["enterica serovar Typhimurium", "SPECIES", 257, 285], ["aureus subsp", "SPECIES", 200, 212], ["aureus", "SPECIES", 214, 220], ["enterica subsp", "SPECIES", 241, 255], ["enterica serovar Typhimurium", "SPECIES", 257, 285], ["different concentrations", "TREATMENT", 9, 33], ["enterocin LD3", "TREATMENT", 51, 64], ["plantaricin LD4", "TREATMENT", 69, 84], ["well polypropylene plates", "TREATMENT", 130, 155], ["Staph", "PROBLEM", 193, 198], ["aureus subsp", "PROBLEM", 200, 212], ["aureus", "PROBLEM", 214, 220], ["enterica subsp", "PROBLEM", 241, 255], ["enterica serovar Typhimurium", "TREATMENT", 257, 285], ["\u03bcL cell", "OBSERVATION_MODIFIER", 171, 178], ["Staph", "OBSERVATION", 193, 198], ["subsp", "OBSERVATION", 207, 212], ["subsp", "OBSERVATION_MODIFIER", 250, 255], ["serovar Typhimurium", "OBSERVATION", 266, 285]]], ["The MIC was determined as the lowest concentration of bacteriocin showing no visible bacterial growth (OD600 < 0.05) as suggested previously [17].Estimation of the Synergistic Effect of Bacteriocins ::: Materials and MethodsThe interaction between enterocin LD3 and plantaricin LD4 against Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 was performed using a \u2018checkerboard\u2019 assay as reported by Acosta et al. [21].", [["enterocin LD3", "CHEMICAL", 248, 261], ["plantaricin LD4", "CHEMICAL", 266, 281], ["plantaricin LD4", "CHEMICAL", 266, 281], ["Bacteriocins", "SIMPLE_CHEMICAL", 186, 198], ["enterocin LD3", "SIMPLE_CHEMICAL", 248, 261], ["plantaricin LD4", "SIMPLE_CHEMICAL", 266, 281], ["Staph", "GENE_OR_GENE_PRODUCT", 290, 295], ["aureus", "ORGANISM", 297, 303], ["enterica", "ORGANISM", 338, 346], ["enterica serovar Typhimurium", "ORGANISM", 354, 382], ["ATCC13311", "ORGANISM", 383, 392], ["aureus subsp", "SPECIES", 297, 309], ["aureus", "SPECIES", 311, 317], ["enterica subsp", "SPECIES", 338, 352], ["enterica serovar Typhimurium", "SPECIES", 354, 382], ["aureus subsp", "SPECIES", 297, 309], ["aureus", "SPECIES", 311, 317], ["enterica subsp", "SPECIES", 338, 352], ["enterica serovar Typhimurium", "SPECIES", 354, 382], ["The MIC", "TREATMENT", 0, 7], ["bacteriocin", "TEST", 54, 65], ["visible bacterial growth", "PROBLEM", 77, 101], ["enterocin LD3", "TREATMENT", 248, 261], ["plantaricin", "TREATMENT", 266, 277], ["Staph", "PROBLEM", 290, 295], ["aureus subsp", "PROBLEM", 297, 309], ["aureus", "PROBLEM", 311, 317], ["enterica subsp", "PROBLEM", 338, 352], ["enterica serovar Typhimurium", "TREATMENT", 354, 382], ["a \u2018checkerboard\u2019 assay", "TEST", 413, 435], ["no", "UNCERTAINTY", 74, 76], ["visible", "OBSERVATION_MODIFIER", 77, 84], ["bacterial", "OBSERVATION_MODIFIER", 85, 94], ["growth", "OBSERVATION_MODIFIER", 95, 101], ["Staph", "OBSERVATION", 290, 295], ["subsp", "OBSERVATION", 304, 309], ["subsp", "OBSERVATION_MODIFIER", 347, 352], ["serovar Typhimurium", "OBSERVATION", 363, 382]]], ["Different concentrations of enterocin LD3 (5, 10, 15, 20, 25, 30, 35 and 40 \u03bcg/mL) and plantaricin LD4 (50, 60, 70, 80, 90, 100, 110 and 120 \u03bcg/mL) were added into the wells of microplate in vertical and horizontal orientation, respectively, so that the wells would contain mixed concentrations of the two bacteriocins in different proportions.", [["enterocin LD3", "CHEMICAL", 28, 41], ["plantaricin", "CHEMICAL", 87, 98], ["LD4", "CHEMICAL", 99, 102], ["enterocin LD3", "CHEMICAL", 28, 41], ["plantaricin LD4", "CHEMICAL", 87, 102], ["enterocin LD3", "SIMPLE_CHEMICAL", 28, 41], ["plantaricin LD4", "SIMPLE_CHEMICAL", 87, 102], ["enterocin LD3", "TREATMENT", 28, 41], ["plantaricin LD4", "TEST", 87, 102], ["the two bacteriocins", "TREATMENT", 298, 318], ["concentrations", "OBSERVATION_MODIFIER", 10, 24]]], ["Wells with cells alone without bacteriocin were used as controls.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["bacteriocin", "TREATMENT", 31, 42]]], ["Wells containing bacteriocin alone were used as an additional control (as a blank).", [["bacteriocin", "CHEMICAL", 17, 28], ["Wells containing bacteriocin", "TREATMENT", 0, 28], ["an additional control", "TREATMENT", 48, 69]]], ["Each well was inoculated with 100 \u03bcL (OD600 0.02) NB medium containing Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 individually and incubated at 37 \u00b0C for 24 h in a microplate reader (Molecular devices, Sunnyvale, USA).", [["ATCC13311", "CHEMICAL", 164, 173], ["aureus", "ORGANISM", 78, 84], ["enterica", "ORGANISM", 119, 127], ["enterica serovar Typhimurium", "ORGANISM", 135, 163], ["ATCC13311", "ORGANISM", 164, 173], ["aureus subsp", "SPECIES", 78, 90], ["aureus", "SPECIES", 92, 98], ["enterica subsp", "SPECIES", 119, 133], ["enterica serovar Typhimurium", "SPECIES", 135, 163], ["aureus subsp", "SPECIES", 78, 90], ["aureus", "SPECIES", 92, 98], ["enterica subsp", "SPECIES", 119, 133], ["enterica serovar Typhimurium", "SPECIES", 135, 163], ["Staph", "PROBLEM", 71, 76], ["aureus subsp", "PROBLEM", 78, 90], ["aureus", "PROBLEM", 92, 98], ["enterica subsp", "PROBLEM", 119, 133], ["enterica serovar Typhimurium", "TEST", 135, 163], ["Staph", "OBSERVATION", 71, 76], ["subsp", "OBSERVATION", 85, 90], ["subsp", "OBSERVATION_MODIFIER", 128, 133], ["serovar Typhimurium", "OBSERVATION", 144, 163]]], ["An automated 30-min shake was performed to assure even distribution of bacteriocins and cells in each well.", [["cells", "ANATOMY", 88, 93], ["cells", "CELL", 88, 93], ["bacteriocins", "TREATMENT", 71, 83]]], ["The net absorbance was determined by subtracting the initial OD600 from the final OD600.", [["The net absorbance", "PROBLEM", 0, 18], ["net absorbance", "OBSERVATION", 4, 18]]], ["The fractional inhibitory concentration (FIC) was calculated by dividing the MIC of the bacteriocin in the mixture by the MIC of respective bacteriocin independently.", [["The fractional inhibitory concentration", "TEST", 0, 39], ["the bacteriocin", "TREATMENT", 84, 99], ["the MIC of respective bacteriocin", "TREATMENT", 118, 151]]], ["The FIC index (FICI) was calculated as FICindex = FICenterocin LD3 + FICplantaricin LD4.", [["FICplantaricin", "CHEMICAL", 69, 83], ["FICplantaricin", "CHEMICAL", 69, 83], ["The FIC index", "TEST", 0, 13], ["FICindex", "TEST", 39, 47], ["FICenterocin", "TEST", 50, 62], ["FICplantaricin LD4", "TREATMENT", 69, 87]]], ["According to European Committee for Antimicrobial Susceptibility Testing (EUCAST) [22], a synergistic effect is observed when FICI value \u2264 0.5, an additive effect when 0.5 < FICI value \u2264 1, an indifferent effect (IndE) when 1 < FICI value < 2 and an antagonistic effect (AntE) when FICI value \u2265 2.Estimation of the Synergistic Effect of Bacteriocins ::: Materials and MethodsThe results of the checkerboard assay were represented graphically by plotting the meeting points formed by pairs of concentrations of enterocin LD3 and plantaricin LD4 on a graph known as an isobologram.", [["enterocin LD3", "CHEMICAL", 510, 523], ["plantaricin", "CHEMICAL", 528, 539], ["plantaricin", "CHEMICAL", 528, 539], ["Bacteriocins", "SIMPLE_CHEMICAL", 337, 349], ["enterocin LD3", "SIMPLE_CHEMICAL", 510, 523], ["plantaricin LD4", "SIMPLE_CHEMICAL", 528, 543], ["Antimicrobial Susceptibility Testing", "TEST", 36, 72], ["a synergistic effect", "PROBLEM", 88, 108], ["FICI value", "TEST", 126, 136], ["FICI value", "TEST", 174, 184], ["FICI value", "TEST", 228, 238], ["FICI value", "TEST", 282, 292], ["Methods", "TREATMENT", 368, 375], ["the checkerboard assay", "TEST", 390, 412], ["enterocin LD3", "TREATMENT", 510, 523], ["plantaricin", "TREATMENT", 528, 539], ["an isobologram", "TEST", 564, 578]]], ["MIC values of the bacteriocins used alone were plotted on the x- and y-axes and joined by a line.", [["MIC values", "TEST", 0, 10], ["the bacteriocins", "TREATMENT", 14, 30], ["line", "OBSERVATION", 92, 96]]], ["Then, effective combined concentrations (MIC) of bacteriocins were plotted and compared with the previous line.", [["effective combined concentrations (MIC) of bacteriocins", "TREATMENT", 6, 61]]], ["The isobologram was interpreted examining the position of the ratio points and extrapolating synergy (below the line), antagonism (above the line) and additive effect (on the line) as reported by Amrouche et al. [23].Growth Inhibition Assays ::: Materials and MethodsThe interactive effect of bacteriocins was also studied in terms of time- and concentration-bound growth response of target cells.", [["cells", "ANATOMY", 391, 396], ["cells", "CELL", 391, 396], ["target cells", "CELL_TYPE", 384, 396], ["The isobologram", "TEST", 0, 15], ["extrapolating synergy", "PROBLEM", 79, 100], ["antagonism", "PROBLEM", 119, 129], ["the line", "TREATMENT", 171, 179], ["Methods", "TREATMENT", 260, 267], ["bacteriocins", "TREATMENT", 293, 305], ["target cells", "PROBLEM", 384, 396], ["target cells", "OBSERVATION", 384, 396]]], ["Staph. aureus subsp. aureus ATCC25923 was treated with enterocin LD3 (25 \u03bcg/mL) and plantaricin LD4 (90 \u03bcg/mL) individually and in combination (115 \u03bcg/mL).", [["enterocin LD3", "CHEMICAL", 55, 68], ["plantaricin LD4", "CHEMICAL", 84, 99], ["enterocin LD3", "CHEMICAL", 55, 68], ["plantaricin LD4", "CHEMICAL", 84, 99], ["aureus", "ORGANISM", 7, 13], ["aureus", "ORGANISM", 21, 27], ["enterocin LD3", "SIMPLE_CHEMICAL", 55, 68], ["plantaricin LD4", "SIMPLE_CHEMICAL", 84, 99], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["Staph", "PROBLEM", 0, 5], ["aureus subsp", "PROBLEM", 7, 19], ["aureus", "PROBLEM", 21, 27], ["enterocin LD3", "TREATMENT", 55, 68], ["plantaricin LD4", "TREATMENT", 84, 99], ["subsp", "OBSERVATION", 14, 19]]], ["Similarly, Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 was treated with enterocin LD3 (30 \u03bcg/mL) and plantaricin LD4 (100 \u03bcg/mL) individually and in combination (130 \u03bcg/mL).", [["enterocin LD3", "CHEMICAL", 89, 102], ["plantaricin LD4", "CHEMICAL", 118, 133], ["enterocin LD3", "CHEMICAL", 89, 102], ["plantaricin LD4", "CHEMICAL", 118, 133], ["enterica", "ORGANISM", 17, 25], ["enterica serovar Typhimurium", "ORGANISM", 33, 61], ["ATCC13311", "ORGANISM", 62, 71], ["enterocin LD3", "SIMPLE_CHEMICAL", 89, 102], ["plantaricin LD4", "SIMPLE_CHEMICAL", 118, 133], ["Salm", "PROTEIN", 11, 15], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "PROBLEM", 17, 31], ["enterica serovar Typhimurium", "TREATMENT", 33, 61], ["enterocin LD3", "TREATMENT", 89, 102], ["plantaricin LD4", "TREATMENT", 118, 133], ["subsp", "OBSERVATION_MODIFIER", 26, 31]]], ["The absorbance was monitored at regular intervals of 2 h up to 24 h using a microplate reader (Molecular devices, Sunnyvale, USA).Estimation of Live/Dead Cells ::: Materials and MethodsThe concentration-based killing of Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells was further confirmed by staining with a mixture of 4\u2032, 6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) (Merck, Darmstadt, Germany, USA) as reported by Lee et al. [24].", [["Cells", "ANATOMY", 154, 159], ["ATCC13311 cells", "ANATOMY", 313, 328], ["4\u2032, 6-diamidino-2-phenylindole", "CHEMICAL", 381, 411], ["DAPI", "CHEMICAL", 413, 417], ["propidium iodide", "CHEMICAL", 423, 439], ["4\u2032, 6-diamidino-2-phenylindole", "CHEMICAL", 381, 411], ["DAPI", "CHEMICAL", 413, 417], ["propidium iodide", "CHEMICAL", 423, 439], ["Cells", "CELL", 154, 159], ["aureus", "ORGANISM", 227, 233], ["enterica", "ORGANISM", 268, 276], ["enterica serovar", "ORGANISM", 284, 300], ["Typhimurium", "ORGANISM", 301, 312], ["ATCC13311 cells", "CELL", 313, 328], ["4\u2032, 6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 381, 411], ["DAPI", "SIMPLE_CHEMICAL", 413, 417], ["propidium iodide", "SIMPLE_CHEMICAL", 423, 439], ["PI", "SIMPLE_CHEMICAL", 441, 443], ["enterica serovar Typhimurium ATCC13311 cells", "CELL_LINE", 284, 328], ["aureus subsp", "SPECIES", 227, 239], ["aureus", "SPECIES", 241, 247], ["enterica subsp", "SPECIES", 268, 282], ["enterica serovar Typhimurium", "SPECIES", 284, 312], ["aureus subsp", "SPECIES", 227, 239], ["aureus", "SPECIES", 241, 247], ["enterica subsp", "SPECIES", 268, 282], ["enterica serovar Typhimurium", "SPECIES", 284, 312], ["The absorbance", "TEST", 0, 14], ["a microplate reader (Molecular devices", "TREATMENT", 74, 112], ["Materials", "TREATMENT", 164, 173], ["Methods", "TREATMENT", 178, 185], ["Staph", "PROBLEM", 220, 225], ["aureus subsp", "PROBLEM", 227, 239], ["aureus", "PROBLEM", 241, 247], ["enterica subsp", "PROBLEM", 268, 282], ["enterica serovar Typhimurium", "TEST", 284, 312], ["a mixture", "TEST", 368, 377], ["diamidino", "TEST", 387, 396], ["phenylindole (DAPI", "TREATMENT", 399, 417], ["propidium iodide", "TREATMENT", 423, 439], ["absorbance", "OBSERVATION_MODIFIER", 4, 14], ["Staph", "OBSERVATION", 220, 225], ["subsp", "OBSERVATION", 234, 239], ["subsp", "OBSERVATION_MODIFIER", 277, 282], ["serovar Typhimurium", "OBSERVATION", 293, 312]]], ["For viable staining, 10 \u03bcL of a 1 mg/mL stock solution of each PI and DAPI was added to 1 mL of target cells treated with bacteriocin independently and in combination for 24 h.", [["cells", "ANATOMY", 103, 108], ["DAPI", "CHEMICAL", 70, 74], ["PI", "SIMPLE_CHEMICAL", 63, 65], ["DAPI", "SIMPLE_CHEMICAL", 70, 74], ["cells", "CELL", 103, 108], ["target cells", "CELL_TYPE", 96, 108], ["DAPI", "TREATMENT", 70, 74], ["target cells", "TREATMENT", 96, 108], ["bacteriocin", "TREATMENT", 122, 133]]], ["Here, to observe the independent effect of bacteriocins on Staph. aureus subsp. aureus ATCC25923, 25 \u03bcg/mL of enterocin LD3 and 90 \u03bcg/mL of plantaricin LD4 were used, and for combined effect, a total of 115 \u03bcg/mL were added.", [["ATCC25923", "CHEMICAL", 87, 96], ["enterocin LD3", "CHEMICAL", 110, 123], ["plantaricin LD4", "CHEMICAL", 140, 155], ["Staph", "SIMPLE_CHEMICAL", 59, 64], ["aureus", "ORGANISM", 66, 72], ["aureus", "ORGANISM", 80, 86], ["enterocin LD3", "SIMPLE_CHEMICAL", 110, 123], ["plantaricin", "SIMPLE_CHEMICAL", 140, 151], ["LD4", "SIMPLE_CHEMICAL", 152, 155], ["aureus subsp", "SPECIES", 66, 78], ["aureus", "SPECIES", 80, 86], ["aureus subsp", "SPECIES", 66, 78], ["aureus", "SPECIES", 80, 86], ["bacteriocins", "TREATMENT", 43, 55], ["Staph", "PROBLEM", 59, 64], ["aureus subsp", "PROBLEM", 66, 78], ["aureus", "TEST", 80, 86], ["enterocin LD3", "TREATMENT", 110, 123], ["plantaricin LD4", "TREATMENT", 140, 155], ["Staph", "OBSERVATION", 59, 64], ["subsp", "OBSERVATION", 73, 78]]], ["On the other hand, enterocin LD3 as 30 \u03bcg/mL and plantaricin LD4 as 100 \u03bcg/mL were used to observe the individual effect on Salm. enterica subsp. enterica serovar Typhimurium ATCC13311, whereas for obtaining the synergistic effect, a mixture of bacteriocins (130 \u03bcg/mL) was used.", [["enterocin", "CHEMICAL", 19, 28], ["plantaricin", "CHEMICAL", 49, 60], ["ATCC13311", "CHEMICAL", 175, 184], ["enterocin", "CHEMICAL", 19, 28], ["plantaricin", "CHEMICAL", 49, 60], ["enterocin", "SIMPLE_CHEMICAL", 19, 28], ["LD3", "SIMPLE_CHEMICAL", 29, 32], ["plantaricin", "SIMPLE_CHEMICAL", 49, 60], ["LD4", "SIMPLE_CHEMICAL", 61, 64], ["enterica", "ORGANISM", 130, 138], ["enterica serovar Typhimurium", "ORGANISM", 146, 174], ["ATCC13311", "ORGANISM", 175, 184], ["enterica subsp", "SPECIES", 130, 144], ["enterica serovar Typhimurium", "SPECIES", 146, 174], ["enterica subsp", "SPECIES", 130, 144], ["enterica serovar Typhimurium", "SPECIES", 146, 174], ["enterocin LD3", "TREATMENT", 19, 32], ["plantaricin LD4", "TREATMENT", 49, 64], ["enterica subsp", "PROBLEM", 130, 144], ["enterica serovar Typhimurium", "TEST", 146, 174], ["a mixture of bacteriocins", "TREATMENT", 232, 257], ["subsp", "OBSERVATION_MODIFIER", 139, 144], ["serovar Typhimurium", "OBSERVATION", 155, 174]]], ["As positive control, cells grown for 24 h (~ 106 CFU/mL) in normal saline (0.8% NaCl) were used.", [["cells", "ANATOMY", 21, 26], ["NaCl", "CHEMICAL", 80, 84], ["NaCl", "CHEMICAL", 80, 84], ["cells", "CELL", 21, 26], ["saline", "SIMPLE_CHEMICAL", 67, 73], ["cells", "TEST", 21, 26], ["normal saline (0.8% NaCl)", "TREATMENT", 60, 85]]], ["The treated and untreated cell suspensions were incubated with the mixture of PI and DAPI for 10 min.", [["cell", "ANATOMY", 26, 30], ["DAPI", "CHEMICAL", 85, 89], ["cell suspensions", "CELL", 26, 42], ["PI", "SIMPLE_CHEMICAL", 78, 80], ["DAPI", "SIMPLE_CHEMICAL", 85, 89], ["untreated cell suspensions", "TREATMENT", 16, 42], ["PI", "TREATMENT", 78, 80], ["DAPI", "TREATMENT", 85, 89], ["untreated cell suspensions", "OBSERVATION", 16, 42]]], ["The staining was carried out at room temperature before the live/dead cells were analysed at excitation 330\u2013380 nm using a fluorescent microscope (DS-Fi2, Nikon Eclipse, Japan) with \u00d7 40 magnification.Fourier Transform Infrared Spectroscopy (FTIR) ::: Materials and MethodsFTIR spectroscopy is capable of monitoring conformational, compositional and quantitative differences of biochemical compounds in microbial cells.", [["cells", "ANATOMY", 70, 75], ["cells", "ANATOMY", 413, 418], ["cells", "CELL", 70, 75], ["microbial cells", "CELL", 403, 418], ["dead cells", "CELL_TYPE", 65, 75], ["microbial cells", "CELL_TYPE", 403, 418], ["The staining", "TEST", 0, 12], ["the live/dead cells", "TREATMENT", 56, 75], ["a fluorescent microscope", "TEST", 121, 145], ["DS", "TEST", 147, 149], ["Infrared Spectroscopy", "TEST", 219, 240], ["MethodsFTIR spectroscopy", "TEST", 266, 290], ["biochemical compounds in microbial cells", "PROBLEM", 378, 418], ["biochemical compounds", "OBSERVATION", 378, 399], ["microbial cells", "OBSERVATION", 403, 418]]], ["Therefore, this technique was used to evaluate the cellular response of bacteriocin-treated and untreated cells as reported by Zoumpopoulou et al. [25].", [["cellular", "ANATOMY", 51, 59], ["cells", "ANATOMY", 106, 111], ["bacteriocin", "CHEMICAL", 72, 83], ["cellular", "CELL", 51, 59], ["cells", "CELL", 106, 111], ["bacteriocin-treated and untreated cells", "CELL_LINE", 72, 111], ["this technique", "TREATMENT", 11, 25], ["bacteriocin", "TREATMENT", 72, 83], ["untreated cells", "PROBLEM", 96, 111]]], ["Briefly ~ 106 CFU/mL cells of Staph. aureus subsp. aureus ATCC25923 were treated with enterocin LD3 (25 \u03bcg/mL) and plantaricin LD4 (90 \u03bcg/mL) individually and in combination (115 \u03bcg/mL).", [["cells", "ANATOMY", 21, 26], ["ATCC25923", "CHEMICAL", 58, 67], ["enterocin LD3", "CHEMICAL", 86, 99], ["plantaricin LD4", "CHEMICAL", 115, 130], ["enterocin LD3", "CHEMICAL", 86, 99], ["plantaricin LD4", "CHEMICAL", 115, 130], ["cells", "CELL", 21, 26], ["aureus", "ORGANISM", 37, 43], ["enterocin LD3", "SIMPLE_CHEMICAL", 86, 99], ["plantaricin LD4", "SIMPLE_CHEMICAL", 115, 130], ["aureus subsp", "SPECIES", 37, 49], ["aureus", "SPECIES", 51, 57], ["aureus subsp", "SPECIES", 37, 49], ["aureus", "SPECIES", 51, 57], ["Staph", "PROBLEM", 30, 35], ["aureus subsp", "PROBLEM", 37, 49], ["aureus", "PROBLEM", 51, 57], ["enterocin LD3", "TREATMENT", 86, 99], ["plantaricin LD4", "TREATMENT", 115, 130], ["106 CFU", "OBSERVATION_MODIFIER", 10, 17], ["Staph", "OBSERVATION", 30, 35], ["subsp", "OBSERVATION", 44, 49]]], ["Similarly, Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 was treated with enterocin LD3 (30 \u03bcg/mL) and plantaricin LD4 (100 \u03bcg/mL) individually and in combination (130 \u03bcg/mL) and incubated at 37 \u00b0C, 200 rpm for 10 h.", [["enterocin LD3", "CHEMICAL", 89, 102], ["plantaricin LD4", "CHEMICAL", 118, 133], ["enterocin LD3", "CHEMICAL", 89, 102], ["plantaricin LD4", "CHEMICAL", 118, 133], ["enterica", "ORGANISM", 17, 25], ["enterica serovar Typhimurium", "ORGANISM", 33, 61], ["ATCC13311", "ORGANISM", 62, 71], ["enterocin LD3", "SIMPLE_CHEMICAL", 89, 102], ["plantaricin LD4", "SIMPLE_CHEMICAL", 118, 133], ["Salm", "PROTEIN", 11, 15], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "PROBLEM", 17, 31], ["enterica serovar Typhimurium", "TREATMENT", 33, 61], ["enterocin LD3", "TREATMENT", 89, 102], ["plantaricin LD4", "TREATMENT", 118, 133], ["subsp", "OBSERVATION_MODIFIER", 26, 31], ["serovar Typhimurium", "OBSERVATION", 42, 61]]], ["The untreated cells were used as controls.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["The untreated cells", "TREATMENT", 0, 19], ["untreated cells", "OBSERVATION", 4, 19]]], ["After incubation for 10 h, cell suspensions were washed twice with sterile saline (0.85% NaCl).", [["cell", "ANATOMY", 27, 31], ["NaCl", "CHEMICAL", 89, 93], ["NaCl", "CHEMICAL", 89, 93], ["cell", "CELL", 27, 31], ["saline", "SIMPLE_CHEMICAL", 75, 81], ["cell suspensions", "TREATMENT", 27, 43], ["sterile saline (0.85% NaCl)", "TREATMENT", 67, 94]]], ["Infrared absorbance spectra of bacteriocin-treated and untreated target cells were monitored using an FTIR spectrophotometer (Bruker, Bremen, Germany) on diamond-attenuated total reflectance accessory.", [["cells", "ANATOMY", 72, 77], ["bacteriocin", "CHEMICAL", 31, 42], ["cells", "CELL", 72, 77], ["bacteriocin-treated and untreated target cells", "CELL_LINE", 31, 77], ["Infrared absorbance spectra of bacteriocin", "TREATMENT", 0, 42], ["untreated target cells", "PROBLEM", 55, 77], ["an FTIR spectrophotometer", "TEST", 99, 124], ["total", "OBSERVATION_MODIFIER", 173, 178], ["reflectance", "OBSERVATION_MODIFIER", 179, 190], ["accessory", "OBSERVATION_MODIFIER", 191, 200]]], ["For spectra acquisition, Opus software was used.", [["spectra acquisition", "TEST", 4, 23], ["Opus software", "TEST", 25, 38]]], ["The cells were placed in direct contact with the internal reflecting diamond crystal.", [["cells", "ANATOMY", 4, 9], ["diamond", "CHEMICAL", 69, 76], ["cells", "CELL", 4, 9], ["The cells", "TREATMENT", 0, 9], ["diamond crystal", "OBSERVATION", 69, 84]]], ["Multiple scans were obtained to reduce error.", [["Multiple scans", "TEST", 0, 14]]], ["Each spectrum was baseline corrected, and the spectral range was set from 500/cm to 4000/cm at a resolution of 8/cm.Transmission Electron Microscopy (TEM) ::: Materials and MethodsTEM analysis was performed to explore alterations in the morphology of target cells treated individually and with a mixture of bacteriocins.", [["cells", "ANATOMY", 258, 263], ["cells", "CELL", 258, 263], ["target cells", "CELL_TYPE", 251, 263], ["Transmission Electron Microscopy", "TEST", 116, 148], ["MethodsTEM analysis", "TEST", 173, 192], ["target cells", "PROBLEM", 251, 263], ["a mixture of bacteriocins", "TREATMENT", 294, 319], ["target cells", "OBSERVATION", 251, 263]]], ["The cells of Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 were harvested from mid-log phase (~ 106 CFU/mL) by centrifugation at 7000 g, for 10 min at 4 \u00b0C, and used for TEM analysis as reported by Zhang et al. [26].", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["Staph", "GENE_OR_GENE_PRODUCT", 13, 18], ["aureus", "ORGANISM", 20, 26], ["enterica", "ORGANISM", 61, 69], ["enterica serovar Typhimurium", "ORGANISM", 77, 105], ["ATCC13311", "ORGANISM", 106, 115], ["aureus subsp", "SPECIES", 20, 32], ["aureus", "SPECIES", 34, 40], ["enterica subsp", "SPECIES", 61, 75], ["enterica serovar Typhimurium", "SPECIES", 77, 105], ["aureus subsp", "SPECIES", 20, 32], ["aureus", "SPECIES", 34, 40], ["enterica subsp", "SPECIES", 61, 75], ["enterica serovar Typhimurium", "SPECIES", 77, 105], ["Staph", "PROBLEM", 13, 18], ["aureus subsp", "PROBLEM", 20, 32], ["aureus", "PROBLEM", 34, 40], ["enterica subsp", "PROBLEM", 61, 75], ["enterica serovar Typhimurium", "TREATMENT", 77, 105], ["TEM analysis", "TEST", 227, 239], ["Staph", "OBSERVATION", 13, 18], ["subsp", "OBSERVATION", 27, 32], ["subsp", "OBSERVATION_MODIFIER", 70, 75], ["serovar Typhimurium", "OBSERVATION", 86, 105]]], ["The cells were washed individually twice with normal saline and individually treated with bacteriocins alone and in combination for 24 h.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["saline", "SIMPLE_CHEMICAL", 53, 59], ["The cells", "TREATMENT", 0, 9], ["normal saline", "TREATMENT", 46, 59], ["bacteriocins", "TREATMENT", 90, 102]]], ["For analysis of bacteriocins acting independently, Staph. aureus subsp. aureus ATCC25923 cells were treated with enterocin LD3 (25 \u03bcg/mL) and plantaricin LD4 (90 \u03bcg/mL), whereas Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells were treated with enterocin LD3 (30 \u03bcg/mL) and plantaricin LD4 (100 \u03bcg/mL) for independent effect of bacteriocins.", [["ATCC25923 cells", "ANATOMY", 79, 94], ["ATCC13311 cells", "ANATOMY", 229, 244], ["enterocin LD3", "CHEMICAL", 113, 126], ["plantaricin LD4", "CHEMICAL", 142, 157], ["enterocin LD3", "CHEMICAL", 263, 276], ["plantaricin LD4", "CHEMICAL", 292, 307], ["enterocin LD3", "CHEMICAL", 113, 126], ["plantaricin", "CHEMICAL", 142, 153], ["enterocin LD3", "CHEMICAL", 263, 276], ["plantaricin LD4", "CHEMICAL", 292, 307], ["aureus", "ORGANISM", 58, 64], ["ATCC25923 cells", "CELL", 79, 94], ["enterocin LD3", "SIMPLE_CHEMICAL", 113, 126], ["plantaricin LD4", "SIMPLE_CHEMICAL", 142, 157], ["enterica", "ORGANISM", 184, 192], ["enterica serovar", "ORGANISM", 200, 216], ["Typhimurium", "ORGANISM", 217, 228], ["ATCC13311 cells", "CELL", 229, 244], ["enterocin LD3", "SIMPLE_CHEMICAL", 263, 276], ["plantaricin LD4", "SIMPLE_CHEMICAL", 292, 307], ["ATCC25923 cells", "CELL_LINE", 79, 94], ["ATCC13311 cells", "CELL_LINE", 229, 244], ["aureus subsp", "SPECIES", 58, 70], ["aureus", "SPECIES", 72, 78], ["enterica subsp", "SPECIES", 184, 198], ["enterica serovar Typhimurium", "SPECIES", 200, 228], ["aureus subsp", "SPECIES", 58, 70], ["aureus", "SPECIES", 72, 78], ["enterica subsp", "SPECIES", 184, 198], ["enterica serovar Typhimurium", "SPECIES", 200, 228], ["bacteriocins", "TREATMENT", 16, 28], ["Staph", "PROBLEM", 51, 56], ["aureus subsp", "PROBLEM", 58, 70], ["aureus ATCC25923 cells", "PROBLEM", 72, 94], ["enterocin LD3", "TREATMENT", 113, 126], ["plantaricin LD4", "TREATMENT", 142, 157], ["enterica subsp", "PROBLEM", 184, 198], ["enterica serovar Typhimurium ATCC13311 cells", "TREATMENT", 200, 244], ["enterocin LD3", "TREATMENT", 263, 276], ["plantaricin LD4", "TREATMENT", 292, 307], ["bacteriocins", "TREATMENT", 346, 358], ["subsp", "OBSERVATION", 65, 70], ["subsp", "OBSERVATION_MODIFIER", 193, 198], ["serovar Typhimurium", "OBSERVATION", 209, 228]]], ["On the other hand, to evaluate the synergistic effect, 115 and 130 \u03bcg/mL mixed concentrations of bacteriocins were used for Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311, respectively.", [["aureus", "ORGANISM", 131, 137], ["enterica", "ORGANISM", 172, 180], ["enterica serovar Typhimurium", "ORGANISM", 188, 216], ["ATCC13311", "ORGANISM", 217, 226], ["aureus subsp", "SPECIES", 131, 143], ["aureus", "SPECIES", 145, 151], ["enterica subsp", "SPECIES", 172, 186], ["enterica serovar Typhimurium", "SPECIES", 188, 216], ["aureus subsp", "SPECIES", 131, 143], ["aureus", "SPECIES", 145, 151], ["enterica subsp", "SPECIES", 172, 186], ["enterica serovar Typhimurium", "SPECIES", 188, 216], ["130 \u03bcg/mL mixed concentrations of bacteriocins", "TREATMENT", 63, 109], ["Staph", "PROBLEM", 124, 129], ["aureus subsp", "PROBLEM", 131, 143], ["aureus", "PROBLEM", 145, 151], ["enterica subsp", "PROBLEM", 172, 186], ["enterica serovar Typhimurium", "TREATMENT", 188, 216], ["subsp", "OBSERVATION", 138, 143], ["subsp", "OBSERVATION_MODIFIER", 181, 186], ["serovar Typhimurium", "OBSERVATION", 197, 216]]], ["Untreated cells were resuspended in normal saline and used as controls.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["saline", "SIMPLE_CHEMICAL", 43, 49], ["Untreated cells", "PROBLEM", 0, 15], ["normal saline", "TREATMENT", 36, 49]]], ["After treatment, cells were processed to visualize under transmission electron microscope as reported previously [17].Antibacterial Spectrum ::: Materials and MethodsTo observe the host-range of bacteriocins alone and in combination against other pathogenic bacteria such as Proteus mirabilis ATCC43071, Pseudomonas aeruginosa ATCC27853, E. coli ATCC25922, Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311, Serratia marcescens ATCC27137 and indicator strain, Micrococcus luteus MTCC106, agar well diffusion assay (AWDA) was performed overlaying soft nutrient agar (0.8%) seeded with respective pathogenic strain (~ 106 CFU/mL) on the nutrient base agar as reported previously [27].", [["cells", "ANATOMY", 17, 22], ["cells", "CELL", 17, 22], ["Proteus mirabilis ATCC43071", "ORGANISM", 275, 302], ["Pseudomonas aeruginosa", "ORGANISM", 304, 326], ["ATCC27853", "ORGANISM", 327, 336], ["E. coli", "ORGANISM", 338, 345], ["ATCC25922", "ORGANISM", 346, 355], ["aureus", "ORGANISM", 364, 370], ["enterica", "ORGANISM", 405, 413], ["enterica serovar Typhimurium", "ORGANISM", 421, 449], ["ATCC13311", "ORGANISM", 450, 459], ["Serratia marcescens", "ORGANISM", 461, 480], ["ATCC27137", "ORGANISM", 481, 490], ["Micrococcus luteus", "ORGANISM", 513, 531], ["MTCC106", "ORGANISM", 532, 539], ["Proteus mirabilis", "SPECIES", 275, 292], ["Pseudomonas aeruginosa", "SPECIES", 304, 326], ["E. coli", "SPECIES", 338, 345], ["aureus subsp", "SPECIES", 364, 376], ["aureus", "SPECIES", 378, 384], ["enterica subsp", "SPECIES", 405, 419], ["enterica serovar Typhimurium", "SPECIES", 421, 449], ["Serratia marcescens", "SPECIES", 461, 480], ["Micrococcus luteus", "SPECIES", 513, 531], ["Proteus mirabilis", "SPECIES", 275, 292], ["Pseudomonas aeruginosa", "SPECIES", 304, 326], ["E. coli", "SPECIES", 338, 345], ["aureus subsp", "SPECIES", 364, 376], ["aureus", "SPECIES", 378, 384], ["enterica subsp", "SPECIES", 405, 419], ["enterica serovar Typhimurium", "SPECIES", 421, 449], ["Serratia marcescens", "SPECIES", 461, 480], ["Micrococcus luteus", "SPECIES", 513, 531], ["treatment", "TREATMENT", 6, 15], ["Methods", "TREATMENT", 159, 166], ["bacteriocins", "TREATMENT", 195, 207], ["other pathogenic bacteria", "PROBLEM", 241, 266], ["Proteus mirabilis", "TEST", 275, 292], ["Pseudomonas aeruginosa", "PROBLEM", 304, 326], ["E. coli", "TEST", 338, 345], ["Staph", "PROBLEM", 357, 362], ["aureus subsp", "PROBLEM", 364, 376], ["aureus", "PROBLEM", 378, 384], ["enterica subsp", "PROBLEM", 405, 419], ["enterica serovar Typhimurium", "TEST", 421, 449], ["Serratia marcescens", "TEST", 461, 480], ["indicator strain", "PROBLEM", 495, 511], ["Micrococcus luteus MTCC106", "TEST", 513, 539], ["agar well diffusion assay", "TEST", 541, 566], ["soft nutrient agar", "TREATMENT", 599, 617], ["respective pathogenic strain", "PROBLEM", 637, 665], ["subsp", "OBSERVATION", 371, 376], ["subsp", "OBSERVATION_MODIFIER", 414, 419], ["serovar Typhimurium", "OBSERVATION", 430, 449], ["Micrococcus luteus", "OBSERVATION", 513, 531]]], ["On such plates, the wells were cut out (6.0 mm diameter) and filled with aliquots of 100 \u03bcL of enterocin LD3 (50 \u03bcg/mL) and plantaricin LD4 (50 \u03bcg/mL) independent and in combination (25 \u03bcg/mL each, total 50 \u03bcg/mL) in the wells.", [["enterocin LD3", "CHEMICAL", 95, 108], ["plantaricin LD4", "CHEMICAL", 124, 139], ["enterocin LD3", "CHEMICAL", 95, 108], ["plantaricin LD4", "CHEMICAL", 124, 139], ["enterocin LD3", "SIMPLE_CHEMICAL", 95, 108], ["plantaricin LD4", "SIMPLE_CHEMICAL", 124, 139], ["such plates", "TREATMENT", 3, 14], ["enterocin LD3", "TREATMENT", 95, 108], ["plantaricin LD4", "TREATMENT", 124, 139]]], ["The plate was incubated for 18 h at 37 \u00b0C. The zone of growth inhibition (mm) was measured.Statistical Analysis ::: Materials and MethodsThe data presented are means \u00b1 standard deviation (SD) of three independent experiments.", [["plate", "OBSERVATION_MODIFIER", 4, 9], ["zone", "OBSERVATION_MODIFIER", 47, 51], ["growth", "OBSERVATION_MODIFIER", 55, 61], ["inhibition", "OBSERVATION_MODIFIER", 62, 72]]], ["The level of statistical significance was estimated as p < 0.05 using Student\u2019s t test.", [["Student\u2019s t test", "TEST", 70, 86]]], ["Florescence microscopy and TEM analysis were performed three times for reproducibility of the results.Synergistic Effect of Enterocin LD3 and Plantaricin LD4 ::: ResultsThe growth of target strains was drastically reduced as the concentration of bacteriocin was increased.", [["Plantaricin", "CHEMICAL", 142, 153], ["Enterocin LD3", "CHEMICAL", 124, 137], ["Plantaricin LD4", "CHEMICAL", 142, 157], ["Enterocin LD3", "SIMPLE_CHEMICAL", 124, 137], ["Plantaricin LD4", "SIMPLE_CHEMICAL", 142, 157], ["Florescence microscopy", "TEST", 0, 22], ["TEM analysis", "TEST", 27, 39], ["Enterocin", "TREATMENT", 124, 133], ["target strains", "PROBLEM", 183, 197], ["the concentration of bacteriocin", "TREATMENT", 225, 257], ["growth", "OBSERVATION_MODIFIER", 173, 179], ["target", "OBSERVATION_MODIFIER", 183, 189], ["strains", "OBSERVATION_MODIFIER", 190, 197], ["drastically", "OBSERVATION_MODIFIER", 202, 213], ["reduced", "OBSERVATION_MODIFIER", 214, 221], ["increased", "OBSERVATION_MODIFIER", 262, 271]]], ["The growth of Staph. aureus subsp. aureus ATCC25923 was completely inhibited in the presence of 180 and 220 \u03bcg/mL enterocin LD3 and plantaricin LD4, respectively.", [["ATCC25923", "CHEMICAL", 42, 51], ["plantaricin", "CHEMICAL", 132, 143], ["Staph", "GENE_OR_GENE_PRODUCT", 14, 19], ["aureus", "ORGANISM", 21, 27], ["aureus", "ORGANISM", 35, 41], ["ATCC25923", "SIMPLE_CHEMICAL", 42, 51], ["enterocin LD3", "SIMPLE_CHEMICAL", 114, 127], ["plantaricin LD4", "SIMPLE_CHEMICAL", 132, 147], ["aureus subsp", "SPECIES", 21, 33], ["aureus", "SPECIES", 35, 41], ["aureus subsp", "SPECIES", 21, 33], ["aureus", "SPECIES", 35, 41], ["Staph", "PROBLEM", 14, 19], ["aureus subsp", "PROBLEM", 21, 33], ["aureus", "PROBLEM", 35, 41], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["Staph", "OBSERVATION", 14, 19], ["subsp", "OBSERVATION", 28, 33]]], ["Therefore, MICs of these bacteriocins were considered 180 and 220 \u03bcg/mL against Staph. aureus subsp. aureus ATCC25923 (Fig. 1a).", [["aureus", "ORGANISM", 87, 93], ["aureus subsp", "SPECIES", 87, 99], ["aureus", "SPECIES", 101, 107], ["aureus subsp", "SPECIES", 87, 99], ["aureus", "SPECIES", 101, 107], ["these bacteriocins", "TEST", 19, 37], ["Staph", "PROBLEM", 80, 85], ["aureus subsp", "PROBLEM", 87, 99], ["aureus", "PROBLEM", 101, 107], ["subsp", "OBSERVATION", 94, 99]]], ["Similarly, the MIC of enterocin LD3 and plantaricin LD4 were found to be 240 and 320 \u03bcg/mL, respectively, against Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 (Fig. 1b).", [["enterocin LD3", "CHEMICAL", 22, 35], ["plantaricin", "CHEMICAL", 40, 51], ["plantaricin LD4", "CHEMICAL", 40, 55], ["enterocin LD3", "SIMPLE_CHEMICAL", 22, 35], ["plantaricin LD4", "SIMPLE_CHEMICAL", 40, 55], ["enterica", "ORGANISM", 120, 128], ["enterica serovar Typhimurium", "ORGANISM", 136, 164], ["enterica subsp", "SPECIES", 120, 134], ["enterica serovar Typhimurium", "SPECIES", 136, 164], ["enterica subsp", "SPECIES", 120, 134], ["enterica serovar Typhimurium", "SPECIES", 136, 164], ["the MIC of enterocin LD3", "TEST", 11, 35], ["plantaricin LD4", "TEST", 40, 55], ["enterica subsp", "PROBLEM", 120, 134], ["enterica serovar Typhimurium", "TREATMENT", 136, 164], ["subsp", "OBSERVATION_MODIFIER", 129, 134], ["serovar Typhimurium", "OBSERVATION", 145, 164]]], ["The corresponding values of MICs of enterocin LD3 and plantaricin LD4 in combination was observed as 25 and 90 \u03bcg/mL (115 \u03bcg/mL), respectively, against Staph. aureus subsp. aureus ATCC25923 (Fig. 2a) whereas 30 and 100 \u03bcg/mL (130 \u03bcg/mL) against Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 (Fig. 2b).", [["enterocin LD3", "CHEMICAL", 36, 49], ["plantaricin LD4", "CHEMICAL", 54, 69], ["ATCC25923", "CHEMICAL", 180, 189], ["enterocin LD3", "CHEMICAL", 36, 49], ["plantaricin LD4", "CHEMICAL", 54, 69], ["enterocin LD3", "SIMPLE_CHEMICAL", 36, 49], ["plantaricin LD4", "SIMPLE_CHEMICAL", 54, 69], ["aureus", "ORGANISM", 159, 165], ["aureus ATCC25923", "ORGANISM", 173, 189], ["enterica", "ORGANISM", 251, 259], ["enterica", "ORGANISM", 267, 275], ["serovar Typhimurium", "ORGANISM", 276, 295], ["aureus subsp", "SPECIES", 159, 171], ["aureus", "SPECIES", 173, 179], ["enterica subsp", "SPECIES", 251, 265], ["enterica serovar Typhimurium", "SPECIES", 267, 295], ["aureus subsp", "SPECIES", 159, 171], ["aureus", "SPECIES", 173, 179], ["enterica subsp", "SPECIES", 251, 265], ["enterica serovar Typhimurium", "SPECIES", 267, 295], ["MICs", "TEST", 28, 32], ["enterocin LD3", "TEST", 36, 49], ["plantaricin LD4", "TEST", 54, 69], ["Staph", "PROBLEM", 152, 157], ["aureus subsp", "PROBLEM", 159, 171], ["aureus", "PROBLEM", 173, 179], ["enterica subsp", "PROBLEM", 251, 265], ["enterica serovar Typhimurium", "TREATMENT", 267, 295], ["Staph", "OBSERVATION", 152, 157], ["subsp", "OBSERVATION", 166, 171], ["subsp", "OBSERVATION_MODIFIER", 260, 265], ["serovar Typhimurium", "OBSERVATION", 276, 295]]], ["Thus, MIC of enterocin LD3 in combination was reduced to approx.", [["MIC", "CHEMICAL", 6, 9], ["enterocin LD3", "CHEMICAL", 13, 26], ["enterocin LD3", "CHEMICAL", 13, 26], ["enterocin LD3", "SIMPLE_CHEMICAL", 13, 26], ["MIC of enterocin LD3", "TREATMENT", 6, 26]]], ["1/8th against Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311.", [["Staph", "GENE_OR_GENE_PRODUCT", 14, 19], ["aureus", "ORGANISM", 21, 27], ["enterica", "ORGANISM", 62, 70], ["enterica serovar Typhimurium", "ORGANISM", 78, 106], ["ATCC13311", "ORGANISM", 107, 116], ["aureus subsp", "SPECIES", 21, 33], ["aureus", "SPECIES", 35, 41], ["enterica subsp", "SPECIES", 62, 76], ["enterica serovar Typhimurium", "SPECIES", 78, 106], ["aureus subsp", "SPECIES", 21, 33], ["aureus", "SPECIES", 35, 41], ["enterica subsp", "SPECIES", 62, 76], ["enterica serovar Typhimurium", "SPECIES", 78, 106], ["Staph", "PROBLEM", 14, 19], ["aureus subsp", "PROBLEM", 21, 33], ["aureus", "PROBLEM", 35, 41], ["enterica subsp", "PROBLEM", 62, 76], ["enterica serovar Typhimurium", "TREATMENT", 78, 106], ["Staph", "OBSERVATION", 14, 19], ["subsp", "OBSERVATION", 28, 33], ["subsp", "OBSERVATION_MODIFIER", 71, 76], ["serovar Typhimurium", "OBSERVATION", 87, 106]]], ["Similarly, the MIC of plantaricin LD4 in combination was reduced to approx.", [["plantaricin LD4", "CHEMICAL", 22, 37], ["plantaricin LD4", "CHEMICAL", 22, 37], ["plantaricin LD4", "SIMPLE_CHEMICAL", 22, 37], ["the MIC of plantaricin LD4", "TREATMENT", 11, 37], ["reduced", "OBSERVATION_MODIFIER", 57, 64]]], ["Therefore, enterocin LD3 and plantaricin LD4 showed lower MICs in combination as compared with their individual effect against Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311.", [["enterocin LD3", "CHEMICAL", 11, 24], ["plantaricin", "CHEMICAL", 29, 40], ["MICs", "CHEMICAL", 58, 62], ["plantaricin LD4", "CHEMICAL", 29, 44], ["enterocin LD3", "SIMPLE_CHEMICAL", 11, 24], ["plantaricin LD4", "SIMPLE_CHEMICAL", 29, 44], ["MICs", "SIMPLE_CHEMICAL", 58, 62], ["Staph", "SIMPLE_CHEMICAL", 127, 132], ["aureus", "ORGANISM", 134, 140], ["enterica", "ORGANISM", 175, 183], ["enterica serovar Typhimurium", "ORGANISM", 191, 219], ["ATCC13311", "ORGANISM", 220, 229], ["aureus subsp", "SPECIES", 134, 146], ["aureus", "SPECIES", 148, 154], ["enterica subsp", "SPECIES", 175, 189], ["enterica serovar Typhimurium", "SPECIES", 191, 219], ["aureus subsp", "SPECIES", 134, 146], ["aureus", "SPECIES", 148, 154], ["enterica subsp", "SPECIES", 175, 189], ["enterica serovar Typhimurium", "SPECIES", 191, 219], ["enterocin LD3", "TEST", 11, 24], ["plantaricin LD4", "TEST", 29, 44], ["lower MICs", "PROBLEM", 52, 62], ["Staph", "PROBLEM", 127, 132], ["aureus subsp", "PROBLEM", 134, 146], ["aureus", "PROBLEM", 148, 154], ["enterica subsp", "PROBLEM", 175, 189], ["enterica serovar Typhimurium", "TREATMENT", 191, 219], ["lower MICs", "OBSERVATION", 52, 62], ["Staph", "OBSERVATION", 127, 132], ["subsp", "OBSERVATION", 141, 146], ["subsp", "OBSERVATION_MODIFIER", 184, 189], ["serovar Typhimurium", "OBSERVATION", 200, 219]]], ["The FICs of enterocin LD3 and plantaricin LD4 against Staph. aureus subsp. aureus ATCC25923 were 0.10 and 0.40, whereas corresponding FICs were 0.12 and 0.31 against Salm. enterica subsp. enterica serovar Typhimurium ATCC13311, respectively.", [["enterocin LD3", "CHEMICAL", 12, 25], ["plantaricin LD4", "CHEMICAL", 30, 45], ["ATCC25923", "CHEMICAL", 82, 91], ["plantaricin LD4", "CHEMICAL", 30, 45], ["enterocin LD3", "SIMPLE_CHEMICAL", 12, 25], ["plantaricin LD4", "SIMPLE_CHEMICAL", 30, 45], ["aureus", "ORGANISM", 61, 67], ["enterica", "ORGANISM", 172, 180], ["enterica serovar Typhimurium", "ORGANISM", 188, 216], ["ATCC13311", "ORGANISM", 217, 226], ["aureus subsp", "SPECIES", 61, 73], ["aureus", "SPECIES", 75, 81], ["enterica subsp", "SPECIES", 172, 186], ["enterica serovar Typhimurium", "SPECIES", 188, 216], ["aureus subsp", "SPECIES", 61, 73], ["aureus", "SPECIES", 75, 81], ["enterica subsp", "SPECIES", 172, 186], ["enterica serovar Typhimurium", "SPECIES", 188, 216], ["The FICs", "TEST", 0, 8], ["enterocin LD3", "TREATMENT", 12, 25], ["plantaricin", "TREATMENT", 30, 41], ["Staph", "PROBLEM", 54, 59], ["aureus subsp", "PROBLEM", 61, 73], ["aureus ATCC25923", "TEST", 75, 91], ["FICs", "TEST", 134, 138], ["enterica subsp", "PROBLEM", 172, 186], ["enterica serovar Typhimurium", "TREATMENT", 188, 216], ["Staph", "OBSERVATION", 54, 59], ["subsp", "OBSERVATION", 68, 73], ["subsp", "OBSERVATION_MODIFIER", 181, 186], ["serovar Typhimurium", "OBSERVATION", 197, 216]]], ["Therefore, the FIC index was calculated as 0.50 against Staph. aureus subsp. aureus ATCC25923 and 0.43 against Salm. enterica subsp. enterica serovar Typhimurium ATCC13311.", [["ATCC25923", "CHEMICAL", 84, 93], ["aureus", "ORGANISM", 63, 69], ["enterica", "ORGANISM", 117, 125], ["enterica serovar Typhimurium", "ORGANISM", 133, 161], ["ATCC13311", "ORGANISM", 162, 171], ["aureus subsp", "SPECIES", 63, 75], ["aureus", "SPECIES", 77, 83], ["enterica subsp", "SPECIES", 117, 131], ["enterica serovar Typhimurium", "SPECIES", 133, 161], ["aureus subsp", "SPECIES", 63, 75], ["aureus", "SPECIES", 77, 83], ["enterica subsp", "SPECIES", 117, 131], ["enterica serovar Typhimurium", "SPECIES", 133, 161], ["the FIC index", "TEST", 11, 24], ["Staph", "PROBLEM", 56, 61], ["aureus subsp", "PROBLEM", 63, 75], ["aureus", "PROBLEM", 77, 83], ["enterica subsp", "PROBLEM", 117, 131], ["enterica serovar Typhimurium", "TREATMENT", 133, 161], ["subsp", "OBSERVATION", 70, 75], ["subsp", "OBSERVATION_MODIFIER", 126, 131], ["serovar Typhimurium", "OBSERVATION", 142, 161]]], ["Since the FIC index of both bacteriocins is \u2264 0.5, the synergistic interaction of enterocin LD3 and plantaricin LD4 was apparent.", [["enterocin LD3", "CHEMICAL", 82, 95], ["plantaricin", "CHEMICAL", 100, 111], ["plantaricin", "CHEMICAL", 100, 111], ["enterocin LD3", "SIMPLE_CHEMICAL", 82, 95], ["plantaricin LD4", "SIMPLE_CHEMICAL", 100, 115], ["enterocin LD3", "PROTEIN", 82, 95], ["the FIC index", "TEST", 6, 19], ["both bacteriocins", "TEST", 23, 40], ["enterocin LD3", "TREATMENT", 82, 95]]], ["The isobologram provided a graphical representation of the nature of bacteriocin interaction.", [["The isobologram", "TEST", 0, 15], ["bacteriocin interaction", "PROBLEM", 69, 92]]], ["It was constructed showing that the combination of two bacteriocins inhibiting target strains falls below the plotted straight line, of which the end point reflects the independent MICs of the bacteriocins (Fig. 3a, b).", [["two bacteriocins", "TREATMENT", 51, 67], ["target strains falls", "PROBLEM", 79, 99], ["the plotted straight line", "TREATMENT", 106, 131], ["the bacteriocins", "TREATMENT", 189, 205], ["straight line", "OBSERVATION", 118, 131]]], ["This further signifies synergy between enterocin LD3 and plantaricin LD4 against Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311.", [["enterocin LD3", "CHEMICAL", 39, 52], ["plantaricin", "CHEMICAL", 57, 68], ["plantaricin", "CHEMICAL", 57, 68], ["enterocin LD3", "SIMPLE_CHEMICAL", 39, 52], ["plantaricin LD4", "SIMPLE_CHEMICAL", 57, 72], ["Staph", "GENE_OR_GENE_PRODUCT", 81, 86], ["aureus", "ORGANISM", 88, 94], ["enterica", "ORGANISM", 129, 137], ["enterica serovar Typhimurium", "ORGANISM", 145, 173], ["ATCC13311", "ORGANISM", 174, 183], ["aureus subsp", "SPECIES", 88, 100], ["aureus", "SPECIES", 102, 108], ["enterica subsp", "SPECIES", 129, 143], ["enterica serovar Typhimurium", "SPECIES", 145, 173], ["aureus subsp", "SPECIES", 88, 100], ["aureus", "SPECIES", 102, 108], ["enterica subsp", "SPECIES", 129, 143], ["enterica serovar Typhimurium", "SPECIES", 145, 173], ["synergy", "PROBLEM", 23, 30], ["enterocin LD3", "TREATMENT", 39, 52], ["plantaricin", "TREATMENT", 57, 68], ["Staph", "PROBLEM", 81, 86], ["aureus subsp", "PROBLEM", 88, 100], ["aureus", "PROBLEM", 102, 108], ["enterica subsp", "PROBLEM", 129, 143], ["enterica serovar Typhimurium", "TREATMENT", 145, 173], ["Staph", "OBSERVATION", 81, 86], ["subsp", "OBSERVATION", 95, 100], ["subsp", "OBSERVATION_MODIFIER", 138, 143], ["serovar Typhimurium", "OBSERVATION", 154, 173]]], ["Therefore, enterocin LD3 and plantaricin LD4 showed synergistic effect against the target bacteria tested.Combined Bacteriocins Caused Higher Growth Inhibition ::: ResultsIt was found that untreated Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells followed normal growth pattern and grew up to OD600 0.702 and 0.937, respectively.", [["ATCC13311 cells", "ANATOMY", 292, 307], ["enterocin LD3", "CHEMICAL", 11, 24], ["plantaricin", "CHEMICAL", 29, 40], ["LD4", "CHEMICAL", 41, 44], ["plantaricin LD4", "CHEMICAL", 29, 44], ["enterocin LD3", "SIMPLE_CHEMICAL", 11, 24], ["plantaricin LD4", "SIMPLE_CHEMICAL", 29, 44], ["aureus", "ORGANISM", 206, 212], ["enterica", "ORGANISM", 247, 255], ["enterica serovar", "ORGANISM", 263, 279], ["Typhimurium", "ORGANISM", 280, 291], ["ATCC13311 cells", "CELL", 292, 307], ["ATCC13311 cells", "CELL_LINE", 292, 307], ["aureus subsp", "SPECIES", 206, 218], ["aureus", "SPECIES", 220, 226], ["enterica subsp", "SPECIES", 247, 261], ["enterica serovar Typhimurium", "SPECIES", 263, 291], ["aureus subsp", "SPECIES", 206, 218], ["aureus", "SPECIES", 220, 226], ["enterica subsp", "SPECIES", 247, 261], ["enterica serovar Typhimurium", "SPECIES", 263, 291], ["enterocin LD3", "TEST", 11, 24], ["plantaricin LD4", "TEST", 29, 44], ["synergistic effect", "PROBLEM", 52, 70], ["the target bacteria", "PROBLEM", 79, 98], ["Combined Bacteriocins", "PROBLEM", 106, 127], ["untreated Staph", "PROBLEM", 189, 204], ["aureus subsp", "PROBLEM", 206, 218], ["aureus", "PROBLEM", 220, 226], ["enterica subsp", "PROBLEM", 247, 261], ["enterica serovar Typhimurium ATCC13311 cells", "TEST", 263, 307], ["bacteria", "OBSERVATION", 90, 98], ["untreated", "OBSERVATION_MODIFIER", 189, 198], ["Staph", "OBSERVATION", 199, 204], ["subsp", "OBSERVATION", 213, 218], ["subsp", "OBSERVATION_MODIFIER", 256, 261], ["serovar Typhimurium", "OBSERVATION", 272, 291], ["growth", "OBSERVATION_MODIFIER", 324, 330], ["pattern", "OBSERVATION_MODIFIER", 331, 338]]], ["When Staph. aureus subsp. aureus ATCC25923 cells were treated with enterocin LD3 (25 \u03bcg/mL) and plantaricin LD4 (90 \u03bcg/mL) individually, growth was partially inhibited and found to be OD600 0.47 and 0.54, respectively, at 24 h, whereas combined effect of bacteriocins (115 \u03bcg/mL) on Staph. aureus subsp. aureus ATCC25923 showed complete inhibition (OD600 0.028) as compared with untreated cells.", [["ATCC25923 cells", "ANATOMY", 33, 48], ["cells", "ANATOMY", 389, 394], ["enterocin LD3", "CHEMICAL", 67, 80], ["plantaricin LD4", "CHEMICAL", 96, 111], ["ATCC25923", "CHEMICAL", 311, 320], ["enterocin LD3", "CHEMICAL", 67, 80], ["plantaricin", "CHEMICAL", 96, 107], ["aureus", "ORGANISM", 12, 18], ["ATCC25923 cells", "CELL", 33, 48], ["enterocin LD3", "SIMPLE_CHEMICAL", 67, 80], ["plantaricin LD4", "SIMPLE_CHEMICAL", 96, 111], ["aureus", "ORGANISM", 290, 296], ["aureus", "ORGANISM", 304, 310], ["ATCC25923", "SIMPLE_CHEMICAL", 311, 320], ["cells", "CELL", 389, 394], ["ATCC25923 cells", "CELL_LINE", 33, 48], ["aureus subsp", "SPECIES", 12, 24], ["aureus", "SPECIES", 26, 32], ["aureus subsp", "SPECIES", 290, 302], ["aureus", "SPECIES", 304, 310], ["aureus subsp", "SPECIES", 12, 24], ["aureus", "SPECIES", 26, 32], ["aureus subsp", "SPECIES", 290, 302], ["aureus", "SPECIES", 304, 310], ["Staph", "PROBLEM", 5, 10], ["aureus subsp", "PROBLEM", 12, 24], ["aureus ATCC25923 cells", "PROBLEM", 26, 48], ["enterocin LD3", "TREATMENT", 67, 80], ["plantaricin LD4", "TREATMENT", 96, 111], ["bacteriocins", "TEST", 255, 267], ["Staph", "PROBLEM", 283, 288], ["aureus subsp", "PROBLEM", 290, 302], ["aureus", "PROBLEM", 304, 310], ["Staph", "OBSERVATION", 5, 10], ["subsp", "OBSERVATION", 19, 24], ["Staph", "OBSERVATION", 283, 288], ["subsp", "OBSERVATION", 297, 302], ["complete", "OBSERVATION_MODIFIER", 328, 336], ["inhibition", "OBSERVATION_MODIFIER", 337, 347], ["untreated cells", "OBSERVATION", 379, 394]]], ["Similarly, Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 showed growth up to OD600 0.79 and 0.70 in the presence of individual enterocin LD3 (30 \u03bcg/mL) and plantaricin LD4 (100 \u03bcg/mL), but the growth (OD600 0.023) was completely inhibited in the presence of combination (130 \u03bcg/mL) of bacteriocins (data not shown).", [["ATCC13311", "CHEMICAL", 62, 71], ["enterocin", "CHEMICAL", 142, 151], ["plantaricin LD4", "CHEMICAL", 171, 186], ["plantaricin LD4", "CHEMICAL", 171, 186], ["enterica", "ORGANISM", 17, 25], ["enterica serovar Typhimurium", "ORGANISM", 33, 61], ["ATCC13311", "ORGANISM", 62, 71], ["enterocin LD3", "SIMPLE_CHEMICAL", 142, 155], ["plantaricin LD4", "SIMPLE_CHEMICAL", 171, 186], ["Salm", "PROTEIN", 11, 15], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "PROBLEM", 17, 31], ["enterica serovar Typhimurium", "TEST", 33, 61], ["growth", "TEST", 79, 85], ["individual enterocin LD3", "TEST", 131, 155], ["plantaricin LD4", "TEST", 171, 186], ["bacteriocins", "TREATMENT", 300, 312], ["subsp", "OBSERVATION_MODIFIER", 26, 31], ["serovar Typhimurium", "OBSERVATION", 42, 61], ["growth", "OBSERVATION_MODIFIER", 79, 85]]], ["Therefore, significant growth inhibition of target strains was observed when bacteriocins were used in combination than alone.Combined Bacteriocins Caused Higher Lethality ::: ResultsThe cell membrane permeability was also determined by fluorescent microscopy using DAPI and PI which could distinguish intact cells with ruptured membranes.", [["cell membrane", "ANATOMY", 187, 200], ["cells", "ANATOMY", 309, 314], ["membranes", "ANATOMY", 329, 338], ["DAPI", "CHEMICAL", 266, 270], ["cell membrane", "CELLULAR_COMPONENT", 187, 200], ["DAPI", "SIMPLE_CHEMICAL", 266, 270], ["PI", "SIMPLE_CHEMICAL", 275, 277], ["cells", "CELL", 309, 314], ["membranes", "CELLULAR_COMPONENT", 329, 338], ["significant growth inhibition of target strains", "PROBLEM", 11, 58], ["bacteriocins", "TREATMENT", 77, 89], ["fluorescent microscopy", "TEST", 237, 259], ["DAPI and PI", "TEST", 266, 277], ["ruptured membranes", "PROBLEM", 320, 338], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["growth", "OBSERVATION_MODIFIER", 23, 29], ["inhibition", "OBSERVATION_MODIFIER", 30, 40], ["Higher Lethality", "OBSERVATION", 155, 171], ["cell membrane permeability", "OBSERVATION", 187, 213], ["intact cells", "OBSERVATION", 302, 314], ["ruptured membranes", "OBSERVATION", 320, 338]]], ["The untreated cells (live) were stained blue (Fig. 4a, e) with DAPI and dead cells stained red (Fig. 4d, h) with PI.", [["cells", "ANATOMY", 14, 19], ["cells", "ANATOMY", 77, 82], ["DAPI", "CHEMICAL", 63, 67], ["cells", "CELL", 14, 19], ["DAPI", "SIMPLE_CHEMICAL", 63, 67], ["cells", "CELL", 77, 82], ["untreated cells", "CELL_TYPE", 4, 19], ["dead cells", "CELL_TYPE", 72, 82], ["The untreated cells", "PROBLEM", 0, 19], ["DAPI", "TEST", 63, 67], ["dead cells", "PROBLEM", 72, 82], ["PI", "PROBLEM", 113, 115], ["untreated cells", "OBSERVATION", 4, 19], ["dead cells", "OBSERVATION", 72, 82]]], ["After treatment of cells with enterocin LD3 (Fig. 4b, f) or plantaricin LD4 (Fig. 4c, g) individually, light pink fluorescence was observed in Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells, indicating that the cell membrane of the treated cells was damaged.", [["cells", "ANATOMY", 19, 24], ["ATCC13311 cells", "ANATOMY", 236, 251], ["cell membrane", "ANATOMY", 273, 286], ["cells", "ANATOMY", 302, 307], ["plantaricin", "CHEMICAL", 60, 71], ["cells", "CELL", 19, 24], ["enterocin LD3", "SIMPLE_CHEMICAL", 30, 43], ["plantaricin LD4", "SIMPLE_CHEMICAL", 60, 75], ["aureus", "ORGANISM", 150, 156], ["enterica", "ORGANISM", 191, 199], ["enterica serovar", "ORGANISM", 207, 223], ["Typhimurium", "ORGANISM", 224, 235], ["ATCC13311 cells", "CELL", 236, 251], ["cell membrane", "CELLULAR_COMPONENT", 273, 286], ["cells", "CELL", 302, 307], ["enterica serovar Typhimurium ATCC13311 cells", "CELL_LINE", 207, 251], ["treated cells", "CELL_LINE", 294, 307], ["aureus subsp", "SPECIES", 150, 162], ["aureus", "SPECIES", 164, 170], ["enterica subsp", "SPECIES", 191, 205], ["enterica serovar Typhimurium", "SPECIES", 207, 235], ["aureus subsp", "SPECIES", 150, 162], ["aureus", "SPECIES", 164, 170], ["enterica subsp", "SPECIES", 191, 205], ["enterica serovar Typhimurium", "SPECIES", 207, 235], ["cells", "PROBLEM", 19, 24], ["enterocin LD3", "TREATMENT", 30, 43], ["plantaricin LD4", "TREATMENT", 60, 75], ["light pink fluorescence", "PROBLEM", 103, 126], ["Staph", "PROBLEM", 143, 148], ["aureus subsp", "PROBLEM", 150, 162], ["aureus", "PROBLEM", 164, 170], ["enterica subsp", "PROBLEM", 191, 205], ["enterica serovar Typhimurium ATCC13311 cells", "PROBLEM", 207, 251], ["Staph", "OBSERVATION", 143, 148], ["subsp", "OBSERVATION", 157, 162], ["subsp", "OBSERVATION_MODIFIER", 200, 205], ["serovar Typhimurium", "OBSERVATION", 216, 235], ["ATCC13311 cells", "OBSERVATION", 236, 251], ["cell membrane", "OBSERVATION", 273, 286], ["treated cells", "OBSERVATION", 294, 307]]], ["When cells were treated with combined bacteriocins, dead cells were found to be red indicating higher effect of bacteriocins (Fig. 4d, h).", [["cells", "ANATOMY", 5, 10], ["cells", "ANATOMY", 57, 62], ["cells", "CELL", 5, 10], ["cells", "CELL", 57, 62], ["dead cells", "CELL_TYPE", 52, 62], ["combined bacteriocins", "TREATMENT", 29, 50], ["dead cells", "PROBLEM", 52, 62], ["bacteriocins", "TREATMENT", 112, 124], ["higher effect", "OBSERVATION_MODIFIER", 95, 108]]], ["However, there is possible explanation for the reduction in DAPI fluorescence, and increase in PI fluorescence of target cells indicating the combined bacteriocin effect was more potent than the effects independently.Enterocin LD3 Interacts with Cell Membrane and Nucleic Acids, Whereas Plantaricin LD4 Does Not ::: ResultsTo observe the effect of bacteriocins independently and in combination on the cell membranes and nucleic acids of Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells, FTIR analysis was performed.", [["cells", "ANATOMY", 121, 126], ["Cell Membrane", "ANATOMY", 246, 259], ["cell membranes", "ANATOMY", 401, 415], ["ATCC13311 cells", "ANATOMY", 530, 545], ["nucleic acids", "CHEMICAL", 420, 433], ["DAPI", "CHEMICAL", 60, 64], ["Plantaricin", "CHEMICAL", 287, 298], ["DAPI", "SIMPLE_CHEMICAL", 60, 64], ["PI", "SIMPLE_CHEMICAL", 95, 97], ["cells", "CELL", 121, 126], ["Cell Membrane", "CELLULAR_COMPONENT", 246, 259], ["Nucleic Acids", "SIMPLE_CHEMICAL", 264, 277], ["cell membranes", "CELLULAR_COMPONENT", 401, 415], ["nucleic acids", "SIMPLE_CHEMICAL", 420, 433], ["aureus", "ORGANISM", 444, 450], ["enterica", "ORGANISM", 485, 493], ["enterica serovar", "ORGANISM", 501, 517], ["Typhimurium", "ORGANISM", 518, 529], ["ATCC13311 cells", "CELL", 530, 545], ["target cells", "CELL_TYPE", 114, 126], ["LD3", "PROTEIN", 227, 230], ["enterica serovar Typhimurium ATCC13311 cells", "CELL_LINE", 501, 545], ["aureus subsp", "SPECIES", 444, 456], ["aureus", "SPECIES", 458, 464], ["enterica subsp", "SPECIES", 485, 499], ["enterica serovar Typhimurium", "SPECIES", 501, 529], ["aureus subsp", "SPECIES", 444, 456], ["aureus", "SPECIES", 458, 464], ["enterica subsp", "SPECIES", 485, 499], ["enterica serovar Typhimurium", "SPECIES", 501, 529], ["the reduction in DAPI fluorescence", "PROBLEM", 43, 77], ["increase in PI fluorescence of target cells", "PROBLEM", 83, 126], ["the combined bacteriocin effect", "PROBLEM", 138, 169], ["Enterocin", "TREATMENT", 217, 226], ["Cell Membrane", "TREATMENT", 246, 259], ["Nucleic Acids", "TREATMENT", 264, 277], ["bacteriocins", "TREATMENT", 348, 360], ["the cell membranes", "TREATMENT", 397, 415], ["Staph", "PROBLEM", 437, 442], ["aureus subsp", "PROBLEM", 444, 456], ["aureus", "PROBLEM", 458, 464], ["enterica subsp", "PROBLEM", 485, 499], ["enterica serovar Typhimurium", "TEST", 501, 529], ["FTIR analysis", "TEST", 547, 560], ["possible explanation for", "UNCERTAINTY", 18, 42], ["reduction", "OBSERVATION_MODIFIER", 47, 56], ["DAPI fluorescence", "OBSERVATION", 60, 77], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["PI fluorescence", "OBSERVATION", 95, 110], ["target cells", "OBSERVATION", 114, 126], ["Cell Membrane", "OBSERVATION", 246, 259], ["Staph", "OBSERVATION", 437, 442], ["subsp", "OBSERVATION", 451, 456], ["subsp", "OBSERVATION_MODIFIER", 494, 499], ["serovar Typhimurium", "OBSERVATION", 510, 529]]], ["The Staph. aureus subsp. aureus ATCC25923 cells after treatment with enterocin LD3 alone showed increased absorbance at ~ 1094.30 and ~ 1451.82/cm corresponding to nucleic acids and phospholipids, respectively (Fig. 5a), whereas plantaricin LD4-treated Staph. aureus subsp. aureus ATCC25923 cells did not show such increase in the wavelength corresponding to nucleic acids and phospholipids (Fig. 5b).", [["ATCC25923 cells", "ANATOMY", 32, 47], ["ATCC25923 cells", "ANATOMY", 281, 296], ["enterocin LD3", "CHEMICAL", 69, 82], ["nucleic acids", "CHEMICAL", 164, 177], ["plantaricin LD4", "CHEMICAL", 229, 244], ["nucleic acids", "CHEMICAL", 359, 372], ["enterocin LD3", "CHEMICAL", 69, 82], ["aureus", "ORGANISM", 11, 17], ["ATCC25923 cells", "CELL", 32, 47], ["enterocin LD3", "SIMPLE_CHEMICAL", 69, 82], ["nucleic acids", "SIMPLE_CHEMICAL", 164, 177], ["phospholipids", "SIMPLE_CHEMICAL", 182, 195], ["plantaricin LD4", "SIMPLE_CHEMICAL", 229, 244], ["Staph", "SIMPLE_CHEMICAL", 253, 258], ["aureus", "ORGANISM", 260, 266], ["ATCC25923 cells", "CELL", 281, 296], ["nucleic acids", "SIMPLE_CHEMICAL", 359, 372], ["phospholipids", "SIMPLE_CHEMICAL", 377, 390], ["ATCC25923 cells", "CELL_LINE", 32, 47], ["LD4", "PROTEIN", 241, 244], ["ATCC25923 cells", "CELL_LINE", 281, 296], ["aureus subsp", "SPECIES", 11, 23], ["aureus", "SPECIES", 25, 31], ["aureus subsp", "SPECIES", 260, 272], ["aureus", "SPECIES", 274, 280], ["aureus subsp", "SPECIES", 11, 23], ["aureus", "SPECIES", 25, 31], ["aureus subsp", "SPECIES", 260, 272], ["aureus", "SPECIES", 274, 280], ["The Staph", "PROBLEM", 0, 9], ["aureus subsp", "PROBLEM", 11, 23], ["aureus", "PROBLEM", 25, 31], ["enterocin LD3", "TREATMENT", 69, 82], ["increased absorbance", "PROBLEM", 96, 116], ["nucleic acids", "TEST", 164, 177], ["phospholipids", "TEST", 182, 195], ["plantaricin LD4", "TEST", 229, 244], ["Staph", "PROBLEM", 253, 258], ["aureus subsp", "PROBLEM", 260, 272], ["aureus ATCC25923 cells", "PROBLEM", 274, 296], ["nucleic acids", "TEST", 359, 372], ["phospholipids", "TREATMENT", 377, 390], ["Staph", "OBSERVATION", 4, 9], ["subsp", "OBSERVATION", 18, 23], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["absorbance", "OBSERVATION_MODIFIER", 106, 116], ["Staph", "OBSERVATION", 253, 258], ["subsp", "OBSERVATION", 267, 272]]], ["When Staph. aureus subsp. aureus ATCC25923 cells were treated with a mixture of enterocin LD3 and plantaricin LD4, higher absorbance at ~ 1094.30 and ~ 1451.82/cm was observed as compared with their effects alone (Fig. 5c).", [["ATCC25923 cells", "ANATOMY", 33, 48], ["plantaricin", "CHEMICAL", 98, 109], ["plantaricin", "CHEMICAL", 98, 109], ["aureus", "ORGANISM", 12, 18], ["ATCC25923 cells", "CELL", 33, 48], ["enterocin LD3", "SIMPLE_CHEMICAL", 80, 93], ["plantaricin LD4", "SIMPLE_CHEMICAL", 98, 113], ["ATCC25923 cells", "CELL_LINE", 33, 48], ["aureus subsp", "SPECIES", 12, 24], ["aureus", "SPECIES", 26, 32], ["aureus subsp", "SPECIES", 12, 24], ["aureus", "SPECIES", 26, 32], ["Staph", "PROBLEM", 5, 10], ["aureus subsp", "PROBLEM", 12, 24], ["aureus ATCC25923 cells", "PROBLEM", 26, 48], ["enterocin LD3", "TREATMENT", 80, 93], ["plantaricin", "TREATMENT", 98, 109], ["higher absorbance", "PROBLEM", 115, 132], ["Staph", "OBSERVATION", 5, 10], ["subsp", "OBSERVATION", 19, 24], ["ATCC25923 cells", "OBSERVATION", 33, 48], ["higher", "OBSERVATION_MODIFIER", 115, 121], ["absorbance", "OBSERVATION_MODIFIER", 122, 132]]], ["Similarly, Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells after treatment with enterocin LD3 independently showed increase in the absorbance at ~ 1094.30 and ~ 1451.82/cm corresponding to nucleic acids and phospholipids, respectively (Fig. 6a).", [["ATCC13311 cells", "ANATOMY", 62, 77], ["enterocin", "CHEMICAL", 99, 108], ["nucleic acids", "CHEMICAL", 208, 221], ["enterocin LD3", "CHEMICAL", 99, 112], ["enterica", "ORGANISM", 17, 25], ["enterica serovar", "ORGANISM", 33, 49], ["Typhimurium", "ORGANISM", 50, 61], ["ATCC13311 cells", "CELL", 62, 77], ["enterocin LD3", "SIMPLE_CHEMICAL", 99, 112], ["nucleic acids", "SIMPLE_CHEMICAL", 208, 221], ["phospholipids", "SIMPLE_CHEMICAL", 226, 239], ["Salm", "PROTEIN", 11, 15], ["ATCC13311 cells", "CELL_LINE", 62, 77], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "SPECIES", 17, 31], ["enterica serovar Typhimurium", "SPECIES", 33, 61], ["enterica subsp", "PROBLEM", 17, 31], ["enterica serovar Typhimurium ATCC13311 cells", "TREATMENT", 33, 77], ["enterocin", "TREATMENT", 99, 108], ["the absorbance", "TEST", 146, 160], ["nucleic acids", "TEST", 208, 221], ["phospholipids", "TEST", 226, 239], ["subsp", "OBSERVATION_MODIFIER", 26, 31], ["serovar Typhimurium", "OBSERVATION", 42, 61], ["increase", "OBSERVATION_MODIFIER", 134, 142], ["absorbance", "OBSERVATION_MODIFIER", 150, 160]]], ["The plantaricin LD4-treated Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells did not show such alteration in the wavelength corresponding to nucleic acids and phospholipids (Fig. 6b).", [["ATCC13311 cells", "ANATOMY", 79, 94], ["plantaricin LD4", "CHEMICAL", 4, 19], ["nucleic acids", "CHEMICAL", 159, 172], ["plantaricin LD4", "SIMPLE_CHEMICAL", 4, 19], ["enterica", "ORGANISM", 34, 42], ["enterica serovar", "ORGANISM", 50, 66], ["Typhimurium", "ORGANISM", 67, 78], ["ATCC13311 cells", "CELL", 79, 94], ["nucleic acids", "SIMPLE_CHEMICAL", 159, 172], ["phospholipids", "SIMPLE_CHEMICAL", 177, 190], ["plantaricin LD4-treated Salm", "CELL_LINE", 4, 32], ["ATCC13311 cells", "CELL_LINE", 79, 94], ["enterica subsp", "SPECIES", 34, 48], ["enterica serovar Typhimurium", "SPECIES", 50, 78], ["enterica subsp", "SPECIES", 34, 48], ["enterica serovar Typhimurium", "SPECIES", 50, 78], ["The plantaricin LD4", "TEST", 0, 19], ["enterica subsp", "PROBLEM", 34, 48], ["enterica serovar Typhimurium ATCC13311 cells", "TEST", 50, 94], ["such alteration in the wavelength", "PROBLEM", 108, 141], ["nucleic acids", "TEST", 159, 172], ["phospholipids (Fig.", "TREATMENT", 177, 196], ["subsp", "OBSERVATION_MODIFIER", 43, 48], ["serovar Typhimurium", "OBSERVATION", 59, 78]]], ["The Salm. enterica subsp. enterica serovar Typhimurium ATCC13311cells treated with a mixture of enterocin LD3 and plantaricin LD4 showed higher absorbance at ~ 1094.30 and ~ 1451.82/cm as compared with the effects of the bacteriocins independently (Fig. 6c) indicating synergy between two bacteriocins.", [["ATCC13311cells", "ANATOMY", 55, 69], ["enterocin", "CHEMICAL", 96, 105], ["plantaricin", "CHEMICAL", 114, 125], ["plantaricin LD4", "CHEMICAL", 114, 129], ["enterica", "ORGANISM", 10, 18], ["enterica serovar", "ORGANISM", 26, 42], ["Typhimurium", "ORGANISM", 43, 54], ["ATCC13311cells", "CELL", 55, 69], ["enterocin LD3", "SIMPLE_CHEMICAL", 96, 109], ["plantaricin LD4", "SIMPLE_CHEMICAL", 114, 129], ["Salm", "PROTEIN", 4, 8], ["ATCC13311cells", "CELL_LINE", 55, 69], ["enterica subsp", "SPECIES", 10, 24], ["enterica serovar Typhimurium", "SPECIES", 26, 54], ["enterica subsp", "SPECIES", 10, 24], ["enterica serovar Typhimurium", "SPECIES", 26, 54], ["enterica subsp", "PROBLEM", 10, 24], ["enterica serovar Typhimurium ATCC13311cells", "TREATMENT", 26, 69], ["enterocin LD3", "TREATMENT", 96, 109], ["plantaricin LD4", "TEST", 114, 129], ["higher absorbance", "PROBLEM", 137, 154], ["the bacteriocins", "TREATMENT", 217, 233], ["synergy", "PROBLEM", 269, 276], ["two bacteriocins", "TREATMENT", 285, 301], ["subsp", "OBSERVATION_MODIFIER", 19, 24], ["serovar Typhimurium", "OBSERVATION", 35, 54], ["higher", "OBSERVATION_MODIFIER", 137, 143], ["absorbance", "OBSERVATION_MODIFIER", 144, 154]]], ["Enterocin LD3 and plantaricin LD4 also showed higher absorbance in the range of 2800 and 3000/cm against both cells exhibiting typical C\u2013H stretching and vibrations corresponding to the CH3- and CH2- functional groups.The Morphological Damage of Cell Was Higher in Combined Treatment ::: ResultsThe TEM analysis was used to visualize the morphology and intracellular images of target cells.", [["cells", "ANATOMY", 110, 115], ["Cell", "ANATOMY", 246, 250], ["intracellular", "ANATOMY", 353, 366], ["cells", "ANATOMY", 384, 389], ["Enterocin", "CHEMICAL", 0, 9], ["plantaricin", "CHEMICAL", 18, 29], ["C\u2013H", "CHEMICAL", 135, 138], ["plantaricin LD4", "CHEMICAL", 18, 33], ["C\u2013H", "CHEMICAL", 135, 138], ["CH3", "CHEMICAL", 186, 189], ["CH2", "CHEMICAL", 195, 198], ["Enterocin LD3", "SIMPLE_CHEMICAL", 0, 13], ["plantaricin LD4", "SIMPLE_CHEMICAL", 18, 33], ["cells", "CELL", 110, 115], ["C\u2013H", "SIMPLE_CHEMICAL", 135, 138], ["Cell", "CELL", 246, 250], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 353, 366], ["cells", "CELL", 384, 389], ["CH2", "PROTEIN", 195, 198], ["target cells", "CELL_TYPE", 377, 389], ["Enterocin LD3", "TEST", 0, 13], ["plantaricin LD4", "TEST", 18, 33], ["higher absorbance", "PROBLEM", 46, 63], ["both cells", "PROBLEM", 105, 115], ["typical C\u2013H stretching and vibrations", "PROBLEM", 127, 164], ["the CH3", "TEST", 182, 189], ["The TEM analysis", "TEST", 295, 311], ["intracellular images", "TEST", 353, 373], ["higher", "OBSERVATION_MODIFIER", 46, 52], ["absorbance", "OBSERVATION_MODIFIER", 53, 63], ["C\u2013H stretching", "OBSERVATION", 135, 149], ["Morphological", "OBSERVATION_MODIFIER", 222, 235], ["Damage", "OBSERVATION_MODIFIER", 236, 242], ["Cell", "OBSERVATION", 246, 250], ["Higher", "OBSERVATION_MODIFIER", 255, 261], ["target cells", "OBSERVATION", 377, 389]]], ["Untreated Staph. aureus subsp. aureus ATCC25923 cells displayed a highly homogenous intracellular density and round shape (Fig. 7a), but enterocin LD3-treated cells showed disruption of the cell membrane and release of intracellular contents (Fig. 7b).", [["ATCC25923 cells", "ANATOMY", 38, 53], ["intracellular", "ANATOMY", 84, 97], ["cells", "ANATOMY", 159, 164], ["cell membrane", "ANATOMY", 190, 203], ["intracellular", "ANATOMY", 219, 232], ["enterocin LD3", "CHEMICAL", 137, 150], ["aureus", "ORGANISM", 17, 23], ["ATCC25923 cells", "CELL", 38, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["enterocin LD3", "SIMPLE_CHEMICAL", 137, 150], ["cells", "CELL", 159, 164], ["cell membrane", "CELLULAR_COMPONENT", 190, 203], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 219, 232], ["ATCC25923 cells", "CELL_LINE", 38, 53], ["enterocin LD3-treated cells", "CELL_LINE", 137, 164], ["aureus subsp", "SPECIES", 17, 29], ["aureus", "SPECIES", 31, 37], ["aureus subsp", "SPECIES", 17, 29], ["aureus", "SPECIES", 31, 37], ["Untreated Staph", "PROBLEM", 0, 15], ["aureus subsp", "PROBLEM", 17, 29], ["aureus ATCC25923 cells", "PROBLEM", 31, 53], ["a highly homogenous intracellular density", "PROBLEM", 64, 105], ["enterocin LD3", "TEST", 137, 150], ["disruption of the cell membrane", "PROBLEM", 172, 203], ["intracellular contents", "PROBLEM", 219, 241], ["Staph", "OBSERVATION", 10, 15], ["subsp", "OBSERVATION", 24, 29], ["ATCC25923 cells", "OBSERVATION", 38, 53], ["highly", "OBSERVATION_MODIFIER", 66, 72], ["homogenous", "OBSERVATION_MODIFIER", 73, 83], ["intracellular", "OBSERVATION_MODIFIER", 84, 97], ["density", "OBSERVATION", 98, 105], ["round", "OBSERVATION_MODIFIER", 110, 115], ["shape", "OBSERVATION_MODIFIER", 116, 121], ["cell membrane", "OBSERVATION", 190, 203], ["intracellular contents", "OBSERVATION", 219, 241]]], ["Staph. aureus subsp. aureus ATCC25923 cells treated with plantaricin LD4 also exhibited cellular damages (Fig. 7c), while enterocin LD3 and plantaricin LD4 combined treatment caused higher damage to most cells, showing sunken cell surface and shrinking cytoplasm (Fig. 7d).", [["ATCC25923 cells", "ANATOMY", 28, 43], ["cellular", "ANATOMY", 88, 96], ["cells", "ANATOMY", 204, 209], ["cell surface", "ANATOMY", 226, 238], ["cytoplasm", "ANATOMY", 253, 262], ["plantaricin", "CHEMICAL", 57, 68], ["enterocin LD3", "CHEMICAL", 122, 135], ["plantaricin", "CHEMICAL", 140, 151], ["LD4", "CHEMICAL", 152, 155], ["plantaricin LD4", "CHEMICAL", 57, 72], ["plantaricin LD4", "CHEMICAL", 140, 155], ["aureus", "ORGANISM", 7, 13], ["ATCC25923 cells", "CELL", 28, 43], ["plantaricin LD4", "SIMPLE_CHEMICAL", 57, 72], ["cellular", "CELL", 88, 96], ["enterocin LD3", "SIMPLE_CHEMICAL", 122, 135], ["plantaricin LD4", "SIMPLE_CHEMICAL", 140, 155], ["cells", "CELL", 204, 209], ["cell surface", "CELLULAR_COMPONENT", 226, 238], ["cytoplasm", "ORGANISM_SUBSTANCE", 253, 262], ["ATCC25923 cells", "CELL_LINE", 28, 43], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["Staph", "PROBLEM", 0, 5], ["aureus subsp", "PROBLEM", 7, 19], ["aureus", "PROBLEM", 21, 27], ["plantaricin LD4", "TREATMENT", 57, 72], ["cellular damages", "PROBLEM", 88, 104], ["enterocin LD3", "TREATMENT", 122, 135], ["plantaricin LD4", "TREATMENT", 140, 155], ["treatment", "TREATMENT", 165, 174], ["higher damage to most cells", "PROBLEM", 182, 209], ["sunken cell surface", "PROBLEM", 219, 238], ["shrinking cytoplasm", "PROBLEM", 243, 262], ["subsp", "OBSERVATION", 14, 19], ["cellular damages", "OBSERVATION", 88, 104], ["most cells", "OBSERVATION_MODIFIER", 199, 209], ["sunken cell", "OBSERVATION", 219, 230], ["surface", "OBSERVATION_MODIFIER", 231, 238], ["shrinking cytoplasm", "OBSERVATION", 243, 262]]], ["Irregularity of the cell surface and the increase of the cell mass were undoubtedly evident which indicated the perforation of cell membrane with consequent cell deformation after combined bacteriocin treatment.", [["cell surface", "ANATOMY", 20, 32], ["cell", "ANATOMY", 57, 61], ["cell membrane", "ANATOMY", 127, 140], ["cell", "ANATOMY", 157, 161], ["cell surface", "CELLULAR_COMPONENT", 20, 32], ["cell", "CELL", 57, 61], ["cell membrane", "CELLULAR_COMPONENT", 127, 140], ["cell", "CELL", 157, 161], ["Irregularity of the cell surface", "PROBLEM", 0, 32], ["the cell mass", "PROBLEM", 53, 66], ["the perforation of cell membrane", "PROBLEM", 108, 140], ["consequent cell deformation", "TREATMENT", 146, 173], ["combined bacteriocin treatment", "TREATMENT", 180, 210], ["cell", "OBSERVATION_MODIFIER", 20, 24], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["cell mass", "OBSERVATION", 57, 66], ["perforation", "OBSERVATION", 112, 123], ["cell membrane", "OBSERVATION", 127, 140], ["consequent cell deformation", "OBSERVATION", 146, 173], ["bacteriocin treatment", "OBSERVATION", 189, 210]]], ["The untreated Salm. enterica subsp. enterica serovar Typhimurium ATCC13311cells maintained typical rods and intact status (Fig. 7e).", [["ATCC13311cells", "ANATOMY", 65, 79], ["rods", "ANATOMY", 99, 103], ["enterica", "ORGANISM", 20, 28], ["enterica serovar", "ORGANISM", 36, 52], ["Typhimurium", "ORGANISM", 53, 64], ["ATCC13311cells", "CELL", 65, 79], ["ATCC13311cells", "CELL_LINE", 65, 79], ["enterica subsp", "SPECIES", 20, 34], ["enterica serovar Typhimurium", "SPECIES", 36, 64], ["enterica subsp", "SPECIES", 20, 34], ["enterica serovar Typhimurium", "SPECIES", 36, 64], ["enterica subsp", "PROBLEM", 20, 34], ["enterica serovar Typhimurium", "TEST", 36, 64], ["typical rods", "PROBLEM", 91, 103], ["untreated", "OBSERVATION_MODIFIER", 4, 13], ["Salm", "OBSERVATION", 14, 18], ["subsp", "OBSERVATION_MODIFIER", 29, 34], ["serovar Typhimurium", "OBSERVATION", 45, 64], ["rods", "OBSERVATION_MODIFIER", 99, 103], ["intact", "OBSERVATION_MODIFIER", 108, 114]]], ["When held in contact with enterocin LD3, cells showed an alternation in morphology and ruptured cells were observed (Fig. 7f).", [["cells", "ANATOMY", 41, 46], ["cells", "ANATOMY", 96, 101], ["cells", "CELL", 41, 46], ["cells", "CELL", 96, 101], ["enterocin LD3", "CELL_LINE", 26, 39], ["ruptured cells", "CELL_TYPE", 87, 101], ["enterocin LD3", "TREATMENT", 26, 39], ["an alternation in morphology", "PROBLEM", 54, 82], ["ruptured cells", "PROBLEM", 87, 101], ["ruptured cells", "OBSERVATION", 87, 101]]], ["Similarly, plantaricin LD4 induced a dramatic change in the Salm. enterica subsp. enterica serovar Typhimurium ATCC13311cells showing various alterations (Fig. 7g).", [["ATCC13311cells", "ANATOMY", 111, 125], ["plantaricin", "CHEMICAL", 11, 22], ["plantaricin LD4", "CHEMICAL", 11, 26], ["plantaricin LD4", "SIMPLE_CHEMICAL", 11, 26], ["enterica", "ORGANISM", 66, 74], ["enterica serovar", "ORGANISM", 82, 98], ["Typhimurium", "ORGANISM", 99, 110], ["ATCC13311cells", "CELL", 111, 125], ["plantaricin LD4", "PROTEIN", 11, 26], ["enterica serovar Typhimurium ATCC13311cells", "CELL_LINE", 82, 125], ["enterica subsp", "SPECIES", 66, 80], ["enterica serovar Typhimurium", "SPECIES", 82, 110], ["enterica subsp", "SPECIES", 66, 80], ["enterica serovar Typhimurium", "SPECIES", 82, 110], ["a dramatic change", "PROBLEM", 35, 52], ["enterica subsp", "PROBLEM", 66, 80], ["enterica serovar Typhimurium", "TEST", 82, 110], ["various alterations", "PROBLEM", 134, 153], ["dramatic", "OBSERVATION_MODIFIER", 37, 45], ["change", "OBSERVATION_MODIFIER", 46, 52], ["subsp", "OBSERVATION_MODIFIER", 75, 80], ["serovar Typhimurium", "OBSERVATION", 91, 110]]], ["Therefore, enterocin LD3 and plantaricin LD4 showed cellular damages of both Gram-positive (Staph. aureus subsp. aureus ATCC25923) and Gram-negative (Salm. enterica subsp. enterica serovar Typhimurium ATCC13311) bacteria.", [["cellular", "ANATOMY", 52, 60], ["enterocin LD3", "CHEMICAL", 11, 24], ["plantaricin", "CHEMICAL", 29, 40], ["plantaricin LD4", "CHEMICAL", 29, 44], ["enterocin LD3", "SIMPLE_CHEMICAL", 11, 24], ["plantaricin LD4", "SIMPLE_CHEMICAL", 29, 44], ["cellular", "CELL", 52, 60], ["Gram-", "GENE_OR_GENE_PRODUCT", 77, 82], ["Staph", "GENE_OR_GENE_PRODUCT", 92, 97], ["aureus", "ORGANISM", 99, 105], ["enterica", "ORGANISM", 156, 164], ["enterica serovar Typhimurium", "ORGANISM", 172, 200], ["ATCC13311", "ORGANISM", 201, 210], ["aureus subsp", "SPECIES", 99, 111], ["aureus", "SPECIES", 113, 119], ["enterica subsp", "SPECIES", 156, 170], ["enterica serovar Typhimurium", "SPECIES", 172, 200], ["aureus subsp", "SPECIES", 99, 111], ["aureus", "SPECIES", 113, 119], ["enterica subsp", "SPECIES", 156, 170], ["enterica serovar Typhimurium", "SPECIES", 172, 200], ["enterocin LD3", "TEST", 11, 24], ["plantaricin LD4", "TEST", 29, 44], ["cellular damages of both Gram-positive (Staph", "PROBLEM", 52, 97], ["aureus subsp", "PROBLEM", 99, 111], ["aureus", "TEST", 113, 119], ["Gram-", "TEST", 135, 140], ["enterica subsp", "PROBLEM", 156, 170], ["enterica serovar Typhimurium", "TEST", 172, 200], ["bacteria", "PROBLEM", 212, 220], ["cellular damages", "OBSERVATION", 52, 68], ["Staph", "OBSERVATION", 92, 97], ["subsp", "OBSERVATION", 106, 111], ["subsp", "OBSERVATION_MODIFIER", 165, 170], ["bacteria", "OBSERVATION_MODIFIER", 212, 220]]], ["In the presence of combined concentrations of these bacteriocins, the outer membrane of Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells was highly damaged, cell membrane was found to be protruding into the cytoplasm, and several cells displayed ruptures and loss of cytoplasm, indicating cytoplasmic membrane was severely affected when both bacteriocins were present together (Fig. 7h).", [["outer membrane", "ANATOMY", 70, 84], ["ATCC13311 cells", "ANATOMY", 139, 154], ["cell membrane", "ANATOMY", 175, 188], ["cytoplasm", "ANATOMY", 225, 234], ["cells", "ANATOMY", 248, 253], ["cytoplasm", "ANATOMY", 285, 294], ["cytoplasmic membrane", "ANATOMY", 307, 327], ["ruptures", "DISEASE", 264, 272], ["outer membrane", "CELLULAR_COMPONENT", 70, 84], ["enterica", "ORGANISM", 94, 102], ["enterica serovar", "ORGANISM", 110, 126], ["Typhimurium", "ORGANISM", 127, 138], ["ATCC13311 cells", "CELL", 139, 154], ["cell membrane", "CELLULAR_COMPONENT", 175, 188], ["cytoplasm", "ORGANISM_SUBSTANCE", 225, 234], ["cells", "CELL", 248, 253], ["cytoplasm", "ORGANISM_SUBSTANCE", 285, 294], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 307, 327], ["ATCC13311 cells", "CELL_LINE", 139, 154], ["enterica subsp", "SPECIES", 94, 108], ["enterica serovar Typhimurium", "SPECIES", 110, 138], ["enterica subsp", "SPECIES", 94, 108], ["enterica serovar Typhimurium", "SPECIES", 110, 138], ["these bacteriocins", "TREATMENT", 46, 64], ["enterica subsp", "PROBLEM", 94, 108], ["enterica serovar Typhimurium", "TEST", 110, 138], ["cell membrane", "PROBLEM", 175, 188], ["several cells", "PROBLEM", 240, 253], ["ruptures", "PROBLEM", 264, 272], ["loss of cytoplasm", "PROBLEM", 277, 294], ["cytoplasmic membrane", "PROBLEM", 307, 327], ["subsp", "OBSERVATION_MODIFIER", 103, 108], ["serovar Typhimurium", "OBSERVATION", 119, 138], ["highly", "OBSERVATION_MODIFIER", 159, 165], ["damaged", "OBSERVATION_MODIFIER", 166, 173], ["cell membrane", "OBSERVATION", 175, 188], ["cytoplasm", "ANATOMY_MODIFIER", 225, 234], ["ruptures", "OBSERVATION", 264, 272], ["loss", "OBSERVATION_MODIFIER", 277, 281], ["cytoplasm", "OBSERVATION_MODIFIER", 285, 294], ["cytoplasmic membrane", "OBSERVATION", 307, 327]]], ["Thus, combined effects of enterocin LD3 and plantaricin LD4 caused higher cell damage and bactericidal effect as compared with their activity alone.Antibacterial Spectrum ::: ResultsEnterocin LD3 and plantaricin LD4 inhibited the target pathogens and indicator strain, Micrococcus luteus MTCC106, showing distinct zones of growth inhibition.", [["cell", "ANATOMY", 74, 78], ["enterocin LD3", "CHEMICAL", 26, 39], ["plantaricin", "CHEMICAL", 44, 55], ["LD4", "CHEMICAL", 56, 59], ["LD3", "CHEMICAL", 192, 195], ["plantaricin", "CHEMICAL", 200, 211], ["LD4", "CHEMICAL", 212, 215], ["plantaricin LD4", "CHEMICAL", 44, 59], ["plantaricin LD4", "CHEMICAL", 200, 215], ["enterocin LD3", "SIMPLE_CHEMICAL", 26, 39], ["plantaricin LD4", "SIMPLE_CHEMICAL", 44, 59], ["cell", "CELL", 74, 78], ["Enterocin LD3", "SIMPLE_CHEMICAL", 182, 195], ["plantaricin LD4", "SIMPLE_CHEMICAL", 200, 215], ["Micrococcus luteus", "ORGANISM", 269, 287], ["MTCC106", "ORGANISM", 288, 295], ["Micrococcus luteus", "SPECIES", 269, 287], ["Micrococcus luteus", "SPECIES", 269, 287], ["enterocin LD3", "TREATMENT", 26, 39], ["plantaricin LD4", "TREATMENT", 44, 59], ["higher cell damage", "PROBLEM", 67, 85], ["bactericidal effect", "PROBLEM", 90, 109], ["Enterocin LD3", "TREATMENT", 182, 195], ["plantaricin LD4", "TREATMENT", 200, 215], ["the target pathogens", "PROBLEM", 226, 246], ["indicator strain", "PROBLEM", 251, 267], ["Micrococcus luteus MTCC106", "TEST", 269, 295], ["distinct zones of growth inhibition", "PROBLEM", 305, 340], ["higher cell damage", "OBSERVATION", 67, 85], ["bactericidal effect", "OBSERVATION", 90, 109], ["distinct", "OBSERVATION_MODIFIER", 305, 313], ["zones", "OBSERVATION_MODIFIER", 314, 319], ["growth inhibition", "OBSERVATION", 323, 340]]], ["The size zones of growth inhibition were smaller (8\u201322 mm) when bacteriocin was used alone and higher (11\u201326 mm) when used in combination, further suggesting the synergy between the bacteriocins.", [["growth inhibition", "PROBLEM", 18, 35], ["bacteriocin", "TREATMENT", 64, 75], ["the synergy", "PROBLEM", 158, 169], ["the bacteriocins", "TREATMENT", 178, 194], ["size", "OBSERVATION_MODIFIER", 4, 8], ["zones", "OBSERVATION_MODIFIER", 9, 14], ["growth", "OBSERVATION_MODIFIER", 18, 24], ["inhibition", "OBSERVATION_MODIFIER", 25, 35], ["smaller", "OBSERVATION_MODIFIER", 41, 48], ["higher", "OBSERVATION_MODIFIER", 95, 101]]], ["S. marcescens ATCC27137 was neither inhibited by either bacteriocin acting independently or in combination (Table 1).DiscussionRecently, few bacteriocins of LAB have been used for the food safety, and others have potential therapeutic applications [11].", [["LAB", "CHEMICAL", 157, 160], ["S. marcescens", "ORGANISM", 0, 13], ["ATCC27137", "ORGANISM", 14, 23], ["LAB", "SIMPLE_CHEMICAL", 157, 160], ["S. marcescens", "SPECIES", 0, 13], ["S. marcescens", "SPECIES", 0, 13], ["S. marcescens", "TEST", 0, 13]]], ["Nisin is one of the most studied bacteriocin being used as food preservative but does not inhibit Gram-negative bacteria [28].", [["Nisin", "CHEMICAL", 0, 5], ["Nisin", "CHEMICAL", 0, 5], ["Nisin", "SIMPLE_CHEMICAL", 0, 5], ["Gram", "SIMPLE_CHEMICAL", 98, 102], ["Nisin", "TREATMENT", 0, 5], ["the most studied bacteriocin", "TREATMENT", 16, 44], ["Gram", "TEST", 98, 102], ["negative bacteria", "PROBLEM", 103, 120]]], ["Therefore, there is a need to explore more bacteriocins for their potential applications.", [["bacteriocins", "TREATMENT", 43, 55]]], ["Moreover, combinatorial effects of bacteriocins may enhance efficacy against target bacteria and reduce economic burden in the respective industries.", [["bacteriocins", "TREATMENT", 35, 47], ["target bacteria", "PROBLEM", 77, 92], ["economic burden in the respective industries", "PROBLEM", 104, 148], ["economic", "OBSERVATION_MODIFIER", 104, 112], ["burden", "OBSERVATION_MODIFIER", 113, 119], ["respective industries", "OBSERVATION", 127, 148]]], ["Keeping these views in consideration, two bacteriocins from different producers, enterocin LD3 and plantaricin LD4, were studied to evaluate their individual and combined effects.DiscussionIn this study, we have shown the efficacy of these bacteriocins in combination against two important food-borne pathogens, Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311.", [["enterocin", "CHEMICAL", 81, 90], ["plantaricin", "CHEMICAL", 99, 110], ["plantaricin", "CHEMICAL", 99, 110], ["enterocin LD3", "SIMPLE_CHEMICAL", 81, 94], ["plantaricin LD4", "SIMPLE_CHEMICAL", 99, 114], ["aureus", "ORGANISM", 319, 325], ["enterica", "ORGANISM", 360, 368], ["enterica serovar Typhimurium", "ORGANISM", 376, 404], ["ATCC13311", "ORGANISM", 405, 414], ["aureus subsp", "SPECIES", 319, 331], ["aureus", "SPECIES", 333, 339], ["enterica subsp", "SPECIES", 360, 374], ["enterica serovar Typhimurium", "SPECIES", 376, 404], ["aureus subsp", "SPECIES", 319, 331], ["aureus", "SPECIES", 333, 339], ["enterica subsp", "SPECIES", 360, 374], ["enterica serovar Typhimurium", "SPECIES", 376, 404], ["these views", "TEST", 8, 19], ["two bacteriocins", "TREATMENT", 38, 54], ["enterocin", "TREATMENT", 81, 90], ["this study", "TEST", 192, 202], ["these bacteriocins", "TREATMENT", 234, 252], ["borne pathogens", "PROBLEM", 295, 310], ["Staph", "PROBLEM", 312, 317], ["aureus subsp", "PROBLEM", 319, 331], ["aureus", "PROBLEM", 333, 339], ["enterica subsp", "PROBLEM", 360, 374], ["enterica serovar Typhimurium", "TREATMENT", 376, 404], ["subsp", "OBSERVATION", 326, 331], ["subsp", "OBSERVATION_MODIFIER", 369, 374], ["serovar Typhimurium", "OBSERVATION", 385, 404]]], ["The MICs of enterocin LD3 and plantaricin LD4 (180 and 220 \u03bcg/mL against Staph. aureus subsp. aureus ATCC25923 and 240 and 320 \u03bcg/mL against Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311), when compared with other bacteriocins, were found to be comparatively lower than enterocin DD93 (200 \u03bcg/mL) against Staph. aureus and plantaricin MG (500 \u03bcg/mL) against Salm.", [["enterocin LD3", "CHEMICAL", 12, 25], ["plantaricin LD4", "CHEMICAL", 30, 45], ["ATCC25923", "CHEMICAL", 101, 110], ["DD93", "CHEMICAL", 337, 341], ["plantaricin", "CHEMICAL", 380, 391], ["enterocin LD3", "CHEMICAL", 12, 25], ["plantaricin LD4", "CHEMICAL", 30, 45], ["enterocin DD93", "CHEMICAL", 327, 341], ["enterocin LD3", "SIMPLE_CHEMICAL", 12, 25], ["plantaricin LD4", "SIMPLE_CHEMICAL", 30, 45], ["aureus", "ORGANISM", 80, 86], ["aureus", "ORGANISM", 148, 154], ["enterica", "ORGANISM", 189, 197], ["enterica serovar Typhimurium", "ORGANISM", 205, 233], ["ATCC13311", "ORGANISM", 234, 243], ["enterocin DD93", "SIMPLE_CHEMICAL", 327, 341], ["aureus", "ORGANISM", 369, 375], ["plantaricin MG", "SIMPLE_CHEMICAL", 380, 394], ["aureus subsp", "SPECIES", 80, 92], ["aureus", "SPECIES", 94, 100], ["aureus subsp", "SPECIES", 148, 160], ["aureus", "SPECIES", 162, 168], ["enterica subsp", "SPECIES", 189, 203], ["enterica serovar Typhimurium", "SPECIES", 205, 233], ["aureus", "SPECIES", 369, 375], ["aureus subsp", "SPECIES", 80, 92], ["aureus", "SPECIES", 94, 100], ["aureus subsp", "SPECIES", 148, 160], ["aureus", "SPECIES", 162, 168], ["enterica subsp", "SPECIES", 189, 203], ["enterica serovar Typhimurium", "SPECIES", 205, 233], ["aureus", "SPECIES", 369, 375], ["The MICs of enterocin LD3", "TEST", 0, 25], ["plantaricin LD4", "TEST", 30, 45], ["Staph", "PROBLEM", 73, 78], ["aureus subsp", "PROBLEM", 80, 92], ["aureus ATCC25923", "TEST", 94, 110], ["Staph", "PROBLEM", 141, 146], ["aureus subsp", "PROBLEM", 148, 160], ["aureus", "PROBLEM", 162, 168], ["enterica subsp", "PROBLEM", 189, 203], ["enterica serovar Typhimurium", "TEST", 205, 233], ["other bacteriocins", "TEST", 265, 283], ["enterocin DD93", "TREATMENT", 327, 341], ["Staph", "PROBLEM", 362, 367], ["aureus", "PROBLEM", 369, 375], ["plantaricin MG", "TREATMENT", 380, 394], ["subsp", "OBSERVATION", 87, 92], ["subsp", "OBSERVATION", 155, 160], ["subsp", "OBSERVATION_MODIFIER", 198, 203]]], ["Typhimurium [20, 29].", [["Typhimurium", "ORGANISM", 0, 11], ["Typhimurium", "SPECIES", 0, 11], ["Typhimurium", "SPECIES", 0, 11], ["Typhimurium", "TEST", 0, 11]]], ["Furthermore, the MIC of enterocin LD3 and plantaricin LD4 in combination was significantly reduced.", [["enterocin LD3", "CHEMICAL", 24, 37], ["plantaricin LD4", "CHEMICAL", 42, 57], ["plantaricin LD4", "CHEMICAL", 42, 57], ["enterocin LD3", "SIMPLE_CHEMICAL", 24, 37], ["plantaricin LD4", "SIMPLE_CHEMICAL", 42, 57], ["enterocin LD3", "TREATMENT", 24, 37], ["plantaricin LD4", "TREATMENT", 42, 57], ["significantly", "OBSERVATION_MODIFIER", 77, 90], ["reduced", "OBSERVATION", 91, 98]]], ["The reduced combined MICs of enterocin LD3 and plantaricin LD4 (130 \u03bcg/mL, respectively) against Salm. enterica subsp. enterica serovar Typhimurium ATCC13311are in the range of CLSI susceptible breakpoints (\u2264 256 \u03bcg/mL for sulphamethoxazole against Salmonella and E. coli).", [["enterocin LD3", "CHEMICAL", 29, 42], ["plantaricin LD4", "CHEMICAL", 47, 62], ["sulphamethoxazole", "CHEMICAL", 223, 240], ["plantaricin LD4", "CHEMICAL", 47, 62], ["sulphamethoxazole", "CHEMICAL", 223, 240], ["enterocin LD3", "SIMPLE_CHEMICAL", 29, 42], ["plantaricin LD4", "SIMPLE_CHEMICAL", 47, 62], ["enterica", "ORGANISM", 103, 111], ["enterica serovar Typhimurium", "ORGANISM", 119, 147], ["ATCC13311are", "ORGANISM", 148, 160], ["sulphamethoxazole", "SIMPLE_CHEMICAL", 223, 240], ["E. coli", "ORGANISM", 264, 271], ["enterica subsp", "SPECIES", 103, 117], ["enterica serovar Typhimurium", "SPECIES", 119, 147], ["E. coli", "SPECIES", 264, 271], ["enterica subsp", "SPECIES", 103, 117], ["enterica serovar Typhimurium", "SPECIES", 119, 147], ["Salmonella", "SPECIES", 249, 259], ["E. coli", "SPECIES", 264, 271], ["enterocin LD3", "TREATMENT", 29, 42], ["plantaricin LD4", "TREATMENT", 47, 62], ["enterica subsp", "PROBLEM", 103, 117], ["enterica serovar Typhimurium", "TREATMENT", 119, 147], ["CLSI susceptible breakpoints", "PROBLEM", 177, 205], ["sulphamethoxazole", "TREATMENT", 223, 240], ["Salmonella", "PROBLEM", 249, 259], ["E. coli", "PROBLEM", 264, 271], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["subsp", "OBSERVATION_MODIFIER", 112, 117], ["serovar Typhimurium", "OBSERVATION", 128, 147], ["susceptible breakpoints", "OBSERVATION", 182, 205], ["E. coli", "OBSERVATION", 264, 271]]], ["The breakpoint for ceftaroline against Staph. aureus is \u2264 1 \u03bcg mL [19, 20] which is much lower than the combined MICs of enterocin LD3 and plantaricin LD4 (115 \u03bcg/mL) against Staph. aureus subsp. aureus ATCC25923.", [["ceftaroline", "CHEMICAL", 19, 30], ["enterocin LD3", "CHEMICAL", 121, 134], ["plantaricin LD4", "CHEMICAL", 139, 154], ["ATCC25923", "CHEMICAL", 203, 212], ["ceftaroline", "CHEMICAL", 19, 30], ["plantaricin LD4", "CHEMICAL", 139, 154], ["ceftaroline", "SIMPLE_CHEMICAL", 19, 30], ["aureus", "ORGANISM", 46, 52], ["enterocin LD3", "SIMPLE_CHEMICAL", 121, 134], ["plantaricin LD4", "SIMPLE_CHEMICAL", 139, 154], ["aureus", "ORGANISM", 182, 188], ["aureus", "SPECIES", 46, 52], ["aureus subsp", "SPECIES", 182, 194], ["aureus", "SPECIES", 196, 202], ["aureus", "SPECIES", 46, 52], ["aureus subsp", "SPECIES", 182, 194], ["aureus", "SPECIES", 196, 202], ["ceftaroline", "TREATMENT", 19, 30], ["Staph", "PROBLEM", 39, 44], ["aureus", "PROBLEM", 46, 52], ["enterocin LD3", "TREATMENT", 121, 134], ["plantaricin LD4", "TREATMENT", 139, 154], ["Staph", "PROBLEM", 175, 180], ["aureus subsp", "PROBLEM", 182, 194], ["aureus", "PROBLEM", 196, 202], ["subsp", "OBSERVATION", 189, 194]]], ["These observations have indicated that there is further scope to reduce the MICs of these bacteriocins using genetic modifications, increasing purity level and testing synergy with existing antimicrobials.", [["the MICs", "TREATMENT", 72, 80], ["these bacteriocins", "TREATMENT", 84, 102], ["genetic modifications", "TREATMENT", 109, 130], ["increasing purity level", "PROBLEM", 132, 155], ["existing antimicrobials", "TREATMENT", 181, 204]]], ["Though the breakpoints are different for different microorganisms and different antibiotics, these are universally adopted susceptibility concentrations useful in clinical settings.", [["the breakpoints", "PROBLEM", 7, 22], ["different microorganisms", "PROBLEM", 41, 65], ["different antibiotics", "TREATMENT", 70, 91], ["different", "OBSERVATION_MODIFIER", 27, 36]]], ["Other studies have reported that nisin and pediocin in combination showed synergistic activity against L. sakei and caused an additive effect against B. cereus and L. monocytogenes.", [["nisin", "CHEMICAL", 33, 38], ["pediocin", "CHEMICAL", 43, 51], ["L. sakei", "CHEMICAL", 103, 111], ["pediocin", "CHEMICAL", 43, 51], ["nisin", "SIMPLE_CHEMICAL", 33, 38], ["pediocin", "SIMPLE_CHEMICAL", 43, 51], ["L. sakei", "ORGANISM", 103, 111], ["B. cereus", "ORGANISM", 150, 159], ["L. monocytogenes", "ORGANISM", 164, 180], ["L. sakei", "SPECIES", 103, 111], ["B. cereus", "SPECIES", 150, 159], ["L. monocytogenes", "SPECIES", 164, 180], ["L. sakei", "SPECIES", 103, 111], ["B. cereus", "SPECIES", 150, 159], ["L. monocytogenes", "SPECIES", 164, 180], ["Other studies", "TEST", 0, 13], ["nisin", "TREATMENT", 33, 38], ["pediocin", "TREATMENT", 43, 51], ["synergistic activity", "PROBLEM", 74, 94], ["L. sakei", "PROBLEM", 103, 111], ["B. cereus and L. monocytogenes", "PROBLEM", 150, 180], ["monocytogenes", "OBSERVATION", 167, 180]]], ["Similarly, the mixture of nisin and enterocin MT104B displayed a synergistic activity against Staph. aureus [13].", [["nisin", "CHEMICAL", 26, 31], ["enterocin MT104B", "CHEMICAL", 36, 52], ["enterocin MT104B", "CHEMICAL", 36, 52], ["nisin", "SIMPLE_CHEMICAL", 26, 31], ["enterocin MT104B", "SIMPLE_CHEMICAL", 36, 52], ["Staph", "SIMPLE_CHEMICAL", 94, 99], ["aureus", "SPECIES", 101, 107], ["aureus", "SPECIES", 101, 107], ["nisin", "TREATMENT", 26, 31], ["enterocin MT104B", "TREATMENT", 36, 52], ["Staph", "PROBLEM", 94, 99], ["aureus", "PROBLEM", 101, 107]]], ["Ferreira et al. [29] showed that a combination of pediocin 34, nisin and enterocin F99 was highly effective with lowered concentrations against target strains as compared with individual effects.", [["pediocin 34, nisin", "CHEMICAL", 50, 68], ["enterocin F99", "CHEMICAL", 73, 86], ["pediocin 34", "CHEMICAL", 50, 61], ["enterocin F99", "CHEMICAL", 73, 86], ["pediocin 34", "SIMPLE_CHEMICAL", 50, 61], ["nisin", "SIMPLE_CHEMICAL", 63, 68], ["enterocin F99", "SIMPLE_CHEMICAL", 73, 86], ["Ferreira et al.", "TEST", 0, 15], ["pediocin", "TREATMENT", 50, 58], ["nisin", "TREATMENT", 63, 68], ["enterocin", "TREATMENT", 73, 82], ["target strains", "PROBLEM", 144, 158]]], ["However, there are no such reports on use of combined enterocin and plantaricin against food-borne or clinical pathogens.DiscussionAccording to EUCAST [19], a synergistic effect is observed when FICI value \u2264 0.5.", [["enterocin", "CHEMICAL", 54, 63], ["plantaricin", "CHEMICAL", 68, 79], ["enterocin", "CHEMICAL", 54, 63], ["plantaricin", "CHEMICAL", 68, 79], ["enterocin", "SIMPLE_CHEMICAL", 54, 63], ["plantaricin", "SIMPLE_CHEMICAL", 68, 79], ["combined enterocin", "TREATMENT", 45, 63], ["plantaricin", "TREATMENT", 68, 79], ["clinical pathogens", "PROBLEM", 102, 120], ["a synergistic effect", "PROBLEM", 157, 177], ["FICI value", "TEST", 195, 205], ["no", "UNCERTAINTY", 19, 21]]], ["The FIC indices calculated as 0.50 against Staph. aureus subsp. aureus ATCC25923 and 0.43 against Salm. enterica subsp. enterica serovar Typhimurium ATCC13311were found to be \u2264 0.5 indicating the synergy between two enterocin LD3 and plantaricin LD4.", [["ATCC13311", "ANATOMY", 149, 158], ["ATCC25923", "CHEMICAL", 71, 80], ["enterocin", "CHEMICAL", 216, 225], ["plantaricin", "CHEMICAL", 234, 245], ["plantaricin", "CHEMICAL", 234, 245], ["aureus", "ORGANISM", 50, 56], ["enterica", "ORGANISM", 104, 112], ["enterica serovar Typhimurium", "ORGANISM", 120, 148], ["ATCC13311", "ORGANISM", 149, 158], ["enterocin LD3", "SIMPLE_CHEMICAL", 216, 229], ["plantaricin LD4", "SIMPLE_CHEMICAL", 234, 249], ["enterocin LD3", "PROTEIN", 216, 229], ["aureus subsp", "SPECIES", 50, 62], ["aureus", "SPECIES", 64, 70], ["enterica subsp", "SPECIES", 104, 118], ["enterica serovar Typhimurium", "SPECIES", 120, 148], ["aureus subsp", "SPECIES", 50, 62], ["aureus", "SPECIES", 64, 70], ["enterica subsp", "SPECIES", 104, 118], ["enterica serovar Typhimurium ATCC13311", "SPECIES", 120, 158], ["The FIC indices", "TEST", 0, 15], ["Staph", "PROBLEM", 43, 48], ["aureus subsp", "PROBLEM", 50, 62], ["aureus", "PROBLEM", 64, 70], ["enterica subsp", "PROBLEM", 104, 118], ["enterica serovar Typhimurium ATCC", "TEST", 120, 153], ["the synergy", "PROBLEM", 192, 203], ["two enterocin LD3", "TREATMENT", 212, 229], ["plantaricin LD4", "TREATMENT", 234, 249], ["subsp", "OBSERVATION", 57, 62], ["subsp", "OBSERVATION_MODIFIER", 113, 118]]], ["The FIC index defines the nature of interaction of two antimicrobials and indicates full synergy if \u2264 0.5 [20, 21].", [["The FIC index", "TEST", 0, 13], ["two antimicrobials", "TREATMENT", 51, 69], ["FIC", "OBSERVATION_MODIFIER", 4, 7], ["index", "OBSERVATION", 8, 13]]], ["The isobologram further signifies synergy between two bacteriocins against Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 where combined MICs fall below the strait line.", [["MICs", "CHEMICAL", 193, 197], ["Staph", "GENE_OR_GENE_PRODUCT", 75, 80], ["aureus", "ORGANISM", 82, 88], ["enterica", "ORGANISM", 123, 131], ["enterica serovar Typhimurium", "ORGANISM", 139, 167], ["ATCC13311", "ORGANISM", 168, 177], ["aureus subsp", "SPECIES", 82, 94], ["aureus", "SPECIES", 96, 102], ["enterica subsp", "SPECIES", 123, 137], ["enterica serovar Typhimurium", "SPECIES", 139, 167], ["aureus subsp", "SPECIES", 82, 94], ["aureus", "SPECIES", 96, 102], ["enterica subsp", "SPECIES", 123, 137], ["enterica serovar Typhimurium", "SPECIES", 139, 167], ["The isobologram", "TEST", 0, 15], ["synergy", "PROBLEM", 34, 41], ["two bacteriocins", "TREATMENT", 50, 66], ["Staph", "PROBLEM", 75, 80], ["aureus subsp", "PROBLEM", 82, 94], ["aureus", "PROBLEM", 96, 102], ["enterica subsp", "PROBLEM", 123, 137], ["enterica serovar Typhimurium", "TREATMENT", 139, 167], ["combined MICs fall", "PROBLEM", 184, 202], ["subsp", "OBSERVATION", 89, 94], ["subsp", "OBSERVATION_MODIFIER", 132, 137], ["serovar Typhimurium", "OBSERVATION", 148, 167], ["strait line", "OBSERVATION", 213, 224]]], ["The isobologram interpretation examining the position of the ratio points suggests synergy if it is below the line [23].", [["The isobologram interpretation", "TEST", 0, 30], ["synergy", "PROBLEM", 83, 90]]], ["These findings here indicated that synergistic interaction between the two bacteriocins could be due to their different mode of action against target bacteria.", [["synergistic interaction", "PROBLEM", 35, 58], ["the two bacteriocins", "TREATMENT", 67, 87], ["target bacteria", "PROBLEM", 143, 158]]], ["One of them could be involved in pore formation/disruption of the outer cell membrane allowing access of the other bacteriocin in target cells as also suggested by Chi and Holo [8].", [["pore", "ANATOMY", 33, 37], ["outer cell membrane", "ANATOMY", 66, 85], ["cells", "ANATOMY", 137, 142], ["pore", "CELLULAR_COMPONENT", 33, 37], ["outer cell membrane", "CELLULAR_COMPONENT", 66, 85], ["cells", "CELL", 137, 142], ["target cells", "CELL_TYPE", 130, 142], ["the outer cell membrane", "TREATMENT", 62, 85], ["the other bacteriocin", "TREATMENT", 105, 126], ["could be involved", "UNCERTAINTY", 12, 29], ["pore formation", "OBSERVATION", 33, 47], ["disruption", "OBSERVATION", 48, 58], ["outer", "ANATOMY_MODIFIER", 66, 71], ["cell membrane", "OBSERVATION", 72, 85]]], ["The mechanism of action of plantaricin LD4 is not exactly known, but our recent findings suggest that enterocin LD3 causes membrane disruption and enters inside the cells interacting with nucleic acids [17].DiscussionThe effect of bacteriocins was also observed on the growth response of Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311.", [["membrane", "ANATOMY", 123, 131], ["cells", "ANATOMY", 165, 170], ["plantaricin", "CHEMICAL", 27, 38], ["enterocin", "CHEMICAL", 102, 111], ["nucleic acids", "CHEMICAL", 188, 201], ["plantaricin LD4", "CHEMICAL", 27, 42], ["plantaricin LD4", "SIMPLE_CHEMICAL", 27, 42], ["enterocin LD3", "GENE_OR_GENE_PRODUCT", 102, 115], ["membrane", "CELLULAR_COMPONENT", 123, 131], ["cells", "CELL", 165, 170], ["aureus", "ORGANISM", 295, 301], ["enterica", "ORGANISM", 336, 344], ["enterica serovar Typhimurium", "ORGANISM", 352, 380], ["ATCC13311", "ORGANISM", 381, 390], ["enterocin LD3", "PROTEIN", 102, 115], ["aureus subsp", "SPECIES", 295, 307], ["aureus", "SPECIES", 309, 315], ["enterica subsp", "SPECIES", 336, 350], ["enterica serovar Typhimurium", "SPECIES", 352, 380], ["aureus subsp", "SPECIES", 295, 307], ["aureus", "SPECIES", 309, 315], ["enterica subsp", "SPECIES", 336, 350], ["enterica serovar Typhimurium", "SPECIES", 352, 380], ["plantaricin LD4", "PROBLEM", 27, 42], ["enterocin", "TREATMENT", 102, 111], ["membrane disruption", "PROBLEM", 123, 142], ["nucleic acids", "TEST", 188, 201], ["bacteriocins", "TREATMENT", 231, 243], ["Staph", "PROBLEM", 288, 293], ["aureus subsp", "PROBLEM", 295, 307], ["aureus", "PROBLEM", 309, 315], ["enterica subsp", "PROBLEM", 336, 350], ["enterica serovar Typhimurium", "TREATMENT", 352, 380], ["membrane disruption", "OBSERVATION", 123, 142], ["Staph", "OBSERVATION", 288, 293], ["subsp", "OBSERVATION", 302, 307], ["subsp", "OBSERVATION_MODIFIER", 345, 350], ["serovar Typhimurium", "OBSERVATION", 361, 380]]], ["The untreated cells of Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 followed a normal growth pattern.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["aureus", "ORGANISM", 30, 36], ["enterica", "ORGANISM", 71, 79], ["enterica serovar Typhimurium", "ORGANISM", 87, 115], ["ATCC13311", "ORGANISM", 116, 125], ["aureus subsp", "SPECIES", 30, 42], ["aureus", "SPECIES", 44, 50], ["enterica subsp", "SPECIES", 71, 85], ["enterica serovar Typhimurium", "SPECIES", 87, 115], ["aureus subsp", "SPECIES", 30, 42], ["aureus", "SPECIES", 44, 50], ["enterica subsp", "SPECIES", 71, 85], ["enterica serovar Typhimurium", "SPECIES", 87, 115], ["Staph", "PROBLEM", 23, 28], ["aureus subsp", "PROBLEM", 30, 42], ["aureus", "PROBLEM", 44, 50], ["enterica subsp", "PROBLEM", 71, 85], ["enterica serovar Typhimurium", "TEST", 87, 115], ["untreated cells", "OBSERVATION", 4, 19], ["Staph", "OBSERVATION", 23, 28], ["subsp", "OBSERVATION", 37, 42], ["subsp", "OBSERVATION_MODIFIER", 80, 85], ["serovar Typhimurium", "OBSERVATION", 96, 115], ["growth pattern", "OBSERVATION", 144, 158]]], ["When the cells were treated with individual bacteriocin, there was partial inhibition of growth recorded, whereas complete growth inhibition was found when both bacteriocins were applied in combination.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["individual bacteriocin", "TREATMENT", 33, 55], ["partial inhibition of growth", "PROBLEM", 67, 95], ["complete growth inhibition", "PROBLEM", 114, 140], ["both bacteriocins", "TREATMENT", 156, 173]]], ["Therefore, significant growth inhibition of target strains was observed when bacteriocins were used in combination than alone.", [["significant growth inhibition of target strains", "PROBLEM", 11, 58], ["bacteriocins", "TREATMENT", 77, 89], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["growth", "OBSERVATION_MODIFIER", 23, 29], ["inhibition", "OBSERVATION_MODIFIER", 30, 40]]], ["Therefore, synergistic property of antimicrobials may improve kill kinetics.", [["antimicrobials", "TREATMENT", 35, 49]]], ["Further the synergistic interaction of antimicrobials may also reduce the development of resistance in pathogenic bacterial strains as suggested by Al Atya et al. [30].", [["antimicrobials", "TREATMENT", 39, 53], ["resistance in pathogenic bacterial strains", "PROBLEM", 89, 131], ["pathogenic bacterial strains", "OBSERVATION", 103, 131]]], ["In earlier reports, the combination of lactocin 705, enterocin CRL35 and nisin was found to be synergistically active against L. monocytogenes FBUNT where viability loss occurred after incubation for 3 h [31].", [["lactocin 705", "CHEMICAL", 39, 51], ["enterocin CRL35", "CHEMICAL", 53, 68], ["nisin", "CHEMICAL", 73, 78], ["viability loss", "DISEASE", 155, 169], ["lactocin 705", "CHEMICAL", 39, 51], ["enterocin", "CHEMICAL", 53, 62], ["lactocin 705", "SIMPLE_CHEMICAL", 39, 51], ["enterocin CRL35", "SIMPLE_CHEMICAL", 53, 68], ["nisin", "SIMPLE_CHEMICAL", 73, 78], ["L. monocytogenes FBUNT", "ORGANISM", 126, 148], ["L. monocytogenes", "SPECIES", 126, 142], ["L. monocytogenes", "SPECIES", 126, 142], ["lactocin", "TREATMENT", 39, 47], ["enterocin CRL35", "TREATMENT", 53, 68], ["nisin", "TREATMENT", 73, 78], ["viability loss", "PROBLEM", 155, 169], ["monocytogenes", "OBSERVATION", 129, 142], ["viability loss", "OBSERVATION", 155, 169]]], ["However, to the best of our knowledge, there are no studies where enterocin and plantaricin reported to show synergistic interactions against Gram-negative bacteria.", [["enterocin", "CHEMICAL", 66, 75], ["plantaricin", "CHEMICAL", 80, 91], ["enterocin", "CHEMICAL", 66, 75], ["plantaricin", "CHEMICAL", 80, 91], ["enterocin", "SIMPLE_CHEMICAL", 66, 75], ["plantaricin", "SIMPLE_CHEMICAL", 80, 91], ["Gram", "GENE_OR_GENE_PRODUCT", 142, 146], ["studies", "TEST", 52, 59], ["enterocin", "TREATMENT", 66, 75], ["plantaricin", "TREATMENT", 80, 91], ["synergistic interactions", "PROBLEM", 109, 133], ["Gram-negative bacteria", "PROBLEM", 142, 164], ["negative bacteria", "OBSERVATION", 147, 164]]], ["In the present study, we are reporting not only inhibition of Gram-positive and Gram-negative bacteria by enterocin LD3 and plantaricin LD4 but also their synergy against Gram-negative pathogens.", [["enterocin LD3", "CHEMICAL", 106, 119], ["plantaricin", "CHEMICAL", 124, 135], ["plantaricin", "CHEMICAL", 124, 135], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 62, 75], ["Gram", "GENE_OR_GENE_PRODUCT", 80, 84], ["enterocin LD3", "SIMPLE_CHEMICAL", 106, 119], ["plantaricin LD4", "SIMPLE_CHEMICAL", 124, 139], ["Gram", "GENE_OR_GENE_PRODUCT", 171, 175], ["the present study", "TEST", 3, 20], ["Gram-positive and Gram-negative bacteria", "PROBLEM", 62, 102], ["enterocin LD3", "TREATMENT", 106, 119], ["plantaricin LD4", "TREATMENT", 124, 139], ["Gram-negative pathogens", "PROBLEM", 171, 194], ["negative bacteria", "OBSERVATION_MODIFIER", 85, 102], ["negative pathogens", "OBSERVATION", 176, 194]]], ["The cell killing was further confirmed by the use of membrane permeable stain, PI, which is a nucleic acid staining dye, enters in to cells with compromised membranes and binds to DNA, giving a red fluorescence.", [["cell", "ANATOMY", 4, 8], ["membrane", "ANATOMY", 53, 61], ["cells", "ANATOMY", 134, 139], ["membranes", "ANATOMY", 157, 166], ["nucleic acid", "CHEMICAL", 94, 106], ["cell", "CELL", 4, 8], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["PI", "SIMPLE_CHEMICAL", 79, 81], ["cells", "CELL", 134, 139], ["membranes", "CELLULAR_COMPONENT", 157, 166], ["DNA", "CELLULAR_COMPONENT", 180, 183], ["The cell killing", "PROBLEM", 0, 16], ["membrane permeable stain", "TEST", 53, 77], ["PI", "PROBLEM", 79, 81], ["a nucleic acid staining dye", "PROBLEM", 92, 119], ["compromised membranes", "PROBLEM", 145, 166], ["a red fluorescence", "PROBLEM", 192, 210], ["cell killing", "OBSERVATION", 4, 16], ["compromised membranes", "OBSERVATION", 145, 166]]], ["Thus, bacterial cells with intact membranes exclude PI while being stained by DAPI emit blue fluorescence, whereas bacterial cells with damaged membranes are stained with PI and emit a red fluorescence [32, 33].", [["cells", "ANATOMY", 16, 21], ["membranes", "ANATOMY", 34, 43], ["cells", "ANATOMY", 125, 130], ["membranes", "ANATOMY", 144, 153], ["DAPI", "CHEMICAL", 78, 82], ["bacterial cells", "CELL", 6, 21], ["membranes", "CELLULAR_COMPONENT", 34, 43], ["PI", "SIMPLE_CHEMICAL", 52, 54], ["DAPI", "SIMPLE_CHEMICAL", 78, 82], ["cells", "CELL", 125, 130], ["membranes", "CELLULAR_COMPONENT", 144, 153], ["PI", "SIMPLE_CHEMICAL", 171, 173], ["bacterial cells", "CELL_TYPE", 6, 21], ["bacterial cells", "CELL_TYPE", 115, 130], ["bacterial cells", "PROBLEM", 6, 21], ["PI", "PROBLEM", 52, 54], ["DAPI emit blue fluorescence", "TEST", 78, 105], ["bacterial cells", "PROBLEM", 115, 130], ["damaged membranes", "PROBLEM", 136, 153], ["PI", "PROBLEM", 171, 173], ["a red fluorescence", "TEST", 183, 201], ["bacterial cells", "OBSERVATION", 6, 21], ["intact membranes", "OBSERVATION", 27, 43], ["bacterial cells", "OBSERVATION", 115, 130], ["damaged membranes", "OBSERVATION", 136, 153]]], ["After treatment with enterocin LD3 or plantaricin LD4, light pink fluorescence was observed in Staph. aureus subsp. aureus ATCC25923 and Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells, indicating that the cell membrane of the treated cells was damaged.", [["ATCC13311 cells", "ANATOMY", 188, 203], ["cell membrane", "ANATOMY", 225, 238], ["cells", "ANATOMY", 254, 259], ["enterocin LD3", "CHEMICAL", 21, 34], ["plantaricin", "CHEMICAL", 38, 49], ["plantaricin", "CHEMICAL", 38, 49], ["enterocin LD3", "SIMPLE_CHEMICAL", 21, 34], ["plantaricin LD4", "SIMPLE_CHEMICAL", 38, 53], ["aureus", "ORGANISM", 102, 108], ["enterica", "ORGANISM", 143, 151], ["enterica serovar", "ORGANISM", 159, 175], ["Typhimurium", "ORGANISM", 176, 187], ["ATCC13311 cells", "CELL", 188, 203], ["cell membrane", "CELLULAR_COMPONENT", 225, 238], ["cells", "CELL", 254, 259], ["enterica serovar Typhimurium ATCC13311 cells", "CELL_LINE", 159, 203], ["treated cells", "CELL_LINE", 246, 259], ["aureus subsp", "SPECIES", 102, 114], ["aureus", "SPECIES", 116, 122], ["enterica subsp", "SPECIES", 143, 157], ["enterica serovar Typhimurium", "SPECIES", 159, 187], ["aureus subsp", "SPECIES", 102, 114], ["aureus", "SPECIES", 116, 122], ["enterica subsp", "SPECIES", 143, 157], ["enterica serovar Typhimurium", "SPECIES", 159, 187], ["treatment", "TREATMENT", 6, 15], ["enterocin LD3", "TREATMENT", 21, 34], ["plantaricin LD4", "TREATMENT", 38, 53], ["light pink fluorescence", "PROBLEM", 55, 78], ["Staph", "PROBLEM", 95, 100], ["aureus subsp", "PROBLEM", 102, 114], ["aureus", "PROBLEM", 116, 122], ["enterica subsp", "PROBLEM", 143, 157], ["enterica serovar Typhimurium ATCC13311 cells", "PROBLEM", 159, 203], ["Staph", "OBSERVATION", 95, 100], ["subsp", "OBSERVATION", 109, 114], ["subsp", "OBSERVATION_MODIFIER", 152, 157], ["serovar Typhimurium", "OBSERVATION", 168, 187], ["ATCC13311 cells", "OBSERVATION", 188, 203], ["cell membrane", "OBSERVATION", 225, 238], ["treated cells", "OBSERVATION", 246, 259]]], ["In combination treatment, dead cells were found to be red suggesting higher effect of bacteriocins.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["dead cells", "CELL_TYPE", 26, 36], ["combination treatment", "TREATMENT", 3, 24], ["dead cells", "PROBLEM", 26, 36], ["bacteriocins", "TREATMENT", 86, 98], ["higher effect", "OBSERVATION_MODIFIER", 69, 82]]], ["The synergy among the bacteriocin is possible explanation for the increase in PI fluorescence of target cells.DiscussionThe FTIR analysis of target cells was performed to monitor the specific interaction of the bacteriocins with cellular targets.", [["cells", "ANATOMY", 104, 109], ["cells", "ANATOMY", 148, 153], ["cellular", "ANATOMY", 229, 237], ["PI", "SIMPLE_CHEMICAL", 78, 80], ["cells", "CELL", 104, 109], ["cells", "CELL", 148, 153], ["cellular", "CELL", 229, 237], ["target cells", "CELL_TYPE", 97, 109], ["target cells", "CELL_TYPE", 141, 153], ["the bacteriocin", "TREATMENT", 18, 33], ["the increase in PI fluorescence of target cells", "PROBLEM", 62, 109], ["The FTIR analysis", "TEST", 120, 137], ["target cells", "PROBLEM", 141, 153], ["the bacteriocins", "TREATMENT", 207, 223], ["cellular targets", "TREATMENT", 229, 245], ["possible explanation for", "UNCERTAINTY", 37, 61], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["PI fluorescence", "OBSERVATION", 78, 93], ["target cells", "OBSERVATION", 97, 109]]], ["The valuable information about the biochemical composition of the target bacteria may be used to evaluate the mechanism of action of bacteriocins in treated cells [34].", [["cells", "ANATOMY", 157, 162], ["cells", "CELL", 157, 162], ["treated cells", "CELL_LINE", 149, 162], ["the target bacteria", "PROBLEM", 62, 81], ["bacteriocins", "TREATMENT", 133, 145]]], ["Therefore, bacteriocin-treated cells were scanned using FTIR to monitor the interaction of bacteriocins with cellular targets.", [["cells", "ANATOMY", 31, 36], ["cellular", "ANATOMY", 109, 117], ["bacteriocin", "CHEMICAL", 11, 22], ["cells", "CELL", 31, 36], ["cellular", "CELL", 109, 117], ["bacteriocin-treated cells", "CELL_LINE", 11, 36], ["bacteriocin-treated cells", "TREATMENT", 11, 36], ["FTIR", "TEST", 56, 60], ["bacteriocins", "TREATMENT", 91, 103], ["cellular targets", "TREATMENT", 109, 125]]], ["The FTIR spectra of enterocin LD3-treated cells showed alteration at ~ 1094.30/cm corresponding to nucleic acids [35] suggesting enterocin LD3 may enter inside the cells and interacts with nucleic acids.", [["cells", "ANATOMY", 42, 47], ["cells", "ANATOMY", 164, 169], ["enterocin LD3", "CHEMICAL", 20, 33], ["nucleic acids", "CHEMICAL", 99, 112], ["enterocin", "CHEMICAL", 129, 138], ["nucleic acids", "CHEMICAL", 189, 202], ["enterocin LD3", "CHEMICAL", 20, 33], ["enterocin LD3", "SIMPLE_CHEMICAL", 20, 33], ["cells", "CELL", 42, 47], ["enterocin LD3", "SIMPLE_CHEMICAL", 129, 142], ["cells", "CELL", 164, 169], ["nucleic acids", "SIMPLE_CHEMICAL", 189, 202], ["enterocin LD3-treated cells", "CELL_LINE", 20, 47], ["LD3", "PROTEIN", 139, 142], ["The FTIR spectra", "TEST", 0, 16], ["enterocin LD3", "TEST", 20, 33], ["nucleic acids", "TEST", 99, 112], ["enterocin LD3", "TREATMENT", 129, 142], ["nucleic acids", "TREATMENT", 189, 202]]], ["The spectrum was also found to be altered (increased absorbance) at the region ~ 1451.82/cm corresponding to phospholipids [36] indicating the interaction of enterocin LD3 with membrane lipids.", [["membrane", "ANATOMY", 177, 185], ["enterocin LD3", "CHEMICAL", 158, 171], ["enterocin LD3", "SIMPLE_CHEMICAL", 158, 171], ["membrane lipids", "CELLULAR_COMPONENT", 177, 192], ["enterocin LD3", "PROTEIN", 158, 171], ["altered (increased absorbance", "PROBLEM", 34, 63], ["phospholipids", "TEST", 109, 122], ["enterocin", "TREATMENT", 158, 167], ["membrane lipids", "TREATMENT", 177, 192], ["altered", "OBSERVATION", 34, 41], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["absorbance", "OBSERVATION_MODIFIER", 53, 63]]], ["These observations indicated that enterocin LD3 not only interacts with cell membrane but also enters inside the target cells interacting with nucleic acids.", [["cell membrane", "ANATOMY", 72, 85], ["cells", "ANATOMY", 120, 125], ["enterocin", "CHEMICAL", 34, 43], ["nucleic acids", "CHEMICAL", 143, 156], ["enterocin LD3", "SIMPLE_CHEMICAL", 34, 47], ["cell membrane", "CELLULAR_COMPONENT", 72, 85], ["cells", "CELL", 120, 125], ["nucleic acids", "SIMPLE_CHEMICAL", 143, 156], ["enterocin LD3", "PROTEIN", 34, 47], ["target cells", "CELL_TYPE", 113, 125], ["enterocin LD3", "PROBLEM", 34, 47], ["cell membrane", "TREATMENT", 72, 85], ["nucleic acids", "TREATMENT", 143, 156], ["cell membrane", "OBSERVATION", 72, 85], ["target cells", "OBSERVATION", 113, 125]]], ["In contrast, plantaricin LD4-treated cells did not show such alteration in the wavelength corresponding to phospholipids and nucleic acids suggesting plantaricin LD4 kills target cells using other mechanism which is different to enterocin LD3.", [["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 179, 184], ["plantaricin LD4", "CHEMICAL", 13, 28], ["nucleic acids", "CHEMICAL", 125, 138], ["plantaricin", "CHEMICAL", 150, 161], ["plantaricin", "CHEMICAL", 13, 24], ["plantaricin LD4", "SIMPLE_CHEMICAL", 13, 28], ["cells", "CELL", 37, 42], ["phospholipids", "SIMPLE_CHEMICAL", 107, 120], ["nucleic acids", "SIMPLE_CHEMICAL", 125, 138], ["plantaricin LD4", "SIMPLE_CHEMICAL", 150, 165], ["cells", "CELL", 179, 184], ["enterocin LD3", "GENE_OR_GENE_PRODUCT", 229, 242], ["plantaricin LD4-treated cells", "CELL_LINE", 13, 42], ["LD4", "PROTEIN", 162, 165], ["target cells", "CELL_TYPE", 172, 184], ["enterocin LD3", "PROTEIN", 229, 242], ["plantaricin LD4", "TEST", 13, 28], ["such alteration in the wavelength", "PROBLEM", 56, 89], ["phospholipids", "TREATMENT", 107, 120], ["nucleic acids", "TEST", 125, 138], ["plantaricin", "TREATMENT", 150, 161]]], ["Our data suggest that different mode of action of both bacteriocins results in division of labour and may be responsible for their synergistic activity against target cells.", [["cells", "ANATOMY", 167, 172], ["cells", "CELL", 167, 172], ["target cells", "CELL_TYPE", 160, 172], ["Our data", "TEST", 0, 8], ["both bacteriocins", "TREATMENT", 50, 67]]], ["Since enterocin LD3 interacts directly with phospholipids, it may be involved in pore formation or cell membrane damage allowing both/other bacteriocins access inside the cells causing cell death.DiscussionThe membrane-acting nature of these bacteriocins was also confirmed using TEM analysis.", [["pore", "ANATOMY", 81, 85], ["cell membrane", "ANATOMY", 99, 112], ["cells", "ANATOMY", 171, 176], ["cell", "ANATOMY", 185, 189], ["membrane", "ANATOMY", 210, 218], ["death", "DISEASE", 190, 195], ["enterocin LD3", "GENE_OR_GENE_PRODUCT", 6, 19], ["phospholipids", "SIMPLE_CHEMICAL", 44, 57], ["pore", "CELLULAR_COMPONENT", 81, 85], ["cell membrane", "CELLULAR_COMPONENT", 99, 112], ["cells", "CELL", 171, 176], ["cell", "CELL", 185, 189], ["membrane", "CELLULAR_COMPONENT", 210, 218], ["enterocin LD3", "PROTEIN", 6, 19], ["enterocin", "TREATMENT", 6, 15], ["phospholipids", "TREATMENT", 44, 57], ["pore formation", "PROBLEM", 81, 95], ["cell membrane damage", "PROBLEM", 99, 119], ["both/other bacteriocins access", "TREATMENT", 129, 159], ["cell death", "PROBLEM", 185, 195], ["these bacteriocins", "TREATMENT", 236, 254], ["TEM analysis", "TEST", 280, 292], ["may be", "UNCERTAINTY", 62, 68], ["cell membrane damage", "OBSERVATION", 99, 119], ["cell death", "OBSERVATION", 185, 195]]], ["It was used to visualize the morphology and capture intracellular images of the target cells.", [["intracellular", "ANATOMY", 52, 65], ["cells", "ANATOMY", 87, 92], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["cells", "CELL", 87, 92], ["target cells", "CELL_TYPE", 80, 92], ["intracellular images", "TEST", 52, 72], ["target cells", "OBSERVATION", 80, 92]]], ["Untreated Staph. aureus subsp. aureus ATCC25923 cells displayed a highly homogenous intracellular density and round shape, but enterocin LD3-treated cells showed disruption of cell membrane and release of intracellular contents.", [["ATCC25923 cells", "ANATOMY", 38, 53], ["intracellular", "ANATOMY", 84, 97], ["cells", "ANATOMY", 149, 154], ["cell membrane", "ANATOMY", 176, 189], ["intracellular", "ANATOMY", 205, 218], ["enterocin LD3", "CHEMICAL", 127, 140], ["aureus", "ORGANISM", 17, 23], ["ATCC25923 cells", "CELL", 38, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["enterocin LD3", "SIMPLE_CHEMICAL", 127, 140], ["cells", "CELL", 149, 154], ["cell membrane", "CELLULAR_COMPONENT", 176, 189], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 205, 218], ["ATCC25923 cells", "CELL_LINE", 38, 53], ["enterocin LD3-treated cells", "CELL_LINE", 127, 154], ["aureus subsp", "SPECIES", 17, 29], ["aureus", "SPECIES", 31, 37], ["aureus subsp", "SPECIES", 17, 29], ["aureus", "SPECIES", 31, 37], ["Untreated Staph", "PROBLEM", 0, 15], ["aureus subsp", "PROBLEM", 17, 29], ["aureus ATCC25923 cells", "PROBLEM", 31, 53], ["a highly homogenous intracellular density and round shape", "PROBLEM", 64, 121], ["enterocin LD3", "TEST", 127, 140], ["disruption of cell membrane", "PROBLEM", 162, 189], ["intracellular contents", "PROBLEM", 205, 227], ["Staph", "OBSERVATION", 10, 15], ["subsp", "OBSERVATION", 24, 29], ["ATCC25923 cells", "OBSERVATION", 38, 53], ["highly", "OBSERVATION_MODIFIER", 66, 72], ["homogenous", "OBSERVATION_MODIFIER", 73, 83], ["intracellular", "OBSERVATION_MODIFIER", 84, 97], ["density", "OBSERVATION", 98, 105], ["round", "OBSERVATION_MODIFIER", 110, 115], ["shape", "OBSERVATION_MODIFIER", 116, 121], ["disruption of cell membrane", "OBSERVATION", 162, 189], ["intracellular contents", "OBSERVATION", 205, 227]]], ["Staph. aureus subsp. aureus ATCC25923 cells treated with plantaricin LD4 also exhibited cellular damages, while enterocin LD3 and plantaricin LD4 combination treatment caused wide surface damage to most cells, showing sunken cell surface and shrinking cytoplasm.", [["ATCC25923 cells", "ANATOMY", 28, 43], ["cellular", "ANATOMY", 88, 96], ["surface", "ANATOMY", 180, 187], ["cells", "ANATOMY", 203, 208], ["cell surface", "ANATOMY", 225, 237], ["cytoplasm", "ANATOMY", 252, 261], ["plantaricin", "CHEMICAL", 57, 68], ["enterocin LD3", "CHEMICAL", 112, 125], ["plantaricin LD4", "CHEMICAL", 130, 145], ["plantaricin LD4", "CHEMICAL", 57, 72], ["plantaricin LD4", "CHEMICAL", 130, 145], ["aureus", "ORGANISM", 7, 13], ["ATCC25923 cells", "CELL", 28, 43], ["plantaricin LD4", "SIMPLE_CHEMICAL", 57, 72], ["cellular", "CELL", 88, 96], ["enterocin LD3", "SIMPLE_CHEMICAL", 112, 125], ["plantaricin LD4", "SIMPLE_CHEMICAL", 130, 145], ["cells", "CELL", 203, 208], ["cell surface", "CELLULAR_COMPONENT", 225, 237], ["cytoplasm", "ORGANISM_SUBSTANCE", 252, 261], ["ATCC25923 cells", "CELL_LINE", 28, 43], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["aureus subsp", "SPECIES", 7, 19], ["aureus", "SPECIES", 21, 27], ["Staph", "PROBLEM", 0, 5], ["aureus subsp", "PROBLEM", 7, 19], ["aureus", "PROBLEM", 21, 27], ["plantaricin LD4", "TREATMENT", 57, 72], ["cellular damages", "PROBLEM", 88, 104], ["enterocin LD3", "TREATMENT", 112, 125], ["plantaricin LD4", "TREATMENT", 130, 145], ["treatment", "TREATMENT", 158, 167], ["wide surface damage to most cells", "PROBLEM", 175, 208], ["sunken cell surface", "PROBLEM", 218, 237], ["shrinking cytoplasm", "PROBLEM", 242, 261], ["subsp", "OBSERVATION", 14, 19], ["cellular damages", "OBSERVATION", 88, 104], ["most cells", "OBSERVATION_MODIFIER", 198, 208], ["sunken cell", "OBSERVATION", 218, 229], ["surface", "OBSERVATION_MODIFIER", 230, 237], ["shrinking cytoplasm", "OBSERVATION", 242, 261]]], ["Irregularity of the cell surface and the increase of cell mass were undoubtedly evident indicating perforation of the cell wall with consequent cell deformation after combined bacteriocin treatment.", [["cell surface", "ANATOMY", 20, 32], ["cell", "ANATOMY", 53, 57], ["cell wall", "ANATOMY", 118, 127], ["cell", "ANATOMY", 144, 148], ["cell surface", "CELLULAR_COMPONENT", 20, 32], ["cell", "CELL", 53, 57], ["cell wall", "TISSUE", 118, 127], ["cell", "CELL", 144, 148], ["Irregularity of the cell surface", "PROBLEM", 0, 32], ["cell mass", "PROBLEM", 53, 62], ["perforation of the cell wall", "PROBLEM", 99, 127], ["consequent cell deformation", "PROBLEM", 133, 160], ["combined bacteriocin treatment", "TREATMENT", 167, 197], ["cell", "OBSERVATION_MODIFIER", 20, 24], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["cell mass", "OBSERVATION", 53, 62], ["perforation", "OBSERVATION", 99, 110], ["cell", "ANATOMY", 118, 122], ["wall", "ANATOMY_MODIFIER", 123, 127], ["consequent cell deformation", "OBSERVATION", 133, 160], ["bacteriocin treatment", "OBSERVATION", 176, 197]]], ["The untreated Salm. enterica subsp. enterica serovar Typhimurium ATCC13311cells maintained typical rods and intact status.", [["ATCC13311cells", "ANATOMY", 65, 79], ["rods", "ANATOMY", 99, 103], ["enterica", "ORGANISM", 20, 28], ["enterica serovar", "ORGANISM", 36, 52], ["Typhimurium", "ORGANISM", 53, 64], ["ATCC13311cells", "CELL", 65, 79], ["ATCC13311cells", "CELL_LINE", 65, 79], ["enterica subsp", "SPECIES", 20, 34], ["enterica serovar Typhimurium", "SPECIES", 36, 64], ["enterica subsp", "SPECIES", 20, 34], ["enterica serovar Typhimurium", "SPECIES", 36, 64], ["enterica subsp", "PROBLEM", 20, 34], ["enterica serovar Typhimurium", "TEST", 36, 64], ["typical rods", "PROBLEM", 91, 103], ["untreated", "OBSERVATION_MODIFIER", 4, 13], ["Salm", "OBSERVATION", 14, 18], ["subsp", "OBSERVATION_MODIFIER", 29, 34], ["serovar Typhimurium", "OBSERVATION", 45, 64], ["typical rods", "OBSERVATION", 91, 103], ["intact status", "OBSERVATION", 108, 121]]], ["When exposed to enterocin LD3, the cells showed an alteration in morphology, and ruptured cells were observed.", [["cells", "ANATOMY", 35, 40], ["cells", "ANATOMY", 90, 95], ["enterocin LD3", "SIMPLE_CHEMICAL", 16, 29], ["cells", "CELL", 35, 40], ["cells", "CELL", 90, 95], ["enterocin LD3", "CELL_LINE", 16, 29], ["ruptured cells", "CELL_TYPE", 81, 95], ["enterocin", "TREATMENT", 16, 25], ["an alteration in morphology", "PROBLEM", 48, 75], ["ruptured cells", "PROBLEM", 81, 95], ["alteration", "OBSERVATION", 51, 61], ["morphology", "OBSERVATION_MODIFIER", 65, 75], ["ruptured cells", "OBSERVATION", 81, 95]]], ["Similarly, plantaricin LD4 induced a dramatic change in the Salm. enterica subsp. enterica serovar Typhimurium ATCC13311cells showing various alterations [37] reported that plantaricin MG damaged outer membrane of Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 with release of cellular contents in the surrounding, but nisin did not show any effect on cell morphology of Salm. enterica subsp. enterica serovar Typhimurium ATCC13311.", [["ATCC13311cells", "ANATOMY", 111, 125], ["outer membrane", "ANATOMY", 196, 210], ["cellular", "ANATOMY", 291, 299], ["cell", "ANATOMY", 366, 370], ["plantaricin", "CHEMICAL", 11, 22], ["plantaricin", "CHEMICAL", 173, 184], ["nisin", "CHEMICAL", 333, 338], ["plantaricin LD4", "CHEMICAL", 11, 26], ["plantaricin LD4", "SIMPLE_CHEMICAL", 11, 26], ["enterica", "ORGANISM", 66, 74], ["enterica serovar", "ORGANISM", 82, 98], ["Typhimurium", "ORGANISM", 99, 110], ["ATCC13311cells", "CELL", 111, 125], ["plantaricin MG", "SIMPLE_CHEMICAL", 173, 187], ["outer membrane", "CELLULAR_COMPONENT", 196, 210], ["enterica", "ORGANISM", 220, 228], ["enterica serovar Typhimurium", "ORGANISM", 236, 264], ["ATCC13311", "ORGANISM", 265, 274], ["cellular", "CELL", 291, 299], ["cell", "CELL", 366, 370], ["enterica", "ORGANISM", 391, 399], ["enterica serovar Typhimurium", "ORGANISM", 407, 435], ["ATCC13311", "ORGANISM", 436, 445], ["plantaricin LD4", "PROTEIN", 11, 26], ["ATCC13311cells", "CELL_LINE", 111, 125], ["enterica subsp", "SPECIES", 66, 80], ["enterica serovar Typhimurium", "SPECIES", 82, 110], ["enterica subsp", "SPECIES", 220, 234], ["enterica serovar Typhimurium", "SPECIES", 236, 264], ["enterica subsp", "SPECIES", 391, 405], ["enterica serovar Typhimurium", "SPECIES", 407, 435], ["enterica subsp", "SPECIES", 66, 80], ["enterica serovar Typhimurium", "SPECIES", 82, 110], ["enterica subsp", "SPECIES", 220, 234], ["enterica serovar Typhimurium", "SPECIES", 236, 264], ["enterica subsp", "SPECIES", 391, 405], ["enterica serovar Typhimurium", "SPECIES", 407, 435], ["a dramatic change", "PROBLEM", 35, 52], ["enterica subsp", "PROBLEM", 66, 80], ["enterica serovar Typhimurium", "TEST", 82, 110], ["various alterations", "PROBLEM", 134, 153], ["plantaricin", "TREATMENT", 173, 184], ["enterica subsp", "PROBLEM", 220, 234], ["enterica serovar Typhimurium", "TEST", 236, 264], ["cellular contents", "PROBLEM", 291, 308], ["enterica subsp", "PROBLEM", 391, 405], ["enterica serovar Typhimurium", "TREATMENT", 407, 435], ["dramatic", "OBSERVATION_MODIFIER", 37, 45], ["change", "OBSERVATION_MODIFIER", 46, 52], ["subsp", "OBSERVATION_MODIFIER", 75, 80], ["serovar Typhimurium", "OBSERVATION", 91, 110], ["Salm", "ANATOMY", 214, 218], ["subsp", "OBSERVATION_MODIFIER", 229, 234], ["serovar Typhimurium", "OBSERVATION", 245, 264], ["cellular contents", "OBSERVATION", 291, 308], ["cell morphology", "OBSERVATION", 366, 381], ["subsp", "OBSERVATION_MODIFIER", 400, 405], ["serovar Typhimurium", "OBSERVATION", 416, 435]]], ["Other reports showed that nisin did not inhibit Salmonella spp.", [["nisin", "CHEMICAL", 26, 31], ["nisin", "SIMPLE_CHEMICAL", 26, 31], ["Salmonella spp", "ORGANISM", 48, 62], ["Salmonella spp", "PROBLEM", 48, 62]]], ["Due to their external membrane consisting of extensive amounts of protein, phospholipids and polysaccharide may act as a barrier to the action of nisin on the cytoplasmic membrane [38, 39].", [["membrane", "ANATOMY", 22, 30], ["cytoplasmic membrane", "ANATOMY", 159, 179], ["nisin", "CHEMICAL", 146, 151], ["membrane", "CELLULAR_COMPONENT", 22, 30], ["phospholipids", "SIMPLE_CHEMICAL", 75, 88], ["polysaccharide", "SIMPLE_CHEMICAL", 93, 107], ["nisin", "GENE_OR_GENE_PRODUCT", 146, 151], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 159, 179], ["extensive amounts of protein", "TREATMENT", 45, 73], ["phospholipids", "TREATMENT", 75, 88], ["polysaccharide", "TREATMENT", 93, 107]]], ["Yildirim et al. [40] explained that enterocin KP alone did not act against intact cells of Salm.", [["cells", "ANATOMY", 82, 87], ["enterocin", "CHEMICAL", 36, 45], ["KP", "CHEMICAL", 46, 48], ["enterocin KP", "CHEMICAL", 36, 48], ["enterocin KP", "SIMPLE_CHEMICAL", 36, 48], ["cells", "CELL", 82, 87], ["intact cells", "CELL_TYPE", 75, 87], ["Salm", "PROTEIN", 91, 95], ["enterocin KP", "TREATMENT", 36, 48]]], ["Typhimurium and E. coli but in the presence of physio-chemical sublethal treatments decreases their cell number.", [["cell", "ANATOMY", 100, 104], ["Typhimurium", "ORGANISM", 0, 11], ["E. coli", "ORGANISM", 16, 23], ["cell", "CELL", 100, 104], ["Typhimurium", "SPECIES", 0, 11], ["E. coli", "SPECIES", 16, 23], ["Typhimurium", "SPECIES", 0, 11], ["E. coli", "SPECIES", 16, 23], ["Typhimurium", "PROBLEM", 0, 11], ["E. coli", "PROBLEM", 16, 23], ["physio-chemical sublethal treatments", "TREATMENT", 47, 83], ["E. coli", "OBSERVATION", 16, 23], ["chemical sublethal treatments", "OBSERVATION", 54, 83]]], ["However, in the present study, enterocin LD3 and plantaricin LD4 showed bactericidal effects on both Gram-positive and Gram-negative bacteria.", [["enterocin LD3", "CHEMICAL", 31, 44], ["plantaricin", "CHEMICAL", 49, 60], ["LD4", "CHEMICAL", 61, 64], ["enterocin LD3", "CHEMICAL", 31, 44], ["plantaricin LD4", "CHEMICAL", 49, 64], ["enterocin LD3", "SIMPLE_CHEMICAL", 31, 44], ["plantaricin LD4", "SIMPLE_CHEMICAL", 49, 64], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 101, 114], ["Gram", "GENE_OR_GENE_PRODUCT", 119, 123], ["the present study", "TEST", 12, 29], ["enterocin LD3", "TEST", 31, 44], ["plantaricin LD4", "TEST", 49, 64], ["bactericidal effects", "PROBLEM", 72, 92], ["Gram-negative bacteria", "PROBLEM", 119, 141], ["bactericidal effects", "OBSERVATION", 72, 92], ["negative bacteria", "OBSERVATION", 124, 141]]], ["In the presence of combined concentration of these bacteriocins, the outer membrane of Salm. enterica subsp. enterica serovar Typhimurium ATCC13311 cells was damaged, cell membrane protruded into the cytoplasm, and several cells displayed ruptures and loss of cytoplasm, indicating the cytoplasmic membrane was severely affected by the mixture of bacteriocins.", [["outer membrane", "ANATOMY", 69, 83], ["ATCC13311 cells", "ANATOMY", 138, 153], ["cell membrane", "ANATOMY", 167, 180], ["cytoplasm", "ANATOMY", 200, 209], ["cells", "ANATOMY", 223, 228], ["cytoplasm", "ANATOMY", 260, 269], ["cytoplasmic membrane", "ANATOMY", 286, 306], ["outer membrane", "CELLULAR_COMPONENT", 69, 83], ["enterica", "ORGANISM", 93, 101], ["enterica serovar", "ORGANISM", 109, 125], ["Typhimurium", "ORGANISM", 126, 137], ["ATCC13311 cells", "CELL", 138, 153], ["cell membrane", "CELLULAR_COMPONENT", 167, 180], ["cytoplasm", "ORGANISM_SUBSTANCE", 200, 209], ["cells", "CELL", 223, 228], ["cytoplasm", "ORGANISM_SUBSTANCE", 260, 269], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 286, 306], ["ATCC13311 cells", "CELL_LINE", 138, 153], ["enterica subsp", "SPECIES", 93, 107], ["enterica serovar Typhimurium", "SPECIES", 109, 137], ["enterica subsp", "SPECIES", 93, 107], ["enterica serovar Typhimurium", "SPECIES", 109, 137], ["these bacteriocins", "TREATMENT", 45, 63], ["enterica subsp", "PROBLEM", 93, 107], ["enterica serovar Typhimurium", "TEST", 109, 137], ["cell membrane", "TEST", 167, 180], ["several cells", "PROBLEM", 215, 228], ["ruptures", "PROBLEM", 239, 247], ["loss of cytoplasm", "PROBLEM", 252, 269], ["the cytoplasmic membrane", "PROBLEM", 282, 306], ["bacteriocins", "TREATMENT", 347, 359], ["subsp", "OBSERVATION_MODIFIER", 102, 107], ["serovar Typhimurium", "OBSERVATION", 118, 137], ["ATCC13311 cells", "OBSERVATION", 138, 153], ["cell membrane protruded", "OBSERVATION", 167, 190], ["cytoplasm", "OBSERVATION_MODIFIER", 200, 209], ["ruptures", "OBSERVATION", 239, 247], ["loss", "OBSERVATION_MODIFIER", 252, 256], ["cytoplasm", "OBSERVATION_MODIFIER", 260, 269], ["cytoplasmic membrane", "OBSERVATION", 286, 306]]], ["The activity of these bacteriocins alone and in combination was also observed against other pathogens such as P. mirabilis ATCC43071, P. aeruginosa ATCC27853 and E. coli ATCC25922 suggesting their wider applications.", [["P. mirabilis ATCC43071", "ORGANISM", 110, 132], ["P. aeruginosa ATCC27853", "ORGANISM", 134, 157], ["E. coli", "ORGANISM", 162, 169], ["ATCC25922", "ORGANISM", 170, 179], ["P. mirabilis", "SPECIES", 110, 122], ["P. aeruginosa", "SPECIES", 134, 147], ["E. coli", "SPECIES", 162, 169], ["P. mirabilis", "SPECIES", 110, 122], ["P. aeruginosa", "SPECIES", 134, 147], ["E. coli", "SPECIES", 162, 169], ["these bacteriocins", "TREATMENT", 16, 34], ["other pathogens", "PROBLEM", 86, 101], ["P. mirabilis", "TEST", 110, 122], ["P. aeruginosa", "TEST", 134, 147], ["E. coli", "PROBLEM", 162, 169]]], ["However, their effect against S. marcescens ATCC27137 was not recorded either alone or in combination suggesting the possibility to explore other strains of this species for activity testing.", [["S. marcescens ATCC27137", "ORGANISM", 30, 53], ["S. marcescens", "SPECIES", 30, 43], ["S. marcescens", "SPECIES", 30, 43], ["S. marcescens", "TEST", 30, 43], ["other strains of this species", "PROBLEM", 140, 169], ["activity testing", "TEST", 174, 190]]], ["In contrast, bacteriocins produced by E. mundtii 115 and E. faecium DSH20 did not inhibit E. coli, Staph. aureus, Salm.", [["E. mundtii 115", "ORGANISM", 38, 52], ["E. faecium", "ORGANISM", 57, 67], ["DSH20", "ORGANISM", 68, 73], ["E. coli", "ORGANISM", 90, 97], ["Staph", "GENE_OR_GENE_PRODUCT", 99, 104], ["aureus", "ORGANISM", 106, 112], ["E. mundtii", "SPECIES", 38, 48], ["E. faecium", "SPECIES", 57, 67], ["E. coli", "SPECIES", 90, 97], ["aureus", "SPECIES", 106, 112], ["E. mundtii", "SPECIES", 38, 48], ["E. faecium", "SPECIES", 57, 67], ["E. coli", "SPECIES", 90, 97], ["aureus", "SPECIES", 106, 112], ["bacteriocins", "TEST", 13, 25], ["E. mundtii", "TEST", 38, 48], ["E. faecium DSH20", "TEST", 57, 73], ["E. coli", "PROBLEM", 90, 97], ["Staph", "PROBLEM", 99, 104], ["aureus", "PROBLEM", 106, 112], ["coli", "OBSERVATION", 93, 97], ["Staph", "OBSERVATION", 99, 104]]], ["Typhimurium, M. luteus and P. aeruginosa [29, 41].", [["Typhimurium", "ORGANISM", 0, 11], ["M. luteus", "ORGANISM", 13, 22], ["P. aeruginosa", "ORGANISM", 27, 40], ["Typhimurium", "SPECIES", 0, 11], ["M. luteus", "SPECIES", 13, 22], ["P. aeruginosa", "SPECIES", 27, 40], ["Typhimurium", "SPECIES", 0, 11], ["M. luteus", "SPECIES", 13, 22], ["P. aeruginosa", "SPECIES", 27, 40], ["Typhimurium", "TEST", 0, 11], ["P. aeruginosa", "TEST", 27, 40], ["luteus", "ANATOMY", 16, 22]]], ["Furthermore, synergistic interaction may also reduce the costs of application of these bacteriocins.", [["these bacteriocins", "TREATMENT", 81, 99]]], ["In addition, combinatorial therapies with bacteriocins and/or other antimicrobials may broaden antimicrobial spectra and reduce the probability of resistance development probably due to contribution of two different mechanisms of bacteriocin action as also suggested by Gulluce et al. [42].ConclusionsIn the present study, two synergistically acting bacteriocins, enterocin LD3 and plantaricin LD4 have been used against known food-borne pathogens, Staphylococcus aureus subsp. aureus ATCC25923 and Salmonella enterica subsp. enterica serovar Typhimurium ATCC13311.", [["enterocin", "CHEMICAL", 364, 373], ["LD4", "CHEMICAL", 394, 397], ["ATCC25923", "CHEMICAL", 485, 494], ["plantaricin LD4", "CHEMICAL", 382, 397], ["enterocin LD3", "SIMPLE_CHEMICAL", 364, 377], ["plantaricin LD4", "SIMPLE_CHEMICAL", 382, 397], ["Staphylococcus aureus", "ORGANISM", 449, 470], ["subsp", "ORGANISM", 471, 476], ["aureus ATCC25923", "ORGANISM", 478, 494], ["Salmonella enterica", "ORGANISM", 499, 518], ["enterica serovar Typhimurium", "ORGANISM", 526, 554], ["ATCC13311", "ORGANISM", 555, 564], ["Staphylococcus aureus subsp", "SPECIES", 449, 476], ["aureus", "SPECIES", 478, 484], ["Salmonella enterica subsp", "SPECIES", 499, 524], ["enterica serovar Typhimurium", "SPECIES", 526, 554], ["Staphylococcus aureus subsp", "SPECIES", 449, 476], ["aureus", "SPECIES", 478, 484], ["Salmonella enterica subsp", "SPECIES", 499, 524], ["enterica serovar Typhimurium", "SPECIES", 526, 554], ["combinatorial therapies", "TREATMENT", 13, 36], ["bacteriocins", "TREATMENT", 42, 54], ["other antimicrobials", "TREATMENT", 62, 82], ["antimicrobial spectra", "TREATMENT", 95, 116], ["resistance development", "PROBLEM", 147, 169], ["bacteriocin action", "TREATMENT", 230, 248], ["the present study", "TEST", 304, 321], ["two synergistically acting bacteriocins", "TREATMENT", 323, 362], ["enterocin LD3", "TREATMENT", 364, 377], ["plantaricin LD4", "TREATMENT", 382, 397], ["known food-borne pathogens", "PROBLEM", 421, 447], ["Staphylococcus aureus subsp", "PROBLEM", 449, 476], ["aureus", "PROBLEM", 478, 484], ["Salmonella enterica subsp", "PROBLEM", 499, 524], ["enterica serovar Typhimurium", "TREATMENT", 526, 554], ["Staphylococcus aureus", "OBSERVATION", 449, 470], ["Salmonella", "OBSERVATION_MODIFIER", 499, 509], ["enterica subsp", "OBSERVATION", 510, 524], ["serovar Typhimurium", "OBSERVATION", 535, 554]]], ["It was found that enterocin LD3 was more effective on target cells than plantaricin LD4.", [["cells", "ANATOMY", 61, 66], ["enterocin", "CHEMICAL", 18, 27], ["enterocin LD3", "CHEMICAL", 18, 31], ["plantaricin", "CHEMICAL", 72, 83], ["enterocin LD3", "SIMPLE_CHEMICAL", 18, 31], ["cells", "CELL", 61, 66], ["plantaricin LD4", "SIMPLE_CHEMICAL", 72, 87], ["target cells", "CELL_TYPE", 54, 66], ["LD4", "PROTEIN", 84, 87], ["enterocin LD3", "PROBLEM", 18, 31]]], ["When both bacteriocins were used in combination, their effect was manyfold higher than their individual effects suggesting synergy between the two bacteriocins.", [["both bacteriocins", "TREATMENT", 5, 22], ["synergy", "PROBLEM", 123, 130], ["the two bacteriocins", "TREATMENT", 139, 159]]], ["The synergetic effect was observed in terms of reduced MIC, FICI, isobologram interpretation, higher growth inhibition, loss of cell viability and damage to the cell membrane of the target cells.", [["cell", "ANATOMY", 128, 132], ["cell membrane", "ANATOMY", 161, 174], ["cells", "ANATOMY", 189, 194], ["cell", "CELL", 128, 132], ["cell membrane", "CELLULAR_COMPONENT", 161, 174], ["cells", "CELL", 189, 194], ["target cells", "CELL_TYPE", 182, 194], ["reduced MIC", "PROBLEM", 47, 58], ["isobologram interpretation", "TEST", 66, 92], ["higher growth inhibition", "PROBLEM", 94, 118], ["loss of cell viability", "PROBLEM", 120, 142], ["synergetic effect", "OBSERVATION", 4, 21], ["cell viability", "OBSERVATION", 128, 142], ["cell membrane", "OBSERVATION", 161, 174], ["target cells", "OBSERVATION", 182, 194]]], ["Further, inhibition of Gram-positive and Gram-negative pathogenic bacteria is other unique feature suggesting their wider applications in food safety and clinical settings.", [["Gram-positive", "GENE_OR_GENE_PRODUCT", 23, 36], ["Gram", "GENE_OR_GENE_PRODUCT", 41, 45], ["Gram-", "TEST", 23, 28], ["Gram", "TEST", 41, 45], ["negative pathogenic bacteria", "PROBLEM", 46, 74], ["negative pathogenic", "OBSERVATION_MODIFIER", 46, 65], ["bacteria", "OBSERVATION", 66, 74]]], ["Use of synergistically acting compounds may reduce the likelihood of resistance development against target bacteria and may also be economical for industrial applications.", [["synergistically acting compounds", "TREATMENT", 7, 39], ["resistance development", "PROBLEM", 69, 91], ["target bacteria", "PROBLEM", 100, 115], ["industrial applications", "TREATMENT", 147, 170]]]], "PMC7363595": [["Clinical/Scientific Note.An increasing body of evidence suggests that the coronavirus disease 2019 (SARS-CoV2) may be associated with cerebrovascular disease, although most cases have been ischemic strokes related to occlusion of major intracranial vessels [1\u20133].", [["cerebrovascular", "ANATOMY", 134, 149], ["intracranial vessels", "ANATOMY", 236, 256], ["coronavirus disease", "DISEASE", 74, 93], ["SARS-CoV2", "DISEASE", 100, 109], ["cerebrovascular disease", "DISEASE", 134, 157], ["ischemic strokes", "DISEASE", 189, 205], ["SARS-CoV2", "ORGANISM", 100, 109], ["cerebrovascular", "ANATOMICAL_SYSTEM", 134, 149], ["intracranial vessels", "MULTI-TISSUE_STRUCTURE", 236, 256], ["the coronavirus disease", "PROBLEM", 70, 93], ["cerebrovascular disease", "PROBLEM", 134, 157], ["ischemic strokes", "PROBLEM", 189, 205], ["occlusion of major intracranial vessels", "PROBLEM", 217, 256], ["increasing", "OBSERVATION_MODIFIER", 28, 38], ["evidence suggests", "UNCERTAINTY", 47, 64], ["coronavirus disease", "OBSERVATION", 74, 93], ["may be associated with", "UNCERTAINTY", 111, 133], ["cerebrovascular disease", "OBSERVATION", 134, 157], ["ischemic", "OBSERVATION_MODIFIER", 189, 197], ["strokes", "OBSERVATION", 198, 205], ["occlusion", "OBSERVATION", 217, 226], ["intracranial vessels", "ANATOMY", 236, 256]]], ["Intracranial hemorrhages in the setting of SARS-CoV2 infection are exceedingly rare.", [["Intracranial", "ANATOMY", 0, 12], ["Intracranial hemorrhages", "DISEASE", 0, 24], ["SARS-CoV2 infection", "DISEASE", 43, 62], ["Intracranial hemorrhages", "PROBLEM", 0, 24], ["SARS", "PROBLEM", 43, 47], ["CoV2 infection", "PROBLEM", 48, 62], ["hemorrhages", "OBSERVATION", 13, 24], ["SARS", "OBSERVATION", 43, 47], ["CoV2", "ANATOMY", 48, 52], ["infection", "OBSERVATION", 53, 62]]], ["To the best of our knowledge, only two cases has been reported in detail, one with a massive parenchymal brain hemorrhage and the other with an aneurysmal subarachnoid hemorrhage [4,5].", [["parenchymal brain", "ANATOMY", 93, 110], ["brain hemorrhage", "DISEASE", 105, 121], ["aneurysmal subarachnoid hemorrhage", "DISEASE", 144, 178], ["brain", "ORGAN", 105, 110], ["a massive parenchymal brain hemorrhage", "PROBLEM", 83, 121], ["an aneurysmal subarachnoid hemorrhage", "PROBLEM", 141, 178], ["massive", "OBSERVATION_MODIFIER", 85, 92], ["parenchymal", "ANATOMY_MODIFIER", 93, 104], ["brain", "ANATOMY", 105, 110], ["hemorrhage", "OBSERVATION", 111, 121], ["aneurysmal", "OBSERVATION_MODIFIER", 144, 154], ["subarachnoid", "OBSERVATION_MODIFIER", 155, 167], ["hemorrhage", "OBSERVATION", 168, 178]]], ["One additional patient was just mentioned (no details) in a large series of patients with neurological complications related to this infection [3], and the last reported patient had a secondary hemorrhagic transformation of a cerebral infarction after thrombectomy [5].", [["neurological", "ANATOMY", 90, 102], ["cerebral", "ANATOMY", 226, 234], ["infection", "DISEASE", 133, 142], ["hemorrhagic", "DISEASE", 194, 205], ["cerebral infarction", "DISEASE", 226, 245], ["patient", "ORGANISM", 15, 22], ["patients", "ORGANISM", 76, 84], ["patient", "ORGANISM", 170, 177], ["cerebral", "ORGAN", 226, 234], ["patient", "SPECIES", 15, 22], ["patients", "SPECIES", 76, 84], ["patient", "SPECIES", 170, 177], ["neurological complications", "PROBLEM", 90, 116], ["this infection", "PROBLEM", 128, 142], ["a secondary hemorrhagic transformation", "PROBLEM", 182, 220], ["a cerebral infarction", "PROBLEM", 224, 245], ["thrombectomy", "TREATMENT", 252, 264], ["infection", "OBSERVATION", 133, 142], ["secondary", "OBSERVATION_MODIFIER", 184, 193], ["hemorrhagic", "OBSERVATION_MODIFIER", 194, 205], ["transformation", "OBSERVATION", 206, 220], ["cerebral", "ANATOMY", 226, 234], ["infarction", "OBSERVATION", 235, 245], ["thrombectomy", "OBSERVATION", 252, 264]]], ["Here, we report our experience with two patients with SARS-CoV2 who developed an otherwise unexplained intracranial hemorrhage.", [["intracranial", "ANATOMY", 103, 115], ["SARS-CoV2", "DISEASE", 54, 63], ["intracranial hemorrhage", "DISEASE", 103, 126], ["patients", "ORGANISM", 40, 48], ["intracranial hemorrhage", "PATHOLOGICAL_FORMATION", 103, 126], ["patients", "SPECIES", 40, 48], ["SARS", "PROBLEM", 54, 58], ["an otherwise unexplained intracranial hemorrhage", "PROBLEM", 78, 126], ["otherwise", "OBSERVATION_MODIFIER", 81, 90], ["unexplained", "OBSERVATION_MODIFIER", 91, 102], ["intracranial", "ANATOMY", 103, 115], ["hemorrhage", "OBSERVATION", 116, 126]]], ["These cases represented the 1.5% of 132 consecutive patients with SARS-CoV2 admitted to Cl\u00ednica Guayaquil (Guayaquil, Ecuador) over a two-month period.", [["SARS-CoV2", "DISEASE", 66, 75], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["SARS", "PROBLEM", 66, 70]]], ["Four additional patients of the above-mentioned series had ischemic strokes (likely related to large vessel disease in three and to cerebral hypoperfusion in one), but were not the subject of this report.Clinical/Scientific Note.The two patients with SARS-CoV2 infection who developed an otherwise unexplained intracranial hemorrhage were women, aged 78 (case 1) and 65 (case 2) years, respectively.", [["vessel", "ANATOMY", 101, 107], ["cerebral", "ANATOMY", 132, 140], ["intracranial", "ANATOMY", 310, 322], ["ischemic strokes", "DISEASE", 59, 75], ["vessel disease", "DISEASE", 101, 115], ["cerebral hypoperfusion", "DISEASE", 132, 154], ["SARS-CoV2 infection", "DISEASE", 251, 270], ["intracranial hemorrhage", "DISEASE", 310, 333], ["patients", "ORGANISM", 16, 24], ["vessel", "MULTI-TISSUE_STRUCTURE", 101, 107], ["cerebral", "ORGAN", 132, 140], ["patients", "ORGANISM", 237, 245], ["women", "ORGANISM", 339, 344], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 237, 245], ["women", "SPECIES", 339, 344], ["ischemic strokes", "PROBLEM", 59, 75], ["large vessel disease", "PROBLEM", 95, 115], ["cerebral hypoperfusion", "PROBLEM", 132, 154], ["SARS", "PROBLEM", 251, 255], ["CoV2 infection", "PROBLEM", 256, 270], ["an otherwise unexplained intracranial hemorrhage", "PROBLEM", 285, 333], ["ischemic", "OBSERVATION_MODIFIER", 59, 67], ["strokes", "OBSERVATION", 68, 75], ["likely related to", "UNCERTAINTY", 77, 94], ["large", "OBSERVATION_MODIFIER", 95, 100], ["vessel", "ANATOMY", 101, 107], ["disease", "OBSERVATION", 108, 115], ["cerebral", "ANATOMY", 132, 140], ["hypoperfusion", "OBSERVATION", 141, 154], ["infection", "OBSERVATION", 261, 270], ["otherwise", "OBSERVATION_MODIFIER", 288, 297], ["unexplained", "OBSERVATION_MODIFIER", 298, 309], ["intracranial", "ANATOMY", 310, 322], ["hemorrhage", "OBSERVATION", 323, 333]]], ["Diagnosis had been confirmed by detection of coronavirus 2 (CoV-2) viral nuclei acid in nasopharyngeal swab specimens by the use of Real-Time Reverse-Transcriptase-Polymerase Chain Reaction assay.", [["nasopharyngeal swab specimens", "ANATOMY", 88, 117], ["coronavirus 2", "ORGANISM", 45, 58], ["CoV-2", "ORGANISM", 60, 65], ["nasopharyngeal swab specimens", "ORGANISM_SUBSTANCE", 88, 117], ["coronavirus", "PROBLEM", 45, 56], ["CoV", "TEST", 60, 63], ["viral nuclei acid", "TEST", 67, 84], ["nasopharyngeal swab specimens", "TEST", 88, 117], ["nasopharyngeal", "ANATOMY", 88, 102]]], ["Both were admitted to the Intensive Care Unit (ICU) because of severe acute respiratory syndrome (SARS) requiring artificial mechanical ventilation.", [["acute respiratory syndrome", "DISEASE", 70, 96], ["SARS", "DISEASE", 98, 102], ["severe acute respiratory syndrome", "PROBLEM", 63, 96], ["SARS", "PROBLEM", 98, 102], ["artificial mechanical ventilation", "TREATMENT", 114, 147], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["respiratory syndrome", "OBSERVATION", 76, 96], ["mechanical ventilation", "OBSERVATION", 125, 147]]], ["At the time of admission to the ICU, the two patients had a normal neurological examination.", [["neurological", "ANATOMY", 67, 79], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["With the exception of one patient (case 2) with controlled arterial hypertension, there were no risk factors for ICH such as hypertension, alcohol use, cigarette smoking, or use of any oral anticoagulants and/or antiplatelet agents.", [["arterial", "ANATOMY", 59, 67], ["oral", "ANATOMY", 185, 189], ["arterial hypertension", "DISEASE", 59, 80], ["ICH", "DISEASE", 113, 116], ["hypertension", "DISEASE", 125, 137], ["alcohol", "CHEMICAL", 139, 146], ["alcohol", "CHEMICAL", 139, 146], ["patient", "ORGANISM", 26, 33], ["arterial", "MULTI-TISSUE_STRUCTURE", 59, 67], ["alcohol", "SIMPLE_CHEMICAL", 139, 146], ["oral", "ORGANISM_SUBDIVISION", 185, 189], ["antiplatelet agents", "SIMPLE_CHEMICAL", 212, 231], ["patient", "SPECIES", 26, 33], ["controlled arterial hypertension", "PROBLEM", 48, 80], ["risk factors", "PROBLEM", 96, 108], ["ICH", "PROBLEM", 113, 116], ["hypertension", "PROBLEM", 125, 137], ["any oral anticoagulants", "TREATMENT", 181, 204], ["antiplatelet agents", "TREATMENT", 212, 231], ["arterial", "ANATOMY", 59, 67], ["hypertension", "OBSERVATION", 68, 80], ["no", "UNCERTAINTY", 93, 95]]], ["During their hospital stay, blood pressure remained below 140/90 mmHg.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["blood pressure", "TEST", 28, 42]]], ["There was no evidence of abnormal heart rhythms on ECG monitoring.", [["heart", "ANATOMY", 34, 39], ["abnormal heart rhythms", "DISEASE", 25, 47], ["heart", "ORGAN", 34, 39], ["abnormal heart rhythms", "PROBLEM", 25, 47], ["ECG monitoring", "TEST", 51, 65], ["no evidence of", "UNCERTAINTY", 10, 24], ["abnormal", "OBSERVATION_MODIFIER", 25, 33], ["heart", "ANATOMY", 34, 39], ["rhythms", "OBSERVATION", 40, 47]]], ["Decreased level of consciousness, off sedation, prompted CT.", [["Decreased level of consciousness", "PROBLEM", 0, 32], ["sedation", "TREATMENT", 38, 46], ["CT", "TEST", 57, 59]]], ["Unenhanced CT showed parenchymal brain hemorrhages in both of them.", [["parenchymal brain", "ANATOMY", 21, 38], ["brain hemorrhages", "DISEASE", 33, 50], ["brain", "ORGAN", 33, 38], ["Unenhanced CT", "TEST", 0, 13], ["parenchymal brain hemorrhages", "PROBLEM", 21, 50], ["parenchymal", "ANATOMY_MODIFIER", 21, 32], ["brain", "ANATOMY", 33, 38], ["hemorrhages", "OBSERVATION", 39, 50], ["both", "ANATOMY_MODIFIER", 54, 58]]], ["Further neuroimaging investigation was not possible because of the poor clinical status of the patients.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["Further neuroimaging investigation", "TEST", 0, 34]]], ["Although, venous thrombosis could not be entirely excluded, there was no evidence of hyperdense veins, dural sinus or sinus distention to suggest acute venous thrombosis in any of the ICH cases.", [["venous", "ANATOMY", 10, 16], ["hyperdense veins", "ANATOMY", 85, 101], ["dural sinus", "ANATOMY", 103, 114], ["sinus", "ANATOMY", 118, 123], ["venous", "ANATOMY", 152, 158], ["venous thrombosis", "DISEASE", 10, 27], ["dural sinus or sinus distention", "DISEASE", 103, 134], ["acute venous thrombosis", "DISEASE", 146, 169], ["ICH", "DISEASE", 184, 187], ["venous", "MULTI-TISSUE_STRUCTURE", 10, 16], ["hyperdense veins", "MULTI-TISSUE_STRUCTURE", 85, 101], ["dural sinus", "MULTI-TISSUE_STRUCTURE", 103, 114], ["sinus", "MULTI-TISSUE_STRUCTURE", 118, 123], ["venous", "PATHOLOGICAL_FORMATION", 152, 158], ["venous thrombosis", "PROBLEM", 10, 27], ["hyperdense veins", "PROBLEM", 85, 101], ["dural sinus or sinus distention", "PROBLEM", 103, 134], ["acute venous thrombosis", "PROBLEM", 146, 169], ["venous", "ANATOMY", 10, 16], ["thrombosis", "OBSERVATION", 17, 27], ["could not be entirely excluded", "UNCERTAINTY", 28, 58], ["no evidence of", "UNCERTAINTY", 70, 84], ["hyperdense", "OBSERVATION", 85, 95], ["veins", "ANATOMY", 96, 101], ["dural sinus", "ANATOMY", 103, 114], ["sinus", "ANATOMY", 118, 123], ["distention", "OBSERVATION", 124, 134], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["venous", "ANATOMY", 152, 158], ["thrombosis", "OBSERVATION", 159, 169], ["ICH", "OBSERVATION", 184, 187]]], ["Hemorrhages were located in the head of the right caudate nucleus in Case 1, and in the left temporal lobe in Case 2; both hemorrhages showed extension into the ventricular system (Fig. 1).", [["head", "ANATOMY", 32, 36], ["right caudate nucleus", "ANATOMY", 44, 65], ["left temporal lobe", "ANATOMY", 88, 106], ["ventricular system", "ANATOMY", 161, 179], ["Hemorrhages", "DISEASE", 0, 11], ["hemorrhages", "DISEASE", 123, 134], ["head", "ORGANISM_SUBDIVISION", 32, 36], ["caudate nucleus", "MULTI-TISSUE_STRUCTURE", 50, 65], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 93, 106], ["ventricular system", "MULTI-TISSUE_STRUCTURE", 161, 179], ["Hemorrhages", "PROBLEM", 0, 11], ["both hemorrhages", "PROBLEM", 118, 134], ["extension into the ventricular system", "PROBLEM", 142, 179], ["head", "ANATOMY_MODIFIER", 32, 36], ["right", "ANATOMY_MODIFIER", 44, 49], ["caudate nucleus", "ANATOMY", 50, 65], ["left temporal lobe", "ANATOMY", 88, 106], ["hemorrhages", "OBSERVATION", 123, 134], ["ventricular system", "ANATOMY", 161, 179]]], ["Blood cells counts, coagulation parameters, glomerular filtration rate, and liver function tests were within normal limits before and after the bleeding episodes.", [["Blood cells", "ANATOMY", 0, 11], ["glomerular", "ANATOMY", 44, 54], ["liver", "ANATOMY", 76, 81], ["bleeding", "DISEASE", 144, 152], ["Blood cells", "CELL", 0, 11], ["glomerular", "TISSUE", 44, 54], ["liver", "ORGAN", 76, 81], ["Blood cells counts", "TEST", 0, 18], ["coagulation parameters", "TEST", 20, 42], ["glomerular filtration rate", "TEST", 44, 70], ["liver function tests", "TEST", 76, 96], ["the bleeding episodes", "PROBLEM", 140, 161], ["liver", "ANATOMY", 76, 81], ["bleeding", "OBSERVATION", 144, 152]]], ["In contrast, D-dimer, C reactive protein and ferritin levels were elevated in both cases.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 13, 20], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 22, 40], ["ferritin", "GENE_OR_GENE_PRODUCT", 45, 53], ["D-dimer", "PROTEIN", 13, 20], ["C reactive protein", "PROTEIN", 22, 40], ["ferritin", "PROTEIN", 45, 53], ["D-dimer", "TEST", 13, 20], ["C reactive protein", "TEST", 22, 40], ["ferritin levels", "TEST", 45, 60], ["reactive", "OBSERVATION_MODIFIER", 24, 32]]], ["With the exception of subcutaneous enoxaparin (40 mg/day), the patients had not been receiving medications known to increase the risk of bleeding.", [["subcutaneous", "ANATOMY", 22, 34], ["enoxaparin", "CHEMICAL", 35, 45], ["bleeding", "DISEASE", 137, 145], ["enoxaparin", "CHEMICAL", 35, 45], ["enoxaparin", "SIMPLE_CHEMICAL", 35, 45], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["subcutaneous enoxaparin", "TREATMENT", 22, 45], ["medications", "TREATMENT", 95, 106], ["bleeding", "PROBLEM", 137, 145], ["subcutaneous", "ANATOMY", 22, 34], ["enoxaparin", "OBSERVATION", 35, 45], ["bleeding", "OBSERVATION", 137, 145]]], ["Patients died 24 and 48 h after the CT scan, respectively.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the CT scan", "TEST", 32, 43]]], ["Autopsies were not performed.Clinical/Scientific Note.Several other viral infections, including dengue virus, West Nile virus, herpes simplex, and VZV infections, have been associated with ICH.", [["viral infections", "DISEASE", 68, 84], ["dengue virus", "DISEASE", 96, 108], ["West Nile virus", "DISEASE", 110, 125], ["herpes simplex", "DISEASE", 127, 141], ["VZV infections", "DISEASE", 147, 161], ["ICH", "DISEASE", 189, 192], ["dengue virus", "ORGANISM", 96, 108], ["West Nile virus", "ORGANISM", 110, 125], ["herpes simplex", "ORGANISM", 127, 141], ["VZV", "ORGANISM", 147, 150], ["dengue virus", "SPECIES", 96, 108], ["West Nile virus", "SPECIES", 110, 125], ["herpes simplex", "SPECIES", 127, 141], ["VZV", "SPECIES", 147, 150], ["dengue virus", "SPECIES", 96, 108], ["West Nile virus", "SPECIES", 110, 125], ["VZV", "SPECIES", 147, 150], ["Autopsies", "TEST", 0, 9], ["Several other viral infections", "PROBLEM", 54, 84], ["dengue virus", "PROBLEM", 96, 108], ["West Nile virus", "PROBLEM", 110, 125], ["herpes simplex", "PROBLEM", 127, 141], ["VZV infections", "PROBLEM", 147, 161], ["ICH", "PROBLEM", 189, 192], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["infections", "OBSERVATION", 74, 84], ["dengue virus", "OBSERVATION", 96, 108], ["herpes simplex", "OBSERVATION", 127, 141], ["VZV infections", "OBSERVATION", 147, 161], ["ICH", "OBSERVATION", 189, 192]]], ["The mechanism appears to be multifactorial with vasculitis, coagulopathy, and platelet dysfunction.", [["platelet", "ANATOMY", 78, 86], ["vasculitis", "DISEASE", 48, 58], ["coagulopathy", "DISEASE", 60, 72], ["platelet dysfunction", "DISEASE", 78, 98], ["platelet", "CELL", 78, 86], ["vasculitis", "PROBLEM", 48, 58], ["coagulopathy", "PROBLEM", 60, 72], ["platelet dysfunction", "PROBLEM", 78, 98], ["appears to be", "UNCERTAINTY", 14, 27], ["multifactorial", "OBSERVATION_MODIFIER", 28, 42], ["vasculitis", "OBSERVATION", 48, 58], ["coagulopathy", "OBSERVATION", 60, 72], ["platelet dysfunction", "OBSERVATION", 78, 98]]], ["Pathogenic mechanisms involved in SARS-CoV2 \u2013 associated hemorrhagic stroke have not been elucidated (8).", [["SARS", "DISEASE", 34, 38], ["hemorrhagic stroke", "DISEASE", 57, 75], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 34, 43], ["Pathogenic mechanisms", "PROBLEM", 0, 21], ["SARS", "PROBLEM", 34, 38], ["hemorrhagic stroke", "PROBLEM", 57, 75], ["hemorrhagic", "OBSERVATION_MODIFIER", 57, 68], ["stroke", "OBSERVATION", 69, 75]]], ["It is plausible to assume that the affinity of the virus (SARS-CoV-2) for ACE2 receptors (expressed in endothelial and arterial smooth muscle cells in the brain) allows the virus to damage intracranial arteries, causing vessel wall rupture and hemorrhages [6].", [["endothelial", "ANATOMY", 103, 114], ["arterial smooth muscle cells", "ANATOMY", 119, 147], ["brain", "ANATOMY", 155, 160], ["intracranial arteries", "ANATOMY", 189, 210], ["vessel wall", "ANATOMY", 220, 231], ["vessel wall rupture", "DISEASE", 220, 239], ["hemorrhages", "DISEASE", 244, 255], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 74, 88], ["endothelial", "CELL", 103, 114], ["arterial smooth muscle cells", "CELL", 119, 147], ["brain", "ORGAN", 155, 160], ["intracranial arteries", "MULTI-TISSUE_STRUCTURE", 189, 210], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 220, 231], ["ACE2 receptors", "PROTEIN", 74, 88], ["endothelial and arterial smooth muscle cells", "CELL_TYPE", 103, 147], ["the virus", "PROBLEM", 47, 56], ["CoV", "TEST", 63, 66], ["ACE2 receptors", "PROBLEM", 74, 88], ["the virus to damage intracranial arteries", "PROBLEM", 169, 210], ["vessel wall rupture", "PROBLEM", 220, 239], ["hemorrhages", "PROBLEM", 244, 255], ["arterial", "ANATOMY_MODIFIER", 119, 127], ["smooth muscle", "ANATOMY", 128, 141], ["brain", "ANATOMY", 155, 160], ["intracranial arteries", "ANATOMY", 189, 210], ["vessel", "ANATOMY", 220, 226], ["wall", "ANATOMY_MODIFIER", 227, 231], ["rupture", "OBSERVATION", 232, 239], ["hemorrhages", "OBSERVATION", 244, 255]]], ["It is also possible that the \u201ccytokine storm\u201d that accompanies this disorder could promote hemorrhagic stroke, as suggested in a SARS-CoV2 patient who developed an acute necrotizing encephalopathy associated with late parenchymal brain hemorrhages [7].Clinical/Scientific Note.While the two patients reported here developed otherwise unexplained intracranial hemorrhages, we cannot completely rule out the presence of competing etiologies since CT angiography, a brain MRI, or MRA of intracranial vessels were not performed due to the poor status of the patients.", [["parenchymal brain", "ANATOMY", 218, 235], ["intracranial", "ANATOMY", 346, 358], ["brain", "ANATOMY", 463, 468], ["intracranial vessels", "ANATOMY", 484, 504], ["hemorrhagic stroke", "DISEASE", 91, 109], ["SARS-CoV2", "DISEASE", 129, 138], ["encephalopathy", "DISEASE", 182, 196], ["parenchymal brain hemorrhages", "DISEASE", 218, 247], ["intracranial hemorrhages", "DISEASE", 346, 370], ["patient", "ORGANISM", 139, 146], ["brain", "ORGAN", 230, 235], ["patients", "ORGANISM", 291, 299], ["intracranial hemorrhages", "PATHOLOGICAL_FORMATION", 346, 370], ["brain", "ORGAN", 463, 468], ["intracranial vessels", "MULTI-TISSUE_STRUCTURE", 484, 504], ["patients", "ORGANISM", 554, 562], ["cytokine", "PROTEIN", 30, 38], ["patient", "SPECIES", 139, 146], ["patients", "SPECIES", 291, 299], ["patients", "SPECIES", 554, 562], ["this disorder", "PROBLEM", 63, 76], ["hemorrhagic stroke", "PROBLEM", 91, 109], ["an acute necrotizing encephalopathy", "PROBLEM", 161, 196], ["late parenchymal brain hemorrhages", "PROBLEM", 213, 247], ["otherwise unexplained intracranial hemorrhages", "PROBLEM", 324, 370], ["CT angiography", "TEST", 445, 459], ["a brain MRI", "TEST", 461, 472], ["MRA of intracranial vessels", "TEST", 477, 504], ["also possible", "UNCERTAINTY", 6, 19], ["hemorrhagic", "OBSERVATION_MODIFIER", 91, 102], ["stroke", "OBSERVATION", 103, 109], ["acute", "OBSERVATION_MODIFIER", 164, 169], ["necrotizing", "OBSERVATION_MODIFIER", 170, 181], ["encephalopathy", "OBSERVATION", 182, 196], ["late", "OBSERVATION_MODIFIER", 213, 217], ["parenchymal", "ANATOMY_MODIFIER", 218, 229], ["brain", "ANATOMY", 230, 235], ["hemorrhages", "OBSERVATION", 236, 247], ["intracranial", "ANATOMY", 346, 358], ["hemorrhages", "OBSERVATION", 359, 370], ["intracranial vessels", "ANATOMY", 484, 504]]], ["Hemorrhages in cerebral lobes and in the head of the caudate nucleus are often related to arterial hypertension, but may also be caused by the rupture of a cavernous angioma, a small arteriovenous malformation or an intracranial aneurysm, which cannot be detected with an unenhanced CT only.", [["cerebral lobes", "ANATOMY", 15, 29], ["head", "ANATOMY", 41, 45], ["caudate nucleus", "ANATOMY", 53, 68], ["arterial", "ANATOMY", 90, 98], ["cavernous angioma", "ANATOMY", 156, 173], ["small arteriovenous malformation", "ANATOMY", 177, 209], ["intracranial aneurysm", "ANATOMY", 216, 237], ["Hemorrhages", "DISEASE", 0, 11], ["arterial hypertension", "DISEASE", 90, 111], ["cavernous angioma", "DISEASE", 156, 173], ["arteriovenous malformation", "DISEASE", 183, 209], ["intracranial aneurysm", "DISEASE", 216, 237], ["cerebral lobes", "MULTI-TISSUE_STRUCTURE", 15, 29], ["head", "ORGAN", 41, 45], ["caudate nucleus", "MULTI-TISSUE_STRUCTURE", 53, 68], ["arterial", "MULTI-TISSUE_STRUCTURE", 90, 98], ["cavernous angioma", "PATHOLOGICAL_FORMATION", 156, 173], ["arteriovenous malformation", "PATHOLOGICAL_FORMATION", 183, 209], ["intracranial aneurysm", "PATHOLOGICAL_FORMATION", 216, 237], ["Hemorrhages in cerebral lobes", "PROBLEM", 0, 29], ["arterial hypertension", "PROBLEM", 90, 111], ["the rupture", "PROBLEM", 139, 150], ["a cavernous angioma", "PROBLEM", 154, 173], ["a small arteriovenous malformation", "PROBLEM", 175, 209], ["an intracranial aneurysm", "PROBLEM", 213, 237], ["an unenhanced CT", "TEST", 269, 285], ["cerebral lobes", "ANATOMY", 15, 29], ["head", "ANATOMY_MODIFIER", 41, 45], ["caudate nucleus", "ANATOMY", 53, 68], ["arterial", "ANATOMY", 90, 98], ["hypertension", "OBSERVATION", 99, 111], ["may also be", "UNCERTAINTY", 117, 128], ["rupture", "OBSERVATION", 143, 150], ["cavernous", "ANATOMY", 156, 165], ["angioma", "OBSERVATION", 166, 173], ["small", "OBSERVATION_MODIFIER", 177, 182], ["arteriovenous", "OBSERVATION_MODIFIER", 183, 196], ["malformation", "OBSERVATION", 197, 209], ["intracranial", "OBSERVATION_MODIFIER", 216, 228], ["aneurysm", "OBSERVATION", 229, 237]]], ["However, both hemorrhages occurred in the setting of severe (and late) SARS-CoV2 disease, in the absence of a sudden increase in blood pressure or other risk factors that may explain the bleeding.", [["blood", "ANATOMY", 129, 134], ["hemorrhages", "DISEASE", 14, 25], ["SARS-CoV2 disease", "DISEASE", 71, 88], ["sudden increase in blood pressure", "DISEASE", 110, 143], ["bleeding", "DISEASE", 187, 195], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["both hemorrhages", "PROBLEM", 9, 25], ["severe (and late) SARS-CoV2 disease", "PROBLEM", 53, 88], ["a sudden increase in blood pressure", "PROBLEM", 108, 143], ["other risk factors", "PROBLEM", 147, 165], ["the bleeding", "PROBLEM", 183, 195], ["both", "OBSERVATION_MODIFIER", 9, 13], ["hemorrhages", "OBSERVATION", 14, 25], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["CoV2 disease", "OBSERVATION", 76, 88], ["increase", "OBSERVATION_MODIFIER", 117, 125], ["blood pressure", "OBSERVATION", 129, 143], ["bleeding", "OBSERVATION", 187, 195]]], ["Further studies are needed to get more insights on the causal relationship between SARS-CoV2 infections and hemorrhagic strokes.Clinical/Scientific Note.", [["SARS-CoV2 infections", "DISEASE", 83, 103], ["hemorrhagic strokes", "DISEASE", 108, 127], ["Further studies", "TEST", 0, 15], ["SARS", "PROBLEM", 83, 87], ["CoV2 infections", "PROBLEM", 88, 103], ["hemorrhagic strokes", "PROBLEM", 108, 127], ["CoV2", "ANATOMY", 88, 92], ["infections", "OBSERVATION", 93, 103], ["hemorrhagic", "OBSERVATION_MODIFIER", 108, 119], ["strokes", "OBSERVATION", 120, 127]]]], "PMC7304725": [["IntroductionVehicle Routing Problem (VRP) is an important combinatorial optimization problem in which the goal is to find the optimal setting of routes for a fleet of vehicles which should deliver some goods from a given origin (depot) to a given set of destinations (customers) [1].", [["a fleet of vehicles", "TREATMENT", 156, 175]]], ["There exist the exact algorithms able to find optimal solutions in a reasonable time for relatively small instances, but generally, those problems are computationally difficult and the state-of-the-art approaches applied in practice are based on heuristics (constructive, improvement and composite) and metaheuristics [4, 5].IntroductionRecently, we can observe a noticeable progress in the development of quantum computing algorithms and it turned out that they may be particularly successful in solving combinatorial optimization problems, such as TSP and VRP [6].", [["TSP", "GENE_OR_GENE_PRODUCT", 550, 553], ["TSP", "PROTEIN", 550, 553], ["the-art approaches", "TREATMENT", 194, 212], ["quantum computing algorithms", "TEST", 406, 434], ["solving combinatorial optimization problems", "TREATMENT", 497, 540], ["small", "OBSERVATION_MODIFIER", 100, 105], ["instances", "OBSERVATION", 106, 115]]], ["The first quantum algorithms for TSP and VRP already exist and in the scientific literature we can find algorithms which can be run on gate-based quantum computers [7\u201317] as well as quantum annealing algorithms which can be run on adiabatic quantum computers [18\u201324].IntroductionIn this paper, we present new methods for solving VRP and its more practical variant, CVRP (Capacitated Vehicle Routing Problem), in which all vehicles have a limited capacity.", [["TSP", "PROTEIN", 33, 36], ["TSP and VRP", "TREATMENT", 33, 44], ["quantum annealing algorithms", "TREATMENT", 182, 210], ["solving VRP", "TREATMENT", 321, 332], ["CVRP (Capacitated Vehicle", "TREATMENT", 365, 390]]], ["The algorithms introduced in this paper are based on quantum annealing, because due to the number of available qubits, those algorithms have currently a greater chance to give any practical improvement over classical algorithms.IntroductionWe developed and present four algorithms: Full QUBO Solver (FQS), Average Partition Solver (AVS), DBSCAN Solver (DBSS) and Solution Partitioning Solver (SPS).", [["The algorithms", "TREATMENT", 0, 14], ["quantum annealing", "TREATMENT", 53, 70], ["IntroductionWe", "TREATMENT", 228, 242], ["Full QUBO Solver (FQS", "TREATMENT", 282, 303], ["Average Partition Solver (AVS), DBSCAN Solver (DBSS)", "TREATMENT", 306, 358]]], ["The first and second one are designed only for solving VRP, DBSCAN solver can also solve CVRP if capacities of all vehicles are equal, SPS is able to solve CVRP with arbitrary capacities.", [["solving VRP", "TREATMENT", 47, 58], ["DBSCAN solver", "TREATMENT", 60, 73]]], ["It is also important to add that the last two methods are hybrid algorithms and they contain important components which should be run on classical processors.IntroductionIn order to evaluate different algorithms for solving VRP using quantum annealing, we carried out series of experiments using D-Wave\u2019s Leap framework [25] which contains implementations of built-in solvers and allows to implement new solvers.", [["VRP", "CHEMICAL", 224, 227], ["hybrid algorithms", "TREATMENT", 58, 75], ["solving VRP", "TREATMENT", 216, 227], ["quantum annealing", "TREATMENT", 234, 251]]], ["We used QBSolv [26] run on quantum processing unit (QPU) and simulating quantum annealing on classical processors (CPU), as well as hybrid solver [27] run on both, QPU and CPU.IntroductionBeside quantum algorithms, we also wanted to test and compare several well-known classical algorithms which gave good results in previous studies.", [["quantum processing unit", "TREATMENT", 27, 50], ["simulating quantum annealing on classical processors", "TREATMENT", 61, 113], ["previous studies", "TEST", 317, 333]]], ["Based on a comprehensive literature review [5] and further analysis, we selected 4 metaheuristics: based on simulated annealing [28], bee algorithm [29], evolutionary annealing [30] and recursive DBSCAN with simulated annealing [31], respectively.IntroductionIn order to reliably compare different algorithms, we conducted experiments on well-established benchmark datasets [32, 33], as well as on datasets created by us, with realistic road networks (taken from the OpenStreetMap service) and artificially generated orders.IntroductionThe rest of the paper is organized as follows: in Sect.", [["road networks", "MULTI-TISSUE_STRUCTURE", 437, 450], ["further analysis", "TEST", 51, 67], ["bee algorithm", "TEST", 134, 147], ["evolutionary annealing", "TEST", 154, 176], ["recursive DBSCAN", "TEST", 186, 202]]], ["2, we describe in details all the quantum annealing solvers which we used in our experiments.", [["the quantum annealing solvers", "TREATMENT", 30, 59], ["quantum annealing", "OBSERVATION", 34, 51]]], ["Section 5 outlines possible future research directions and concludes the paper.Notation and Assumptions ::: CVRP Solvers Based on Quantum AnnealingWe assume that in each instance of VRP (or CVRP) we have a road network represented as a directed connected graph with vertices and edges.", [["VRP", "PROBLEM", 182, 185], ["a directed connected graph with vertices and edges", "TREATMENT", 234, 284]]], ["We also assume that the depots and destinations to which the orders of customers should be delivered are always located in vertices of the road network (in the case of benchmark instances and artificial networks, it may be even assumed that the road network is defined by locations of orders, while in the case of realistic road networks, real locations of orders are usually close enough to vertices determining the road network graph).Notation and Assumptions ::: CVRP Solvers Based on Quantum AnnealingLet M be the number of available vehicles and N the number of orders.", [["depots", "TISSUE", 24, 30], ["road network", "MULTI-TISSUE_STRUCTURE", 139, 151], ["road network", "MULTI-TISSUE_STRUCTURE", 245, 257], ["road networks", "MULTI-TISSUE_STRUCTURE", 324, 337], ["road network", "MULTI-TISSUE_STRUCTURE", 417, 429]]]], "PMC7168007": [["INTRODUCTIONThe cystatin (Csn) superfamily of proteins are natural cysteine proteinase (CysP) inhibitors; however, their rate of inhibition of known CysP varies greatly among the different members.", [["cysteine", "CHEMICAL", 67, 75], ["cystatin", "GENE_OR_GENE_PRODUCT", 16, 24], ["Csn", "GENE_OR_GENE_PRODUCT", 26, 29], ["natural cysteine proteinase", "GENE_OR_GENE_PRODUCT", 59, 86], ["CysP", "GENE_OR_GENE_PRODUCT", 88, 92], ["CysP", "GENE_OR_GENE_PRODUCT", 149, 153], ["cystatin (Csn) superfamily", "PROTEIN", 16, 42], ["CysP", "PROTEIN", 149, 153], ["cystatin (Csn) superfamily of proteins", "TREATMENT", 16, 54], ["natural cysteine proteinase (CysP) inhibitors", "TREATMENT", 59, 104], ["known CysP varies", "PROBLEM", 143, 160]]], ["These variations may allow for a more vast defense mechanism against diseases of bacterial and/or viral origin.", [["diseases", "PROBLEM", 69, 77], ["bacterial and/or viral origin", "PROBLEM", 81, 110], ["bacterial", "OBSERVATION_MODIFIER", 81, 90], ["viral origin", "OBSERVATION", 98, 110]]], ["Several Csns have been shown to possess viral inhibitory properties.", [["Csns", "CHEMICAL", 8, 12], ["Csns", "GENE_OR_GENE_PRODUCT", 8, 12], ["Csns", "PROTEIN", 8, 12], ["viral inhibitory", "OBSERVATION", 40, 56]]], ["These include chicken egg white (CEW) Csn and oryzacystatin (rice Csn) and the ability to inhibit poliovirus replication.", [["oryzacystatin", "CHEMICAL", 46, 59], ["chicken", "ORGANISM", 14, 21], ["egg", "ORGANISM_SUBDIVISION", 22, 25], ["white (CEW) Csn", "GENE_OR_GENE_PRODUCT", 26, 41], ["oryzacystatin", "GENE_OR_GENE_PRODUCT", 46, 59], ["rice Csn", "ORGANISM", 61, 69], ["poliovirus", "ORGANISM", 98, 108], ["chicken", "SPECIES", 14, 21], ["rice", "SPECIES", 61, 65], ["chicken", "SPECIES", 14, 21], ["rice", "SPECIES", 61, 65], ["poliovirus", "SPECIES", 98, 108], ["chicken egg white (CEW)", "TREATMENT", 14, 37], ["oryzacystatin (rice Csn", "TREATMENT", 46, 69], ["poliovirus replication", "TREATMENT", 98, 120]]], ["1, 2 Oryzacystatin has also been shown to inhibit herpes simplex virus Type 1 (HSV\u20101) in vitro and in vivo.", [["Oryzacystatin", "CHEMICAL", 5, 18], ["herpes simplex virus", "DISEASE", 50, 70], ["Oryzacystatin", "CHEMICAL", 5, 18], ["Oryzacystatin", "GENE_OR_GENE_PRODUCT", 5, 18], ["herpes simplex virus Type 1", "ORGANISM", 50, 77], ["HSV\u20101", "ORGANISM", 79, 84], ["herpes simplex virus", "SPECIES", 50, 70], ["herpes simplex virus Type 1", "SPECIES", 50, 77], ["HSV", "SPECIES", 79, 82], ["herpes simplex virus Type", "PROBLEM", 50, 75]]], ["3 Human cystatin C (CsnC) has the ability to inhibit HSV\u20101 and coronavirus replication.", [["CsnC", "CHEMICAL", 20, 24], ["Human", "ORGANISM", 2, 7], ["cystatin C", "GENE_OR_GENE_PRODUCT", 8, 18], ["CsnC", "GENE_OR_GENE_PRODUCT", 20, 24], ["HSV\u20101", "ORGANISM", 53, 58], ["coronavirus", "ORGANISM", 63, 74], ["Human cystatin C", "PROTEIN", 2, 18], ["CsnC", "PROTEIN", 20, 24], ["Human", "SPECIES", 2, 7], ["HSV\u20101", "SPECIES", 53, 58], ["Human cystatin C (CsnC)", "TREATMENT", 2, 25], ["HSV\u2010", "TREATMENT", 53, 57], ["coronavirus replication", "TREATMENT", 63, 86]]], ["4, 5 Human whole saliva and salivary fractions containing CsnSN have been shown to inhibit HSV\u20101 replication.", [["salivary fractions", "ANATOMY", 28, 46], ["CsnSN", "CHEMICAL", 58, 63], ["CsnSN", "CHEMICAL", 58, 63], ["Human", "ORGANISM", 5, 10], ["saliva", "ORGANISM_SUBSTANCE", 17, 23], ["salivary fractions", "ORGANISM_SUBSTANCE", 28, 46], ["CsnSN", "SIMPLE_CHEMICAL", 58, 63], ["HSV\u20101", "ORGANISM", 91, 96], ["CsnSN", "PROTEIN", 58, 63], ["Human", "SPECIES", 5, 10], ["Human", "SPECIES", 5, 10], ["HSV\u20101", "SPECIES", 91, 96], ["5 Human whole saliva and salivary fractions", "TREATMENT", 3, 46], ["CsnSN", "TREATMENT", 58, 63]]], ["6, 7 Thus we are interested in determining the mechanism of inhibition of HSV\u20101 by CsnC and CsnSN.", [["HSV\u20101", "GENE_OR_GENE_PRODUCT", 74, 79], ["CsnC", "GENE_OR_GENE_PRODUCT", 83, 87], ["CsnSN", "GENE_OR_GENE_PRODUCT", 92, 97], ["CsnC", "PROTEIN", 83, 87], ["CsnSN", "PROTEIN", 92, 97], ["HSV\u20101", "SPECIES", 74, 79], ["HSV\u2010", "TREATMENT", 74, 78]]], ["We have shown that rCsnSN, and confirmed that rCsnC, reduce the viral yield of HSV\u20101 when these proteins are added exogenously to CV\u20101 cells at the start of HSV\u20101 infection.", [["CV\u20101 cells", "ANATOMY", 130, 140], ["infection", "DISEASE", 163, 172], ["rCsnSN", "GENE_OR_GENE_PRODUCT", 19, 25], ["rCsnC", "GENE_OR_GENE_PRODUCT", 46, 51], ["HSV\u20101", "ORGANISM", 79, 84], ["CV\u20101 cells", "CELL", 130, 140], ["HSV\u20101", "ORGANISM", 157, 162], ["rCsnSN", "PROTEIN", 19, 25], ["rCsnC", "PROTEIN", 46, 51], ["HSV\u20101", "SPECIES", 79, 84], ["HSV\u20101", "SPECIES", 157, 162], ["HSV", "PROBLEM", 79, 82], ["these proteins", "TEST", 90, 104], ["HSV\u20101 infection", "PROBLEM", 157, 172], ["infection", "OBSERVATION", 163, 172]]], ["8 It is thought that the Csns may enter the cells after the cell membranes become permeable as a result of the viral infection 4 and are thus able to inhibit viral and/or host cell CysP necessary for the viral replication.", [["cells", "ANATOMY", 44, 49], ["cell membranes", "ANATOMY", 60, 74], ["cell", "ANATOMY", 176, 180], ["infection", "DISEASE", 117, 126], ["Csns", "GENE_OR_GENE_PRODUCT", 25, 29], ["cells", "CELL", 44, 49], ["cell membranes", "CELLULAR_COMPONENT", 60, 74], ["host cell", "CELL", 171, 180], ["CysP", "GENE_OR_GENE_PRODUCT", 181, 185], ["Csns", "PROTEIN", 25, 29], ["CysP", "PROTEIN", 181, 185], ["the cell membranes", "TREATMENT", 56, 74], ["the viral infection", "PROBLEM", 107, 126], ["viral and/or host cell CysP", "PROBLEM", 158, 185], ["the viral replication", "TREATMENT", 200, 221], ["viral", "OBSERVATION_MODIFIER", 111, 116], ["infection", "OBSERVATION", 117, 126], ["host cell", "OBSERVATION", 171, 180], ["viral replication", "OBSERVATION", 204, 221]]], ["Poliovirus replication is inhibited by CEW Csn through a CysP necessary for polyprotein processing and essential for viral replication and propagation.", [["Poliovirus", "ORGANISM", 0, 10], ["CEW Csn", "GENE_OR_GENE_PRODUCT", 39, 46], ["CysP", "GENE_OR_GENE_PRODUCT", 57, 61], ["CEW Csn", "PROTEIN", 39, 46], ["CysP", "PROTEIN", 57, 61], ["Poliovirus", "SPECIES", 0, 10], ["Poliovirus replication", "TREATMENT", 0, 22], ["a CysP", "TREATMENT", 55, 61], ["polyprotein processing", "TREATMENT", 76, 98], ["viral replication", "TREATMENT", 117, 134]]], ["1 Also, a serine proteinase encoded by HSV\u20101 has been identified and found to be necessary for the packaging of the mature virions.", [["virions", "ANATOMY", 123, 130], ["serine", "CHEMICAL", 10, 16], ["HSV\u20101", "ORGANISM", 39, 44], ["serine proteinase", "PROTEIN", 10, 27], ["HSV\u20101", "PROTEIN", 39, 44], ["HSV\u20101", "SPECIES", 39, 44], ["a serine proteinase", "TEST", 8, 27], ["HSV", "TEST", 39, 42], ["mature", "OBSERVATION_MODIFIER", 116, 122], ["virions", "OBSERVATION", 123, 130]]], ["9 Therefore, it is plausible that CsnC and/or CsnSN inhibit HSV\u20101 replication through a CysP.INTRODUCTIONWe hypothesize that if Csn is produced in large amounts by the cells prior to or during the viral infection, then it may more effectively inhibit HSV\u20101 replication.", [["cells", "ANATOMY", 168, 173], ["CsnSN", "CHEMICAL", 46, 51], ["Csn", "CHEMICAL", 128, 131], ["infection", "DISEASE", 203, 212], ["CsnC", "GENE_OR_GENE_PRODUCT", 34, 38], ["CsnSN", "GENE_OR_GENE_PRODUCT", 46, 51], ["HSV\u20101", "ORGANISM", 60, 65], ["Csn", "GENE_OR_GENE_PRODUCT", 128, 131], ["cells", "CELL", 168, 173], ["HSV\u20101", "ORGANISM", 251, 256], ["CsnC", "PROTEIN", 34, 38], ["Csn", "PROTEIN", 128, 131], ["HSV\u20101", "SPECIES", 60, 65], ["HSV\u20101", "SPECIES", 251, 256], ["CsnSN", "TREATMENT", 46, 51], ["HSV", "PROBLEM", 60, 63], ["the viral infection", "PROBLEM", 193, 212], ["infection", "OBSERVATION", 203, 212]]], ["Our hypothesis is supported by a recent study that showed that the introduction of the corn Csn gene into rice plants resulted in high levels of expression of the corn Csn mRNA and protein.", [["Csn", "GENE_OR_GENE_PRODUCT", 92, 95], ["rice plants", "ORGANISM", 106, 117], ["Csn", "GENE_OR_GENE_PRODUCT", 168, 171], ["corn Csn gene", "DNA", 87, 100], ["corn Csn mRNA", "RNA", 163, 176], ["corn", "SPECIES", 87, 91], ["rice", "SPECIES", 106, 110], ["corn", "SPECIES", 163, 167], ["corn", "SPECIES", 87, 91], ["rice", "SPECIES", 106, 110], ["corn", "SPECIES", 163, 167], ["a recent study", "TEST", 31, 45]]], ["The corn Csn produced in rice served as an effective inhibitor of insect pest gut CysP.", [["gut", "ANATOMY", 78, 81], ["Csn", "CHEMICAL", 9, 12], ["CysP", "CHEMICAL", 82, 86], ["corn Csn", "SIMPLE_CHEMICAL", 4, 12], ["rice", "ORGANISM", 25, 29], ["gut", "ORGANISM_SUBDIVISION", 78, 81], ["CysP", "SIMPLE_CHEMICAL", 82, 86], ["corn Csn", "PROTEIN", 4, 12], ["corn", "SPECIES", 4, 8], ["rice", "SPECIES", 25, 29], ["corn", "SPECIES", 4, 8], ["rice", "SPECIES", 25, 29], ["an effective inhibitor", "TREATMENT", 40, 62]]], ["10 To evaluate our hypothesis, we are using transfection technology for establishing CV\u20101 cell lines that will continuously produce CsnSN and CsnC mRNA and protein, with a goal of using these cell lines for HSV\u20101 inhibition studies.", [["cell lines", "ANATOMY", 90, 100], ["cell lines", "ANATOMY", 192, 202], ["CV\u20101 cell lines", "CELL", 85, 100], ["CsnSN", "GENE_OR_GENE_PRODUCT", 132, 137], ["CsnC", "GENE_OR_GENE_PRODUCT", 142, 146], ["cell lines", "CELL", 192, 202], ["HSV\u20101", "ORGANISM", 207, 212], ["CV\u20101 cell lines", "CELL_LINE", 85, 100], ["CsnSN and CsnC mRNA", "RNA", 132, 151], ["cell lines", "CELL_LINE", 192, 202], ["HSV\u20101", "SPECIES", 207, 212], ["transfection technology", "TREATMENT", 44, 67], ["establishing CV\u20101 cell lines", "TREATMENT", 72, 100], ["these cell lines", "TREATMENT", 186, 202], ["HSV\u20101 inhibition studies", "TEST", 207, 231]]], ["These studies will allow us to better understand the mechanism of interaction and thereby inhibition of HSV\u20101 by Csns.RESULTS AND DISCUSSIONIn order to establish cell lines expressing high levels of Csn for HSV\u20101 inhibition studies, we have initially cloned cDNA fragments encoding the secreted peptide of CsnC and CsnSN (120 and 121 amino acids, respectively) into the eukaryotic expression vector pcDNA 3.0, under the control of the CMV promoter.", [["cell lines", "ANATOMY", 162, 172], ["amino acids", "CHEMICAL", 334, 345], ["amino acids", "CHEMICAL", 334, 345], ["HSV\u20101", "ORGANISM", 104, 109], ["Csns", "GENE_OR_GENE_PRODUCT", 113, 117], ["cell lines", "CELL", 162, 172], ["Csn", "GENE_OR_GENE_PRODUCT", 199, 202], ["HSV\u20101", "ORGANISM", 207, 212], ["CsnC", "GENE_OR_GENE_PRODUCT", 306, 310], ["CsnSN", "GENE_OR_GENE_PRODUCT", 315, 320], ["amino acids", "AMINO_ACID", 334, 345], ["pcDNA", "GENE_OR_GENE_PRODUCT", 399, 404], ["CMV", "ORGANISM", 435, 438], ["Csns", "PROTEIN", 113, 117], ["cell lines", "CELL_LINE", 162, 172], ["Csn", "PROTEIN", 199, 202], ["cDNA fragments", "DNA", 258, 272], ["CsnC", "PROTEIN", 306, 310], ["CsnSN", "PROTEIN", 315, 320], ["CMV promoter", "DNA", 435, 447], ["HSV\u20101", "SPECIES", 104, 109], ["HSV\u20101", "SPECIES", 207, 212], ["These studies", "TEST", 0, 13], ["HSV", "PROBLEM", 104, 107], ["cell lines", "TREATMENT", 162, 172], ["HSV\u20101 inhibition studies", "TEST", 207, 231], ["initially cloned cDNA fragments", "PROBLEM", 241, 272], ["amino acids", "TEST", 334, 345], ["the CMV promoter", "TREATMENT", 431, 447], ["CMV promoter", "OBSERVATION", 435, 447]]], ["The recombinant plasmids were transfected into COS\u20101 cells.", [["plasmids", "ANATOMY", 16, 24], ["COS\u20101 cells", "ANATOMY", 47, 58], ["COS\u20101 cells", "CELL", 47, 58], ["recombinant plasmids", "DNA", 4, 24], ["COS\u20101 cells", "CELL_LINE", 47, 58], ["The recombinant plasmids", "TREATMENT", 0, 24], ["plasmids", "OBSERVATION", 16, 24]]], ["Stable clones were selected with G418 and isolated onto 24\u2010well plates.", [["clones", "ANATOMY", 7, 13], ["G418", "CHEMICAL", 33, 37], ["G418", "CHEMICAL", 33, 37], ["clones", "CELL", 7, 13], ["G418", "TREATMENT", 33, 37], ["clones", "OBSERVATION", 7, 13]]], ["Simultaneous to individual clone selection, we analyzed a heterogeneous population of cells for mRNA and protein production.", [["cells", "ANATOMY", 86, 91], ["clone", "CELL", 27, 32], ["cells", "CELL", 86, 91], ["mRNA", "RNA", 96, 100], ["individual clone selection", "TEST", 16, 42], ["mRNA and protein production", "PROBLEM", 96, 123], ["heterogeneous", "OBSERVATION_MODIFIER", 58, 71]]], ["The Northern blot analysis showed a very large increase in mRNA of both CsnC and CsnSN (refer to Fig. 1A), whereas the Western blot analysis was inconclusive (data not shown).", [["CsnC", "GENE_OR_GENE_PRODUCT", 72, 76], ["CsnSN", "GENE_OR_GENE_PRODUCT", 81, 86], ["Fig. 1A", "GENE_OR_GENE_PRODUCT", 97, 104], ["mRNA", "RNA", 59, 63], ["CsnC", "PROTEIN", 72, 76], ["CsnSN", "PROTEIN", 81, 86], ["Fig. 1A", "PROTEIN", 97, 104], ["The Northern blot analysis", "TEST", 0, 26], ["the Western blot analysis", "TEST", 115, 140], ["very", "OBSERVATION_MODIFIER", 36, 40], ["large", "OBSERVATION_MODIFIER", 41, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["Upon evaluation of individual clones (>20 for each of CsnC and SN), we found no increase in the Csn mRNA or protein production in any of the clones.", [["clones", "ANATOMY", 30, 36], ["clones", "ANATOMY", 141, 147], ["clones", "CELL", 30, 36], ["CsnC", "GENE_OR_GENE_PRODUCT", 54, 58], ["Csn", "GENE_OR_GENE_PRODUCT", 96, 99], ["clones", "CELL", 141, 147], ["CsnC", "PROTEIN", 54, 58], ["Csn mRNA", "RNA", 96, 104], ["evaluation", "TEST", 5, 15], ["individual clones", "TEST", 19, 36], ["the Csn mRNA", "PROBLEM", 92, 104], ["protein production", "PROBLEM", 108, 126], ["no", "UNCERTAINTY", 77, 79], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["Csn mRNA", "OBSERVATION", 96, 104], ["protein production", "OBSERVATION", 108, 126]]], ["These results indicate that even though the individual clones were antibiotic resistant, they were false positive.RESULTS AND DISCUSSIONIn order to better evaluate the ability to transfect eukaryotic cells with CsnC or CsnSN, we used transient transfections.", [["cells", "ANATOMY", 200, 205], ["clones", "CELL", 55, 61], ["cells", "CELL", 200, 205], ["CsnC", "GENE_OR_GENE_PRODUCT", 211, 215], ["CsnSN", "GENE_OR_GENE_PRODUCT", 219, 224], ["eukaryotic cells", "CELL_TYPE", 189, 205], ["CsnC", "PROTEIN", 211, 215], ["CsnSN", "PROTEIN", 219, 224], ["the individual clones", "PROBLEM", 40, 61], ["antibiotic", "TREATMENT", 67, 77], ["false positive", "PROBLEM", 99, 113], ["CsnC", "TREATMENT", 211, 215], ["CsnSN", "TREATMENT", 219, 224], ["transient transfections", "TREATMENT", 234, 257]]], ["We examined both lipofectamine and calcium phosphate transfection methods, as well as CV\u20101 and NIH\u2010293 cells.", [["NIH\u2010293 cells", "ANATOMY", 95, 108], ["lipofectamine", "CHEMICAL", 17, 30], ["calcium phosphate", "CHEMICAL", 35, 52], ["lipofectamine", "CHEMICAL", 17, 30], ["calcium phosphate", "CHEMICAL", 35, 52], ["lipofectamine", "SIMPLE_CHEMICAL", 17, 30], ["calcium", "SIMPLE_CHEMICAL", 35, 42], ["CV\u20101", "CELL", 86, 90], ["NIH\u2010293 cells", "CELL", 95, 108], ["NIH\u2010293 cells", "CELL_LINE", 95, 108], ["both lipofectamine", "TREATMENT", 12, 30], ["calcium phosphate transfection methods", "TREATMENT", 35, 73], ["CV", "TEST", 86, 88]]], ["We found that both CV\u20101 and NIH\u2010293 transfected best with lipofectamine and that the NIH\u2010293 cells have little or no endogenous CsnC (refer to Fig. 1B).", [["NIH\u2010293", "ANATOMY", 28, 35], ["NIH\u2010293 cells", "ANATOMY", 85, 98], ["lipofectamine", "CHEMICAL", 58, 71], ["lipofectamine", "CHEMICAL", 58, 71], ["NIH\u2010293", "CELL", 28, 35], ["lipofectamine", "CELL", 58, 71], ["NIH\u2010293 cells", "CELL", 85, 98], ["CsnC", "GENE_OR_GENE_PRODUCT", 128, 132], ["NIH\u2010293 cells", "CELL_LINE", 85, 98], ["endogenous CsnC", "PROTEIN", 117, 132], ["NIH\u2010293", "SPECIES", 28, 35], ["NIH\u2010293", "SPECIES", 85, 92], ["CV", "TEST", 19, 21], ["lipofectamine", "TREATMENT", 58, 71], ["endogenous CsnC", "PROBLEM", 117, 132]]], ["As compared to CV\u20101 cells, NIH\u2010293 cells were less infectable by HSV\u20101; therefore, in subsequent transfections and HSV\u20101 infections we used CV\u20101 cells.", [["CV\u20101 cells", "ANATOMY", 15, 25], ["NIH\u2010293 cells", "ANATOMY", 27, 40], ["CV\u20101 cells", "ANATOMY", 140, 150], ["infections", "DISEASE", 121, 131], ["CV\u20101 cells", "CELL", 15, 25], ["NIH\u2010293 cells", "CELL", 27, 40], ["HSV\u20101", "ORGANISM", 65, 70], ["HSV\u20101", "ORGANISM", 115, 120], ["CV\u20101 cells", "CELL", 140, 150], ["CV\u20101 cells", "CELL_LINE", 15, 25], ["NIH\u2010293 cells", "CELL_LINE", 27, 40], ["CV\u20101 cells", "CELL_LINE", 140, 150], ["NIH\u2010293", "SPECIES", 27, 34], ["HSV\u20101", "SPECIES", 65, 70], ["HSV\u20101", "SPECIES", 115, 120], ["CV\u20101 cells", "TEST", 15, 25], ["NIH", "TEST", 27, 30], ["HSV", "TEST", 65, 68], ["HSV", "PROBLEM", 115, 118], ["1 infections", "PROBLEM", 119, 131]]], ["We have successfully transiently transfected CV\u20101 cells with untargeted CsnC cDNA, as documented by an increase in CsnC protein production by Western blot analysis of total cell protein (as shown in Fig. 2A).", [["CV\u20101 cells", "ANATOMY", 45, 55], ["cell", "ANATOMY", 173, 177], ["CV\u20101 cells", "CELL", 45, 55], ["CsnC", "GENE_OR_GENE_PRODUCT", 72, 76], ["CsnC", "GENE_OR_GENE_PRODUCT", 115, 119], ["cell", "CELL", 173, 177], ["CV\u20101 cells", "CELL_LINE", 45, 55], ["CsnC cDNA", "DNA", 72, 81], ["CsnC", "PROTEIN", 115, 119], ["total cell protein", "PROTEIN", 167, 185], ["untargeted CsnC cDNA", "PROBLEM", 61, 81], ["an increase in CsnC protein production", "PROBLEM", 100, 138], ["total cell protein", "TEST", 167, 185], ["increase", "OBSERVATION_MODIFIER", 103, 111]]], ["However, transiently transfected CV\u20101 cells with untargeted CsnSN cDNA have shown no increase in CsnSN protein production (data not shown); the reason for this remains unclear.", [["CV\u20101 cells", "ANATOMY", 33, 43], ["CV\u20101 cells", "CELL", 33, 43], ["CsnSN", "GENE_OR_GENE_PRODUCT", 60, 65], ["CsnSN protein", "GENE_OR_GENE_PRODUCT", 97, 110], ["CV\u20101 cells", "CELL_LINE", 33, 43], ["CsnSN cDNA", "DNA", 60, 70], ["CsnSN", "PROTEIN", 97, 102], ["transiently transfected CV\u20101 cells", "PROBLEM", 9, 43], ["untargeted CsnSN cDNA", "TEST", 49, 70], ["increase in CsnSN protein production", "PROBLEM", 85, 121], ["no", "UNCERTAINTY", 82, 84], ["increase", "OBSERVATION_MODIFIER", 85, 93]]], ["Further, we have successfully transiently transfected CV\u20101 cells with CsnC and CsnSN cDNA containing a nuclear retention signal (147 aa residues of GAL4\u2010encoding sequence 11 added to the 5\u2032 end of the Csns), as reflected by a production of GAL4/CsnSN and GAL4/CsnC proteins, shown in Figure 2B and C, respectively.", [["CV\u20101 cells", "ANATOMY", 54, 64], ["nuclear", "ANATOMY", 103, 110], ["CV\u20101 cells", "CELL", 54, 64], ["CsnC", "GENE_OR_GENE_PRODUCT", 70, 74], ["CsnSN", "GENE_OR_GENE_PRODUCT", 79, 84], ["GAL4", "GENE_OR_GENE_PRODUCT", 148, 152], ["Csns", "GENE_OR_GENE_PRODUCT", 201, 205], ["GAL4", "GENE_OR_GENE_PRODUCT", 240, 244], ["CsnSN", "GENE_OR_GENE_PRODUCT", 245, 250], ["GAL4", "GENE_OR_GENE_PRODUCT", 255, 259], ["CsnC", "GENE_OR_GENE_PRODUCT", 260, 264], ["CV\u20101 cells", "CELL_LINE", 54, 64], ["CsnC and CsnSN cDNA", "DNA", 70, 89], ["GAL4\u2010encoding sequence 11", "DNA", 148, 173], ["5\u2032 end", "DNA", 187, 193], ["Csns", "PROTEIN", 201, 205], ["GAL4", "PROTEIN", 240, 244], ["CsnSN", "PROTEIN", 245, 250], ["GAL4", "PROTEIN", 255, 259], ["CsnC proteins", "PROTEIN", 260, 273], ["CsnC", "TREATMENT", 70, 74], ["CsnSN cDNA", "TEST", 79, 89], ["a nuclear retention signal", "TEST", 101, 127], ["aa residues", "TEST", 133, 144], ["GAL4\u2010encoding sequence", "TEST", 148, 170], ["GAL4/CsnSN", "TEST", 240, 250], ["GAL4/CsnC proteins", "TEST", 255, 273]]], ["We targeted the nucleus because most HSV\u20101 functions (i.e., transcription, replication, and packaging) occur within the host cell nucleus.RESULTS AND DISCUSSIONCurrently, we are in the process of reselecting stable clones expressing high levels of rCsnC and rCsnSN \u00b1 nuclear signal.", [["nucleus", "ANATOMY", 16, 23], ["cell nucleus", "ANATOMY", 125, 137], ["nucleus", "CELLULAR_COMPONENT", 16, 23], ["HSV\u20101", "ORGANISM", 37, 42], ["cell nucleus", "CELLULAR_COMPONENT", 125, 137], ["clones", "CELL", 215, 221], ["rCsnC", "GENE_OR_GENE_PRODUCT", 248, 253], ["rCsnSN", "GENE_OR_GENE_PRODUCT", 258, 264], ["rCsnC", "PROTEIN", 248, 253], ["rCsnSN", "PROTEIN", 258, 264], ["HSV\u20101", "SPECIES", 37, 42], ["replication", "TREATMENT", 75, 86], ["packaging", "TREATMENT", 92, 101], ["nucleus", "ANATOMY", 16, 23], ["host cell nucleus", "OBSERVATION", 120, 137]]], ["However, for these experiments we have subcloned CsnC and CsnSN cDNA fragments into the pcDNA 3.1 eukaryotic expression vector because the stable clones are selected with zeocin (250 \u03bcg/mL), which should yield less false positives and shorten the selection time.RESULTS AND DISCUSSIONWe have also explored the possibility of HSV\u20101 inhibition using the transiently transfected CV\u20101 cells with CsnSN.", [["clones", "ANATOMY", 146, 152], ["CV\u20101 cells", "ANATOMY", 376, 386], ["zeocin", "CHEMICAL", 171, 177], ["zeocin", "CHEMICAL", 171, 177], ["CsnC", "GENE_OR_GENE_PRODUCT", 49, 53], ["CsnSN", "GENE_OR_GENE_PRODUCT", 58, 63], ["pcDNA", "GENE_OR_GENE_PRODUCT", 88, 93], ["clones", "CELL", 146, 152], ["zeocin", "SIMPLE_CHEMICAL", 171, 177], ["HSV\u20101", "ORGANISM", 325, 330], ["CV\u20101 cells", "CELL", 376, 386], ["CsnSN", "CELL", 392, 397], ["CsnC and CsnSN cDNA fragments", "DNA", 49, 78], ["pcDNA 3.1 eukaryotic expression vector", "DNA", 88, 126], ["CV\u20101 cells", "CELL_LINE", 376, 386], ["CsnSN", "PROTEIN", 392, 397], ["HSV\u20101", "SPECIES", 325, 330], ["subcloned CsnC", "TREATMENT", 39, 53], ["CsnSN cDNA fragments", "TREATMENT", 58, 78], ["eukaryotic expression vector", "TREATMENT", 98, 126], ["zeocin", "TREATMENT", 171, 177], ["HSV\u20101 inhibition", "TREATMENT", 325, 341], ["CsnSN", "TREATMENT", 392, 397], ["stable", "OBSERVATION_MODIFIER", 139, 145], ["clones", "OBSERVATION", 146, 152], ["false positives", "OBSERVATION", 215, 230]]], ["The cells were infected with HSV\u20101 (m.o.i. of 0.1) at 24, 36, and 48 h posttransfection (p.t.).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["HSV\u20101", "TEST", 29, 34], ["m.o.i.", "TEST", 36, 42], ["infected", "OBSERVATION_MODIFIER", 15, 23]]], ["The results indicate that at 48 h p.t. we have achieved a similar degree of HSV\u20101 inhibition as compared with the exogenously added rCsnSN (\u02dc 1 log of HSV\u20101 virus yield reduction, data not shown).", [["HSV\u20101", "ORGANISM", 76, 81], ["HSV\u20101 virus", "ORGANISM", 151, 162], ["HSV\u20101", "SPECIES", 76, 81], ["HSV", "PROBLEM", 76, 79], ["the exogenously added rCsnSN", "TREATMENT", 110, 138], ["HSV\u20101 virus yield reduction", "TREATMENT", 151, 178]]], ["This is probably because in transient transfections, only a small fraction of the cells become transfected, and the level of transfection is not consistent between each transfection.", [["cells", "ANATOMY", 82, 87], ["cells", "CELL", 82, 87], ["transient transfections", "PROBLEM", 28, 51], ["a small fraction of the cells", "PROBLEM", 58, 87], ["probably because", "UNCERTAINTY", 8, 24], ["transient", "OBSERVATION_MODIFIER", 28, 37], ["transfections", "OBSERVATION", 38, 51], ["small", "OBSERVATION_MODIFIER", 60, 65], ["fraction", "OBSERVATION_MODIFIER", 66, 74], ["transfected", "OBSERVATION", 95, 106], ["transfection", "OBSERVATION", 125, 137], ["not consistent", "UNCERTAINTY", 141, 155], ["transfection", "OBSERVATION", 169, 181]]], ["Therefore, it is necessary to obtain stable cell lines that express high amounts of CsnC or CsnSN in order to evaluate the mechanism of HSV\u20101 inhibition by Csns.RESULTS AND DISCUSSIONIn conclusion, our first attempt to establish stable cell lines producing CsnSN or CsnC were unsuccessful.", [["cell lines", "ANATOMY", 44, 54], ["cell lines", "ANATOMY", 236, 246], ["CsnSN", "CHEMICAL", 257, 262], ["CsnC", "CHEMICAL", 266, 270], ["cell lines", "CELL", 44, 54], ["CsnC", "GENE_OR_GENE_PRODUCT", 84, 88], ["CsnSN", "GENE_OR_GENE_PRODUCT", 92, 97], ["HSV\u20101", "ORGANISM", 136, 141], ["Csns", "GENE_OR_GENE_PRODUCT", 156, 160], ["cell lines", "CELL", 236, 246], ["CsnSN", "SIMPLE_CHEMICAL", 257, 262], ["CsnC", "SIMPLE_CHEMICAL", 266, 270], ["stable cell lines", "CELL_LINE", 37, 54], ["CsnC", "PROTEIN", 84, 88], ["CsnSN", "PROTEIN", 92, 97], ["Csns", "PROTEIN", 156, 160], ["stable cell lines", "CELL_LINE", 229, 246], ["CsnSN", "PROTEIN", 257, 262], ["CsnC", "PROTEIN", 266, 270], ["HSV\u20101", "SPECIES", 136, 141], ["stable cell lines", "TREATMENT", 37, 54], ["CsnC", "TREATMENT", 84, 88], ["CsnSN", "TREATMENT", 92, 97], ["HSV", "PROBLEM", 136, 139], ["stable cell lines", "TREATMENT", 229, 246], ["CsnC", "TREATMENT", 266, 270], ["cell lines", "OBSERVATION", 44, 54], ["cell lines", "OBSERVATION", 236, 246]]], ["This may be due to a large incidence of false positives, or perhaps because it is not possible to produce stable cell lines expressing high levels of Csns (CysP inhibitors).", [["cell lines", "ANATOMY", 113, 123], ["cell lines", "CELL", 113, 123], ["Csns", "GENE_OR_GENE_PRODUCT", 150, 154], ["CysP", "GENE_OR_GENE_PRODUCT", 156, 160], ["stable cell lines", "CELL_LINE", 106, 123], ["Csns", "PROTEIN", 150, 154], ["false positives", "PROBLEM", 40, 55], ["Csns (CysP inhibitors", "TREATMENT", 150, 171], ["may be due to", "UNCERTAINTY", 5, 18], ["large", "OBSERVATION_MODIFIER", 21, 26], ["false positives", "OBSERVATION", 40, 55], ["not possible", "UNCERTAINTY", 82, 94], ["stable", "OBSERVATION_MODIFIER", 106, 112], ["cell lines", "OBSERVATION", 113, 123]]], ["In fact, it has been shown that it is very difficult to obtain transfected cells with expression levels of calpain (CysP) and/or its natural inhibitor, calpastatin, significantly different from that of control cells.", [["cells", "ANATOMY", 75, 80], ["cells", "ANATOMY", 210, 215], ["cells", "CELL", 75, 80], ["calpain", "GENE_OR_GENE_PRODUCT", 107, 114], ["CysP", "GENE_OR_GENE_PRODUCT", 116, 120], ["calpastatin", "GENE_OR_GENE_PRODUCT", 152, 163], ["cells", "CELL", 210, 215], ["transfected cells", "CELL_LINE", 63, 80], ["calpain", "PROTEIN", 107, 114], ["CysP", "PROTEIN", 116, 120], ["calpastatin", "PROTEIN", 152, 163], ["control cells", "CELL_TYPE", 202, 215], ["transfected cells", "PROBLEM", 63, 80], ["calpain (CysP)", "TREATMENT", 107, 121], ["its natural inhibitor", "TREATMENT", 129, 150], ["calpastatin", "TREATMENT", 152, 163]]], ["Large deviations from the normal level seem to be lethal.", [["Large deviations", "PROBLEM", 0, 16], ["deviations", "OBSERVATION", 6, 16], ["normal", "OBSERVATION", 26, 32], ["seem to be", "UNCERTAINTY", 39, 49], ["lethal", "OBSERVATION", 50, 56]]], ["12 It is also documented that rice plants transfected with the rice Csn gene did not express high levels of rice Csn mRNA or protein (insufficient for the effective protection against insect pests).", [["insect pests", "DISEASE", 184, 196], ["rice plants", "ORGANISM", 30, 41], ["Csn", "GENE_OR_GENE_PRODUCT", 68, 71], ["Csn", "GENE_OR_GENE_PRODUCT", 113, 116], ["rice Csn gene", "DNA", 63, 76], ["rice Csn mRNA", "RNA", 108, 121], ["rice", "SPECIES", 30, 34], ["rice", "SPECIES", 63, 67], ["rice", "SPECIES", 108, 112], ["rice", "SPECIES", 30, 34], ["rice", "SPECIES", 63, 67], ["rice", "SPECIES", 108, 112]]], ["13 On the other hand, the study by Irie et al.10 has shown that transfection of the rice plants with the corn Csn gene yielded transgenic rice plants with levels of corn Csn protein more than 20 times higher than that of the intrinsic oryzacystatin.", [["Csn", "CHEMICAL", 110, 113], ["oryzacystatin", "CHEMICAL", 235, 248], ["oryzacystatin", "CHEMICAL", 235, 248], ["rice plants", "ORGANISM", 84, 95], ["Csn", "GENE_OR_GENE_PRODUCT", 110, 113], ["Csn", "GENE_OR_GENE_PRODUCT", 170, 173], ["oryzacystatin", "SIMPLE_CHEMICAL", 235, 248], ["corn Csn gene", "DNA", 105, 118], ["corn Csn protein", "PROTEIN", 165, 181], ["rice", "SPECIES", 84, 88], ["corn", "SPECIES", 105, 109], ["rice", "SPECIES", 138, 142], ["corn", "SPECIES", 165, 169], ["rice", "SPECIES", 84, 88], ["corn", "SPECIES", 105, 109], ["rice", "SPECIES", 138, 142], ["corn", "SPECIES", 165, 169], ["the study", "TEST", 22, 31], ["the rice plants", "TREATMENT", 80, 95], ["transgenic rice plants", "TREATMENT", 127, 149], ["corn Csn protein", "TREATMENT", 165, 181], ["the intrinsic oryzacystatin", "TREATMENT", 221, 248]]], ["More importantly the corn Csn protein effectively inhibited insect pest gut CysP.", [["gut", "ANATOMY", 72, 75], ["Csn", "CHEMICAL", 26, 29], ["CysP", "CHEMICAL", 76, 80], ["Csn", "GENE_OR_GENE_PRODUCT", 26, 29], ["gut", "ORGANISM_SUBDIVISION", 72, 75], ["CysP", "SIMPLE_CHEMICAL", 76, 80], ["corn Csn protein", "PROTEIN", 21, 37], ["corn", "SPECIES", 21, 25], ["corn", "SPECIES", 21, 25]]], ["Therefore, we remain optimistic that we will be successful in establishing cell lines that will produce high levels of CsnSN and CsnC that can be used to determine the mechanism of HSV\u20101 inhibition by cystatins.ACKNOWLEDGMENTSWe thank Dr. Te Chung Lee for the GAL4 nuclear signal plasmid; Dr. Michael J. Levine for the CsnSN #221 antibody, and use of his facilities; and Dr. E. James Bergey for help with the HSV\u20101 plaque\u2010reduction assay.", [["cell lines", "ANATOMY", 75, 85], ["cell lines", "CELL", 75, 85], ["CsnSN", "GENE_OR_GENE_PRODUCT", 119, 124], ["CsnC", "GENE_OR_GENE_PRODUCT", 129, 133], ["HSV\u20101", "ORGANISM", 181, 186], ["cystatins", "GENE_OR_GENE_PRODUCT", 201, 210], ["GAL4", "GENE_OR_GENE_PRODUCT", 260, 264], ["HSV", "ORGANISM", 409, 412], ["cell lines", "CELL_LINE", 75, 85], ["CsnSN", "PROTEIN", 119, 124], ["CsnC", "PROTEIN", 129, 133], ["cystatins", "PROTEIN", 201, 210], ["GAL4 nuclear signal plasmid", "DNA", 260, 287], ["CsnSN #221 antibody", "PROTEIN", 319, 338], ["HSV\u20101", "SPECIES", 181, 186], ["HSV\u20101", "SPECIES", 409, 414], ["establishing cell lines", "TREATMENT", 62, 85], ["CsnSN", "TREATMENT", 119, 124], ["CsnC", "TREATMENT", 129, 133], ["HSV", "PROBLEM", 181, 184], ["cell lines", "OBSERVATION", 75, 85]]]], "dce0cbba733091ff4b6767d481c96c7b80983e48": [["IntroductionThe outbreak of Kaposi sarcoma, its prodrome -LAS [11, 17] , and opportunistic infections in homosexual men from the United States and Europe [4] and in patients from Central Africa [7] has Abbreviations: AIDS = acquired immune Deficiency syndrome; LAS=unexplained, generalized lymphadenopathy syndrome; sp.=species; EM=electronmicroscopy; rIFN ~A=recombinant leukocyte c~A Interferon; CVLP=coronavirus-like particles; CsC1 = cesium chloride initiated intensive search for causative and opportunistic infectious agents.", [["Kaposi sarcoma", "ANATOMY", 28, 42], ["Kaposi sarcoma", "DISEASE", 28, 42], ["LAS", "DISEASE", 58, 61], ["opportunistic infections", "DISEASE", 77, 101], ["AIDS", "DISEASE", 217, 221], ["acquired immune Deficiency syndrome", "DISEASE", 224, 259], ["LAS", "DISEASE", 261, 264], ["lymphadenopathy syndrome", "DISEASE", 290, 314], ["cesium chloride", "CHEMICAL", 438, 453], ["cesium chloride", "CHEMICAL", 438, 453], ["Kaposi sarcoma", "CANCER", 28, 42], ["men", "ORGANISM", 116, 119], ["patients", "ORGANISM", 165, 173], ["leukocyte c~A Interferon", "GENE_OR_GENE_PRODUCT", 372, 396], ["CVLP", "GENE_OR_GENE_PRODUCT", 398, 402], ["coronavirus", "ORGANISM", 403, 414], ["CsC1", "SIMPLE_CHEMICAL", 431, 435], ["cesium chloride", "SIMPLE_CHEMICAL", 438, 453], ["men", "SPECIES", 116, 119], ["patients", "SPECIES", 165, 173], ["coronavirus", "SPECIES", 403, 414], ["Kaposi sarcoma", "PROBLEM", 28, 42], ["its prodrome", "PROBLEM", 44, 56], ["opportunistic infections", "PROBLEM", 77, 101], ["AIDS", "PROBLEM", 217, 221], ["acquired immune Deficiency syndrome", "PROBLEM", 224, 259], ["generalized lymphadenopathy syndrome", "PROBLEM", 278, 314], ["sp", "PROBLEM", 316, 318], ["electronmicroscopy", "TEST", 332, 350], ["rIFN", "TEST", 352, 356], ["recombinant leukocyte", "TEST", 360, 381], ["A Interferon", "TREATMENT", 384, 396], ["CVLP", "TEST", 398, 402], ["coronavirus-like particles", "PROBLEM", 403, 429], ["cesium chloride", "TREATMENT", 438, 453], ["opportunistic infectious agents", "TREATMENT", 499, 530], ["Kaposi sarcoma", "OBSERVATION", 28, 42], ["opportunistic", "OBSERVATION_MODIFIER", 77, 90], ["infections", "OBSERVATION", 91, 101], ["generalized", "OBSERVATION_MODIFIER", 278, 289], ["lymphadenopathy", "OBSERVATION", 290, 305], ["leukocyte", "ANATOMY", 372, 381]]], ["Considerable evidence has recently been accumulated with regard to the etiologic role of human T-lymphotropic retroviruses LAV/HTLV-III [1, 8, 9] .", [["human T-lymphotropic retroviruses LAV", "ORGANISM", 89, 126], ["HTLV-III", "ORGANISM", 127, 135], ["human", "SPECIES", 89, 94], ["human T-lymphotropic retroviruses LAV/HTLV-III", "SPECIES", 89, 135]]], ["However, high prevalences of antibody to LAV/HTLV-III among homosexuals [5] suggest that the exposure to the virus is much more common than AIDS itself.", [["AIDS", "DISEASE", 140, 144], ["LAV/HTLV-III", "ORGANISM", 41, 53], ["homosexuals [5", "ORGANISM", 60, 74], ["HTLV-III", "SPECIES", 45, 53], ["antibody", "TEST", 29, 37], ["LAV", "TEST", 41, 44], ["the virus", "PROBLEM", 105, 114]]], ["Thus, host response to infection can be expected to range from subclinical to severe and may be influenced by concomitant infectious agents.", [["infection", "DISEASE", 23, 32], ["infection", "PROBLEM", 23, 32], ["concomitant infectious agents", "PROBLEM", 110, 139], ["infection", "OBSERVATION", 23, 32], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["may be", "UNCERTAINTY", 89, 95], ["infectious", "OBSERVATION", 122, 132]]], ["Multiple intestinal parasitic infestations and other microbial infections are often seen in homosexual men [19] .", [["intestinal", "ANATOMY", 9, 19], ["intestinal parasitic infestations", "DISEASE", 9, 42], ["microbial infections", "DISEASE", 53, 73], ["intestinal", "ORGAN", 9, 19], ["men", "ORGANISM", 103, 106], ["men", "SPECIES", 103, 106], ["Multiple intestinal parasitic infestations", "PROBLEM", 0, 42], ["other microbial infections", "PROBLEM", 47, 73], ["intestinal", "ANATOMY", 9, 19], ["parasitic", "OBSERVATION_MODIFIER", 20, 29], ["infestations", "OBSERVATION", 30, 42], ["microbial", "OBSERVATION_MODIFIER", 53, 62], ["infections", "OBSERVATION", 63, 73]]], ["In the search for viruses, we observed CVLP in the feces of homosexual men and report here on a prospective study for the presence of these particles in stool and serum specimens of patients belonging to a high risk group of AIDS.Patients and ControlsDetailed clinical, parasitological, serological and immunologic data were available from 35 homosexually or bisexually active males originating from Germany and from one African male whose feces were screened for the presence of virus particles.", [["feces", "ANATOMY", 51, 56], ["stool", "ANATOMY", 153, 158], ["serum specimens", "ANATOMY", 163, 178], ["AIDS", "DISEASE", 225, 229], ["CVLP", "GENE_OR_GENE_PRODUCT", 39, 43], ["feces", "ORGANISM_SUBDIVISION", 51, 56], ["men", "ORGANISM", 71, 74], ["stool", "ORGANISM_SUBSTANCE", 153, 158], ["serum specimens", "ORGANISM_SUBSTANCE", 163, 178], ["patients", "ORGANISM", 182, 190], ["Patients", "ORGANISM", 230, 238], ["males", "ORGANISM", 377, 382], ["feces", "ORGANISM", 440, 445], ["CVLP", "PROTEIN", 39, 43], ["men", "SPECIES", 71, 74], ["patients", "SPECIES", 182, 190], ["Patients", "SPECIES", 230, 238], ["viruses", "PROBLEM", 18, 25], ["a prospective study", "TEST", 94, 113], ["these particles in stool", "PROBLEM", 134, 158], ["serum specimens", "TEST", 163, 178], ["AIDS", "PROBLEM", 225, 229], ["immunologic data", "TEST", 303, 319], ["virus particles", "PROBLEM", 480, 495], ["viruses", "OBSERVATION", 18, 25], ["virus", "OBSERVATION", 480, 485]]], ["Two of them who showed systemic manitbstation of Kaposi sarcoma were studied while under experimental rIFN c~A therapy.", [["Kaposi sarcoma", "ANATOMY", 49, 63], ["Kaposi sarcoma", "DISEASE", 49, 63], ["Kaposi sarcoma", "CANCER", 49, 63], ["Kaposi sarcoma", "PROBLEM", 49, 63], ["A therapy", "TREATMENT", 109, 118], ["Kaposi sarcoma", "OBSERVATION", 49, 63]]], ["One European and one African patient had opportunistic infections and met the criteria for AIDS [4] .", [["opportunistic infections", "DISEASE", 41, 65], ["AIDS", "DISEASE", 91, 95], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["opportunistic infections", "PROBLEM", 41, 65], ["AIDS", "PROBLEM", 91, 95], ["opportunistic", "OBSERVATION_MODIFIER", 41, 54], ["infections", "OBSERVATION", 55, 65]]], ["Twelve patients had clinical signs compatible with the prodrome of AIDS (LAS) [t 1, 17], whereas six had unexplained chronic enterocolitis.", [["AIDS", "DISEASE", 67, 71], ["LAS", "DISEASE", 73, 76], ["chronic enterocolitis", "DISEASE", 117, 138], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["clinical signs", "PROBLEM", 20, 34], ["AIDS", "PROBLEM", 67, 71], ["unexplained chronic enterocolitis", "PROBLEM", 105, 138], ["chronic", "OBSERVATION_MODIFIER", 117, 124], ["enterocolitis", "OBSERVATION", 125, 138]]], ["Of the remaining cases, eight were hospitalized for acute hepatitis B and one for amebic liver abscess which was acquired during the patient's stay in the tropics.", [["liver abscess", "ANATOMY", 89, 102], ["acute hepatitis B", "DISEASE", 52, 69], ["amebic liver abscess", "DISEASE", 82, 102], ["liver", "ORGAN", 89, 94], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["acute hepatitis B", "PROBLEM", 52, 69], ["amebic liver abscess", "PROBLEM", 82, 102], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["hepatitis", "OBSERVATION", 58, 67], ["liver", "ANATOMY", 89, 94], ["abscess", "OBSERVATION", 95, 102]]], ["In five homosexuals, studied in detail, signs or symptoms of AIDS or LAS could be excluded.", [["AIDS", "DISEASE", 61, 65], ["LAS", "DISEASE", 69, 72], ["symptoms", "PROBLEM", 49, 57], ["AIDS", "PROBLEM", 61, 65], ["LAS", "PROBLEM", 69, 72]]], ["Sixteen healthy heterosexual males (including medical staff taking care of patients with AIDS or related diseases) and two females with diarrhea (yersiniosis in one case, unexplained in the other case) were studied as controls and in parallel with patients' specimens.Laboratory InvestigationsThe routine laboratory profile included hematology, hemostaseology, blood chemistry, and urinary analysis.", [["specimens", "ANATOMY", 258, 267], ["blood", "ANATOMY", 361, 366], ["urinary", "ANATOMY", 382, 389], ["AIDS", "DISEASE", 89, 93], ["diarrhea", "DISEASE", 136, 144], ["yersiniosis", "DISEASE", 146, 157], ["males", "ORGANISM", 29, 34], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 248, 256], ["specimens", "CELL", 258, 267], ["blood", "ORGANISM_SUBSTANCE", 361, 366], ["urinary", "ORGANISM_SUBSTANCE", 382, 389], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 248, 256], ["AIDS", "PROBLEM", 89, 93], ["related diseases", "PROBLEM", 97, 113], ["diarrhea", "PROBLEM", 136, 144], ["yersiniosis", "PROBLEM", 146, 157], ["patients' specimens", "TEST", 248, 267], ["Laboratory Investigations", "TEST", 268, 293], ["hemostaseology", "TEST", 345, 359], ["blood chemistry", "TEST", 361, 376], ["urinary analysis", "TEST", 382, 398], ["urinary", "ANATOMY", 382, 389]]], ["Between one and three stool samples were examined on consecutive days for the presence of protozoa or helminths' eggs; stool cultures were performed to test for pathogenic bacteria, i.e., Salmonella sp., Shigella sp., Yersinia sp., and Campylobacter sp.", [["stool samples", "ANATOMY", 22, 35], ["eggs", "ANATOMY", 113, 117], ["stool cultures", "ANATOMY", 119, 133], ["eggs", "ORGANISM_SUBSTANCE", 113, 117], ["Salmonella sp.", "ORGANISM", 188, 202], ["Shigella sp.", "ORGANISM", 204, 216], ["Yersinia sp.", "ORGANISM", 218, 230], ["Campylobacter sp", "ORGANISM", 236, 252], ["Salmonella sp.", "SPECIES", 188, 202], ["Shigella sp.", "SPECIES", 204, 216], ["Yersinia sp.", "SPECIES", 218, 230], ["Salmonella sp.", "SPECIES", 188, 202], ["Shigella sp.", "SPECIES", 204, 216], ["Yersinia sp.", "SPECIES", 218, 230], ["three stool samples", "TEST", 16, 35], ["protozoa", "PROBLEM", 90, 98], ["helminths' eggs", "PROBLEM", 102, 117], ["stool cultures", "TEST", 119, 133], ["pathogenic bacteria", "PROBLEM", 161, 180], ["Salmonella sp.", "PROBLEM", 188, 202], ["Shigella sp.", "PROBLEM", 204, 216], ["Yersinia", "PROBLEM", 218, 226], ["Campylobacter", "PROBLEM", 236, 249], ["Campylobacter sp", "OBSERVATION", 236, 252]]], ["In all symptomatic cases, a proctoscopy and a lymph node biopsy were performed.", [["lymph node", "ANATOMY", 46, 56], ["lymph node", "MULTI-TISSUE_STRUCTURE", 46, 56], ["biopsy", "MULTI-TISSUE_STRUCTURE", 57, 63], ["a proctoscopy", "TEST", 26, 39], ["a lymph node biopsy", "TEST", 44, 63], ["symptomatic", "OBSERVATION_MODIFIER", 7, 18], ["lymph node", "OBSERVATION", 46, 56]]], ["Serological tests for hepatitis A, hepatitis B, cytomegalovirus, EpsteimBarr virus, syphilis, and others were performed.ImmunologyPatients evaluated prospectively were tested for cutaneous anergy by a multitest procedure (Multitest M&ieux, Lyon, France) for six different recall antigens.", [["cutaneous", "ANATOMY", 179, 188], ["hepatitis A, hepatitis B", "DISEASE", 22, 46], ["syphilis", "DISEASE", 84, 92], ["hepatitis A", "ORGANISM", 22, 33], ["hepatitis B", "ORGANISM", 35, 46], ["cytomegalovirus", "ORGANISM", 48, 63], ["EpsteimBarr virus", "ORGANISM", 65, 82], ["EpsteimBarr virus", "SPECIES", 65, 82], ["hepatitis A", "SPECIES", 22, 33], ["hepatitis B", "SPECIES", 35, 46], ["EpsteimBarr virus", "SPECIES", 65, 82], ["Serological tests", "TEST", 0, 17], ["hepatitis A", "TEST", 22, 33], ["hepatitis B", "TEST", 35, 46], ["cytomegalovirus", "PROBLEM", 48, 63], ["EpsteimBarr virus", "TEST", 65, 82], ["syphilis", "TEST", 84, 92], ["cutaneous anergy", "PROBLEM", 179, 195], ["a multitest procedure", "TREATMENT", 199, 220]]], ["For the enumeration of T-lymphocyte subpopulations, mononuclear cells were separated by density medium centrifugation on Ficoll-Paque (Pharmacia, Freiburg, FRG) and nonadherent lymphocytes were obtained after plastic adherence.", [["T-lymphocyte", "ANATOMY", 23, 35], ["mononuclear cells", "ANATOMY", 52, 69], ["lymphocytes", "ANATOMY", 177, 188], ["T-lymphocyte subpopulations", "CELL", 23, 50], ["mononuclear cells", "CELL", 52, 69], ["nonadherent lymphocytes", "CELL", 165, 188], ["T-lymphocyte subpopulations", "CELL_TYPE", 23, 50], ["mononuclear cells", "CELL_TYPE", 52, 69], ["nonadherent lymphocytes", "CELL_TYPE", 165, 188], ["the enumeration", "TEST", 4, 19], ["T-lymphocyte subpopulations", "PROBLEM", 23, 50], ["mononuclear cells", "PROBLEM", 52, 69], ["nonadherent lymphocytes", "TEST", 165, 188], ["lymphocyte subpopulations", "OBSERVATION", 25, 50], ["mononuclear cells", "OBSERVATION", 52, 69], ["density", "OBSERVATION_MODIFIER", 88, 95], ["medium centrifugation", "OBSERVATION", 96, 117], ["nonadherent lymphocytes", "OBSERVATION", 165, 188]]], ["The differentiation antigens were identified by indirect immunofluorescence using monoclonal antibodiesElectron MicroscopyA suspension of feces in distilled water (up to 1 : 10 v/v) was homogenized and centrifuged for 10 rain at 1,500 g in order to remove debris and bacteria.", [["feces", "ANATOMY", 138, 143], ["feces", "ORGANISM_SUBSTANCE", 138, 143], ["differentiation antigens", "PROTEIN", 4, 28], ["monoclonal antibodies", "PROTEIN", 82, 103], ["The differentiation antigens", "TEST", 0, 28], ["indirect immunofluorescence", "TEST", 48, 75], ["monoclonal antibodies", "TEST", 82, 103], ["debris", "PROBLEM", 256, 262], ["bacteria", "PROBLEM", 267, 275], ["debris", "OBSERVATION", 256, 262], ["bacteria", "OBSERVATION", 267, 275]]], ["The supernatant was further diluted 1 : 3 with water and the suspended material was pelleted at 25,000 g for 30 min in a specially designed centrifuge tube onto pioloform coated grids [t8].", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["the suspended material", "TREATMENT", 57, 79], ["a specially designed centrifuge tube onto pioloform coated grids", "TREATMENT", 119, 183], ["t8", "ANATOMY", 185, 187]]], ["The specimens were negative stained with sodium-silico-tungstate and screened for the presence of virus particles using a Philips EM 301 elecrron microscope.", [["specimens", "ANATOMY", 4, 13], ["sodium-silico-tungstate", "CHEMICAL", 41, 64], ["sodium", "CHEMICAL", 41, 47], ["tungstate", "CHEMICAL", 55, 64], ["specimens", "CANCER", 4, 13], ["sodium-silico-tungstate", "SIMPLE_CHEMICAL", 41, 64], ["The specimens", "TEST", 0, 13], ["sodium", "TEST", 41, 47], ["virus particles", "PROBLEM", 98, 113]]], ["In the same way as feces, serum of nine homosexual and 18 heterosexual males was cleared of subcellular debris and pelleted at 25,000 g for 30 rain directly onto grids.", [["feces", "ANATOMY", 19, 24], ["serum", "ANATOMY", 26, 31], ["subcellular", "ANATOMY", 92, 103], ["feces", "ORGANISM_SUBSTANCE", 19, 24], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["males", "ORGANISM", 71, 76], ["subcellular debris", "PROBLEM", 92, 110], ["debris", "OBSERVATION", 104, 110]]], ["Equal areas of all specimens were screened electronmicroscopicatly for the presence of virus particles until they were considered negative in this respect.Purification of CVLPTwo stool sampts containing large numbers of CVLP were subjected to further characterization [12] .", [["specimens", "ANATOMY", 19, 28], ["specimens", "CANCER", 19, 28], ["CVLP", "GENE_OR_GENE_PRODUCT", 220, 224], ["CVLP", "PROTEIN", 220, 224], ["all specimens", "TEST", 15, 28], ["virus particles", "PROBLEM", 87, 102], ["CVLPTwo stool sampts", "TREATMENT", 171, 191], ["large numbers of CVLP", "PROBLEM", 203, 224], ["further characterization", "TEST", 243, 267], ["areas", "OBSERVATION_MODIFIER", 6, 11], ["large", "OBSERVATION_MODIFIER", 203, 208], ["numbers", "OBSERVATION_MODIFIER", 209, 216]]], ["One volume of the stool suspensions was mixed with nine volumes of a CsC1 solution in phosphate-buffered saline (density 1.20 g/ml).", [["stool suspensions", "ANATOMY", 18, 35], ["CsC1", "CHEMICAL", 69, 73], ["phosphate", "CHEMICAL", 86, 95], ["CsC1", "CHEMICAL", 69, 73], ["phosphate", "CHEMICAL", 86, 95], ["CsC1", "SIMPLE_CHEMICAL", 69, 73], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 86, 111], ["the stool suspensions", "TREATMENT", 14, 35], ["a CsC1 solution in phosphate-buffered saline (density", "TREATMENT", 67, 120], ["volume", "OBSERVATION_MODIFIER", 4, 10], ["stool suspensions", "OBSERVATION", 18, 35]]], ["After centrifugation at 180,000 g for 48 h the clearly visible band was collected, dialyzed against 0.0t Tris buffer (pH 7.40) and used for negative contrast electronmicroscopic examination.StatisticsFor statistical evaluation all patients and controls were divided into three groups: group A, patients with AIDS or LAS; group B, homosexual men with or without clinical symptoms other than those of group A; group C, heterosexual patients and controls.", [["AIDS", "DISEASE", 308, 312], ["LAS", "DISEASE", 316, 319], ["patients", "ORGANISM", 231, 239], ["patients", "ORGANISM", 294, 302], ["men", "ORGANISM", 341, 344], ["patients", "ORGANISM", 430, 438], ["patients", "SPECIES", 231, 239], ["patients", "SPECIES", 294, 302], ["men", "SPECIES", 341, 344], ["patients", "SPECIES", 430, 438], ["centrifugation", "TREATMENT", 6, 20], ["pH", "TEST", 118, 120], ["negative contrast electronmicroscopic examination", "TEST", 140, 189], ["statistical evaluation", "TEST", 204, 226], ["AIDS", "PROBLEM", 308, 312], ["clinical symptoms", "PROBLEM", 361, 378]]], ["Data were analyzed using the chi-square test with Yates' correction.", [["the chi-square test", "TEST", 25, 44]]], ["Patients with AIDS or LAS are clearly distinguished by the inversion of the T4/T8 ratio, the decrease in absolute T4 \u00f7 lymphocytes, and the elevation of the serum neopterin.", [["T4 \u00f7 lymphocytes", "ANATOMY", 114, 130], ["serum", "ANATOMY", 157, 162], ["AIDS", "DISEASE", 14, 18], ["LAS", "DISEASE", 22, 25], ["neopterin", "CHEMICAL", 163, 172], ["Patients", "ORGANISM", 0, 8], ["T8", "GENE_OR_GENE_PRODUCT", 79, 81], ["T4 \u00f7 lymphocytes", "CELL", 114, 130], ["serum", "ORGANISM_SUBSTANCE", 157, 162], ["neopterin", "GENE_OR_GENE_PRODUCT", 163, 172], ["T4 \u00f7 lymphocytes", "CELL_TYPE", 114, 130], ["serum neopterin", "PROTEIN", 157, 172], ["Patients", "SPECIES", 0, 8], ["AIDS", "PROBLEM", 14, 18], ["LAS", "PROBLEM", 22, 25], ["the T4/T8 ratio", "TEST", 72, 87], ["the decrease in absolute T4 \u00f7 lymphocytes", "PROBLEM", 89, 130], ["the elevation of the serum neopterin", "PROBLEM", 136, 172], ["T8", "ANATOMY", 79, 81], ["decrease", "OBSERVATION_MODIFIER", 93, 101], ["absolute T4", "OBSERVATION", 105, 116], ["elevation", "OBSERVATION_MODIFIER", 140, 149]]], ["Cutaneous anergy was observed in 10 of 16 cases.", [["Cutaneous", "ANATOMY", 0, 9], ["Cutaneous anergy", "DISEASE", 0, 16], ["Cutaneous anergy", "PROBLEM", 0, 16], ["anergy", "OBSERVATION", 10, 16]]], ["In contrast, the remaining study population of homosexuals or heterosexuals failed to show such abnormalities.ResultsCultures of three consecutive stool samples examined for the presence of bacterial pathogens in symptomatic homosexuals excluded infections of Salmonella sp., Shigella sp., Yersinia sp., and Campylobacter sp.", [["stool samples", "ANATOMY", 147, 160], ["infections", "DISEASE", 246, 256], ["Salmonella sp.", "ORGANISM", 260, 274], ["Shigella sp.", "ORGANISM", 276, 288], ["Yersinia sp.", "ORGANISM", 290, 302], ["Campylobacter sp", "ORGANISM", 308, 324], ["Salmonella sp.", "SPECIES", 260, 274], ["Shigella sp.", "SPECIES", 276, 288], ["Yersinia sp.", "SPECIES", 290, 302], ["Salmonella sp.", "SPECIES", 260, 274], ["Shigella sp.", "SPECIES", 276, 288], ["Yersinia sp.", "SPECIES", 290, 302], ["the remaining study", "TEST", 13, 32], ["heterosexuals", "PROBLEM", 62, 75], ["such abnormalities", "PROBLEM", 91, 109], ["three consecutive stool samples", "TEST", 129, 160], ["bacterial pathogens", "PROBLEM", 190, 209], ["symptomatic homosexuals", "PROBLEM", 213, 236], ["Salmonella sp.", "PROBLEM", 260, 274], ["Shigella sp.", "PROBLEM", 276, 288], ["Yersinia", "PROBLEM", 290, 298], ["Campylobacter sp", "PROBLEM", 308, 324], ["bacterial pathogens", "OBSERVATION", 190, 209], ["Salmonella sp.", "OBSERVATION", 260, 274], ["Campylobacter sp", "OBSERVATION", 308, 324]]], ["Proctoscopy and mucosal biopsies were performed in symptomatic cases and only \" Cysts of the following protozoa were identified as joint agents: Entamoeba histolytica, E. coli, E. hartmanni, Endolimax nana, Jodamoeba bfitschlii, and Giardia lamblia b There is a significant difference (2c~<0.01) of Group A versus Groups B and C, no statistical difference was observed between Group B and Group C. These tests are orthogonal contrasts a nonspecific irritation was observed.", [["mucosal", "ANATOMY", 16, 23], ["Cysts", "ANATOMY", 80, 85], ["joint", "ANATOMY", 131, 136], ["Entamoeba histolytica", "DISEASE", 145, 166], ["Giardia lamblia", "DISEASE", 233, 248], ["mucosal biopsies", "CANCER", 16, 32], ["Entamoeba histolytica", "ORGANISM", 145, 166], ["E. coli", "ORGANISM", 168, 175], ["E. hartmanni", "ORGANISM", 177, 189], ["Endolimax nana", "ORGANISM", 191, 205], ["Jodamoeba bfitschlii", "ORGANISM", 207, 227], ["Giardia lamblia", "ORGANISM", 233, 248], ["Entamoeba histolytica", "SPECIES", 145, 166], ["E. coli", "SPECIES", 168, 175], ["E. hartmanni", "SPECIES", 177, 189], ["Endolimax nana", "SPECIES", 191, 205], ["Jodamoeba bfitschlii", "SPECIES", 207, 227], ["Giardia lamblia", "SPECIES", 233, 248], ["Entamoeba histolytica", "SPECIES", 145, 166], ["E. coli", "SPECIES", 168, 175], ["E. hartmanni", "SPECIES", 177, 189], ["Endolimax nana", "SPECIES", 191, 205], ["Jodamoeba bfitschlii", "SPECIES", 207, 227], ["Giardia lamblia", "SPECIES", 233, 248], ["Proctoscopy", "TEST", 0, 11], ["mucosal biopsies", "TEST", 16, 32], ["Cysts", "PROBLEM", 80, 85], ["Entamoeba histolytica", "PROBLEM", 145, 166], ["E. coli", "PROBLEM", 168, 175], ["E. hartmanni", "PROBLEM", 177, 189], ["Endolimax nana", "PROBLEM", 191, 205], ["Jodamoeba bfitschlii", "PROBLEM", 207, 227], ["Giardia lamblia", "PROBLEM", 233, 248], ["a significant difference", "PROBLEM", 260, 284], ["statistical difference", "PROBLEM", 333, 355], ["These tests", "TEST", 398, 409], ["a nonspecific irritation", "PROBLEM", 435, 459], ["mucosal", "ANATOMY", 16, 23], ["biopsies", "OBSERVATION", 24, 32], ["Cysts", "OBSERVATION", 80, 85], ["joint", "ANATOMY", 131, 136], ["E. coli", "OBSERVATION_MODIFIER", 168, 175], ["hartmanni", "ANATOMY", 180, 189], ["nana", "OBSERVATION_MODIFIER", 201, 205], ["Jodamoeba bfitschlii", "OBSERVATION", 207, 227], ["Giardia lamblia", "OBSERVATION", 233, 248], ["significant", "OBSERVATION_MODIFIER", 262, 273], ["difference", "OBSERVATION_MODIFIER", 274, 284], ["no", "UNCERTAINTY", 330, 332], ["nonspecific", "OBSERVATION_MODIFIER", 437, 448], ["irritation", "OBSERVATION", 449, 459]]], ["Lymph node histology in all cases with lymphadenopathy revealed follicular hyperplasia.", [["Lymph node", "ANATOMY", 0, 10], ["follicular hyperplasia", "ANATOMY", 64, 86], ["lymphadenopathy", "DISEASE", 39, 54], ["follicular hyperplasia", "DISEASE", 64, 86], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 0, 10], ["follicular hyperplasia", "PATHOLOGICAL_FORMATION", 64, 86], ["Lymph node histology", "TEST", 0, 20], ["lymphadenopathy", "PROBLEM", 39, 54], ["follicular hyperplasia", "PROBLEM", 64, 86], ["node histology", "OBSERVATION", 6, 20], ["lymphadenopathy", "OBSERVATION", 39, 54], ["follicular hyperplasia", "OBSERVATION", 64, 86]]], ["The serological, parasitological and virological investigations are concluded in Table 2 .", [["The serological", "TEST", 0, 15], ["parasitological and virological investigations", "TEST", 17, 63]]], ["A high proportion of patients with AIDS or LAS revealed antibodies against hepatitis A, hepatitis B, cytomegatovirus, and syphilis, but so also did homosexuals not belonging to these groups.", [["AIDS", "DISEASE", 35, 39], ["LAS", "DISEASE", 43, 46], ["hepatitis A, hepatitis B", "DISEASE", 75, 99], ["syphilis", "DISEASE", 122, 130], ["patients", "ORGANISM", 21, 29], ["hepatitis A", "ORGANISM", 75, 86], ["hepatitis B", "ORGANISM", 88, 99], ["cytomegatovirus", "CANCER", 101, 116], ["antibodies", "PROTEIN", 56, 66], ["patients", "SPECIES", 21, 29], ["hepatitis A", "SPECIES", 75, 86], ["hepatitis B", "SPECIES", 88, 99], ["AIDS", "PROBLEM", 35, 39], ["LAS", "PROBLEM", 43, 46], ["antibodies", "PROBLEM", 56, 66], ["hepatitis A", "PROBLEM", 75, 86], ["hepatitis B", "PROBLEM", 88, 99], ["cytomegatovirus", "PROBLEM", 101, 116], ["syphilis", "PROBLEM", 122, 130], ["syphilis", "OBSERVATION", 122, 130]]], ["The parasitological stool investigations revealed that 40% to 70% of homosexual men harbor cysts either of apathogenic intestinal protozoa, i.e., Entamoeba coli, Entamoeba hartmanni, Endolimax nana, Jodamoeba buetschlii, or of pathogenic intestinal protozoa, i.e. Entamoeba histolytica or Giardia lamblia (Table 2) .", [["cysts", "ANATOMY", 91, 96], ["intestinal", "ANATOMY", 119, 129], ["intestinal", "ANATOMY", 238, 248], ["intestinal protozoa", "DISEASE", 119, 138], ["Entamoeba coli", "DISEASE", 146, 160], ["intestinal protozoa", "DISEASE", 238, 257], ["Entamoeba histolytica", "DISEASE", 264, 285], ["Giardia lamblia", "DISEASE", 289, 304], ["men", "ORGANISM", 80, 83], ["intestinal", "ORGAN", 119, 129], ["Entamoeba coli", "ORGANISM", 146, 160], ["Entamoeba hartmanni", "ORGANISM", 162, 181], ["Endolimax nana", "ORGANISM", 183, 197], ["Jodamoeba buetschlii", "ORGANISM", 199, 219], ["intestinal", "ORGAN", 238, 248], ["Entamoeba histolytica", "ORGANISM", 264, 285], ["Giardia lamblia", "ORGANISM", 289, 304], ["men", "SPECIES", 80, 83], ["Entamoeba coli", "SPECIES", 146, 160], ["Entamoeba hartmanni", "SPECIES", 162, 181], ["Endolimax nana", "SPECIES", 183, 197], ["Jodamoeba buetschlii", "SPECIES", 199, 219], ["Entamoeba histolytica", "SPECIES", 264, 285], ["Giardia lamblia", "SPECIES", 289, 304], ["Entamoeba coli", "SPECIES", 146, 160], ["Entamoeba hartmanni", "SPECIES", 162, 181], ["Endolimax nana", "SPECIES", 183, 197], ["Jodamoeba buetschlii", "SPECIES", 199, 219], ["Entamoeba histolytica", "SPECIES", 264, 285], ["Giardia lamblia", "SPECIES", 289, 304], ["The parasitological stool investigations", "TEST", 0, 40], ["homosexual men harbor cysts", "PROBLEM", 69, 96], ["apathogenic intestinal protozoa", "PROBLEM", 107, 138], ["Entamoeba coli", "PROBLEM", 146, 160], ["Entamoeba hartmanni", "PROBLEM", 162, 181], ["Endolimax nana", "PROBLEM", 183, 197], ["Jodamoeba buetschlii", "PROBLEM", 199, 219], ["pathogenic intestinal protozoa", "PROBLEM", 227, 257], ["Entamoeba histolytica", "PROBLEM", 264, 285], ["Giardia lamblia", "PROBLEM", 289, 304], ["cysts", "OBSERVATION", 91, 96], ["apathogenic intestinal protozoa", "OBSERVATION", 107, 138], ["Entamoeba coli", "OBSERVATION", 146, 160], ["Entamoeba hartmanni", "OBSERVATION", 162, 181], ["pathogenic", "OBSERVATION_MODIFIER", 227, 237], ["intestinal", "ANATOMY", 238, 248], ["protozoa", "OBSERVATION", 249, 257], ["Entamoeba", "OBSERVATION_MODIFIER", 264, 273], ["histolytica", "OBSERVATION_MODIFIER", 274, 285], ["Giardia lamblia", "OBSERVATION", 289, 304]]], ["By the negative staining technique, distinct particles were visualized electronmicroscopically in i 1 homosexual patients.", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["distinct", "OBSERVATION_MODIFIER", 36, 44], ["particles", "OBSERVATION_MODIFIER", 45, 54]]], ["These particles are to be classified as CVLP because of their typical pleomorphic appearance and their regular radiating projections (Figs.", [["their typical pleomorphic appearance", "PROBLEM", 56, 92], ["pleomorphic", "OBSERVATION_MODIFIER", 70, 81], ["radiating", "OBSERVATION_MODIFIER", 111, 120]]], ["No other distinct structural entities resembling known viruses were found in any specimen.", [["specimen", "ANATOMY", 81, 89], ["other distinct structural entities", "PROBLEM", 3, 37], ["known viruses", "PROBLEM", 49, 62], ["distinct", "OBSERVATION_MODIFIER", 9, 17], ["viruses", "OBSERVATION", 55, 62]]], ["In order to distinguish the particles from cellular debris, the material was further characterized by CsC1 density gradient centrifugation.", [["cellular debris", "ANATOMY", 43, 58], ["cellular", "CELL", 43, 51], ["CsC1", "SIMPLE_CHEMICAL", 102, 106], ["cellular debris", "PROBLEM", 43, 58], ["CsC1 density gradient centrifugation", "TREATMENT", 102, 138], ["particles", "OBSERVATION_MODIFIER", 28, 37], ["cellular debris", "OBSERVATION", 43, 58], ["CsC1 density", "OBSERVATION", 102, 114], ["gradient centrifugation", "OBSERVATION", 115, 138]]], ["A buoyant density of 1.21 g/ml was observed for those particles which clearly identifies CVLP.", [["CVLP", "PROTEIN", 89, 93], ["A buoyant density", "TREATMENT", 0, 17], ["buoyant", "OBSERVATION_MODIFIER", 2, 9], ["density", "OBSERVATION", 10, 17], ["1.21 g", "OBSERVATION_MODIFIER", 21, 27]]], ["Six patients were studied repeatedly over a period of 12 months and CVLP could be identified in all samples re-examined.", [["samples", "ANATOMY", 100, 107], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["CVLP", "TREATMENT", 68, 72], ["all samples", "TEST", 96, 107]]], ["Eight of 16 patients (50%) with AIDS or LAS were found to excrete particles within the feces, a finding which is significantly .01) or with the immunologic findings of an inversed T4/T8 ratio (1-=0.46, P<0.01), whereas no correlation could be found with enteritic symptoms.", [["feces", "ANATOMY", 87, 92], ["AIDS", "DISEASE", 32, 36], ["LAS", "DISEASE", 40, 43], ["patients", "ORGANISM", 12, 20], ["feces", "ORGANISM_SUBDIVISION", 87, 92], ["patients", "SPECIES", 12, 20], ["AIDS", "PROBLEM", 32, 36], ["LAS", "PROBLEM", 40, 43], ["an inversed T4/T8 ratio", "TEST", 168, 191], ["enteritic symptoms", "PROBLEM", 254, 272], ["feces", "ANATOMY", 87, 92], ["T8", "ANATOMY", 183, 185]]], ["Among seven sera from homosexual males with AIDS or LAS, tested for the presence of such particles, one specimen contained a small number of CVLP, whereas no particles were found in 18 heterosexual controls.DiscussionOur findings clearly show that homosexual men are preferentially exposed to a number of infectious or transmittable agents including apathogenic intestinal protozoa.", [["sera", "ANATOMY", 12, 16], ["specimen", "ANATOMY", 104, 112], ["intestinal", "ANATOMY", 362, 372], ["AIDS", "DISEASE", 44, 48], ["apathogenic intestinal protozoa", "DISEASE", 350, 381], ["sera", "ORGANISM_SUBSTANCE", 12, 16], ["CVLP", "GENE_OR_GENE_PRODUCT", 141, 145], ["men", "ORGANISM", 259, 262], ["intestinal", "ORGAN", 362, 372], ["CVLP", "PROTEIN", 141, 145], ["men", "SPECIES", 259, 262], ["AIDS", "PROBLEM", 44, 48], ["such particles", "PROBLEM", 84, 98], ["a small number of CVLP", "PROBLEM", 123, 145], ["particles", "PROBLEM", 158, 167], ["transmittable agents", "TREATMENT", 319, 339], ["apathogenic intestinal protozoa", "PROBLEM", 350, 381], ["small", "OBSERVATION_MODIFIER", 125, 130], ["infectious", "OBSERVATION", 305, 315], ["intestinal", "ANATOMY", 362, 372], ["protozoa", "OBSERVATION", 373, 381]]], ["With the exception of the clear immunologic aberrations seen in patients with AIDS or LAS, most of the homosexual males were found to have markers of presumably sexually transmitted diseases to a similar extent.", [["AIDS", "DISEASE", 78, 82], ["LAS", "DISEASE", 86, 89], ["sexually transmitted diseases", "DISEASE", 161, 190], ["patients", "ORGANISM", 64, 72], ["males", "ORGANISM", 114, 119], ["patients", "SPECIES", 64, 72], ["the clear immunologic aberrations", "PROBLEM", 22, 55], ["AIDS", "PROBLEM", 78, 82], ["LAS", "PROBLEM", 86, 89], ["sexually transmitted diseases", "PROBLEM", 161, 190], ["clear", "OBSERVATION_MODIFIER", 26, 31], ["immunologic aberrations", "OBSERVATION", 32, 55], ["similar extent", "OBSERVATION_MODIFIER", 196, 210]]], ["In 50% of the patients with AIDS or LAS, however, we found structurally distinct viral particles in the feces by the negative staining technique.", [["feces", "ANATOMY", 104, 109], ["AIDS", "DISEASE", 28, 32], ["LAS", "DISEASE", 36, 39], ["patients", "ORGANISM", 14, 22], ["feces", "ORGANISM_SUBSTANCE", 104, 109], ["patients", "SPECIES", 14, 22], ["AIDS", "PROBLEM", 28, 32], ["structurally distinct viral particles in the feces", "PROBLEM", 59, 109], ["distinct", "OBSERVATION_MODIFIER", 72, 80], ["viral particles", "OBSERVATION", 81, 96], ["feces", "ANATOMY", 104, 109]]], ["They showed the typical morphology of coronaviruses characterized by a corona of widely spaced radiating projections [15, 16] and resembled a buoyant density (CsC1) of 1.21 g/ml characteristic of CVLP [12] .", [["coronaviruses", "ORGANISM", 38, 51], ["coronaviruses", "PROBLEM", 38, 51], ["CVLP", "TEST", 196, 200], ["typical morphology", "OBSERVATION_MODIFIER", 16, 34], ["coronaviruses", "OBSERVATION", 38, 51], ["corona", "OBSERVATION_MODIFIER", 71, 77], ["buoyant", "OBSERVATION_MODIFIER", 142, 149], ["density", "OBSERVATION", 150, 157]]], ["The sensitivity in detecting CVLP by our protocol of stool preparation and the EM exploration is not known.", [["CVLP", "CANCER", 29, 33], ["stool", "ORGANISM_SUBSTANCE", 53, 58], ["The sensitivity", "TEST", 0, 15], ["stool preparation", "TREATMENT", 53, 70], ["the EM exploration", "TEST", 75, 93]]], ["However, the observed frequency must be considered as a minimum because samples with low numbers of particles might have been overlooked by the EM method.", [["samples", "ANATOMY", 72, 79], ["low numbers of particles", "PROBLEM", 85, 109]]], ["71 Human coronaviruses (strain 229 E and OC43) are associated with lower respiratory tract disease and are responsible for 15% of common colds [16] .", [["lower respiratory tract", "ANATOMY", 67, 90], ["lower respiratory tract disease", "DISEASE", 67, 98], ["colds", "DISEASE", 137, 142], ["Human coronaviruses", "ORGANISM", 3, 22], ["strain 229 E", "ORGANISM", 24, 36], ["OC43", "GENE_OR_GENE_PRODUCT", 41, 45], ["tract", "ORGANISM_SUBDIVISION", 85, 90], ["Human", "SPECIES", 3, 8], ["Human coronaviruses", "SPECIES", 3, 22], ["lower respiratory tract disease", "PROBLEM", 67, 98], ["common colds", "PROBLEM", 130, 142], ["associated with", "UNCERTAINTY", 51, 66], ["lower", "ANATOMY_MODIFIER", 67, 72], ["respiratory tract", "ANATOMY", 73, 90]]], ["These viruses are distributed world-wide and antibodies ware present with high prevalences [14, 22] .", [["antibodies", "PROTEIN", 45, 55], ["These viruses", "PROBLEM", 0, 13], ["viruses", "OBSERVATION", 6, 13]]], ["In addition,some human coronaviruses may be associated with enteric infections [2, 3, 13] .", [["enteric infections", "DISEASE", 60, 78], ["human", "ORGANISM", 17, 22], ["coronaviruses", "ORGANISM", 23, 36], ["human", "SPECIES", 17, 22], ["human coronaviruses", "SPECIES", 17, 36], ["some human coronaviruses", "PROBLEM", 12, 36], ["enteric infections", "PROBLEM", 60, 78], ["human coronaviruses", "OBSERVATION", 17, 36], ["may be associated with", "UNCERTAINTY", 37, 59], ["infections", "OBSERVATION", 68, 78]]], ["However, their causative role and their serological relationship to other human coronaviruses has not yet been demonstrated [25] .", [["human", "ORGANISM", 74, 79], ["human", "SPECIES", 74, 79], ["human coronaviruses", "SPECIES", 74, 93], ["other human coronaviruses", "PROBLEM", 68, 93]]], ["Two distinct groups of enteric coronaviruses can be differentiated: one is a minor group of enteric coronaviruses that has been reported from neonates associated with epidemic gastroenteritis [24] , and the other occurs in babies in nursery homes and causes a necrotizing ulcerocolitis [6] .", [["enteric coronaviruses", "DISEASE", 23, 44], ["enteric coronaviruses", "DISEASE", 92, 113], ["gastroenteritis", "DISEASE", 176, 191], ["ulcerocolitis", "DISEASE", 272, 285], ["coronaviruses", "ORGANISM", 31, 44], ["coronaviruses", "ORGANISM", 100, 113], ["neonates", "ORGANISM", 142, 150], ["babies", "ORGANISM", 223, 229], ["enteric coronaviruses", "PROBLEM", 23, 44], ["a minor group of enteric coronaviruses", "PROBLEM", 75, 113], ["epidemic gastroenteritis", "PROBLEM", 167, 191], ["a necrotizing ulcerocolitis", "PROBLEM", 258, 285], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["groups", "OBSERVATION_MODIFIER", 13, 19], ["enteric coronaviruses", "OBSERVATION", 23, 44], ["enteric coronaviruses", "OBSERVATION", 92, 113], ["epidemic", "OBSERVATION_MODIFIER", 167, 175], ["gastroenteritis", "OBSERVATION", 176, 191], ["necrotizing", "OBSERVATION_MODIFIER", 260, 271], ["ulcerocolitis", "OBSERVATION", 272, 285]]], ["The major group has been reported from many parts of the world in children and adults with gastrointestinal diseases, although a significant proportion of the unaffected population also shed these particles [3, 12] .", [["gastrointestinal", "ANATOMY", 91, 107], ["gastrointestinal diseases", "DISEASE", 91, 116], ["children", "ORGANISM", 66, 74], ["gastrointestinal", "ORGAN", 91, 107], ["children", "SPECIES", 66, 74], ["gastrointestinal diseases", "PROBLEM", 91, 116], ["the unaffected population", "PROBLEM", 155, 180], ["gastrointestinal", "ANATOMY", 91, 107], ["diseases", "OBSERVATION", 108, 116]]], ["It is deduced that coronavirus infection might become endemic under low standard of personal hygiene as there is a high incidence found in the rural population in Southern India [15] and among Australian aborigines [23] .DiscussionWhile no information is available with regard to the mode of transmission of enteric coronaviruses, similarities to other viral and microbial agents present in the homosexual population become obvious.", [["coronavirus infection", "DISEASE", 19, 40], ["enteric coronaviruses", "DISEASE", 308, 329], ["coronavirus", "ORGANISM", 19, 30], ["enteric coronaviruses", "ORGANISM", 308, 329], ["coronavirus infection", "PROBLEM", 19, 40], ["enteric coronaviruses", "PROBLEM", 308, 329], ["microbial agents", "TREATMENT", 363, 379], ["coronavirus", "OBSERVATION_MODIFIER", 19, 30], ["infection", "OBSERVATION", 31, 40], ["enteric coronaviruses", "ANATOMY", 308, 329]]], ["The particular intimate contacts of homosexuals favor a fecal-oral route of transmission [19] .", [["oral", "ANATOMY", 62, 66], ["fecal", "ORGANISM_SUBDIVISION", 56, 61], ["oral", "ORGANISM_SUBDIVISION", 62, 66]]], ["In epidemiologic studies it has been shown that the enteric coronaviruses are occasionally excreted in the feces over a long period of time (up to 85 months) [3] .", [["feces", "ANATOMY", 107, 112], ["enteric coronaviruses", "ORGANISM", 52, 73], ["feces", "ORGANISM_SUBDIVISION", 107, 112], ["epidemiologic studies", "TEST", 3, 24], ["the enteric coronaviruses", "PROBLEM", 48, 73], ["enteric coronaviruses", "ANATOMY", 52, 73], ["occasionally", "OBSERVATION_MODIFIER", 78, 90], ["excreted", "OBSERVATION_MODIFIER", 91, 99], ["feces", "OBSERVATION_MODIFIER", 107, 112]]], ["This was also found in our patients with LAS or AIDS, even during potent antiviral therapy with rIFN ~A. However, the most striking finding was the presence of the virus in the blood of one patient with LAS and intermittent diarrhea.", [["blood", "ANATOMY", 177, 182], ["LAS", "DISEASE", 41, 44], ["AIDS", "DISEASE", 48, 52], ["LAS", "DISEASE", 203, 206], ["intermittent diarrhea", "DISEASE", 211, 232], ["patients", "ORGANISM", 27, 35], ["blood", "ORGANISM_SUBSTANCE", 177, 182], ["patient", "ORGANISM", 190, 197], ["patients", "SPECIES", 27, 35], ["patient", "SPECIES", 190, 197], ["LAS", "PROBLEM", 41, 44], ["AIDS", "PROBLEM", 48, 52], ["potent antiviral therapy", "TREATMENT", 66, 90], ["rIFN", "TREATMENT", 96, 100], ["the virus", "PROBLEM", 160, 169], ["LAS", "PROBLEM", 203, 206], ["intermittent diarrhea", "PROBLEM", 211, 232], ["virus", "OBSERVATION", 164, 169], ["intermittent", "OBSERVATION_MODIFIER", 211, 223], ["diarrhea", "OBSERVATION", 224, 232]]], ["This illustrates that the organ tropism of most of the known animal or human coronaviruses [25] might not be present in the examined group of homosexual males.", [["organ", "ANATOMY", 26, 31], ["organ", "ORGAN", 26, 31], ["human coronaviruses", "ORGANISM", 71, 90], ["human", "SPECIES", 71, 76], ["human coronaviruses", "SPECIES", 71, 90], ["human coronaviruses", "PROBLEM", 71, 90], ["homosexual males", "OBSERVATION", 142, 158]]], ["In contrast to acute infections caused by most of the known animal and human coronaviruses, some murine and feline types involve multiple organs and have a strong tendency to establish persistent and chronic diseases [10, 25] .", [["organs", "ANATOMY", 138, 144], ["infections", "DISEASE", 21, 31], ["human", "ORGANISM", 71, 76], ["coronaviruses", "ORGANISM", 77, 90], ["murine", "ORGANISM", 97, 103], ["feline", "ORGANISM", 108, 114], ["organs", "ORGAN", 138, 144], ["human", "SPECIES", 71, 76], ["murine", "SPECIES", 97, 103], ["human coronaviruses", "SPECIES", 71, 90], ["acute infections", "PROBLEM", 15, 31], ["the known animal and human coronaviruses", "PROBLEM", 50, 90], ["persistent and chronic diseases", "PROBLEM", 185, 216], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["infections", "OBSERVATION", 21, 31], ["persistent", "OBSERVATION_MODIFIER", 185, 195], ["chronic", "OBSERVATION_MODIFIER", 200, 207], ["diseases", "OBSERVATION", 208, 216]]], ["It remains open to question whether the detection of CVLP in human feces and blood demonstrates the systemic spread and multiple organ tropism of an up until now unrecognized strain of the CVLP.DiscussionIt appears that CVLP might act as another infectious agent in homosexual men and that chronic infections might establish themselves because of the particular immunodeficient state characteristic of AIDS or diseases belonging to the AIDS-related complex.", [["feces", "ANATOMY", 67, 72], ["blood", "ANATOMY", 77, 82], ["organ", "ANATOMY", 129, 134], ["CVLP", "CHEMICAL", 220, 224], ["chronic infections", "DISEASE", 290, 308], ["AIDS", "DISEASE", 402, 406], ["AIDS", "DISEASE", 436, 440], ["CVLP", "GENE_OR_GENE_PRODUCT", 53, 57], ["human", "ORGANISM", 61, 66], ["feces", "ORGANISM_SUBSTANCE", 67, 72], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["organ", "ORGAN", 129, 134], ["CVLP", "CANCER", 189, 193], ["CVLP", "GENE_OR_GENE_PRODUCT", 220, 224], ["men", "ORGANISM", 277, 280], ["CVLP", "PROTEIN", 53, 57], ["AIDS-related complex", "PROTEIN", 436, 456], ["human", "SPECIES", 61, 66], ["men", "SPECIES", 277, 280], ["human", "SPECIES", 61, 66], ["the detection of CVLP in human feces", "TEST", 36, 72], ["blood", "TEST", 77, 82], ["the systemic spread", "PROBLEM", 96, 115], ["multiple organ tropism", "PROBLEM", 120, 142], ["CVLP", "TREATMENT", 220, 224], ["chronic infections", "PROBLEM", 290, 308], ["AIDS", "PROBLEM", 402, 406], ["diseases", "PROBLEM", 410, 418], ["chronic", "OBSERVATION_MODIFIER", 290, 297], ["infections", "OBSERVATION", 298, 308], ["complex", "OBSERVATION_MODIFIER", 449, 456]]]], "c0f102738445b0a4c2af4323fe69d319d9e09eda": [["INTRODUCTIONSystemic lupus erythematosis (SLE) is a common autoimmune disease.", [["lupus erythematosis", "DISEASE", 21, 40], ["SLE", "DISEASE", 42, 45], ["autoimmune disease", "DISEASE", 59, 77], ["SLE", "CANCER", 42, 45], ["INTRODUCTIONSystemic lupus erythematosis (SLE)", "PROBLEM", 0, 46], ["a common autoimmune disease", "PROBLEM", 50, 77], ["lupus erythematosis", "OBSERVATION", 21, 40], ["common", "OBSERVATION_MODIFIER", 52, 58], ["autoimmune", "OBSERVATION", 59, 69]]], ["The pathogenesis of SLE and the induced factors of active SLE are not completely clear, but it is generally considered that SLE is caused by both hereditary and environmental factors that ultimately lead to an abnormal immune response.", [["SLE", "DISEASE", 20, 23], ["SLE", "DISEASE", 58, 61], ["SLE", "DISEASE", 124, 127], ["hereditary", "DISEASE", 146, 156], ["SLE", "CANCER", 20, 23], ["SLE", "CANCER", 58, 61], ["SLE", "PROBLEM", 20, 23], ["active SLE", "PROBLEM", 51, 61], ["SLE", "PROBLEM", 124, 127], ["both hereditary and environmental factors", "PROBLEM", 141, 182], ["an abnormal immune response", "PROBLEM", 207, 234], ["SLE", "OBSERVATION", 20, 23], ["active", "OBSERVATION_MODIFIER", 51, 57], ["SLE", "OBSERVATION", 58, 61], ["immune response", "OBSERVATION", 219, 234]]], ["Sunlight and ultraviolet (UV) rays have been considered to be the most important environmental factors in the induction of SLE.", [["SLE", "DISEASE", 123, 126], ["Sunlight and ultraviolet (UV) rays", "TREATMENT", 0, 34], ["SLE", "PROBLEM", 123, 126]]], ["1 Based on this, a high incidence of SLE should occur in summer and autumn when there is stronger sunlight and more intense UV rays.", [["SLE", "DISEASE", 37, 40], ["SLE", "PROBLEM", 37, 40], ["SLE", "OBSERVATION", 37, 40]]], ["However, in clinical practice, we have found that more patients with SLE visit hospital at the end of autumn and at the end of winter, as well as at the beginning of winter and the beginning of spring, while in the summer and the autumn, less patients with SLE visit hospital.", [["SLE", "DISEASE", 69, 72], ["SLE", "DISEASE", 257, 260], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 243, 251]]], ["In order to confirm that high incidences of SLE should occur in summer and autumn when sunlight and UV rays are strong, we retrospectively analyzed the characteristics of seasonal distribution of active SLE and its correlation with meteorological factors in 640 patients, who live in the city of Zhanjiang, China and had active SLE between January 1997 and December 2006.MATERIALS AND METHODSAll study methods were approved by ethics committee of Affiliated Hospital of Guangdong Medical College.", [["SLE", "DISEASE", 44, 47], ["SLE", "DISEASE", 203, 206], ["SLE", "DISEASE", 328, 331], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["high incidences of SLE", "PROBLEM", 25, 47], ["sunlight and UV rays", "TEST", 87, 107], ["active SLE", "PROBLEM", 196, 206], ["SLE", "OBSERVATION", 44, 47], ["active", "OBSERVATION_MODIFIER", 196, 202], ["SLE", "OBSERVATION", 203, 206]]], ["All the subjects enrolled in the study gave written formal consent to participate.Clinical dataThe 640 patients with active SLE were attented the Affiliated Hospital of Guangdong Medical College between January 1997 and December 2006.", [["SLE", "DISEASE", 124, 127], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["the study", "TEST", 29, 38]]], ["All patients conformed to the diagnostic criteria for SLE published by the American College of Rheumatology in 1982.", [["SLE", "DISEASE", 54, 57], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["2 Of the 640 patients, 567 were female and 73 were male, with a mean age of (28.8\u00a112.1) years (range: 5-69).", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["Disease duration was between 2 days and 20 years.", [["Disease duration", "PROBLEM", 0, 16]]], ["SLE disease activity index (SLEDAI) was evaluated with a SLEDAI score system in all patients.", [["SLE", "DISEASE", 0, 3], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["SLE disease activity index", "PROBLEM", 0, 26], ["a SLEDAI score system", "TEST", 55, 76]]], ["The patients with SLEDAI $10 were considered to have severely active SLE and were included in the study.", [["SLE", "DISEASE", 69, 72], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["SLEDAI $", "TREATMENT", 18, 26], ["severely active SLE", "PROBLEM", 53, 72], ["the study", "TEST", 94, 103], ["active", "OBSERVATION_MODIFIER", 62, 68], ["SLE", "OBSERVATION", 69, 72]]], ["Of the 640 patients, SLE occurred for the first time or recurred Copyright \u00df 2011 CLINICS -This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. as a result of stopping treatment when their condition improved.", [["SLE", "DISEASE", 21, 24], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["SLE", "PROBLEM", 21, 24], ["stopping treatment", "TREATMENT", 412, 430]]], ["Of the patients who had been hospitalized several times as a result of a flare episode with SLEDAI $10, we only recorded the first data.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["a flare episode", "PROBLEM", 71, 86]]], ["The patients in whom SLEDAI score could not be calculated as a result of incomplete clinical data, infection, or who were living more than 100 km from the city center were excluded from this study.Meteorological dataMeteorological data between January 1997 and December 2006 were obtained from the Weather Bureau of Zhanjiang City, and the mean temperature and humidity of each month were calculated.Analysis of dataThe absolute and relative numbers of the patients with active SLE (relative to the total number of inpatients) were calculated.", [["infection", "DISEASE", 99, 108], ["SLE", "DISEASE", 478, 481], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 457, 465], ["SLEDAI", "PROTEIN", 21, 27], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 457, 465], ["SLEDAI score", "TEST", 21, 33], ["incomplete clinical data", "PROBLEM", 73, 97], ["infection", "PROBLEM", 99, 108], ["this study", "TEST", 186, 196], ["the mean temperature", "TEST", 336, 356], ["Analysis of data", "TEST", 400, 416], ["active SLE", "PROBLEM", 471, 481], ["infection", "OBSERVATION", 99, 108], ["absolute", "OBSERVATION_MODIFIER", 420, 428], ["relative", "OBSERVATION_MODIFIER", 433, 441], ["numbers", "OBSERVATION_MODIFIER", 442, 449], ["active", "OBSERVATION_MODIFIER", 471, 477], ["SLE", "OBSERVATION", 478, 481]]], ["The correlations between the number of patients with active SLE and meteorological factors including temperature and humidity were analyzed.Statistical analysisStatistical analysis was performed with SPSS (12.0) software. x 2 test was used for the comparison of ratios.", [["SLE", "DISEASE", 60, 63], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["active SLE", "PROBLEM", 53, 63], ["temperature and humidity", "TREATMENT", 101, 125], ["Statistical analysisStatistical analysis", "TEST", 140, 180], ["SPSS", "TEST", 200, 204], ["x 2 test", "TEST", 222, 230], ["the comparison of ratios", "TEST", 244, 268], ["active", "OBSERVATION_MODIFIER", 53, 59], ["SLE", "OBSERVATION", 60, 63]]], ["Spearman analysis was used to evaluate the correlations between the number of patients with active SLE and meteorological factors.", [["SLE", "DISEASE", 99, 102], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["Spearman analysis", "TEST", 0, 17], ["active SLE", "PROBLEM", 92, 102], ["meteorological factors", "PROBLEM", 107, 129], ["active", "OBSERVATION_MODIFIER", 92, 98], ["SLE", "OBSERVATION", 99, 102]]], ["Statistical significance was established at p,0.05.Characteristics of seasonal distribution of patients with active systemic lupus erythematosus (SLE)Between January 1997 and December 2006, there were 640 patients who conformed to the diagnostic criteria for SLE and had a SLEDAI score of $10.", [["systemic lupus erythematosus", "DISEASE", 116, 144], ["SLE", "DISEASE", 146, 149], ["SLE", "DISEASE", 259, 262], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 205, 213], ["active systemic lupus erythematosus", "PROBLEM", 109, 144], ["SLE", "PROBLEM", 259, 262], ["seasonal distribution", "OBSERVATION", 70, 91], ["active", "OBSERVATION_MODIFIER", 109, 115], ["systemic", "OBSERVATION_MODIFIER", 116, 124], ["lupus erythematosus", "OBSERVATION", 125, 144]]], ["Results indicated that the number of patients with active SLE was highest in winter (December, January and February) and lowest at the junction between summer and autumn (July, August and September).", [["SLE", "DISEASE", 58, 61], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["active SLE", "PROBLEM", 51, 61], ["active", "OBSERVATION_MODIFIER", 51, 57], ["SLE", "OBSERVATION", 58, 61]]], ["Distribution of the 640 patients over 12 months is shown in Figure 1 and Table 1 .Ratios of patients with active systemic lupus erythematosus (SLE) relative to total inpatientsResults indicated that the total number of inpatients was less in January and February, and there was no significant difference in the number of inpatients between other months.", [["systemic lupus erythematosus", "DISEASE", 113, 141], ["SLE", "DISEASE", 143, 146], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 92, 100], ["active systemic lupus erythematosus", "PROBLEM", 106, 141], ["active", "OBSERVATION_MODIFIER", 106, 112], ["systemic", "OBSERVATION_MODIFIER", 113, 121], ["lupus erythematosus", "OBSERVATION", 122, 141], ["no", "UNCERTAINTY", 278, 280], ["significant", "OBSERVATION_MODIFIER", 281, 292], ["difference", "OBSERVATION_MODIFIER", 293, 303]]], ["The ratios of patients with active SLE relative to total inpatients are shown in Table 2 .", [["SLE", "DISEASE", 35, 38], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["active SLE", "PROBLEM", 28, 38]]], ["The trend of relative ratios of patients with active SLE was consistent with that of the absolute number of patients with active SLE.", [["SLE", "DISEASE", 53, 56], ["SLE", "DISEASE", 129, 132], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 108, 116], ["active SLE", "PROBLEM", 46, 56], ["active SLE", "PROBLEM", 122, 132], ["active", "OBSERVATION_MODIFIER", 46, 52], ["SLE", "OBSERVATION", 53, 56], ["active", "OBSERVATION_MODIFIER", 122, 128], ["SLE", "OBSERVATION", 129, 132]]], ["Namely, that the relative ratios of patients with active SLE were the highest in December, January and February, and lowest in July, August and September.", [["SLE", "DISEASE", 57, 60], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["active SLE", "PROBLEM", 50, 60]]], ["The relative ratio of patients with active SLE was significantly higher in winter (December, January and February) than in spring (March, April and May), summer (June, July and August) and autumn (September, October and November) (p,0.001).", [["SLE", "DISEASE", 43, 46], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["active SLE", "PROBLEM", 36, 46], ["active", "OBSERVATION_MODIFIER", 36, 42], ["SLE", "OBSERVATION", 43, 46]]], ["There was no statistical significance in relative ratios of patients with active SLE between spring, summer and autumn (p.0.05).Correlation between the number of patients with active systemic lupus erythematosus (SLE) and the mean temperatureThe years between January 1997 and December 2006, were divided into 120 months with a 'month' categorized as a unit.", [["SLE", "DISEASE", 81, 84], ["systemic lupus erythematosus", "DISEASE", 183, 211], ["SLE", "DISEASE", 213, 216], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 162, 170], ["active SLE", "PROBLEM", 74, 84], ["active systemic lupus erythematosus", "PROBLEM", 176, 211], ["SLE)", "PROBLEM", 213, 217], ["the mean temperature", "TEST", 222, 242], ["no", "UNCERTAINTY", 10, 12], ["active", "OBSERVATION_MODIFIER", 74, 80], ["SLE", "OBSERVATION", 81, 84], ["active", "OBSERVATION_MODIFIER", 176, 182], ["systemic", "OBSERVATION_MODIFIER", 183, 191], ["lupus erythematosus", "OBSERVATION", 192, 211]]], ["Then the mean temperature of each month was calculated.", [["the mean temperature", "TEST", 5, 25]]], ["The correlations between the number of patients with active SLE and the mean temperature in the same month were analyzed; it was found that there was a significantly inverse correlation between both (r = -0.352, p,0.001, Figure 2 and Table 1 ).Correlation between the number of patients with active systemic lupus erythematosus (SLE) and mean humidityThe years between January 1997 and December 2006 were divided into 120 months with a 'month' categorized as a unit, and then the mean humidity of each month was calculated.", [["SLE", "DISEASE", 60, 63], ["systemic lupus erythematosus", "DISEASE", 299, 327], ["SLE", "DISEASE", 329, 332], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 278, 286], ["active SLE", "PROBLEM", 53, 63], ["the mean temperature", "TEST", 68, 88], ["p,", "TEST", 212, 214], ["Figure", "TEST", 221, 227], ["active systemic lupus erythematosus", "PROBLEM", 292, 327], ["mean humidity", "TEST", 338, 351], ["active", "OBSERVATION_MODIFIER", 53, 59], ["SLE", "OBSERVATION", 60, 63], ["active", "OBSERVATION_MODIFIER", 292, 298], ["systemic", "OBSERVATION_MODIFIER", 299, 307], ["lupus erythematosus", "OBSERVATION", 308, 327]]], ["The correlations between the number of patients with active SLE and the mean humidity in the same month were analyzed; it was found that there was no significant correlation between either (r = -0.053, p.0.05, Figure 3 ).DISCUSSIONAside from hereditary factors and sexual hormones, 3, 4 environmental factors are also among the main factors in the induction of SLE.", [["SLE", "DISEASE", 60, 63], ["SLE", "DISEASE", 361, 364], ["patients", "ORGANISM", 39, 47], ["SLE", "CANCER", 361, 364], ["hereditary factors", "PROTEIN", 242, 260], ["patients", "SPECIES", 39, 47], ["active SLE", "PROBLEM", 53, 63], ["the mean humidity", "TEST", 68, 85], ["SLE", "PROBLEM", 361, 364], ["active", "OBSERVATION_MODIFIER", 53, 59], ["SLE", "OBSERVATION", 60, 63]]], ["5 Considering environmental factors, UVinduced SLE has attracted much attention.", [["SLE", "DISEASE", 47, 50]]], ["UV light may induce auto-antigenic apoptotic particles resulting in DNA peroxidation and up-regulation of some cytokines and chemotactic factors, resulting in SLE or its recurrence.", [["SLE", "DISEASE", 159, 162], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["SLE", "CANCER", 159, 162], ["cytokines", "PROTEIN", 111, 120], ["chemotactic factors", "PROTEIN", 125, 144], ["UV light", "TREATMENT", 0, 8], ["auto-antigenic apoptotic particles", "PROBLEM", 20, 54], ["DNA peroxidation", "PROBLEM", 68, 84], ["some cytokines", "PROBLEM", 106, 120], ["chemotactic factors", "PROBLEM", 125, 144], ["SLE", "PROBLEM", 159, 162], ["its recurrence", "PROBLEM", 166, 180], ["apoptotic particles", "OBSERVATION", 35, 54], ["DNA peroxidation", "OBSERVATION", 68, 84], ["some", "OBSERVATION_MODIFIER", 106, 110], ["cytokines", "OBSERVATION", 111, 120], ["chemotactic factors", "OBSERVATION", 125, 144], ["recurrence", "OBSERVATION", 170, 180]]], ["6 Based on this, the incidence of SLE in the summer and the autumn, when there is stronger sunlight and stronger UV rays, should be higher.", [["SLE", "DISEASE", 34, 37], ["SLE", "PROBLEM", 34, 37], ["stronger sunlight and stronger UV rays", "PROBLEM", 82, 120], ["SLE", "OBSERVATION", 34, 37], ["autumn", "OBSERVATION", 60, 66], ["higher", "OBSERVATION_MODIFIER", 132, 138]]], ["However, there have been different reports regarding seasonal distribution of active SLE.", [["SLE", "DISEASE", 85, 88], ["SLE", "CANCER", 85, 88], ["active SLE", "PROBLEM", 78, 88], ["active", "OBSERVATION_MODIFIER", 78, 84], ["SLE", "OBSERVATION", 85, 88]]], ["[7] [8] [9] [10] [11] [12] Differing results may be due to the fact that patients lived in various geographical locations, the sample sizes were small, and SLE was stable in the patients who were being followed-up and being treated with drugs, which failed to objectively reflect seasonal distribution of active SLE.DISCUSSIONThe purpose of this study was to explore seasonal distribution of active SLE.", [["sample", "ANATOMY", 127, 133], ["SLE", "DISEASE", 156, 159], ["SLE", "DISEASE", 312, 315], ["SLE", "DISEASE", 399, 402], ["[7] [8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 0, 26], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 178, 186], ["drugs", "TREATMENT", 237, 242], ["active SLE", "PROBLEM", 305, 315], ["this study", "TEST", 341, 351], ["active SLE", "PROBLEM", 392, 402], ["sizes", "OBSERVATION_MODIFIER", 134, 139], ["small", "OBSERVATION_MODIFIER", 145, 150], ["stable", "OBSERVATION_MODIFIER", 164, 170], ["active", "OBSERVATION_MODIFIER", 305, 311], ["SLE", "OBSERVATION", 312, 315], ["active", "OBSERVATION_MODIFIER", 392, 398], ["SLE", "OBSERVATION", 399, 402]]], ["Our hospital is the largest hospital in the local area (Zhanjiang City, Guangdong Province, China) and is also the control center for rheumatic autoimmune disease.", [["rheumatic autoimmune disease", "DISEASE", 134, 162], ["rheumatic autoimmune disease", "PROBLEM", 134, 162], ["largest", "OBSERVATION_MODIFIER", 20, 27], ["rheumatic", "OBSERVATION_MODIFIER", 134, 143], ["autoimmune", "OBSERVATION", 144, 154]]], ["The majority of patients with SLE in Zhanjiang City attend the hospital for diagnosis and treatment.", [["SLE", "DISEASE", 30, 33], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["treatment", "TREATMENT", 90, 99]]], ["Patients with active SLE in this study reside in Zhanjiang City.", [["SLE", "DISEASE", 21, 24], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["active SLE", "PROBLEM", 14, 24], ["this study", "TEST", 28, 38], ["active", "OBSERVATION_MODIFIER", 14, 20], ["SLE", "OBSERVATION", 21, 24]]], ["According to the SLEDAI score system, SLEDAI ,5 was considered as mild SLE, 5-10 as moderate and .10 as severe.", [["SLE", "DISEASE", 71, 74], ["SLEDAI", "TEST", 38, 44], ["mild SLE", "PROBLEM", 66, 74], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["SLE", "OBSERVATION", 71, 74], ["severe", "OBSERVATION_MODIFIER", 104, 110]]], ["13 Hormones and immunosuppressive agents are generally given when the SLEDAI is $6.", [["immunosuppressive agents", "TREATMENT", 16, 40]]], ["14 After administration of hormones and immunosuppressive agents, most patients still have moderate SLE (SLEDAI: 5-10) for a lengthy period.", [["SLE", "DISEASE", 100, 103], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["hormones", "TREATMENT", 27, 35], ["immunosuppressive agents", "TREATMENT", 40, 64], ["moderate SLE", "PROBLEM", 91, 103], ["moderate", "OBSERVATION_MODIFIER", 91, 99], ["SLE", "OBSERVATION", 100, 103]]], ["Although therapy is effective, SLEDAI fails to decrease to 0.", [["therapy", "TREATMENT", 9, 16]]], ["To ensure patients had active SLE, only patients with a SLEDAI of $10 were included in this study.", [["SLE", "DISEASE", 30, 33], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 40, 48], ["active SLE", "PROBLEM", 23, 33], ["this study", "TEST", 87, 97]]], ["These patients, therefore, basically reflect the distribution of active SLE in Zhanjiang City.DISCUSSIONOur results indicate that the number of patients with active SLE was highest in winter (December, January and February) and lowest in summer (June, July and August).DISCUSSIONTo eliminate the influence of other factors, we also analyzed the total number of inpatients each month between January 1997 and December 2006 and calculated the ratio of patients with active SLE relative to the total number of inpatients.", [["SLE", "DISEASE", 72, 75], ["SLE", "DISEASE", 165, 168], ["SLE", "DISEASE", 471, 474], ["patients", "ORGANISM", 6, 14], ["SLE", "CANCER", 72, 75], ["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 450, 458], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 450, 458], ["active SLE", "PROBLEM", 65, 75], ["active SLE", "PROBLEM", 464, 474], ["active", "OBSERVATION_MODIFIER", 65, 71], ["SLE", "OBSERVATION", 72, 75], ["active", "OBSERVATION_MODIFIER", 464, 470], ["SLE", "OBSERVATION", 471, 474]]], ["We also found that the relative ratio of patients with active SLE was significantly higher in winter than in other seasons.", [["SLE", "DISEASE", 62, 65], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["active SLE", "PROBLEM", 55, 65], ["active", "OBSERVATION_MODIFIER", 55, 61], ["SLE", "OBSERVATION", 62, 65]]], ["Based on collected meteorological data, the annual mean temperature is 23.2\u02daC. In July, the mean temperature is 29.1\u02daC, there is the most daylight and sunlight intensity is strongest.", [["collected meteorological data", "TEST", 9, 38], ["the annual mean temperature", "TEST", 40, 67], ["the mean temperature", "TEST", 88, 108]]], ["In January, the mean temperature is 16.6\u02daC, there is least daylight and sunlight intensity is weakest.", [["the mean temperature", "TEST", 12, 32], ["sunlight intensity", "OBSERVATION_MODIFIER", 72, 90]]], ["In contrast with the traditional viewpoint that the highest incidence of SLE should occur when sunlight and UV rays are strong, our results show that the number of patients with active SLE is fewer in summer when UV rays are stronger, while there is a higher incidence in winter when UV rays are weaker.", [["SLE", "DISEASE", 73, 76], ["SLE", "DISEASE", 185, 188], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["SLE", "PROBLEM", 73, 76], ["sunlight and UV rays", "TEST", 95, 115], ["active SLE", "PROBLEM", 178, 188], ["UV rays", "TEST", 284, 291], ["SLE", "OBSERVATION", 73, 76], ["active", "OBSERVATION_MODIFIER", 178, 184], ["SLE", "OBSERVATION", 185, 188]]], ["Our study failed to discover whether various lupus lesions have seasonal distribution; however, Schlesinger et al. 15 found that the incidence of membranous lupus nephritis increased in winter.DISCUSSIONIt is known that many infectious diseases have seasonal distributions, and high incidences of infectious diseases mostly occur in winter.", [["lupus lesions", "ANATOMY", 45, 58], ["lupus lesions", "DISEASE", 45, 58], ["lupus nephritis", "DISEASE", 157, 172], ["infectious diseases", "DISEASE", 225, 244], ["infectious diseases", "DISEASE", 297, 316], ["lupus lesions", "PATHOLOGICAL_FORMATION", 45, 58], ["Our study", "TEST", 0, 9], ["various lupus lesions", "PROBLEM", 37, 58], ["membranous lupus nephritis", "PROBLEM", 146, 172], ["many infectious diseases", "PROBLEM", 220, 244], ["seasonal distributions", "PROBLEM", 250, 272], ["infectious diseases", "PROBLEM", 297, 316], ["various", "OBSERVATION_MODIFIER", 37, 44], ["lupus", "OBSERVATION", 45, 50], ["seasonal", "OBSERVATION_MODIFIER", 64, 72], ["distribution", "OBSERVATION_MODIFIER", 73, 85], ["membranous", "OBSERVATION_MODIFIER", 146, 156], ["lupus nephritis", "OBSERVATION", 157, 172], ["increased", "OBSERVATION_MODIFIER", 173, 182], ["many", "OBSERVATION_MODIFIER", 220, 224], ["infectious", "OBSERVATION", 225, 235], ["infectious", "OBSERVATION", 297, 307]]], ["16 Some virus infections are positively correlated with serum anti-ds-DNA antibody titers of patients with SLE.", [["serum", "ANATOMY", 56, 61], ["infections", "DISEASE", 14, 24], ["SLE", "DISEASE", 107, 110], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["patients", "ORGANISM", 93, 101], ["serum anti-ds", "PROTEIN", 56, 69], ["patients", "SPECIES", 93, 101], ["Some virus infections", "PROBLEM", 3, 24], ["serum anti-ds", "TEST", 56, 69], ["DNA antibody titers", "TEST", 70, 89], ["SLE", "PROBLEM", 107, 110], ["virus", "OBSERVATION_MODIFIER", 8, 13], ["infections", "OBSERVATION", 14, 24]]], ["17 A high incidence of virus infection of the respiratory tract occurs in winter and spring.", [["respiratory tract", "ANATOMY", 46, 63], ["infection of the respiratory tract", "DISEASE", 29, 63], ["respiratory tract", "ORGANISM_SUBDIVISION", 46, 63], ["virus infection of the respiratory tract", "PROBLEM", 23, 63], ["high", "OBSERVATION_MODIFIER", 5, 9], ["virus", "OBSERVATION_MODIFIER", 23, 28], ["infection", "OBSERVATION", 29, 38], ["respiratory tract", "ANATOMY", 46, 63]]], ["In order to eliminate the influence of infection factors on seasonal distribution of active SLE, patients who had active SLE combined with an infection were excluded from the study.", [["infection", "DISEASE", 39, 48], ["SLE", "DISEASE", 92, 95], ["SLE", "DISEASE", 121, 124], ["infection", "DISEASE", 142, 151], ["patients", "ORGANISM", 97, 105], ["infection factors", "PROTEIN", 39, 56], ["patients", "SPECIES", 97, 105], ["infection factors", "PROBLEM", 39, 56], ["active SLE", "PROBLEM", 85, 95], ["active SLE", "PROBLEM", 114, 124], ["an infection", "PROBLEM", 139, 151], ["the study", "TEST", 171, 180], ["infection", "OBSERVATION", 39, 48], ["active", "OBSERVATION_MODIFIER", 85, 91], ["SLE", "OBSERVATION", 92, 95], ["active", "OBSERVATION_MODIFIER", 114, 120], ["SLE", "OBSERVATION", 121, 124], ["infection", "OBSERVATION", 142, 151]]], ["Therefore, it can be discounted that infection causes a high incidence of active SLE in the winter and a low incidence in the summer.DISCUSSIONOur study has found that there is no correlation between the absolute number of patients with active SLE and the mean humidity, while there is an inverse correlation between the number of patients with active SLE and the mean temperature, demonstrating that, based on genetic background, a low-temperature environment may be one of the causes to induce SLE.", [["infection", "DISEASE", 37, 46], ["SLE", "DISEASE", 81, 84], ["SLE", "DISEASE", 244, 247], ["SLE", "DISEASE", 352, 355], ["SLE", "DISEASE", 496, 499], ["patients", "ORGANISM", 223, 231], ["patients", "ORGANISM", 331, 339], ["patients", "SPECIES", 223, 231], ["patients", "SPECIES", 331, 339], ["infection", "PROBLEM", 37, 46], ["active SLE", "PROBLEM", 74, 84], ["DISCUSSIONOur study", "TEST", 133, 152], ["active SLE", "PROBLEM", 237, 247], ["active SLE", "PROBLEM", 345, 355], ["genetic background", "TEST", 411, 429], ["a low-temperature environment", "PROBLEM", 431, 460], ["SLE", "PROBLEM", 496, 499], ["infection", "OBSERVATION", 37, 46], ["high", "OBSERVATION_MODIFIER", 56, 60], ["active", "OBSERVATION_MODIFIER", 74, 80], ["SLE", "OBSERVATION", 81, 84], ["low incidence", "OBSERVATION_MODIFIER", 105, 118], ["active", "OBSERVATION_MODIFIER", 237, 243], ["SLE", "OBSERVATION", 244, 247], ["active", "OBSERVATION_MODIFIER", 345, 351], ["SLE", "OBSERVATION", 352, 355]]], ["Some scholars speculate that a high incidence of SLE in winter may be caused by UV accumulation after exposure to strong sunlight in summer.", [["SLE", "DISEASE", 49, 52], ["UV", "CHEMICAL", 80, 82], ["SLE", "PROBLEM", 49, 52], ["UV accumulation", "PROBLEM", 80, 95], ["high", "OBSERVATION_MODIFIER", 31, 35], ["SLE", "OBSERVATION", 49, 52]]], ["11 Leone et al. 18 found that the level of serum anti-dsDNA is increased, while the levels of C3 and C4 are decreased in patients with SLE from August to January.", [["serum", "ANATOMY", 43, 48], ["SLE", "DISEASE", 135, 138], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["anti-dsDNA", "GENE_OR_GENE_PRODUCT", 49, 59], ["C3", "GENE_OR_GENE_PRODUCT", 94, 96], ["C4", "GENE_OR_GENE_PRODUCT", 101, 103], ["patients", "ORGANISM", 121, 129], ["serum anti-dsDNA", "PROTEIN", 43, 59], ["C3", "PROTEIN", 94, 96], ["C4", "PROTEIN", 101, 103], ["patients", "SPECIES", 121, 129], ["Leone et al.", "TEST", 3, 15], ["serum anti-dsDNA", "TEST", 43, 59], ["SLE", "PROBLEM", 135, 138], ["anti-dsDNA", "OBSERVATION", 49, 59], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["C3", "ANATOMY_MODIFIER", 94, 96], ["C4", "ANATOMY_MODIFIER", 101, 103], ["decreased", "OBSERVATION_MODIFIER", 108, 117]]], ["The mechanism of a high incidence of active SLE in winter and a low incidence in summer remains to be further elucidated.DISCUSSIONIn summary, our study indicates that active SLE has seasonal distribution and its mechanism remains to be further explored.", [["SLE", "DISEASE", 44, 47], ["SLE", "DISEASE", 175, 178], ["SLE", "CANCER", 175, 178], ["active SLE", "PROBLEM", 37, 47], ["our study", "TEST", 143, 152], ["active SLE", "PROBLEM", 168, 178], ["high", "OBSERVATION_MODIFIER", 19, 23], ["active", "OBSERVATION_MODIFIER", 37, 43], ["SLE", "OBSERVATION", 44, 47], ["active", "OBSERVATION_MODIFIER", 168, 174], ["SLE", "OBSERVATION", 175, 178]]]]}